0001193125-22-118784.txt : 20220426 0001193125-22-118784.hdr.sgml : 20220426 20220426070133 ACCESSION NUMBER: 0001193125-22-118784 CONFORMED SUBMISSION TYPE: SC TO-T PUBLIC DOCUMENT COUNT: 14 FILED AS OF DATE: 20220426 DATE AS OF CHANGE: 20220426 SUBJECT COMPANY: COMPANY DATA: COMPANY CONFORMED NAME: ANTARES PHARMA, INC. CENTRAL INDEX KEY: 0001016169 STANDARD INDUSTRIAL CLASSIFICATION: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841] IRS NUMBER: 411350192 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: SC TO-T SEC ACT: 1934 Act SEC FILE NUMBER: 005-47575 FILM NUMBER: 22851721 BUSINESS ADDRESS: STREET 1: 100 PRINCETON SOUTH STREET 2: SUITE 300 CITY: EWING STATE: NJ ZIP: 08628 BUSINESS PHONE: 609-359-3020 MAIL ADDRESS: STREET 1: 100 PRINCETON SOUTH STREET 2: SUITE 300 CITY: EWING STATE: NJ ZIP: 08628 FORMER COMPANY: FORMER CONFORMED NAME: ANTARES PHARMA INC DATE OF NAME CHANGE: 20060120 FORMER COMPANY: FORMER CONFORMED NAME: ANTARES PHARMA INC DATE OF NAME CHANGE: 20020520 FORMER COMPANY: FORMER CONFORMED NAME: ANTARES PHARMA INC /MN/ DATE OF NAME CHANGE: 20010604 FILED BY: COMPANY DATA: COMPANY CONFORMED NAME: HALOZYME THERAPEUTICS, INC. CENTRAL INDEX KEY: 0001159036 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 880488686 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: SC TO-T BUSINESS ADDRESS: STREET 1: 11388 SORRENTO VALLEY ROAD CITY: SAN DIEGO STATE: CA ZIP: 92121-1345 BUSINESS PHONE: (858) 794-8889 MAIL ADDRESS: STREET 1: 11388 SORRENTO VALLEY ROAD CITY: SAN DIEGO STATE: CA ZIP: 92121-1345 FORMER COMPANY: FORMER CONFORMED NAME: HALOZYME THERAPEUTICS INC DATE OF NAME CHANGE: 20040312 FORMER COMPANY: FORMER CONFORMED NAME: GLOBAL YACHT SERVICES INC DATE OF NAME CHANGE: 20010912 SC TO-T 1 d347764dsctot.htm SC TO-T SC TO-T

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

SCHEDULE TO

Tender Offer Statement under Section 14(d)(1) or 13(e)(1)

of the Securities Exchange Act of 1934

 

 

Antares Pharma, Inc.

(Name of Subject Company (Issuer))

ATLAS MERGER SUB, INC.

HALOZYME THERAPEUTICS, INC.

(Names of Filing Persons — Offerors)

 

 

Common Stock, Par Value $0.01 Per Share

(Title of Class of Securities)

036642106

(Cusip Number of Class of Securities)

Mark Snyder

Senior Vice President, General Counsel and Corporate Secretary

Halozyme Therapeutics, Inc.

11388 Sorrento Valley Road

San Diego, California 92121

Telephone: (858) 794-8889

(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications on Behalf of Filing Persons)

 

 

Copies to:

Michael J. Aiello, Esq.

Sachin Kohli, Esq.

Weil, Gotshal & Manges LLP

767 Fifth Avenue

New York, New York 10153

(212) 310-8000

 

 

 

Check the box if the filing relates solely to preliminary communications made before the commencement of a tender offer.

Check the appropriate boxes below to designate any transactions to which the statement relates:

 

Third-party tender offer subject to Rule 14d-1.

Issuer tender offer subject to Rule 13e-4.

Going-private transaction subject to Rule 13e-3.

Amendment to Schedule 13D under Rule 13d-2.

 

Check

the following box if the filing is a final amendment reporting the results of the tender offer: ☐

If applicable, check the appropriate box(es) below to designate the appropriate rule provision(s) relied upon:

 

 

Rule 13e-4(i) (Cross-Border Issuer Tender Offer)

 

Rule 14d-1(d) (Cross-Border Third-Party Tender Offer)

 

 

 


This Tender Offer Statement on Schedule TO (together with any amendments and supplements hereto, this “Schedule TO”) is filed by (i) Atlas Merger Sub, Inc., a Delaware corporation (“Purchaser”) and a wholly owned subsidiary of Halozyme Therapeutics, Inc., a Delaware corporation (“Parent”) and Parent. This Schedule TO relates to the offer by Purchaser to purchase all of the outstanding shares of common stock, par value, $0.01 per share (the “Shares”), of Antares Pharma, Inc., a Delaware corporation (the “Company”), at a purchase price of $5.60 per Share (the “Offer Price”) net to the seller in cash, without interest and subject to any withholding of taxes required by applicable legal requirements, on the terms and subject to the conditions set forth in the Offer to Purchase dated April 26, 2022 (together with any amendments or supplements thereto, the “Offer to Purchase”) and in the accompanying Letter of Transmittal, which are annexed to and filed with this Schedule TO as Exhibits (a)(1)(A) and (a)(1)(B), respectively.

All information contained in the Offer to Purchase (including Schedule I to the Offer to Purchase) and the accompanying Letter of Transmittal is hereby expressly incorporated herein by reference in response to Items 1 through 9 and Item 11 of this Schedule TO.

The Agreement and Plan of Merger, dated as of April 12, 2022 (as it may be amended from time to time, the “Merger Agreement”), by and among the Company, Parent and Purchaser, a copy of which is attached as Exhibit (d)(1) hereto, is incorporated herein by reference with respect to Items 4 through 9 and 11 of this Schedule TO.

Item 1. Summary Term Sheet.

The information set forth in the “Summary Term Sheet” of the Offer to Purchase is incorporated herein by reference.

Item 2. Subject Company Information.

(a)    The name of the subject company and the issuer of the securities to which this Schedule TO relates is Antares Pharma, Inc., a Delaware corporation. The Company’s principal executive offices are located at 100 Princeton South, Suite 300, Ewing, New Jersey 08628. The Company’s telephone number is (609) 359-3020.

(b)    This Schedule TO relates to the outstanding Shares. The Company has advised Purchaser and Parent that, as of the close of business on April 22, 2022 (the most recent practicable date) 170,782,427 Shares were issued and outstanding.

(c)    The information concerning the principal market, if any, in which the Shares are traded and certain high and low sales prices for Shares in the principal market in which the Shares are traded are set forth in Section 6 (entitled “Price Range of Shares; Dividends on the Shares”) of the Offer to Purchase is incorporated herein by reference.

Item 3. Identity and Background of the Filing Person.

(a) – (c) This Schedule TO is filed by Purchaser and Parent. The information set forth in Section 8 (entitled “Certain Information Concerning Parent, Purchaser and Certain Related Persons”) of the Offer to Purchase and Schedule I to the Offer to Purchase is incorporated herein by reference.

Item 4. Terms of the Transaction.

(a)(1)(i) – (viii), (xii), (a)(2)(i) – (iv), (vii) The information set forth in the following sections of the Offer to Purchase is incorporated herein by reference:

 

   

the “Summary Term Sheet”

 

   

the “Introduction”

 

   

Section 1 – “Terms of the Offer”


   

Section 2 – “Acceptance for Payment and Payment for Shares”

 

   

Section 3 – “Procedures for Accepting the Offer and Tendering Shares”

 

   

Section 4 – “Withdrawal Rights”

 

   

Section 5 – “Certain U.S. Federal Income Tax Consequences of the Offer”

 

   

Section 11 – “The Merger Agreement; Other Agreements”

 

   

Section 12 – “Purpose of the Offer; Plans for the Company”

 

   

Section 13 – “Certain Effects of the Offer”

 

   

Section 15 – “Conditions of the Offer”

 

   

Section 16 – “Certain Legal Matters; Regulatory Approvals”

 

   

Section 17 – “Appraisal Rights”

 

   

Section 19 – “Miscellaneous”

(a)(1)(ix) – (xi), (a)(2)(v) – (vi) Not applicable.

Item 5. Past Contacts, Transactions, Negotiations and Agreements.

(a), (b) The information set forth in the following sections of the Offer to Purchase is incorporated herein by reference:

 

   

the “Summary Term Sheet”

 

   

the “Introduction”

 

   

Section 7 – “Certain Information Concerning the Company”

 

   

Section 8 – “Certain Information Concerning Parent, Purchaser and Certain Related Persons”

 

   

Section 10 – “Background of the Offer; Past Contacts or Negotiations with the Company”

 

   

Section 11 – “The Merger Agreement; Other Agreements”

 

   

Section 12 – “Purpose of the Offer; Plans for the Company”

 

   

Schedule I

Item 6. Purposes of the Transaction and Plans or Proposals.

(a), (c)(1) – (7) The information set forth in the following sections of the Offer to Purchase is incorporated herein by reference:

 

   

the “Summary Term Sheet”

 

   

the “Introduction”

 

   

Section 6 – “Price Range of Shares; Dividends on the Shares”

 

   

Section 10 – “Background of the Offer; Past Contacts or Negotiations with the Company”

 

   

Section 11 – “The Merger Agreement; Other Agreements”

 

   

Section 12 – “Purpose of the Offer; Plans for the Company”

 

   

Section 13 – “Certain Effects of the Offer”

 

   

Section 14 – “Dividends and Distributions”

 

   

Schedule I


Item 7. Source and Amount of Funds or Other Consideration.

(a), (d) The information set forth in the following sections of the Offer to Purchase is incorporated herein by reference:

 

   

the “Summary Term Sheet”

 

   

the “Introduction”

 

   

Section 9 – “Source and Amount of Funds”

 

   

Section 11 – “The Merger Agreement; Other Agreements”

(b) The Offer is not subject to a financing condition.

Item 8. Interest in Securities of the Subject Company.

(a), (b) The information set forth in the following sections of the Offer to Purchase is incorporated herein by reference:

 

   

the “Summary Term Sheet”

 

   

Section 8 – “Certain Information Concerning Parent, Purchaser and Certain Related Persons”

 

   

Section 11 – “The Merger Agreement; Other Agreements”

 

   

Section 12 – “Purpose of the Offer; Plans for the Company”

 

   

Schedule I

Item 9. Persons/Assets, Retained, Employed, Compensated or Used.

(a) The information set forth in the following sections of the Offer to Purchase is incorporated herein by reference:

 

   

the “Summary Term Sheet”

 

   

the “Introduction”

 

   

Section 3 – “Procedures for Accepting the Offer and Tendering Shares”

 

   

Section 10 – “Background of the Offer; Past Contacts or Negotiations with the Company”

 

   

Section 18 – “Fees and Expenses”

Item 10. Financial Statements.

(a), (b) Not applicable.

Item 11. Additional Information.

(a)(1) The information set forth in the following sections of the Offer to Purchase is incorporated herein by reference:

 

   

Section 8 – “Certain Information Concerning Parent, Purchaser and Certain Related Persons”

 

   

Section 10 – “Background of the Offer; Past Contacts or Negotiations with the Company”

 

   

Section 11 – “The Merger Agreement; Other Agreements”

 

   

Section 12 – “Purpose of the Offer; Plans for the Company”


(a)(2) The information set forth in the following sections of the Offer to Purchase is incorporated herein by reference:

 

   

the “Summary Term Sheet”

 

   

the “Introduction”

 

   

Section 12 – “Purpose of the Offer; Plans for the Company”

 

   

Section 15 – “Conditions of the Offer”

 

   

Section 16 – “Certain Legal Matters; Regulatory Approvals”

(a)(3) The information set forth in the following sections of the Offer to Purchase is incorporated herein by reference:

 

   

the “Summary Term Sheet”

 

   

the “Introduction”

 

   

Section 15 – “Conditions of the Offer”

 

   

Section 16 – “Certain Legal Matters; Regulatory Approvals”

(a)(4) The information set forth in the following sections of the Offer to Purchase is incorporated herein by reference:

 

   

Section 13 – “Certain Effects of the Offer”

(a)(5) The information set forth in the following sections of the Offer to Purchase is incorporated herein by reference:

 

   

the “Summary Term Sheet”

 

   

the “Introduction”

 

   

Section 15 – “Conditions of the Offer”

 

   

Section 16 – “Certain Legal Matters; Regulatory Approvals”

(c) The information set forth in the Offer to Purchase is incorporated herein by reference.

Item 12. Exhibits.

 

Exhibit No.   Description
(a)(1)(A)   Offer to Purchase, dated April 26, 2022.*
(a)(1)(B)   Letter of Transmittal (including Guidelines for Certification of Taxpayer Identification Number on IRS Form W-9).*
(a)(1)(C)   Letter to Brokers, Dealers, Commercial Banks, Trust Companies and Other Nominees.*
(a)(1)(D)   Letter to Clients for use by Brokers, Dealers, Commercial Banks, Trust Companies and Other Nominees.*
(a)(1)(E)   Summary Advertisement, as published in The Wall Street Journal, dated April 26, 2022.*
(a)(5)(A)   Email to employees of Antares Pharma, Inc., dated April 13, 2022 (incorporated herein by reference to Exhibit (a)(5)(A) to the Schedule TO-C filed by Parent with the SEC on April 13, 2022).
(a)(5)(B)   Email to employees of Halozyme Therapeutics, Inc., dated April 13, 2022 (incorporated herein by reference to Exhibit (a)(5)(B) to the Schedule TO-C filed by Parent with the SEC on April 13, 2022).


Exhibit No.   Description
(a)(5)(C)   Halozyme Therapeutics, Inc. employee FAQs, dated April 13, 2022 (incorporated herein by reference to Exhibit (a)(5)(C) to the Schedule TO-C filed by Parent with the SEC on April 13, 2022).
(a)(5)(D)   Letter to partners of Halozyme Therapeutics, Inc., dated April 13, 2022 (incorporated herein by reference to Exhibit (a)(5)(D) to the Schedule TO-C filed by Parent with the SEC on April 13, 2022).
(a)(5)(E)   Halozyme Therapeutics, Inc. infographic, published on April 13, 2022 (incorporated herein by reference to Exhibit (a)(5)(E) to the Schedule TO-C filed by Parent with the SEC on April 13, 2022).
(a)(5)(F)   Social media posts (Twitter and LinkedIn) of Halozyme Therapeutics, Inc., dated April 13, 2022 (incorporated herein by reference to Exhibit (a)(5)(F) to the Schedule TO-C filed by Parent with the SEC on April 13, 2022).
(a)(5)(G)   Transcript of conference call of Halozyme Therapeutics, Inc., held on April 13, 2022 (incorporated herein by reference to Exhibit (a)(5)(G) to the Schedule TO-C filed by Parent with the SEC on April 14, 2022).
(a)(5)(H)   Joint press release of Halozyme Therapeutics, Inc. and Antares Pharma, Inc., dated as of April 13, 2022 (incorporated herein by reference to Exhibit 99.1 to the Schedule TO-C filed by Parent with the SEC on April 13, 2022).
(a)(5)(I)   Investor Presentation of Halozyme Therapeutics, Inc., dated as of April 13, 2022 (incorporated herein by reference to Exhibit 99.2 to the Schedule TO-C filed by Parent with the SEC on April 13, 2022).
(a)(5)(J)   Press Release of Halozyme Therapeutics, Inc., dated as of April 26, 2022.*
(b)(1)   Commitment Letter, dated as of April 12, 2022, by and among Halozyme Therapeutics, Inc., BofA Securities, Inc. and Bank of America N.A.*
(d)(1)   Agreement and Plan of Merger, dated as of April 12, 2022, by and among Halozyme Therapeutics, Inc., Atlas Merger Sub, Inc. and Antares Pharma, Inc. (incorporated herein by reference to Exhibit 2.1 to Halozyme Therapeutics, Inc.’s Form 8-K (File No. 001-32335), filed with the SEC on April 13, 2022).
(d)(2)   Confidentiality Agreement, dated as of February 18, 2022, by and between Halozyme Therapeutics, Inc. and Antares Pharma, Inc.*
(d)(3)   Exclusivity Agreement, dated as of March 17, 2022, by and between Halozyme Therapeutics, Inc. and Antares Pharma, Inc.*
(g)   Not applicable.
(h)   Not applicable.
107   Fee Filing Table.*

 

*

Filed herewith

Item 13. Information Required by Schedule 13E-3.

Not applicable.


SIGNATURES

After due inquiry and to the best knowledge and belief of the undersigned, each of the undersigned certifies that the information set forth in this statement is true, complete and correct.

Date: April 26, 2022

 

Atlas Merger Sub, Inc.

By:

 

/s/ Nicole LaBrosse

 

Name: Nicole LaBrosse

 

Title:   Treasurer

Halozyme Therapeutics, Inc.

By:

 

/s/ Nicole LaBrosse

 

Name: Nicole LaBrosse

 

Title:   Senior Vice President, Chief Financial Officer


EXHIBIT INDEX

 

Exhibit No.   Description
(a)(1)(A)   Offer to Purchase, dated April 26, 2022.*
(a)(1)(B)   Letter of Transmittal (including Guidelines for Certification of Taxpayer Identification Number on IRS Form W-9).*
(a)(1)(C)   Letter to Brokers, Dealers, Commercial Banks, Trust Companies and Other Nominees.*
(a)(1)(D)   Letter to Clients for use by Brokers, Dealers, Commercial Banks, Trust Companies and Other Nominees.*
(a)(1)(E)   Summary Advertisement, as published in The Wall Street Journal, dated April 26, 2022.*
(a)(5)(A)   Email to employees of Antares Pharma, Inc., dated April 13, 2022 (incorporated herein by reference to Exhibit (a)(5)(A) to the Schedule TO-C filed by Parent with the SEC on April 13, 2022).
(a)(5)(B)   Email to employees of Halozyme Therapeutics, Inc., dated April 13, 2022 (incorporated herein by reference to Exhibit (a)(5)(B) to the Schedule TO-C filed by Parent with the SEC on April 13, 2022).
(a)(5)(C)   Halozyme Therapeutics, Inc. employee FAQs, dated April 13, 2022 (incorporated herein by reference to Exhibit (a)(5)(C) to the Schedule TO-C filed by Parent with the SEC on April 13, 2022).
(a)(5)(D)   Letter to partners of Halozyme Therapeutics, Inc., dated April 13, 2022 (incorporated herein by reference to Exhibit (a)(5)(D) to the Schedule TO-C filed by Parent with the SEC on April 13, 2022).
(a)(5)(E)   Halozyme Therapeutics, Inc. infographic, published on April 13, 2022 (incorporated herein by reference to Exhibit (a)(5)(E) to the Schedule TO-C filed by Parent with the SEC on April 13, 2022).
(a)(5)(F)   Social media posts (Twitter and LinkedIn) of Halozyme Therapeutics, Inc., dated April 13, 2022 (incorporated herein by reference to Exhibit (a)(5)(F) to the Schedule TO-C filed by Parent with the SEC on April 13, 2022).
(a)(5)(G)   Transcript of conference call of Halozyme Therapeutics, Inc., held on April 13, 2022 (incorporated herein by reference to Exhibit (a)(5)(G) to the Schedule TO-C filed by Parent with the SEC on April 14, 2022).
(a)(5)(H)   Joint press release of Halozyme Therapeutics, Inc. and Antares Pharma, Inc., dated as of April 13, 2022 (incorporated herein by reference to Exhibit 99.1 to the Schedule TO-C filed by Parent with the SEC on April 13, 2022).
(a)(5)(I)   Investor Presentation of Halozyme Therapeutics, Inc., dated as of April 13, 2022 (incorporated herein by reference to Exhibit 99.2 to the Schedule TO-C filed by Parent with the SEC on April 13, 2022).
(a)(5)(J)   Press Release of Halozyme Therapeutics, Inc., dated as of April 26, 2022.*
(b)(1)   Commitment Letter, dated as of April 12, 2022, by and among Halozyme Therapeutics, Inc., BofA Securities, Inc. and Bank of America N.A.*
(d)(1)   Agreement and Plan of Merger, dated as of April 12, 2022, by and among Halozyme Therapeutics, Inc., Atlas Merger Sub, Inc. and Antares Pharma, Inc. (incorporated herein by reference to Exhibit 2.1 to Halozyme Therapeutics, Inc.’s Form 8-K (File No. 001-32335), filed with the SEC on April 13, 2022).


Exhibit No.   Description
(d)(2)   Confidentiality Agreement, dated as of February 18, 2022, by and between Halozyme Therapeutics, Inc. and Antares Pharma, Inc.*
(d)(3)   Exclusivity Agreement, dated as of March 17, 2022, by and between Halozyme Therapeutics, Inc. and Antares Pharma, Inc.*
(g)   Not applicable.
(h)   Not applicable.
107   Fee Filing Table.*

 

*

Filed herewith

EX-99.(A)(1)(A) 2 d347764dex99a1a.htm EXHIBIT (A)(1)(A) Exhibit (a)(1)(A)

Exhibit (a)(1)(A)

 

Offer To Purchase

All Outstanding Shares of Common Stock

of

ANTARES PHARMA, INC.

at

$5.60 Per Share, Net in Cash

by

ATLAS MERGER SUB, INC.,

a wholly owned subsidiary of

HALOZYME THERAPEUTICS, INC.

 

THE OFFER AND WITHDRAWAL RIGHTS WILL EXPIRE AT ONE MINUTE FOLLOWING 11:59 P.M., EASTERN TIME, ON MAY 23, 2022, UNLESS THE OFFER IS EXTENDED OR EARLIER TERMINATED.

Atlas Merger Sub, Inc., a Delaware corporation (“Purchaser”) and a wholly owned subsidiary of Halozyme Therapeutics, Inc., a Delaware corporation (“Parent”), is offering to purchase all of the outstanding shares of common stock, par value $0.01 per share (the “Shares”), of Antares Pharma, Inc., a Delaware corporation (the “Company”), at a purchase price of $5.60 per Share in cash (the “Offer Price”) without interest and subject to any withholding of taxes required by applicable legal requirements, upon the terms and subject to the conditions set forth in this Offer to Purchase and in the related letter of transmittal (the “Letter of Transmittal” which, together with this Offer to Purchase, as they may be amended or supplemented from time to time, collectively constitute the “Offer”).

The Offer is being made pursuant to an Agreement and Plan of Merger, dated as of April 12, 2022 (as it may be amended from time to time, the “Merger Agreement”), among the Company, Parent and Purchaser, pursuant to which, unless otherwise agreed by the Company, Parent and Purchaser, at 8:00 a.m., Eastern Time, on the same date as the consummation of the Offer and subject to the satisfaction or waiver of certain conditions, Purchaser will merge with and into the Company (the “Merger”) and the separate existence of Purchaser will cease and the Company will continue as the surviving corporation (the “Surviving Corporation”), upon the terms and subject to the conditions set forth in the Merger Agreement. The Merger will be governed by Section 251(h) of the General Corporation Law of the State of Delaware, as amended (the “DGCL”), and effected without a vote of the Company stockholders. In the Merger, each Share issued and outstanding immediately prior to the effective time of the Merger (being such date and at such time as the certificate of merger in respect of the Merger has been duly filed with the Secretary of State of the State of Delaware or at such later time and date as may be agreed upon by the parties to the Merger Agreement in writing and specified in the certificate of merger in accordance with the DGCL, the “Effective Time”) (other than Shares (i) held by the Company (or in the Company’s treasury), Parent, any other direct or indirect wholly owned subsidiary of Parent (other than Purchaser) or by stockholders of the Company who have properly exercised and perfected their statutory rights of appraisal under Delaware law, or (ii) irrevocably accepted by Purchaser for purchase in the Offer) will be converted into the right to receive an amount in cash equal to the Offer Price, without interest and subject to any withholding of taxes required by applicable legal requirements.

Under no circumstances will interest be paid on the purchase price for the Shares accepted for payment in the Offer, regardless of any extension of the Offer or any delay in making payment for the Shares.

The obligation of Purchaser to accept for payment and pay for Shares validly tendered (and not validly withdrawn) pursuant to the Offer is subject to the satisfaction of, among other conditions: (i) the Minimum Condition (as defined below in the “Summary Term Sheet”) and (ii) the Regulatory Condition (as defined below in Section 15 – “Conditions of the Offer”) and the HSR Condition (as defined below in Section 15 – “Conditions

 

i


of the Offer”). There is no financing condition to the Offer. The Offer is subject to various additional conditions. See Section 15 – “Conditions of the Offer.” A summary of the principal terms and conditions of the Offer appears in the “Summary Term Sheet” beginning on page 5 of this Offer to Purchase.

The Board of Directors of the Company (the “Company Board”) has unanimously: (i) determined that the Merger Agreement, the Offer and the Merger are fair to, and in the best interest of, the Company and its stockholders; (ii) declared that it is advisable for the Company to enter into the Merger Agreement; (iii) approved the execution, delivery and performance by the Company of the Merger Agreement and the consummation of the transactions contemplated by the Merger Agreement, including the Offer and the Merger; (iv) agreed that the Merger shall be effected under Section 251(h) of the DGCL; and (v) resolved to recommend that the Company’s stockholders accept the Offer and tender their Shares pursuant to the Offer.

This Offer to Purchase and the Letter of Transmittal contain important information, and you should read both carefully and in their entirety before deciding whether to tender your Shares in the Offer.

NEITHER THE OFFER NOR THE MERGER HAS BEEN APPROVED OR DISAPPROVED BY THE UNITED STATES SECURITIES AND EXCHANGE COMMISSION (THE “SEC”) OR ANY STATE SECURITIES COMMISSION, NOR HAS THE SEC OR ANY STATE SECURITIES COMMISSION PASSED UPON THE FAIRNESS OR MERITS OF THE OFFER OR THE MERGER OR UPON THE ACCURACY OR ADEQUACY OF THE INFORMATION CONTAINED IN THIS OFFER TO PURCHASE OR THE LETTER OF TRANSMITTAL. ANY REPRESENTATION TO THE CONTRARY IS UNLAWFUL AND A CRIMINAL OFFENSE.

The Information Agent for the Offer is:

D.F. King & Co., Inc.

48 Wall Street, 22nd Floor

New York, New York 10005

Banks and Brokers may call: (212) 269-5550

Stockholders may call toll free: (888) 628-1041

ATRS@dfking.com

 

ii


IMPORTANT

If your Shares are registered in your name and you wish to tender all or a portion of your Shares to Purchaser in the Offer, you must either (i) complete and sign the Letter of Transmittal that accompanies this Offer to Purchase in accordance with the instructions in the Letter of Transmittal and mail or deliver the Letter of Transmittal and all other required documents to the Depositary (as defined below in the “Summary Term Sheet”) together with certificates representing the Shares tendered or (ii) follow the procedure for book-entry transfer set forth in Section 3 – “Procedures for Accepting the Offer and Tendering Shares.” If your Shares are registered in the name of a broker, dealer, commercial bank, trust company or other nominee, you must contact that institution in order to tender your Shares to Purchaser and request they effect the transaction for you before the expiration of the Offer.

Questions and requests for assistance should be directed to the Information Agent (as defined below in the “Summary Term Sheet”) at the address and telephone numbers set forth on the back cover of this Offer to Purchase. Additional copies of this Offer to Purchase, the related Letter of Transmittal and other materials related to the Offer may also be obtained at our expense from the Information Agent. Additionally, copies of this Offer to Purchase, the related Letter of Transmittal and any other materials related to the Offer may be found at www.sec.gov. You may also contact your broker, dealer, commercial bank, trust company or other nominee for assistance, if your Shares are registered in their name.

This Offer to Purchase and the related Letter of Transmittal contain important information, and you should read both carefully and in their entirety before making a decision with respect to the Offer.

 

iii


TABLE OF CONTENTS

 

          Page  

1.

   Terms of the Offer      3  

2.

   Acceptance for Payment and Payment for Shares      4  

3.

   Procedures for Accepting the Offer and Tendering Shares      5  

4.

   Withdrawal Rights      9  

5.

   Certain U.S. Federal Income Tax Consequences of the Offer      9  

6.

   Price Range of Shares; Dividends on the Shares      12  

7.

   Certain Information Concerning the Company      13  

8.

   Certain Information Concerning Parent, Purchaser and Certain Related Persons      13  

9.

   Source and Amount of Funds      15  

10.

   Background of the Offer; Past Contacts or Negotiations with the Company      17  

11.

   The Merger Agreement; Other Agreements      19  

12.

   Purpose of the Offer; Plans for the Company      41  

13.

   Certain Effects of the Offer      42  

14.

   Dividends and Distributions      43  

15.

   Conditions of the Offer      43  

16.

   Certain Legal Matters; Regulatory Approvals      45  

17.

   Appraisal Rights      47  

18.

   Fees and Expenses      48  

19.

   Miscellaneous      49  

 

iv


SUMMARY TERM SHEET

Atlas Merger Sub, Inc., a Delaware corporation (“Purchaser”) and a wholly owned subsidiary of Halozyme Therapeutics, Inc., a Delaware corporation (“Parent”), is offering to purchase all of the outstanding shares of common stock, par value $0.01 per share (the “Shares”), of Antares Pharma, Inc., a Delaware corporation (the “Company”), at a purchase price of $5.60 per Share in cash (the “Offer Price”) without interest and subject to any withholding of taxes required by applicable legal requirements, upon the terms and subject to the conditions set forth in this Offer to Purchase and in the related letter of transmittal (the “Letter of Transmittal” which, together with this Offer to Purchase, as they may be amended or supplemented from time to time, collectively constitute the “Offer”). The following are some questions you may have as a stockholder of the Company and answers to those questions. The information contained in this summary term sheet is a summary only, and may not contain all of the information that is important to you, and is not meant to be a substitute for the more detailed descriptions and information contained in the remainder of this Offer to Purchase, the Letter of Transmittal and other related materials. You are urged to read carefully this Offer to Purchase, the Letter of Transmittal and other related materials in their entirety. This summary term sheet includes cross-references to other sections of this Offer to Purchase where you will find more complete descriptions of the topics mentioned below. Except as otherwise set forth herein, the information concerning the Company contained in this summary term sheet and elsewhere in this Offer to Purchase has been based upon publicly available documents or records of the Company on file with the Securities and Exchange Commission (the “SEC”) or other public sources or information provided by the Company. Neither Parent nor Purchaser assumes responsibility for the accuracy or completeness of the information concerning the Company contained in such documents and records or accuracy of any such information.

 

Securities Sought    All of the issued and outstanding shares of common stock, par value $0.01 per share, of the Company.

 

Price Offered Per Share

  

 

$5.60 in cash, without interest and subject to any withholding of taxes required by applicable legal requirements.

 

Scheduled Expiration of Offer

  

 

One minute following 11:59 P.M., Eastern Time, on May 23, 2022, unless the Offer is otherwise extended or earlier terminated.

 

Purchaser

  

 

Atlas Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent.

 

Company Board Recommendation

  

 

The Company Board unanimously recommends that the holders of Shares tender their Shares to Purchaser pursuant to the Offer.

Who is offering to buy my securities?

Atlas Merger Sub, Inc., a Delaware corporation, is offering to purchase all of the outstanding Shares at a price per share of $5.60 in cash, without interest and subject to any withholding of taxes required by applicable legal requirements, on the terms and subject to the conditions set forth in this Offer to Purchase. Purchaser was formed solely for the purpose of facilitating the acquisition of the Company. Purchaser has not carried on any activities to date, except for activities incidental to its formation and activities undertaken in connection with the transactions contemplated by the Merger Agreement (the “Transactions”). Purchaser is a wholly owned direct subsidiary of Parent. Parent is a biopharma technology platform company that provides innovative and disruptive solutions with the goal of improving patient experience and outcomes. Parent licenses its technology to biopharmaceutical companies to collaboratively develop products that combine its ENHANZE® drug delivery technology with the collaborators’ proprietary compounds.

Unless the context indicates otherwise, in this Offer to Purchase, we use the terms “us,” “we” and “our” to refer to Purchaser and, where appropriate, Parent. We use the term “Purchaser” to refer to Atlas Merger Sub, Inc.

 

v


alone, the term “Parent” to refer to Halozyme Therapeutics, Inc. alone and the term the “Company” to refer to Antares Pharma, Inc. Unless the context otherwise requires, we use the term “Shares” to refer to shares of common stock, par value $0.01 per share, of the Company.

See Section 8 – “Certain Information Concerning Parent, Purchaser, and Certain Related Persons.”

What is the class and amount of securities sought pursuant to the Offer?

Purchaser is offering to purchase all of the outstanding Shares at the Offer Price in cash, without interest and subject to any withholding of taxes required by applicable legal requirements, on the terms and subject to the conditions set forth in this Offer to Purchase. In this Offer to Purchase, we use the term “Offer” to refer to this offer and the term “Shares” to refer to the Shares that are the subject of the Offer.

See Section 1 – “Terms of the Offer.”

Why are you making the Offer?

We are making the Offer because we want to acquire the Company. Following the consummation of the Offer, we are required to complete the Merger (as defined below) at 8:00 a.m., Eastern Time, on the same date as the consummation of the Offer, unless otherwise agreed by the Company, Parent and Purchaser. Upon completion of the Merger, the Company will become a wholly owned subsidiary of Parent. In addition, we intend to cause the Shares to be delisted from the NASDAQ Global Select Stock Market (“NASDAQ”) and deregistered under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), after completion of the Merger.

Who can participate in the Offer?

The Offer is open to all record holders and beneficial owners of Shares.

How much are you offering to pay?

Purchaser is offering to pay $5.60 per Share in cash, without interest and subject to any withholding of taxes required by applicable legal requirements. We refer to this amount as the “Offer Price.”

See the “Introduction” to this Offer to Purchase.

Will I have to pay any fees or commissions?

If you are the holder of record of your Shares and you directly tender your Shares to us (through the Depositary (as defined herein)) in the Offer, you will not be obligated to pay brokerage fees, commissions or similar expenses. If you own your Shares through a broker, banker or other nominee, and your broker, banker or other nominee tenders your Shares on your behalf, your broker, banker or other nominee may charge you a fee for doing so. You should consult such institutions as to whether any service fees or commissions will apply.

See the “Introduction” to this Offer to Purchase and Section 18 – “Fees and Expenses.”

Is there an agreement governing the Offer?

Yes. The Company, Parent and Purchaser have entered into an Agreement and Plan of Merger, dated as of April 12, 2022 (as it may be amended from time to time, the “Merger Agreement”). The Merger Agreement provides, among other things, for the terms and conditions of the Offer and the subsequent merger of Purchaser with and into the Company, and the separate existence of Purchaser will cease and the Company will continue as the surviving corporation and an indirect wholly owned subsidiary of Parent (such merger, the “Merger”).

See Section 11 – “The Merger Agreement; Other Agreements” and Section 15 – “Conditions of the Offer.”

 

vi


What are the principal U.S. federal income tax consequences of tendering my Shares in the Offer or having my Shares exchanged for cash pursuant to the Merger?

The receipt of cash in exchange for your Shares in the Offer or, assuming you do not tender your Shares pursuant to the Offer and the Offer is consummated, in exchange for your Shares in the Merger, will be a taxable transaction for U.S. federal income tax purposes if you are a U.S. Holder (as defined in Section 5 – “Certain U.S. Federal Income Tax Consequences of the Offer and the Merger”). In general, provided that you are a U.S. Holder and hold your Shares as capital assets, you will recognize capital gain or loss in an amount equal to the difference, if any, between (i) the Offer Price and (ii) your adjusted tax basis in the Shares sold pursuant to the Offer or exchanged for cash pursuant to the Merger. This capital gain or loss will be long-term capital gain or loss if you have held the Shares for more than one year as of the date of your sale or exchange of the Shares pursuant to the Offer or the Merger. See Section 5 – “Certain U.S. Federal Income Tax Consequences of the Offer and the Merger” for a more detailed discussion of the U.S. federal income tax treatment of the Offer and the Merger (including for Non-U.S. Holders (as defined in that section)).

The U.S. federal, state, local and foreign income and other tax consequences to holders or beneficial owners of options or restricted stock units participating in the Merger with respect to such options or restricted stock units are not discussed herein, and such holders or beneficial owners of options or restricted stock units are strongly encouraged to consult their own tax advisors regarding such tax consequences. Stockholders should consult their own tax advisors concerning the U.S. federal income tax consequences relating to the Offer and the Merger in light of their particular circumstances and any consequences arising under the laws of any state, local or foreign taxing jurisdiction. We urge you to consult with your own tax advisor as to the particular tax consequences to you of the Offer and the Merger.

Do you have the financial resources to pay for all of the Shares that Purchaser is offering to purchase pursuant to the Offer?

Yes. We estimate that we will need approximately $960 million to purchase all of the Shares pursuant to the Offer and to complete the Merger. Parent will provide Purchaser with sufficient funds to purchase all Shares validly tendered (and not validly withdrawn) in the Offer and to provide funding for the Merger. Purchaser will acquire these funds from Parent. Parent intends to provide the funds out of available cash on hand and newly obtained incremental financing pursuant to a commitment letter with Bank of America, N.A. and BofA Securities, Inc. (together “BofA”) dated as of April 12, 2022 (the “Debt Commitment Letter”). Neither the Offer nor the Merger is subject to any financing condition.

See Section 9 – “Source and Amount of Funds.”

Is Purchaser’s financial condition relevant to my decision to tender my Shares in the Offer?

We do not think Purchaser’s financial condition is relevant to your decision whether to tender Shares and accept the Offer because:

 

   

the Offer is being made for all outstanding Shares solely for cash;

 

   

through Parent, we will have sufficient funds available to purchase all Shares validly tendered (and not validly withdrawn) in the Offer and, if we consummate the Offer, all Shares converted into the right to receive the Offer Price in the Merger; and

 

   

the Offer and the Merger are not subject to any financing or funding condition.

See Section 9 – “Source and Amount of Funds” and Section 11 – “The Merger Agreement; Other Agreements.”

 

vii


Is there a minimum number of Shares that must be tendered in order for you to purchase any securities?

Yes. The obligation of Purchaser to accept for payment and pay for Shares validly tendered (and not validly withdrawn) pursuant to the Offer is subject to various conditions set forth in Section 15 – “Conditions of the Offer,” including, among other conditions, the Minimum Condition. The “Minimum Condition” means that the number of Shares validly tendered and not validly withdrawn (excluding Shares tendered pursuant to guaranteed delivery procedures that have not yet been “received” (as such term is defined in Section 251(h)(6)(f) of the DGCL)), together with any Shares beneficially owned by Parent or any of its wholly owned subsidiaries (including Purchaser), represents one more than 50% of the total number of Shares outstanding at the time of the expiration of the Offer.

How long do I have to decide whether to tender my Shares in the Offer?

You will have until one minute following 11:59 P.M., Eastern Time, on the Expiration Date (the “Offer Expiration Time”) to tender your Shares in the Offer. The term “Expiration Date” means May 23, 2022, unless the expiration of the Offer is extended to a subsequent date in accordance with the terms of the Merger Agreement, in which event the term “Expiration Date” means such subsequent date. In addition, if, pursuant to the Merger Agreement, we decide to, or are required to, extend the Offer as described below, you will have an additional opportunity to tender your Shares.

If you hold your Shares in street name through a broker, dealer, commercial bank, trust company or other nominee, your nominee may have an earlier deadline to the Offer Expiration Time. You should contact the institution that holds your Shares for more details.

See Section 1 – “Terms of the Offer” and Section 3 – “Procedures for Accepting the Offer and Tendering Shares.”

Can the Offer be extended and under what circumstances?

Yes. The Merger Agreement provides that, subject to the parties’ respective termination rights in the Merger Agreement, (a) if, as of any then-scheduled Offer Expiration Time, any Offer Condition (as defined below) is not satisfied and has not been waived, Purchaser may, in its discretion (and without the consent of the Company or any other person), extend the Offer on one or more occasions, for an additional period of up to ten business days per extension, to permit such Offer Condition to be satisfied and (b) Purchaser will extend the Offer from time to time:

 

  (i)

for any period required by any legal requirement, any interpretation or position of the Securities and Exchange Commission (the “SEC”), the staff thereof or NASDAQ applicable to the Offer; and

 

  (ii)

for periods of up to ten business days per extension until the Regulatory Condition (as defined below in Section 15 – “Conditions of the Offer”) has been satisfied; and

(c) if, as of any then-scheduled Offer Expiration Time, the Minimum Condition or any of the other conditions to Purchaser’s obligation to accept for payment and pay for the Shares set forth on Annex I to the Merger Agreement and described below under Section 15 – “Conditions of the Offer” (the “Offer Conditions”) is not satisfied and has not been waived, Purchaser will (to the extent permitted under the Merger Agreement), at the request of the Company, extend the Offer on one or more occasions for an additional period of up to ten business days per extension, to permit such Offer Condition to be satisfied.

Purchaser will not be required to, and without the Company’s prior written consent, Purchaser will not, extend the Offer beyond the earlier to occur of (x) the valid termination of the Merger Agreement in accordance therewith and (y) the first business day immediately following the End Date. The “End Date” means October 12, 2022.

See Section 1 – “Terms of the Offer” and Section 11 – “The Merger Agreement; Other Agreements.”

 

viii


Will there be a subsequent offering period?

It is not expected that there will be, and the Merger Agreement does not provide for, a “subsequent offering period” in accordance with Rule 14d-11 under the Exchange Act.

See Section 1 – “Terms of the Offer.”

How will I be notified if the Offer is extended?

If we extend the Offer, we will inform Equiniti Trust Company, which is the depositary and paying agent for the Offer (the “Depositary”), of any extension, and will issue a press release announcing the extension no later than 9:00 a.m., Eastern Time, on the next business day after the previously scheduled Expiration Date.

See Section 1 – “Terms of the Offer.”

What are the most significant conditions to the Offer?

The obligation of Purchaser to accept for payment and pay for Shares validly tendered (and not validly withdrawn) pursuant to the Offer is subject to the satisfaction of a number of conditions by one minute following 11:59 P.M., Eastern Time, on the scheduled Expiration Date of the Offer, including, among other conditions:

 

   

the Minimum Condition;

 

   

the Regulatory Condition (as defined below in Section 15 – “Conditions of the Offer”) and the HSR Condition (as defined below in Section 15 – “Conditions of the Offer”);

 

   

the accuracy of the Company’s representations and warranties set forth in the Merger Agreement as of specified times, and the performance of the Company’s covenants set forth in the Merger Agreement, in each case, to specified standards of materiality; and

 

   

no Material Adverse Effect (as defined in Section 11 – “The Merger Agreement; Other Agreements) having occurred after April 12, 2022 that is continuing.

The above Offer Conditions are further described, and other Offer Conditions are described, below in Section 15 – “Conditions of the Offer.” The Offer is not subject to any financing condition.

How do I tender my Shares?

If you hold your Shares directly as the registered owner and such Shares are represented by stock certificates, you may tender your Shares in the Offer by delivering the certificates representing your Shares, together with a properly completed and signed Letter of Transmittal and any other documents required by the Letter of Transmittal, to the Depositary, not later than the Offer Expiration Time. If you hold your Shares as the registered owner and such Shares are represented by book-entry positions, you may follow the procedures for book-entry transfer set forth in Section 3 of this Offer to Purchase, not later than the Offer Expiration Time. The Letter of Transmittal is enclosed with this Offer to Purchase.

If you hold your Shares in street name through a broker, dealer, commercial bank, trust company or other nominee, you must contact the institution that holds your Shares and give instructions that your Shares be tendered. You should contact the institution that holds your Shares for more details.

We are not providing for guaranteed delivery procedures. Therefore, the Company stockholders must allow sufficient time for the necessary tender procedures to be completed during normal business hours of the Depository. In addition, for the Company stockholders who are registered holders, the Letter of Transmittal,

 

ix


properly completed and duly executed, together with any required signature guarantees (or in the case of a book-entry transfer, an Agent’s Message in lieu of the Letter of Transmittal) and any other documents required by the Letter of Transmittal must be received by the Depositary prior to one minute after 11:59 p.m., Eastern time, on the Expiration Date. The Company stockholders must tender their Shares in accordance with the procedures set forth in this Offer to Purchase and the Letter of Transmittal. Tenders received by the Depositary after the Expiration Date will be disregarded and of no effect.

See Section 3 – “Procedures for Accepting the Offer and Tendering Shares.”

If I accept the Offer, how will I get paid?

If the Offer Conditions are satisfied and we accept your validly tendered Shares for payment, payment will be made by deposit of the aggregate purchase price for the Shares accepted in the Offer with the Depositary, which will act as agent for tendering stockholders for the purpose of receiving payments from Purchaser and transmitting payments without interest and net of any withholding of taxes required by applicable legal requirements, to tendering stockholders whose Shares have been accepted for payment.

See Section 3 – “Procedures for Accepting the Offer and Tendering Shares.”

Until what time may I withdraw previously tendered Shares?

You may withdraw your previously tendered Shares at any time until one minute following 11:59 P.M., Eastern Time, on the Expiration Date. In addition, if we have not accepted your Shares for payment by the end of June 27, 2022, you may withdraw them at any time after that date until we accept your Shares for payment.

See Section 4 – “Withdrawal Rights.”

How do I withdraw previously tendered Shares?

To withdraw previously tendered Shares, you must deliver a written notice of withdrawal, or a facsimile of one, with the required information to the Depositary while you still have the right to withdraw Shares. If you tendered Shares by giving instructions to a broker, banker or other nominee, you must instruct the broker, banker or other nominee to arrange for the withdrawal of your Shares.

See Section 4 – “Withdrawal Rights.”

Has the Offer been approved by the Board of Directors of the Company?

Yes. The Company Board has unanimously: (i) determined that the Merger Agreement, the Offer and the Merger are fair to, and in the best interest of, the Company and its stockholders; (ii) declared that it is advisable for the Company to enter into the Merger Agreement; (iii) approved the execution, delivery and performance by the Company of the Merger Agreement and the consummation of the transactions contemplated by the Merger Agreement, including the Offer and the Merger; (iv) agreed that the Merger shall be effected under Section 251(h) of the DGCL; and (v) resolved to recommend that the Company’s stockholders accept the Offer and tender their Shares pursuant to the Offer.

More complete descriptions of the reasons for the Company Board’s recommendation and approval of the Offer and the Merger are set forth in the Company’s Solicitation/Recommendation Statement on Schedule 14D-9 (the “Schedule 14D-9”) that is being mailed to you together with this Offer to Purchase. Stockholders should carefully read the information set forth in the Schedule 14D-9 in its entirety, including the information set forth in Item 4 under the sub-headings “Background of Offer and Merger” and “Reasons for Recommendation.”

 

x


If Shares tendered pursuant to the Offer are purchased by Purchaser, will the Company continue as a public company?

No. We are required to complete the Merger at 8:00 a.m., Eastern Time, on the same date as the consummation of the Offer, unless otherwise agreed by the Company, Parent and Purchaser. Once the Merger takes place, the Company will be a wholly owned subsidiary of Parent. Following the Merger, we intend to cause the Shares to be delisted from NASDAQ and deregistered under the Exchange Act.

See Section 13 – “Certain Effects of the Offer.”

Will a meeting of the Company’s stockholders be required to approve the Merger?

No. Section 251(h) of the DGCL provides that, unless expressly required by its certificate of incorporation, no vote of stockholders will be necessary to authorize the merger of a constituent corporation whose shares are listed on a national securities exchange or held of record by more than 2,000 holders immediately prior to the execution of the applicable agreement of merger by such constituent corporation if, subject to certain statutory provisions:

 

   

the agreement of merger expressly permits or requires that the merger shall be effected by Section 251(h) of the DGCL and provides that such merger be effected as soon as practicable following the consummation of the tender offer;

 

   

an acquiring corporation consummates a tender offer for any and all of the outstanding stock of such constituent corporation that would be entitled to vote on the merger (other than any shares held by the constituent corporation, the corporation making such offer, any person that owns, directly or indirectly, all of the outstanding stock of the corporation making the offer, and any direct or indirect wholly owned subsidiaries of any of the foregoing);

 

   

following the consummation of the tender offer, the acquiring corporation owns at least such percentage of stock of such constituent corporation that, absent Section 251(h) of the DGCL, would otherwise be required to adopt the agreement of merger for such constituent corporation; and

 

   

each outstanding share of each class or series of stock of the constituent corporation that is the subject of and not irrevocably accepted for purchase in the offer is converted in such merger into the same consideration for their stock in the merger as was payable in the tender offer.

If the conditions to the Offer and the Merger are satisfied or waived (to the extent waivable), we are required by the Merger Agreement to effect the Merger pursuant to Section 251(h) of the DGCL without a meeting of the Company’s stockholders and without a vote or any further action by the stockholders.

If I do not tender my Shares but the Offer is consummated, what will happen to my Shares?

If the Offer is consummated and no court of competent jurisdiction in any jurisdiction in which Parent or the Company or any of their respective subsidiaries has any operations, assets or revenues has issued any injunction or order that prevents the consummation of the Merger, and no applicable law, order or other legal restraint, injunction or prohibition is in effect in any jurisdiction in which Parent or the Company or any of their respective subsidiaries has any operations, assets or revenues, that makes consummation of the Merger illegal or otherwise prohibited, Purchaser is required under the Merger Agreement to effect the Merger pursuant to Section 251(h) of the DGCL. At the effective time of the Merger (being such date and at such time as the certificate of merger in respect of the Merger has been duly filed with the Secretary of State of the State of Delaware or at such later time and date as may be agreed upon by the parties to the Merger Agreement in writing and specified in the certificate of merger in accordance with the DGCL, the “Effective Time”), all of the then issued and outstanding Shares (other than Shares (a) held by the Company (or in the Company’s treasury), Parent, any other direct or indirect wholly owned subsidiary of Parent (other than Purchaser) or by stockholders of the Company who have properly

 

xi


exercised and perfected their statutory rights of appraisal under Delaware law, or (b) irrevocably accepted by Purchaser for purchase in the Offer), will be converted in the Merger into the right to receive an amount equal to the Offer Price (without interest and subject to any withholding of taxes required by applicable legal requirements).

If the Merger is completed, the Company’s stockholders who do not tender their Shares in the Offer (other than stockholders who properly exercise appraisal rights) will receive the same amount of cash per Share that they would have received had they tendered their Shares in the Offer. Therefore, if the Offer is consummated and the Merger is completed, the only differences to you between tendering your Shares and not tendering your Shares in the Offer are that (i) you will be paid earlier if you tender your Shares in the Offer and (ii) appraisal rights will not be available to you if you tender Shares in the Offer, but will be available to you in the Merger if you do not tender Shares in the Offer and otherwise comply in all respects with the requirements for appraisal under Section 262 of the DGCL. See Section 17 – “Appraisal Rights.” However, in the unlikely event that the Offer is consummated but the Merger is not completed, the number of the Company’s stockholders and the number of Shares that are still in the hands of the public may be so small that there will no longer be an active public trading market (or, possibly, there may not be any public trading market) for the Shares. Also, in such event, it is possible that the Shares will be delisted from NASDAQ, and the Company will no longer be required to make filings with the SEC under the Exchange Act or will otherwise not be required to comply with the rules relating to publicly held companies to the same extent as it is now.

See the “Introduction” to this Offer to Purchase, Section 11 – “The Merger Agreement; Other Agreements” and Section 13 – “Certain Effects of the Offer.”

What will happen to my stock options, restricted stock units and performance stock units (if any) in the Offer and the Merger?

The Offer is being made only for Shares, and not for outstanding options to purchase Shares (each a “Company Option”), restricted stock units (“Company RSU”) or performance stock units (“Company PSU”) issued by the Company. Holders of outstanding vested but unexercised Company Options, Company RSUs or Company PSUs that have not yet been settled in Shares issued by the Company may participate in the Offer only if they first exercise such Company Options or are issued Shares in respect of such Company RSUs or Company PSUs in accordance with the terms of the applicable equity incentive plan and other applicable agreements of the Company and tender the Shares, if any, issued upon such exercise or in connection with such settlement. Any such exercise or settlement should be completed sufficiently in advance of the Expiration Date to assure the holder of such outstanding Company Options, Company RSUs or Company PSUs that the holder will have sufficient time to comply with the procedures for tendering Shares described below in Section 3 – “Procedures for Accepting the Offer and Tendering Shares.”

Each Company Option that is outstanding immediately prior to the Effective Time will, to the extent unvested, accelerate and become fully vested and exercisable effective prior to the Effective Time. As of the Effective Time, by virtue of the Merger, each Company Option that is outstanding and unexercised as of immediately prior to the Effective Time will be cancelled and converted into the right to receive cash in an amount, net of any applicable withholding taxes, equal to the product of (i) the total number of Shares subject to such Company Option immediately prior to the Effective Time, multiplied by (ii) the excess (if any) of (A) the Merger Consideration over (B) the exercise price payable per Share underlying such Company Option. Any Company Option that has an exercise price that equals or exceeds the Merger Consideration will be canceled as of the Effective Time for no consideration.

As of the Effective Time, by virtue of the Merger, each Company RSU that is outstanding as of immediately prior to the Effective Time will be canceled and automatically converted into the right to receive a cash payment equal to the product of (i) the number of Shares subject to the Company RSU and (ii) the Merger Consideration.

 

xii


Similarly, as of the Effective Time, by virtue of the Merger, each Company PSU that is outstanding as of immediately prior to the Effective Time will be canceled and automatically converted into the right to receive a cash payment equal to the product of (i) the number of Shares subject to the Company PSU (determined at the target level of performance) and (ii) the Merger Consideration.

See Section 11 – “The Merger Agreement; Other Agreements.” What is the market value of my Shares as of a recent date?

On April 12, 2022, the last full day of trading before we publicly announced the execution of the Merger Agreement, the reported closing sales price of the Shares on NASDAQ was $3.74 per Share. On April 25, 2022, the last full day of trading before commencement of the Offer, the reported closing sales price of the Shares on NASDAQ was $5.56 per Share. We encourage you to obtain current market quotations for Shares before deciding whether to tender your Shares.

See Section 6 – “Price Range of Shares; Dividends on the Shares.”

Have any stockholders already agreed to tender their Shares in the Offer or to otherwise support the Offer?

No. We have not previously entered into any agreements with any of the Company’s stockholders with respect to their tender of Shares into the Offer. The Company has informed us that (a) as of April 22, 2022, the executive officers and directors of the Company collectively beneficially owned, in the aggregate, 3,832,221 Shares (excluding Shares issuable upon exercise of Company Options, Company RSUs and Company PSUs) and (b) to the Company’s knowledge after making reasonable inquiry, each of the Company’s executive officers and directors currently intends to tender all of the Shares held of record or beneficially owned by such holder pursuant to the Offer.

Will I have appraisal rights in connection with the Offer?

No appraisal rights will be available to you in connection with the Offer. However, if Purchaser purchases Shares pursuant to the Offer, and the Merger is completed, holders of Shares immediately prior to the Effective Time who (i) did not tender their Shares in the Offer, (ii) follow the procedures set forth in Section 262 of the DGCL and (iii) do not thereafter lose such holders’ appraisal rights (by withdrawal, failure to perfect or otherwise), will be entitled to have their Shares appraised by the Delaware Court of Chancery and to receive payment of the “fair value” of such shares, exclusive of any element of value arising from the accomplishment or expectation of the Merger, together with interest, thereon. The “fair value” could be greater than, less than or the same as the Offer Price.

See Section 17 – “Appraisal Rights.”

Whom should I contact if I have questions about the Offer?

You may contact D.F. King & Co., Inc., the information agent for the Offer (the “Information Agent”), toll free at (888) 628-1041 or by email at ATRS@dfking.com. See the back cover of this Offer to Purchase for additional contact information.

 

xiii


INTRODUCTION

Atlas Merger Sub, Inc., a Delaware corporation (“Purchaser”) and a wholly owned subsidiary of Halozyme Therapeutics, Inc., a Delaware corporation (“Parent”), is offering to purchase all of the outstanding shares of common stock, par value $0.01 per share, (the “Shares”), of Antares Pharma, Inc., a Delaware corporation (the “Company”), at a purchase price of $5.60 per Share in cash (the “Offer Price”) without interest and subject to any withholding of taxes required by applicable legal requirements, upon the terms and subject to the conditions set forth in this Offer to Purchase and in the related letter of transmittal (the “Letter of Transmittal” which, together with this Offer to Purchase, as they may be amended or supplemented from time to time, collectively constitute the “Offer”).

The Offer is being made pursuant to an Agreement and Plan of Merger, dated as of April 12, 2022 (as it may be amended from time to time, the “Merger Agreement”), among the Company, Parent and Purchaser, pursuant to which, unless otherwise agreed by the Company, Parent and Purchaser, at 8:00 a.m., Eastern Time, on the same date as the consummation of the Offer and subject to the satisfaction or waiver of certain conditions, Purchaser will merge with and into the Company (the “Merger”) and the separate existence of Purchaser will cease and the Company will continue as the surviving corporation (the “Surviving Corporation”), upon the terms and subject to the conditions set forth in the Merger Agreement. The Merger will be governed by Section 251(h) of the General Corporation Law of the State of Delaware, as amended (the “DGCL”), and effected without a vote of the Company stockholders. In the Merger, each Share issued and outstanding immediately prior to the effective time of the Merger (being such date and time as the certificate of merger in respect of the Merger has been duly filed with the Secretary of State of the State of Delaware or at such later date and time as may be agreed upon by the parties to the Merger Agreement in writing and specified in the certificate of merger in accordance with the DGCL, the “Effective Time”) (other than Shares (a) held by the Company (or in the Company’s treasury), Parent, any other direct or indirect wholly owned subsidiary of Parent (other than Purchaser) or by stockholders of the Company who have properly exercised and perfected their statutory rights of appraisal under Delaware law, or (b) irrevocably accepted by Purchaser for purchase in the Offer) will be converted into the right to receive an amount in cash equal to the Offer Price, without interest and subject to any withholding of taxes required by applicable legal requirements. Under no circumstances will interest be paid on the purchase price for the Shares accepted for payment in the Offer, regardless of any extension of the Offer or any delay in making payment for the Shares. The Merger Agreement is more fully described in Section 11 – “The Merger Agreement; Other Agreements.”

Tendering stockholders who are the holders of record of their Shares and who tender directly to the Depositary (as defined above in the “Summary Term Sheet”) will not be obligated to pay brokerage fees or commissions or, as provided in Section 6 of the Letter of Transmittal, stock transfer taxes with respect to the purchase of Shares by Purchaser pursuant to the Offer. Stockholders who hold their Shares through a broker, banker or other nominee should consult such institution as to whether it charges any service fees or commissions.

The Company Board has unanimously: (i) determined that the Merger Agreement, the Offer and the Merger are fair to, and in the best interest of, the Company and its stockholders; (ii) declared that it is advisable for the Company to enter into the Merger Agreement; (iii) approved the execution, delivery and performance by the Company of the Merger Agreement and the consummation of the transactions contemplated by the Merger Agreement, including the Offer and the Merger; (iv) agreed that the Merger shall be effected under Section 251(h) of the DGCL; and (v) resolved to recommend that the Company’s stockholders accept the Offer and tender their Shares pursuant to the Offer.

More complete descriptions of the Company Board’s reasons for recommending that the Company’s stockholders accept the Offer and tender their Shares to Purchaser pursuant to the Offer, and for authorizing and approving the Merger Agreement and the transactions contemplated thereby, including the Offer and the Merger (the “Transactions”), are set forth in the Company’s Solicitation/Recommendation Statement on the Schedule 14D-9 (the “Schedule 14D-9”) that is being mailed to you together with this Offer to Purchase.


Stockholders should carefully read the information set forth in the Schedule 14D-9 in its entirety, including the information set forth in Item 4 under the sub-headings “Background of Offer and Merger” and “Reasons for Recommendation.”

The obligation of Purchaser to accept for payment and pay for Shares validly tendered (and not validly withdrawn) pursuant to the Offer is subject to the satisfaction of, among other conditions: (i) the Minimum Condition and (ii) the Regulatory Condition (as defined below in Section 15 – “Conditions of the Offer”) and (iii) the HSR Condition (as defined below in Section 15 – “Conditions of the Offer”). The “Minimum Condition” means that the number of Shares validly tendered and not validly withdrawn together with any Shares owned by Parent or any of its wholly owned subsidiaries (including Purchaser), (but excluding Shares tendered pursuant to guaranteed delivery procedures that have not yet been “received” (as such term is defined in Section 251(h)(6)(f) of the DGCL)), represents one more than 50% of the total number of Shares outstanding at the time of the expiration of the Offer. The Offer also is subject to other conditions set forth in this Offer to Purchase. See Section 15 – “Conditions of the Offer.” There is no financing condition to the Offer.

THIS OFFER TO PURCHASE AND THE RELATED LETTER OF TRANSMITTAL CONTAIN IMPORTANT INFORMATION THAT SHOULD BE READ CAREFULLY IN ITS ENTIRETY BEFORE ANY DECISION IS MADE WITH RESPECT TO THE OFFER.

 

2


THE TENDER OFFER

 

1.

Terms of the Offer

Purchaser is offering to purchase all of the outstanding Shares at the Offer Price in cash (the “Merger Consideration”) without interest and subject to any withholding of taxes required by applicable legal requirements, upon the terms and subject to the conditions set forth in the Offer. Upon the terms and subject to the conditions of the Offer (including, if the Offer is extended or amended, the terms and conditions of such extension or amendment), we will accept for payment and, promptly after the Expiration Date pay for, all Shares validly tendered prior to one minute following 11:59 P.M., Eastern Time, on the Expiration Date (the “Offer Expiration Time”) and not validly withdrawn as described in Section 4 – “Withdrawal Rights.” The term “Expiration Date” means May 23, 2022, unless the expiration of the Offer is extended to a subsequent date in accordance with the terms of the Merger Agreement, in which event the term “Expiration Date” means such subsequent date.

The Offer is conditioned upon, among other things, the satisfaction of the Minimum Condition and the other conditions described in Section 15 – “Conditions of the Offer.”

The Merger Agreement provides that, subject to the parties’ respective termination rights in the Merger Agreement, (a) if, as of any then-scheduled Offer Expiration Time, any Offer Condition (as defined below) is not satisfied and has not been waived, Purchaser may, in its discretion (and without the consent of the Company or any other person), extend the Offer on one or more occasions, for an additional period of up to ten business days per extension, to permit such Offer Condition to be satisfied and (b) Purchaser will extend the Offer from time to time:

 

  (iii)

for any period required by any legal requirement, any interpretation or position of the Securities and Exchange Commission (the “SEC”), the staff thereof or NASDAQ applicable to the Offer; and

 

  (iv)

for periods of up to ten business days per extension until the Regulatory Condition (as defined below in Section 15 – “Conditions of the Offer”) has been satisfied; and

(c) if, as of any then-scheduled Offer Expiration Time, the Minimum Condition or any of the other conditions to Purchaser’s obligation to accept for payment and pay for the Shares set forth on Annex I to the Merger Agreement and described below under Section 15 – “Conditions of the Offer” (the “Offer Conditions”) is not satisfied and has not been waived, Purchaser will (to the extent permitted under the Merger Agreement), at the request of the Company, extend the Offer on one or more occasions for an additional period of up to ten business days per extension, to permit such Offer Condition to be satisfied.

Purchaser will not be required to, and without the Company’s prior written consent, Purchaser will not, extend the Offer beyond the earlier to occur of (x) the valid termination of the Merger Agreement in accordance therewith and (y) the first business day immediately following the End Date. The “End Date” means October 12, 2022.

See Section 11 – “The Merger Agreement; Other Agreements – Termination of the Merger Agreement.”

If we extend the Offer, are delayed in our acceptance for payment of or payment for Shares or are unable to accept Shares for payment pursuant to the Offer for any reason, then, without prejudice to our rights under the Offer, the Depositary may retain tendered Shares on our behalf, and such Shares may not be withdrawn except to the extent that tendering stockholders are entitled to withdrawal rights as described in Section 4 – “Withdrawal Rights.” However, our ability to delay the payment for Shares that we have accepted for payment is subject to any applicable rules and regulations of the SEC, including Rule 14e-1(c) under the Exchange Act, which requires us to pay the consideration offered or return the securities deposited by or on behalf of stockholders promptly after the termination or withdrawal of the Offer.

 

3


Subject to the terms of the Merger Agreement and the applicable rules and regulations of the SEC and other applicable laws and regulations, we expressly reserve the right to waive any Offer Condition to increase the Offer Price and to make any other changes in the terms and conditions of the Offer and inconsistent with the terms of the Merger Agreement. Any extension, delay, termination or amendment of the Offer will be followed as promptly as practicable by a public announcement thereof, and such announcement, in the case of an extension, will be made no later than 9:00 a.m., New York City Time, on the next business day after the previously scheduled Expiration Date. Without limiting the manner in which we may choose to make any public announcement, we intend to make announcements regarding the Offer by issuing a press release and making any appropriate filing with the SEC.

If, subject to the terms of the Merger Agreement, we make a material change in the terms of the Offer or the information concerning the Offer or if we waive a material condition of the Offer, we will disseminate additional tender offer materials and extend the Offer, in each case, if and to the extent required by Rules 14d-3(b)(1), 14d-4(d), 14d-6(c) and 14e-1 under the Exchange Act. The minimum period during which the Offer must remain open following material changes in the terms of the Offer or information concerning the Offer, other than a change in price or a change in percentage of securities sought, will depend upon the facts and circumstances, including the relative materiality of the terms or information changes. In the SEC’s view, an offer should remain open for a minimum of five (5) business days from the date the material change is first published, sent or given to holders of Shares, and with respect to a change in price or a change in the percentage of securities sought, a minimum ten (10) business day period generally is required to allow for adequate dissemination to holders of Shares and investor response.

If, on or before the Expiration Date, we increase the consideration being paid for Shares accepted for payment in the Offer, such increased consideration will be paid to all holders whose Shares are purchased in the Offer, whether or not such Shares were tendered before the announcement of the increase in consideration.

The obligation of Purchaser to accept for payment and pay for Shares validly tendered (and not validly withdrawn) pursuant to the Offer is subject to the satisfaction of the Offer Conditions. Notwithstanding any other provision of the Offer or the Merger Agreement to the contrary, Purchaser shall not be required to accept for payment or (subject to any applicable rules and regulations of the SEC, including Rule 14e-1(c) under the Exchange Act) pay for, and may delay the acceptance for payment or (subject to any such rules and regulations) the payment for, any tendered Shares, and may terminate or amend the Offer, in accordance with and subject to the terms of the Merger Agreement, if any of the Offer Conditions has not been satisfied at the Offer Expiration Time. Under certain circumstances described in the Merger Agreement, we also may terminate the Merger Agreement.

The Company has provided us with its stockholder list and security position listings for the purpose of disseminating the Offer to holders of Shares. This Offer to Purchase and the related Letter of Transmittal, as well as the Schedule 14D-9, will be mailed to record holders of Shares whose names appear on the stockholder list and will be furnished for subsequent transmittal to beneficial owners of Shares to brokers, dealers, commercial banks, trust companies and similar persons whose names, or the names of whose nominees, appear on the stockholder list or, if applicable, who are listed as participants in a clearing agency’s security position listing for subsequent transmittal to beneficial owners of Shares.

 

2.

Acceptance for Payment and Payment for Shares

Subject to the terms of the Offer and the Merger Agreement and the satisfaction or waiver of the Offer Conditions set forth in Section 15 – “Conditions of the Offer,” we will accept for payment and pay for all Shares validly tendered and not validly withdrawn pursuant to the Offer as promptly as practicable (and in any event within three business days) after the Offer Acceptance Time. Subject to any applicable rules and regulations of the SEC, including Rule 14e-1(c) promulgated under the Exchange Act, we expressly reserve the right to delay payment for Shares in order to comply in whole or in part with any applicable law or regulation. See Section 16 – “Certain Legal Matters; Regulatory Approvals.”

 

4


In the case of certificated Shares, we will pay for Shares accepted for payment pursuant to the Offer only after timely receipt by the Depositary of (i) the certificates evidencing such Shares (the “Share Certificates”) pursuant to the procedures set forth in Section 3 – “Procedures for Tendering Shares,” (ii) the Letter of Transmittal (or a manually signed facsimile thereof), properly completed and duly executed, with any required signature guarantees and (iii) any other documents required by the Letter of Transmittal.

In the case of book-entry Shares, we will pay for Shares accepted for payment pursuant to the Offer only after timely receipt by the Depositary of (i) confirmation of a book-entry transfer of such Shares into the Depositary’s account at The Depository Trust Company (“DTC”) (such a confirmation, a “Book-Entry Confirmation”) pursuant to the procedures set forth in Section 3 – “Procedures for Tendering Shares,” (ii) the Letter of Transmittal (or a manually signed facsimile thereof), properly completed and duly executed, with any required signature guarantees and (iii) any other documents required by the Letter of Transmittal; or, in the case of a book-entry transfer, an Agent’s Message in lieu of the Letter of Transmittal and such other documents. The term “Agent’s Message” means a message, transmitted through electronic means by DTC in accordance with the normal procedures of DTC to, and received by, the Depositary and forming part of a Book-Entry Confirmation, that states that DTC has received an express acknowledgment from the participant in DTC tendering the Shares that are the subject of such Book-Entry Confirmation that such participant has received and agrees to be bound by the terms of, the Letter of Transmittal, and that Purchaser may enforce such agreement against such participant. The term “Agent’s Message” also includes any hard copy printout evidencing such message generated by a computer terminal maintained at the Depositary’s office.

For purposes of the Offer, we will be deemed to have accepted for payment, and thereby purchased, Shares validly tendered to Purchaser and not validly withdrawn as, if and when we give oral or written notice to the Depositary of our acceptance for payment of such Shares pursuant to the Offer. Upon the terms and subject to the conditions of the Offer, payment for Shares accepted for payment pursuant to the Offer will be made by deposit of the Offer Price for such Shares with the Depositary, which will act as agent for tendering stockholders for the purpose of receiving payments from us and transmitting such payments to tendering stockholders whose Shares have been accepted for payment. If we extend the Offer, are delayed in our acceptance for payment of or payment for Shares or are unable to accept Shares for payment pursuant to the Offer for any reason, then, without prejudice to our rights under the Offer, the Depositary may retain tendered Shares on our behalf, and such Shares may not be withdrawn except to the extent that tendering stockholders are entitled to withdrawal rights as described in Section 4 – “Withdrawal Rights.” Under no circumstances will interest be paid on the purchase price for the Shares accepted for payment in the Offer, regardless of any extension of the Offer or any delay in making payment for the Shares.

If any tendered Shares are not accepted for payment pursuant to the terms and conditions of the Offer for any reason, or if Share Certificates are submitted evidencing more Shares than are tendered, Share Certificates representing unpurchased shares will be returned, without expense to the tendering stockholder (or, in the case of Shares tendered by book-entry transfer into the Depositary’s account at DTC pursuant to the procedure set forth in Section 3 – “Procedures for Accepting the Offer and Tendering Shares,” such Shares will be credited to an account maintained at DTC), promptly following the expiration or termination of the Offer.

 

3.

Procedures for Accepting the Offer and Tendering Shares

Valid Tenders. In order for a stockholder to validly tender Shares pursuant to the Offer the Letter of Transmittal (or a manually signed facsimile thereof), properly completed and duly executed, together with any required signature guarantees (or, in the case of a book-entry transfer, an Agent’s Message in lieu of the Letter of Transmittal) and any other documents required by the Letter of Transmittal must be received by the Depositary at one of its addresses set forth on the back cover of this Offer to Purchase and either (i) the Share Certificates evidencing tendered Shares must be received by the Depositary at such address or (ii) such Shares must be tendered pursuant to the procedure for book-entry transfer described below under “Book-Entry Transfer” and a Book-Entry Confirmation must be received by the Depositary, in each case prior to the Offer Expiration Time.

 

5


Book-Entry Transfer. The Depositary will establish an account with respect to the Shares at DTC for purposes of the Offer. Any financial institution that is a participant in the system of DTC may make a book-entry delivery of Shares by causing DTC to transfer such Shares into the Depositary’s account at DTC in accordance with DTC’s procedures for such transfer. However, although delivery of Shares may be effected through book-entry transfer at DTC, either the Letter of Transmittal (or a manually signed facsimile thereof), properly completed and duly executed, together with any required signature guarantees, or an Agent’s Message in lieu of the Letter of Transmittal, and any other required documents, must, in any case, be received by the Depositary at one of its addresses set forth on the back cover of this Offer to Purchase prior to the Offer Expiration Time. Delivery of documents to DTC does not constitute delivery to the Depositary.

No Guaranteed Delivery. We are not providing for guaranteed delivery procedures. Therefore, the Company stockholders must allow sufficient time for the necessary tender procedures to be completed during normal business hours of The Depository Trust Company. In addition, for the Company stockholders who are registered holders, the Letter of Transmittal, properly completed and duly executed, together with any required signature guarantees and any other documents required by the Letter of Transmittal (or in the case of a book-entry transfer, an Agent’s Message in lieu of the Letter of Transmittal and such other documents) must be received by the Depositary prior to one minute after 11:59 p.m., Eastern time, on the Expiration Date. The Company stockholders must tender their Shares in accordance with the procedures set forth in this Offer to Purchase and the Letter of Transmittal. Tenders received by the Depositary after the Expiration Date will be disregarded and be of no effect.

Signature Guarantees for Shares. No signature guarantee is required on the Letter of Transmittal; (i) if the Letter of Transmittal is signed by the registered holder(s) (which term, for purposes of this Section 3, includes any participant in DTC’s systems whose name appears on a security position listing as the owner of the Shares) of the Shares tendered therewith, unless such holder or holders have completed either the box entitled “Special Delivery Instructions” or the box entitled “Special Payment Instructions” on the Letter of Transmittal or (ii) if the Shares are tendered for the account of a financial institution (including most commercial banks, savings and loan associations and brokerage houses) that is a member in good standing of the Security Transfer Agents Medallion Program or any other “eligible guarantor institution,” as such term is defined in Rule 17Ad-15 of the Exchange Act (each an “Eligible Institution” and collectively “Eligible Institutions”). In all other cases, all signatures on a Letter of Transmittal must be guaranteed by an Eligible Institution. See Instruction 1 of the Letter of Transmittal. If a Share Certificate is registered in the name of a person or persons other than the signers of the Letter of Transmittal, or if payment is to be made or delivered to, or a Share Certificate not accepted for payment or not tendered is to be issued in, the name(s) of a person or persons other than the registered holder(s), then the Share Certificate must be endorsed or accompanied by appropriate duly executed stock powers, in either case signed exactly as the name(s) of the registered holder(s) appear on the Share Certificate, with the signature(s) on such Share Certificate or stock powers guaranteed by an Eligible Institution as provided in the Letter of Transmittal. See Instructions 1 and 5 of the Letter of Transmittal.

Notwithstanding any other provision of the Merger Agreement or this Offer, payment for Shares accepted for payment pursuant to the Offer will in all cases only be made after timely receipt by the Depositary of (i) certificates evidencing such Shares or a Book-Entry Confirmation of a book-entry transfer of such Shares into the Depositary’s account at DTC pursuant to the procedures set forth in this Section 3, (ii) the Letter of Transmittal (or a manually signed facsimile thereof), properly completed and duly executed, with any required signature guarantees and (iii) any other documents required by the Letter of Transmittal or, in the case of a book-entry transfer, an Agent’s Message in lieu of the Letter of Transmittal and such other documents. Accordingly, tendering stockholders may be paid at different times depending upon when the Share Certificates and Letter of Transmittal, or Book-Entry Confirmations and Agent’s Message, in each case, with respect to Shares are actually received by the Depositary.

THE METHOD OF DELIVERY OF THE SHARES (OR SHARE CERTIFICATES), THE LETTER OF TRANSMITTAL AND ALL OTHER REQUIRED DOCUMENTS, INCLUDING DELIVERY

 

6


THROUGH DTC, IS AT THE ELECTION AND RISK OF THE TENDERING STOCKHOLDER. DELIVERY OF THE SHARES (OR SHARE CERTIFICATES), THE LETTER OF TRANSMITTAL AND ALL OTHER REQUIRED DOCUMENTS WILL BE DEEMED MADE, AND RISK OF LOSS THEREOF SHALL PASS, ONLY WHEN THEY ARE ACTUALLY RECEIVED BY THE DEPOSITARY (INCLUDING, IN THE CASE OF A BOOK-ENTRY TRANSFER OF SHARES, BY BOOK-ENTRY CONFIRMATION WITH RESPECT TO SUCH SHARES). IF SUCH DELIVERY IS BY MAIL, IT IS RECOMMENDED THAT THE SHARES (OR SHARE CERTIFICATES), THE LETTER OF TRANSMITTAL AND ALL OTHER REQUIRED DOCUMENTS BE SENT BY PROPERLY INSURED REGISTERED MAIL WITH RETURN RECEIPT REQUESTED. IN ALL CASES, SUFFICIENT TIME SHOULD BE ALLOWED TO ENSURE TIMELY DELIVERY.

Tender Constitutes Binding Agreement. The tender of Shares pursuant to any one of the procedures described above will constitute the tendering stockholder’s acceptance of the Offer, as well as the tendering stockholder’s representation and warranty that such stockholder has the full power and authority to tender and assign the Shares tendered, as specified in the Letter of Transmittal. Our acceptance for payment of Shares tendered pursuant to the Offer will constitute a binding agreement between the tendering stockholder and us upon the terms and subject to the conditions of the Offer.

Determination of Validity. Purchaser will determine, in its sole discretion, all questions as to the form and validity (including time of receipt) of any notice of withdrawal, and such determination will be final and binding to the fullest extent permitted by law, subject to the rights of holders of Shares to challenge such determination with respect to their Shares in a court of competent jurisdiction. We reserve the absolute right to reject any and all tenders determined by us not to be in proper form or the acceptance for payment of which may, in our opinion, be unlawful. We also reserve the absolute right to waive any defect or irregularity in the tender of any Shares of any particular stockholder, whether or not similar defects or irregularities are waived in the case of other stockholders. No tender of Shares will be deemed to have been validly made until all defects and irregularities have been cured or waived to our satisfaction. None of Purchaser, Parent or any of their respective affiliates or assigns, the Depositary, the Information Agent or any other person will be under any duty to give notification of any defects or irregularities in tenders or incur any liability for failure to give any such notification. Subject to applicable law as applied by a court of competent jurisdiction, the terms of the Merger Agreement and the rights of holders of Shares to challenge such interpretation with respect to their Shares in a court of competent jurisdiction, our interpretation of the terms and conditions of the Offer (including the Letter of Transmittal and the instructions thereto) will be final and binding.

Appointment as Proxy. By executing the Letter of Transmittal as set forth above, the tendering stockholder will irrevocably appoint designees of Purchaser as such stockholder’s attorneys-in-fact and proxies in the manner set forth in the Letter of Transmittal, each with full power of substitution, to the full extent of such stockholder’s rights with respect to the Shares tendered by such stockholder and accepted for payment by Purchaser and with respect to any and all other Shares or other securities or rights issued or issuable in respect of such Shares. All such powers of attorney and proxies will be considered irrevocable and coupled with an interest in the tendered Shares. Such appointment will be effective when, and only to the extent that, we accept for payment the Shares tendered by such stockholder as provided herein. Upon such appointment, all prior powers of attorney, proxies and consents given by such stockholder with respect to such Shares or other securities or rights will, without further action, be revoked and no subsequent powers of attorney, proxies, consents or revocations may be given by such stockholder (and, if given, will not be deemed effective). The designees of Purchaser will thereby be empowered to exercise all voting and other rights with respect to such Shares and other securities or rights, including, without limitation, in respect of any annual, special or adjourned meeting of the Company’s stockholders, actions by written consent in lieu of any such meeting or otherwise, as they in their sole discretion deem proper. We reserve the right to require that, in order for Shares to be deemed validly tendered, immediately upon our acceptance for payment of such Shares, Purchaser must be able to exercise full voting, consent and other rights with respect to such Shares and other related securities or rights, including voting at any meeting of stockholders of the Company.

 

7


Options, Restricted Stock Units and Performance Stock Units. The Offer is being made only for Shares, and not for outstanding Company Options, Company RSUs or Company PSUs issued by the Company. Holders of outstanding vested but unexercised Company Options, Company RSUs or Company PSUs that have not yet been settled in Shares issued by the Company may participate in the Offer only if they first exercise such Company Options or are issued Shares in respect of such Company RSUs or Company PSUs in accordance with the terms of the applicable equity incentive plan and other applicable agreements of the Company and tender the Shares, if any, issued upon such exercise or in connection with such settlement. Any such exercise or settlement should be completed sufficiently in advance of the Expiration Date to assure the holder of such outstanding Company Options, Company RSUs or Company PSUs that the holder will have sufficient time to comply with the procedures for tendering Shares described in this Section 3.

Each Company Option that is outstanding immediately prior to the Effective Time will, to the extent unvested, accelerate and become fully vested and exercisable effective prior to the Effective Time. As of the Effective Time, by virtue of the Merger, each Company Option that is outstanding and unexercised as of immediately prior to the Effective Time will be cancelled and converted into the right to receive cash in an amount, net of any applicable withholding taxes, equal to the product of (i) the total number of Shares subject to such Company Option immediately prior to the Effective Time, multiplied by (ii) the excess (if any) of (A) the Merger Consideration over (B) the exercise price payable per Share underlying such Company Option. Any Company Option that has an exercise price that equals or exceeds the Merger Consideration will be canceled as of the Effective Time for no consideration.

As of the Effective Time, by virtue of the Merger, each Company RSU that is outstanding as of immediately prior to the Effective Time will be canceled and automatically converted into the right to receive a cash payment equal to the product of (i) the number of Shares subject to the Company RSU and (ii) the Merger Consideration.

Similarly, as of the Effective Time, by virtue of the Merger, each Company PSU that is outstanding as of immediately prior to the Effective Time will be canceled and automatically converted into the right to receive a cash payment equal to the product of (i) the number of Shares subject to the Company PSU (determined at the target level of performance) and (ii) the Merger Consideration.

See Section 11 – “The Merger Agreement; Other Agreements” for additional information regarding the treatment of outstanding equity awards in the Merger.

Information Reporting and Backup Withholding. Payments made to stockholders of the Company in the Offer or the Merger generally will be subject to information reporting and may be subject to backup withholding of U.S. federal income tax on payments for Shares purchased in the Offer or exchanged in the Merger (currently at a rate of 24%). To avoid backup withholding, a U.S. stockholder or payee should complete and return the Internal Revenue Service (“IRS”) Form W-9 included in the Letter of Transmittal, listing such U.S. stockholder’s correct taxpayer identification number and certifying that such stockholder is a U.S. person, that the taxpayer identification number provided is correct, and that such stockholder is not subject to backup withholding. Failure to provide the information on the IRS Form W-9 may subject a U.S. stockholder to penalties and backup withholding on a payment pursuant to the Offer or the Merger for all Shares purchased from or exchanged by such stockholder. Certain stockholders or payees (including, among others, corporations, non-resident foreign individuals and foreign entities) are not subject to these backup withholding and reporting requirements. An exempt U.S. stockholder or payee should indicate its exempt status on IRS Form W-9. Any foreign stockholder or payee should submit an IRS Form W-8BEN or IRS Form W-8BEN-E (or other applicable IRS Form W-8) attesting to such stockholder’s foreign status in order to qualify for an exemption from information reporting and backup withholding. A domestic entity that is disregarded as an entity separate from its owner for U.S. federal income tax purposes and has a foreign owner that is treated as a separate entity for U.S. federal income tax purposes must use the appropriate IRS Form W-8, and not the IRS Form W-9. Information disclosed on an applicable IRS Form by a stockholder or payee may be disclosed to the local tax authorities of the foreign stockholder under an applicable tax treaty or an information exchange agreement. Backup withholding is not an

 

8


additional tax. Any amounts withheld under the backup withholding rules will generally be allowed as a credit against a stockholder’s U.S. federal income tax liability and may entitle the holder to a refund, provided the required information is timely furnished to the IRS. Each stockholder and payee should consult their tax advisors as to any qualification for exemption from backup withholding and the procedure for obtaining any such exemption.

 

4.

Withdrawal Rights

Except as otherwise provided in this Section 4, or as provided by applicable law, tenders of Shares made pursuant to the Offer are irrevocable.

Shares tendered pursuant to the Offer may be withdrawn at any time prior to the Offer Expiration Time. Thereafter, tenders are irrevocable, except that Shares tendered may also be withdrawn after June 27, 2022 if Purchaser has not accepted them for payment by the end of June 27, 2022.

For a withdrawal of Shares to be effective, the Depositary must timely receive a written or facsimile transmission notice of withdrawal at one of its addresses set forth on the back cover of this Offer to Purchase. Any notice of withdrawal must specify the name of the person who tendered the Shares to be withdrawn, the number of Shares to be withdrawn and the names in which the Share Certificates are registered, if different from that of the person who tendered such Shares. If Shares have been tendered pursuant to the procedures for book-entry transfer as set forth in Section 3 – “Procedures for Accepting the Offer and Tendering Shares,” any notice of withdrawal must specify the name and number of the account at DTC to be credited with the withdrawn Shares. If Share Certificates representing the Shares to be withdrawn have been delivered or otherwise identified to the Depositary, then, prior to the physical release of such Share Certificates, the name of the registered owners and the serial numbers shown on such Share Certificates must also be furnished to the Depositary.

Withdrawals of tenders of Shares may not be rescinded and any Shares validly withdrawn will be deemed not validly tendered for purposes of the Offer. Withdrawn Shares may, however, be retendered by following one of the procedures for tendering Shares described in Section 3 – “Procedures for Accepting the Offer and Tendering Shares” at any time prior to the Offer Expiration Time.

Purchaser will determine, in its sole discretion, all questions as to the form and validity (including time of receipt) of any notice of withdrawal. Subject to applicable law as applied by a court of competent jurisdiction and the terms of the Merger Agreement, such determination will be final and binding. No withdrawal of Shares shall be deemed to have been properly made until all defects and irregularities have been cured or waived. None of Purchaser, Parent or any of their respective affiliates or assigns, the Depositary, the Information Agent or any other person will be under any duty to give notification of any defects or irregularities in any notice of withdrawal or incur any liability for failure to give such notification.

 

5.

Certain U.S. Federal Income Tax Consequences of the Offer and the Merger

The following discussion is a summary of certain U.S. federal income tax consequences of the Offer and the Merger to stockholders of the Company whose Shares are tendered and accepted for payment pursuant to the Offer or whose Shares are converted into the right to receive cash in the Merger. This summary is for general information purposes only and does not purport to consider all aspects of U.S. federal income taxation that might be relevant to a stockholder of the Company in light of its particular circumstances. In addition, this summary does not describe any tax consequences arising under any applicable tax treaty. This summary is based on current provisions of the Internal Revenue Code of 1986, as amended (the “Code”), regulations promulgated thereunder and administrative and judicial interpretations thereof in effect as of the date of this Offer, all of which are subject to change, possibly with retroactive effect. Any such change could affect the accuracy of the statements and conclusions set forth in this discussion. We have not sought, and do not intend to seek, any ruling from the

 

9


IRS or any opinion of counsel with respect to the statements made and the conclusions reached in the following summary, and no assurance can be given that the IRS will agree with the views expressed herein, or that a court will not sustain any challenge by the IRS. The use of words such as “will” and “should” in any tax-related discussion contained in this summary is not intended to convey a particular level of comfort.

The summary applies only to stockholders of the Company in whose hands Shares are capital assets within the meaning of Section 1221 of the Code (generally, property held for investment). This summary does not address foreign, state or local tax consequences of the Offer or the Merger, nor does it address the U.S. federal income tax consequences of the transactions to special classes of taxpayers (e.g., stockholders that beneficially own (actually or constructively) more than 5% of the total fair market value of the Shares (except as specifically described below), small business investment companies, S corporations, regulated investment companies, real estate investment trusts, controlled foreign corporations, passive foreign investment companies, persons that accumulate earnings to avoid U.S. federal income tax, cooperatives, banks and certain other financial institutions, broker-dealers, insurance companies, mutual funds, tax-exempt organizations, governmental organizations, retirement plans or other tax-deferred accounts, stockholders that are, or hold Shares through, partnerships or other pass-through entities for U.S. federal income tax purposes, United States persons whose functional currency is not the United States dollar, dealers in securities or foreign currency, traders that mark-to-market their securities, entities subject to the U.S. anti-inversion rules, expatriates and former long-term residents of the United States, stockholders holding Shares that are part of a straddle, hedging, constructive sale, conversion or other integrated security transaction for U.S. federal income tax purposes, stockholders who properly exercise appraisal rights with respect to their Shares, stockholders who hold their Shares as “qualified small business stock” or “section 1244 stock,” and stockholders who received Shares in connection with the performance of services (including pursuant to the exercise of employee stock options, stock purchase rights or stock appreciation rights, as restricted stock or otherwise as compensation). In addition, this summary does not address U.S. federal taxes other than income taxes (including any U.S. federal estate or gift tax consequences), any aspect of the U.S. alternative minimum tax or Medicare tax on net investment income, or any state, local or foreign tax consequence, of the Offer and the Merger.

This discussion does not address the tax consequences of acquisitions or dispositions of Shares outside the Offer and the Merger, or transactions pertaining to Company Options that are canceled and converted or Company RSUs or Company PSUs that are converted into the right to receive cash, as the case may be, in connection with the Merger.

For purposes of this summary, the term “U.S. Holder” means a beneficial owner of Shares that, for U.S. federal income tax purposes, is or is treated as: (i) an individual who is a citizen or resident of the United States; (ii) a corporation, or an entity classified as a corporation for U.S. federal income tax purposes, created or organized under the laws of the United States, any state thereof or the District of Columbia; (iii) an estate, the income of which is subject to U.S. federal income tax regardless of its source; or (iv) a trust, if (A) a United States court is able to exercise primary supervision over the trust’s administration and one or more United States persons (within the meaning of Section 7701(a)(30) of the Code) have authority to control all of the trust’s substantial decisions or (B) the trust has a valid election in effect to be treated as a United States person for U.S. federal income tax purposes. This summary uses the term “Non-U.S. Holder” to mean a beneficial owner of Shares (other than a partnership or other entity or arrangement treated as a partnership for U.S. federal income tax purposes) that is not a U.S. Holder.

If a partnership, or another entity or arrangement treated as a partnership for U.S. federal income tax purposes, is a beneficial owner of Shares, the tax treatment of its partners or members generally will depend upon the status of the partner or member and the partnership’s activities. Accordingly, partnerships or other entities treated as partnerships for U.S. federal income tax purposes that are beneficial owners of Shares, and partners or members in those entities, are urged to consult their tax advisors regarding the U.S. federal income tax consequences to them of the Offer and the Merger.

 

10


Tax Consequences to U.S. Holders. The exchange of Shares for cash pursuant to the Offer or the Merger will be a taxable transaction to U.S. Holders for U.S. federal income tax purposes. In general, a U.S. Holder who sells Shares pursuant to the Offer or receives cash in exchange for Shares pursuant to the Merger will recognize capital gain or loss for U.S. federal income tax purposes in an amount equal to the difference, if any, between (i) the amount of cash received (determined before the deduction of withholding taxes, if any) and (ii) the U.S. Holder’s adjusted tax basis in the Shares sold pursuant to the Offer or exchanged for cash pursuant to the Merger. A U.S. Holder’s adjusted tax basis generally will equal the amount that such U.S. Holder paid for the Shares. Gain or loss will be determined separately for each block of Shares (that is, Shares acquired at the same cost in a single transaction) sold pursuant to the Offer or exchanged for cash pursuant to the Merger. Such gain or loss will generally be long-term capital gain or loss, provided that the holding period for such block of Shares is more than one year at the time of consummation of the Offer or the Merger, as the case may be. Long-term capital gain recognized by certain non-corporate U.S. Holders is generally subject to U.S. federal income tax at preferential rates. The deductibility of capital losses by a U.S. Holder is subject to certain limitations.

Tax Consequences to Non-U.S. Holders. Generally, the exchange of Shares for cash pursuant to the Offer or the Merger will not be a taxable transaction to Non-U.S. Holders for U.S. federal income tax purposes, unless: (i) the Non-U.S. Holder is an individual who was present in the United States for 183 days or more during the taxable year of the Offer or the Merger, as the case may be, and certain other conditions are met; (ii) the gain is effectively connected with the Non-U.S. Holder’s conduct of a trade or business in the United States and, if required by an applicable tax treaty, attributable to a permanent establishment maintained by the Non-U.S. Holder in the United States; or (iii) the Company is or has been a United States real property holding corporation, or “USRPHC,” for U.S. federal income tax purposes at any time within the shorter of the Non-U.S. Holder’s holding period and the five-year period preceding the Offer or the Merger, as the case may be, and, if the Shares are “regularly traded on an established securities market” (“regularly traded”), the Non-U.S. Holder owned (directly, indirectly or constructively) more than 5% of the Shares at any time within such period, and certain other conditions are satisfied.

In the case of clause (i) of the preceding paragraph, gain generally will be subject to tax at a flat rate of 30% (or such lower rate as may be specified under an applicable income tax treaty), which may be offset by certain U.S.-source capital losses of the Non-U.S. Holder (even though the individual is not considered a resident of the United States). In the case of clause (ii) of the preceding paragraph, unless a tax treaty provides otherwise, gain will be subject to U.S. federal income tax on a net basis at the rates generally applicable to a U.S. Holder (and such Non-U.S. Holder should generally provide an IRS Form W-8ECI). A Non-U.S. Holder that is a foreign corporation also may be subject to a 30% branch profits tax (or applicable lower treaty rate) with respect to gain recognized under clause (ii). In the case of clause (iii) of the preceding paragraph, so long as the Shares are considered to be regularly traded at any time during the calendar year, a Non-U.S. Holder generally will not be subject to tax on any gain recognized on the exchange of Shares pursuant to the Offer or the Merger, unless the Non-U.S. Holder owned (actually or constructively) more than 5% of the total outstanding Shares at any time during the applicable period described in clause (iii). Non-U.S. Holders that have actually or constructively owned more than 5% of the Shares should consult their tax advisors regarding the process for requesting documentation from the Company to establish whether the Company is, or has been at any time during the applicable period described in clause (iii), a USRPHC for U.S. federal income tax purposes and any consequences with respect thereto. A Non-U.S. Holder may, under certain circumstances, be subject to withholding in an amount equal to 15% of the gross proceeds on the sale or disposition of Shares. However, because we believe that the Shares are regularly traded, no withholding should be required under these rules upon the exchange of Shares pursuant to the Offer or the Merger. Non-U.S. Holders are urged to consult their tax advisors with respect to the particular U.S. federal, state, and local, or foreign tax consequences of the Offer and the Merger and the effect of any applicable tax treaties.

Information Reporting and Backup Withholding. Payments made to stockholders of the Company in the Offer or the Merger may be reported to the IRS. In addition, under U.S. federal income tax laws, backup withholding at the statutory rate (currently 24%) may apply to the amount paid to certain stockholders (who are not exempt

 

11


recipients) pursuant to the Offer or the Merger. To prevent such backup withholding, each stockholder who is a U.S. Holder and who does not otherwise establish an exemption from backup withholding must notify the Depositary or other applicable withholding agent of the stockholder’s taxpayer identification number (generally an employer identification number or social security number) and provide certain other information by completing, under penalty of perjury, an IRS Form W-9, a copy of which is included in the Letter of Transmittal. Failure to timely provide the correct taxpayer identification number on the IRS Form W-9 may subject the U.S. stockholder to penalties imposed by the IRS and backup withholding on any payment pursuant to the Offer or the Merger.

Certain exempt recipients (including, among others, corporations and certain non-U.S. Holders) are exempt from these backup withholding requirements (though U.S. corporations may be required to submit an IRS Form W-9 to establish such exemption). A domestic entity that is disregarded as an entity separate from its owner for U.S. federal income tax purposes and has a foreign owner that is treated as a separate entity for U.S. federal income tax purposes must use the appropriate IRS Form W-8, and not the IRS Form W-9. For a Non-U.S. Holder to demonstrate such an exemption from backup withholding, such Non-U.S. Holder must submit a statement (generally, an IRS Form W-8BEN or W-8BEN-E or other applicable IRS Form W-8), signed under penalty of perjury, attesting to such Non-U.S. Holder’s foreign status. A copy of the appropriate IRS Form W-8 may be obtained from the Depositary or from the IRS website (www.irs.gov).

Backup withholding is not an additional tax. Taxpayers may use amounts withheld as a credit against their U.S. federal income tax liability and may entitle the holder to a refund, provided the required information is timely furnished to the IRS.

Holders are urged to consult their tax advisors regarding the application of backup withholding to their particular circumstances and the availability of, and procedure for obtaining, an exemption from backup withholding.

The tax discussion set forth above is included for general information only and is not tax advice. You are urged to consult your tax advisor to determine the particular tax consequences to you of the Offer and the Merger, including the applicability and effect of U.S. federal, state, local, foreign and other tax laws and treaties. The U.S. federal income and other tax consequences to holders or beneficial owners of options or restricted stock units participating in the Offer or Merger with respect to such options or restricted stock units are not discussed herein and such holders or beneficial owners are strongly encouraged to consult their own tax advisors regarding such tax consequences.

 

6.

Price Range of Shares; Dividends on the Shares

The Shares currently trade on NASDAQ under the symbol “ATRS” The following table sets forth the high and low sale prices per Share for each quarterly period within the preceding fiscal year, as reported by NASDAQ:

 

     High      Low  

Fiscal Year Ending December 31, 2021

     

First Quarter

   $ 5.07      $ 3.78  

Second Quarter

   $ 4.49      $ 3.56  

Third Quarter

   $ 4.63      $ 3.55  

Fourth Quarter

   $ 3.94      $ 3.11  

Fiscal Year Ending December 31, 2022

     

First Quarter

   $ 4.18      $ 3.11  

On April 12, 2022, the last full day of trading before we publicly announced the execution of the Merger Agreement, the reported closing sales price of the Shares on NASDAQ was $3.74 per Share. On April 25, 2022, the last full day of trading before commencement of the Offer, the reported closing sales price of the Shares on NASDAQ was $5.56 per Share. Stockholders are urged to obtain current market quotations for the Shares.

 

12


The Company has not declared or paid dividends to date and does not anticipate doing so.

 

7.

Certain Information Concerning the Company

The summary information set forth below is qualified in its entirety by reference to the Company’s public filings with the SEC (which may be obtained and inspected as described below under “Additional Information”) and should be considered in conjunction with the financial and other information in such filings and other publicly available information regarding the Company. Neither Parent nor Purchaser has any knowledge that would indicate that any statements contained in this Offer to Purchase based on such filings and information is untrue. However, neither Parent nor Purchaser assumes any responsibility for the accuracy or completeness of the information concerning the Company, whether furnished by the Company or contained in such filings, or for any failure by the Company to disclose events that may have occurred or that may affect the significance or accuracy of any such information but which are unknown to Parent or Purchaser.

General. The Company was incorporated as a Delaware corporation on April 29, 2005 and is a specialty pharmaceutical company focused primarily on the development and commercialization of self-administered injectable pharmaceutical products and technologies using the Company’s advanced drug delivery systems. The address of the Company’s principal executive offices and the Company’s phone number at its principal executive offices are as set forth below:

Antares Pharma, Inc.

100 Princeton South, Suite 300

Ewing, New Jersey 08628

Telephone: (609) 359-3020

The information contained in the section titled “Price Range of Shares; Dividends on the Shares” is incorporated herein by reference.

Additional Information. The Shares are registered under the Exchange Act. Accordingly, the Company is subject to the information and reporting requirements of the Exchange Act and, in accordance therewith, is required to file periodic reports, proxy statements and other information with the SEC relating to its business, principal physical properties, capital structure, material pending litigation, operating results, financial condition, directors and officers (including their remuneration and stock options granted to them) and other matters. Information concerning the Company’s directors and officers, their compensation and stock options granted to them, the principal holders of the Company’s securities, any material interests of such persons in transactions with the Company and other matters will be available in the Schedule 14D-9. Such reports, proxy statements and other information are available for inspection at the SEC’s Public Reference Room at 100 F Street, N.E., Washington, D.C. 20549. Please call the SEC at 1-800-SEC-0330 for further information on the public reference room. Copies of such information may be obtainable by mail, upon payment of the SEC’s customary charges, by writing to the SEC at the address above. The SEC also maintains a web site on the Internet at http://www.sec.gov that contains reports, proxy statements and other information regarding registrants, including the Company, that file electronically with the SEC. The Company also maintains an Internet website at http://www.translate.bio. The information contained in, accessible from or connected to the Company’s website is not incorporated into, or otherwise a part of, this Offer to Purchase or any of the Company’s filings with the SEC. The website addresses referred to in this paragraph are inactive text references and are not intended to be actual links to the websites.

 

8.

Certain Information Concerning Parent, Purchaser and Certain Related Persons

Purchaser is a Delaware corporation and a direct wholly owned subsidiary of Parent, and was formed solely for the purpose of facilitating the acquisition of the Company. Purchaser has not carried on any activities to date, except for activities incidental to its formation and activities undertaken in connection with the Transactions.

 

13


Upon consummation of the Merger with and into the Company and the separate existence of Purchaser will cease and the Company will continue as the surviving corporation and a wholly owned subsidiary of Parent. The business address and business telephone number of Purchaser are as set forth below:

Atlas Merger Sub, Inc.

11388 Sorrento Valley Road

San Diego, California 92121

Telephone: (858) 794-8889

Parent is a Delaware corporation. Parent is a biopharma technology platform company that provides innovative and disruptive solutions with the goal of improving patient experience and outcomes. Parent licenses its technology to biopharmaceutical companies to collaboratively develop products that combine its ENHANZE® drug delivery technology with the collaborators’ proprietary compounds. The business address and business telephone number of Parent are as set forth below:

Halozyme Therapeutics, Inc.

11388 Sorrento Valley Road

San Diego, California 92121

Telephone: (858) 794-8889

The summary information set forth in this Section 8 is qualified in its entirety by reference to Parent’s public filings with the SEC (which may be obtained and inspected as described below under “Additional Information”) and should be considered in conjunction with the more comprehensive financial and other information in such filings and other publicly available information.

The name, business address, citizenship, current principal occupation or employment, and five-year employment history of each director and executive officer of Purchaser and Parent and certain other information are set forth in Schedule I to this Offer to Purchase.

During the last five years, none of Purchaser, Parent or, to the best knowledge and belief of Purchaser and Parent after due inquiry, any of the persons listed in Schedule I to this Offer to Purchase (i) has been convicted in a criminal proceeding (excluding traffic violations or similar misdemeanors) or (ii) was a party to any judicial or administrative proceeding (except for matters that were dismissed without sanction or settlement) that resulted in a judgment, decree or final order enjoining the person from future violations of, or prohibiting activities subject to, federal or state securities laws, or a finding of any violation of federal or state securities laws.

As of April 25, 2022, Parent does not beneficially own any Shares.

Except as set forth in Schedule I to, or elsewhere in, this Offer to Purchase: (i) none of Purchaser, Parent or, to the best knowledge and belief of Purchaser and Parent after due inquiry, the persons listed in Schedule I to this Offer to Purchase beneficially owns or has a right to acquire any Shares or any other equity securities of the Company; (ii) none of Purchaser, Parent or, to the best knowledge and belief of Purchaser and Parent after due inquiry, any of the other persons listed in Schedule I to this Offer to Purchase has effected any transaction with respect to the Shares or any other equity securities of the Company during the past 60 days; (iii) none of Purchaser, Parent or, to the best knowledge and belief of Purchaser and Parent after due inquiry, the persons listed in Schedule I to this Offer to Purchase has any contract, arrangement, understanding or relationship with any other person with respect to any securities of the Company (including any contract, arrangement, understanding or relationship concerning the transfer or the voting of any such securities, joint ventures, loan or option arrangements, puts or calls, guaranties of loans, guaranties against loss or the giving or withholding of proxies, consents or authorizations); (iv) during the two years before the date of this Offer to Purchase, there have been no transactions between any of Purchaser, Parent, their subsidiaries or, to the best knowledge and belief of Purchaser and Parent after due inquiry, any of the persons listed in Schedule I to this Offer to Purchase, on the one hand, and the Company or any of its executive officers, directors or affiliates, on the other hand, that

 

14


would require reporting under SEC rules and regulations; and (v) during the two years before the date of this Offer to Purchase, there have been no contracts, negotiations or transactions between Purchaser, Parent, their subsidiaries or, to the best knowledge and belief of Purchaser and Parent after due inquiry, any of the persons listed in Schedule I to this Offer to Purchase, on the one hand, and the Company or any of its affiliates, on the other hand, concerning a merger, consolidation or acquisition, a tender offer or other acquisition of securities, an election of directors or a sale or other transfer of a material amount of assets.

Additional Information. Pursuant to Rule 14d-3 under the Exchange Act, we have filed with the SEC a Tender Offer Statement on Schedule TO (the “Schedule TO”), of which this Offer to Purchase forms a part, and exhibits to the Schedule TO. The Schedule TO and the exhibits thereto, as well as other information filed by Parent and Purchaser with the SEC, are available for inspection at the SEC’s Public Reference Room at 100 F Street, N.E., Washington, D.C. 20549. Please call the SEC at 1-800-SEC-0330 for further information on the public reference room. Copies of such information may be obtainable by mail, upon payment of the SEC’s customary charges, by writing to the SEC at the address above. The SEC also maintains a web site on the Internet at www.sec.gov that contains the Schedule TO and the exhibits thereto and other information that Purchaser has filed electronically with the SEC. Parent also maintains an Internet website at https://halozyme.com/. The information contained in, accessible from or connected to Parent’s website is not incorporated into, or otherwise a part of, this Offer to Purchase or any of the Parent’s filings with the SEC. The website addresses referred to in this paragraph are inactive text references and are not intended to be actual links to the websites.

 

9.

Source and Amount of Funds

We estimate that we will need approximately $960 million to purchase all of the Shares pursuant to the Offer and to complete the Merger. Parent will provide us with sufficient funds to purchase all Shares validly tendered (and not validly withdrawn) in the Offer and to provide funding for the Merger. Purchaser will acquire these funds from Parent, which intends to provide the funds out of available cash on hand and newly obtained incremental financing pursuant to the Debt Commitment Letter.

The Offer is not conditioned upon Parent’s or Purchaser’s ability to finance the purchase of Shares pursuant to the Offer.

Substantially concurrent with the Effective Time, Parent or Purchaser will deposit, or will cause to be deposited, with the Depositary cash sufficient to make payment of the aggregate Offer Price and the aggregate Merger Consideration. We believe that the financial condition of Purchaser is not relevant to a decision by a holder of Shares whether to sell, hold or tender Shares in the Offer because:

 

   

the Offer is being made for all outstanding Shares solely for cash;

 

   

through Parent, we will have sufficient funds available to purchase all Shares validly tendered (and not validly withdrawn) in the Offer and, if we consummate the Offer, all Shares converted into the right to receive the Offer Price in the Merger; and

 

   

the Offer and the Merger are not subject to any financing or funding condition.

Debt Financing

Parent has received a Commitment Letter dated as of April 12, 2022 (the “Debt Commitment Letter”), pursuant to which Bank of America, N.A. and BofA Securities, Inc. (together, “BofA”) have committed to provide, subject to the terms and conditions of the Debt Commitment Letter, to Parent a $375 million senior secured term loan. BofA has also committed to approve, subject to the terms and conditions of the Debt Commitment Letter, an amendment to Parent’s existing revolving credit facility to permit the Merger and make other changes specified in the Debt Commitment Letter. In addition, in the event sufficient additional consents to amend the existing revolving credit facility are not received, BofA has committed to provide, subject to the terms and

 

15


conditions of the Debt Commitment Letter, a replacement $75 million revolving credit facility. The proceeds of the term loan, in addition to a portion of Parent’s existing cash on hand, would be used to pay the Merger Consideration, refinance the Company’s existing indebtedness and pay any fees and expenses in connection with any of the foregoing (such committed Debt Financing, collectively, the “Debt Financing”).

It is anticipated that the senior secured term loan will mature on November 30, 2026 and will call for amortization payments on a quarterly basis as set forth in the Debt Commitment Letter. The applicable interest rate on the senior secured term loan is anticipated to be a forward-looking term rate based on the secured overnight financing rate (“SOFR”) that has been selected or recommended by relevant governmental body, in each case as published on the information service as selected by BofA (“Term SOFR”) plus a Term SOFR adjustment, plus an interest margin ranging from 125 basis points to 225 basis points depending on a consolidated net leverage ratio pricing grid as set forth in the Debt Commitment Letter. The definitive financing documentation is also expected to include a base rate option. All overdue amounts will be payable at a rate of 200 basis points per annum above the otherwise applicable rate.

It is anticipated that voluntary prepayments of the senior secured term loan will be permitted at any time without premium or penalty in the minimum amounts equal to, in the case of Term SOFR loans, the lesser of $5 million and the amount outstanding and in integral multiples of $1 million over $5 million and, in the case of base rate loans, the lesser of $500,000 and the amount outstanding and in integral multiples of $100,000 over $500,000. It is further anticipated that the senior secured term loan will be subject to mandatory prepayment with (1) net cash proceeds from issuances of debt (other than certain permitted debt) and (2) net cash proceeds from certain non-ordinary course asset sales (subject to reinvestment rights and other exceptions).

The documentation governing the Debt Financing has not been finalized. Accordingly, the terms thereof are subject to change.

The funding of the Debt Financing, is subject to the following conditions:

 

   

execution and delivery of definitive financing documentation for the Debt Financing by Parent and each of the other parties party thereto;

 

   

the Merger shall have been consummated or substantially concurrently with the funding of the Debt Financing, on substantially the terms set forth in the Merger Agreement (subject to certain potential modifications deemed not materially adverse to the interests of the lenders as set forth in the Debt Commitment Letter or have not been approved by BofA);

 

   

the material accuracy of certain specified representations to the extent required by the limited conditionality provisions set forth in the Debt Commitment Letter (or if qualified by materiality or material adverse effect, the accuracy thereof);

 

   

BofA having received the pro forma financial statements and financial certificates of Parent and its subsidiaries;

 

   

the provision of applicable documentation under applicable “know your customer” and anti-money laundering rules and regulations, including without limitation the Patriot Act;

 

   

the payment, or arrangement for such payment substantially contemporaneously with the initial funding of the Debt Financing, of all fees and expenses required to be paid to by the Parent;

 

   

all documents and instruments required to be entered into or delivered to create and perfect the security interest of the collateral agent and the other secured parties have been executed and delivered;

 

   

the Closing Date shall not occur prior to May 12, 2022;

 

   

a Material Adverse Effect (as defined in the Merger Agreement) that has occurred since April 12, 2022 that is continuing; and

 

16


   

the refinancing associated with the Transactions shall have been consummated or will be consummated substantially concurrently with the closing of the Debt Financing.

The foregoing summary of certain provisions of the Debt Commitment Letter is qualified by reference to the Debt Commitment Letter itself, which is incorporated herein by reference. We have filed a copy of the Debt Commitment Letter as Exhibit (b)(1) to the Schedule TO.

 

10.

Background of the Offer; Past Contacts or Negotiations with the Company

The following is a description of contacts between representatives of Parent and representatives of the Company that resulted in the execution of the Merger Agreement and the other agreements related to the Offer. For a review of the Company’s activities relating to these contacts, please refer to the Schedule 14D-9.

Background of the Offer

Senior management and the board of directors of Parent regularly review Parent’s growth prospects and overall strategic direction and evaluate potential opportunities to strengthen Parent’s business and enhance value for its stockholders. From time to time, these reviews and evaluations have included potential opportunities for business combinations, partnerships, licensing arrangements and other strategic transactions.

On February 2, 2022, Helen Torley, President and Chief Executive Officer of Parent, contacted Robert Apple, President and Chief Executive Officer of the Company, expressing a desire to speak with Mr. Apple to discuss potential future strategic and business opportunities involving Parent and the Company. On February 3, 2022, Mr. Apple and Dr. Torley met by videoconference, during which meeting Dr. Torley expressed Parent’s interest in a potential acquisition of the Company. Mr. Apple advised Dr. Torley to submit any indication of interest in writing.

On February 7, 2022, Dr. Torley called Mr. Apple to express Parent’s continued interest in a potential acquisition of the Company and to advise Mr. Apple that she would be sending a non-binding proposal to acquire the Company. Later that day, Parent submitted a letter to the Company for a non-binding proposal to acquire all outstanding Shares at a purchase price of $4.90 per Share in cash, which proposal was subject to due diligence, entry into a merger agreement in a customary form for similar public company transactions with standard closing conditions (the “February 7 Proposal”).

The morning of February 9, 2022, Mr. Apple advised Dr. Torley that the Company Board was evaluating the February 7 Proposal.

On February 15, 2022, Mr. Apple spoke with Dr. Torley via telephone to indicate that the Company Board was considering the February 7 Proposal and that the Company believed it advisable for the parties to enter into a customary confidentiality agreement in order to engage in any discussions regarding Parent’s proposal. Following that discussion, on February 16, 2022, Peter Graham, Executive Vice President, General Counsel, Chief Compliance Officer and Secretary of the Company, sent Dr. Torley a draft confidentiality agreement that included a customary standstill provision. Between February 16, 2022 and February 18, 2022, Parent and the Company exchanged drafts of, and negotiated, the confidentiality agreement.

On February 18, 2022, the Company entered into a confidentiality agreement with Parent. Later that day, members of the Company’s senior management and Parent’s senior management met to discuss the Company’s business and operations. On February 23, 2022, the Company granted Parent access to limited due diligence materials in a virtual data room.

Beginning February 18, 2022 until March 17, 2022, members of the Company’s senior management responded to certain threshold due diligence requests from management and representatives of Parent.

 

17


On February 28, 2022, Dr. Torley called Mr. Apple to discuss a revised proposal to be sent by Parent to the Company. Later that day, Parent submitted a revised proposal to the Company to acquire all outstanding Shares at a purchase price of $5.20 per Share in cash, which proposal was subject to due diligence and entry into a 30-day exclusivity period (the “February 28 Proposal”). In the February 28 Proposal, Parent communicated that it expected to be in a position to execute a merger agreement within four weeks.

On March 8, 2022, Mr. Apple had a discussion with Dr. Torley regarding the February 28 Proposal and communicated that the February 28 Proposal was insufficient and did not provide a basis to grant exclusivity and Mr. Apple made a counterproposal of $5.75 per Share (the “Counterproposal”).

On March 13, 2022, Dr. Torley called Mr. Apple and informed him that she had discussed the Counterproposal with the board of directors of Parent and that Parent would be submitting an increased proposal to acquire all outstanding Shares at a purchase price of $5.60 per Share in cash. Mr. Apple informed Dr. Torley that he would discuss Parent’s revised proposal with the Company Board. Later that day, Dr. Torley sent to Mr. Apple a further revised non-binding proposal to acquire all outstanding Shares at a purchase price of $5.60 per Share in cash, subject to due diligence and entry into a 30-day exclusivity period (the “March 13 Proposal”). In the March 13 Proposal, Parent communicated that it expected to be in a position to execute a merger agreement within four weeks.

On March 15, 2022, at the direction of the Company Board, Mr. Apple sent Dr. Torley a draft exclusivity agreement. On March 16, 2022, Mark Snyder, General Counsel of Parent, sent Mr. Graham a revised draft of the exclusivity agreement. On March 17, 2022, following negotiation between the parties and their respective counsel, Parent and the Company executed the exclusivity agreement providing for a period of exclusivity until the earlier of April 11, 2022 or such time that Parent or any of its representatives initiated any discussion with the Company or its representatives regarding a reduction in the $5.60 per share price set forth in the March 13 Proposal.

On March 18, 2022, following entry into the exclusivity agreement, the Company granted Parent and its legal and financial advisors full access to due diligence materials through a virtual data room. In addition to their review of the virtual data room, Parent and its advisors requested and participated in calls and in-person meetings with the Company’s senior management and its representatives as part of Parent’s due diligence investigation. These due diligence calls and meetings and Parent’s confirmatory due diligence investigation continued through the execution of the Merger Agreement. Between March 23, 2022 and April 12, 2022, representatives of the Company, at the direction of the Company’s management, and representatives of Parent held due diligence calls on commercial, manufacturing, technical, clinical/regulatory, pharmacovigilance, information technology, financial, tax, cyber, human resources, litigation, general legal and patent/intellectual property topics.

On March 24, 2022, a representative of Weil, Gotshal & Manges LLP, counsel to Parent (“Weil”), sent representatives of Skadden, Arps, Slate, Meagher & Flom LLP (“Skadden”), transactional legal counsel to the Company, an initial draft of the Merger Agreement prepared by Weil. Between March 24, 2022 and April 12, 2022, Skadden and Weil conducted a number of conference calls and exchanged drafts of the Merger Agreement at the direction of Parent. Among other items, the parties negotiated the amount of the termination fee payable in the event the Company terminated the Merger Agreement to accept a Superior Offer (as defined in the Merger Agreement) and other circumstances in which such fee would be payable, the treatment of outstanding Company equity awards in the proposed transaction and the treatment of equity incentive awards that would otherwise have been granted in June 2022 in the ordinary course.

On March 29, 2022 and March 30, 2022, representatives of the Company’s and Parent’s management met in Minnetonka, Minnesota for a number of in-person meetings, including question and answer sessions with Company’s management. Mr. Apple and Dr. Torley also separately discussed the treatment of outstanding Company equity awards in the proposed transaction and the treatment of equity incentive awards that otherwise would have been granted in June 2022 in the ordinary course.

 

18


On April 5, 2022, Morgan, Lewis & Bockius LLP, corporate counsel to the Company, and Skadden provided Weil with an initial draft of the Company’s disclosure schedules. During the period from April 5, 2022 through April 12, 2022, Skadden and Weil discussed and exchanged drafts of the disclosure schedules and other transaction documents at the direction of the Company.

On April 6, 2022, representatives of the Company’s financial advisor spoke with representatives of Parent’s financial advisor to discuss the status of Parent’s remaining due diligence review and targeted date for execution of a definitive merger agreement.

On April 8, 2022, Mr. Apple and Dr. Torley participated in discussions regarding the treatment of the Company’s outstanding incentive equity awards and the ability of the Company to make ordinary course annual incentive equity awards (or comparable incentive awards) prior to closing. On April 9, 2022, Mr. Apple participated in additional discussions with Dr. Torley regarding the treatment of incentive equity in the Company and Parent’s site visits. On April 10, 2022, Dr. Torley called Mr. Apple and conveyed that Parent would agree to full acceleration of all outstanding employee incentive equity awards prior to closing of the transaction, and settled the treatment of Company employee equity incentive awards that otherwise would have been granted to employees in June 2022 in the ordinary course.

On April 12, 2022, the parties finalized the terms of the proposed Merger Agreement.

After the close of trading on Nasdaq on April 12, 2022, the Company, Parent and Purchaser executed and delivered the Merger Agreement.

Before the opening of trading on Nasdaq on April 13, 2022, the Company and Parent released a joint press release announcing the execution of the Merger Agreement and the forthcoming commencement of a tender offer to acquire all the outstanding Shares for the Offer Price, and Parent filed a current report on Form 8-K.

On April 26, 2022, Purchaser commenced the Offer and the Company filed the Schedule 14D-9.

 

11.

The Merger Agreement; Other Agreements

Merger Agreement

The following summary of the material provisions of the Merger Agreement and all other provisions of the Merger Agreement discussed herein are qualified in their entirety by reference to the Merger Agreement, a copy of which is filed as Exhibit (d)(1) to the Schedule TO and is incorporated herein by reference. For a complete understanding of the Merger Agreement, you are encouraged to read the full text of the Merger Agreement. The Merger Agreement may be examined and copies may be obtained at the places and in the manner set forth in Section 7 – “Certain Information Concerning the Company.” Capitalized terms used herein and not otherwise defined have the respective meanings set forth in the Merger Agreement.

The summary description has been included in this Offer to Purchase to provide you with information regarding the terms of the Merger Agreement and is not intended to modify or supplement any rights or obligations of the parties under the Merger Agreement or any factual information about Parent, Purchaser or the Company or the Transactions contained in public reports filed by Parent or the Company with the SEC. Such information can be found elsewhere in this Offer to Purchase. The Merger Agreement has been filed as an exhibit to the Current Report on Form 8-K filed by Parent with the SEC on April 13, 2022. The Merger Agreement and the summary of its terms contained in the Current Report on Form 8-K filed by Parent with the SEC on April 13, 2022, are incorporated herein by reference as required by applicable SEC regulations and solely to inform investors of its terms. The Merger Agreement contains representations, warranties and covenants, which were made only for the purposes of such agreement and as of specific dates, were made solely for the benefit of the parties to the Merger Agreement (and, in the case of certain covenants relating to indemnification of directors and officers, for the

 

19


benefit of directors and officers of the Company designated as third-party beneficiaries), and are intended not as statements of fact, but rather as a way of allocating risk to one of the parties if those statements prove to be inaccurate. In addition, such representations, warranties and covenants may have been qualified by certain disclosures in confidential disclosure schedules delivered by the Company to Parent and Purchaser in connection with the signing of the Merger Agreement, and may apply standards of materiality in a way that is different from what may be viewed as material by stockholders of, or other investors in, the Company. The holders of Shares and other investors should not rely on the representations, warranties and covenants or any descriptions thereof as characterizations of the actual state of facts or conditions of the Company, Parent, Purchaser or any of their respective subsidiaries or affiliates.

Accordingly, the representations and warranties contained in the Merger Agreement and summarized in this Section 11 should not be relied on by any persons as characterizations of the actual state of facts and circumstances of the Company at the time they were made and the information in the Merger Agreement should be considered in conjunction with the entirety of the factual disclosure about the Company in the Company’s public reports filed with the SEC. Information concerning the subject matter of the representations and warranties may change after the date of the Merger Agreement, which subsequent information may or may not be fully reflected in the Company’s public disclosures. The Merger Agreement should not be read alone, but should instead be read in conjunction with the other information regarding the Offer, the Transactions, the Company, Parent, Purchaser, their respective affiliates and their respective businesses that are contained in, or incorporated by reference into, the Tender Offer Statement on Schedule TO and related exhibits, including this Offer to Purchase, and the Company’s Solicitation/Recommendation Statement on Schedule 14D-9 filed by the Company on April 26, 2022, as well as in the Company’s and Parent’s other public filings.

The Offer

Principal Terms of the Offer

The Offer. Purchaser’s obligation to accept for payment and pay for any Shares validly tendered (and not validly withdrawn) in the Offer is subject to the satisfaction or waiver of the Minimum Condition and the other conditions that are described in Section 15 – “Conditions of the Offer” (each, an “Offer Condition” and collectively, the “Offer Conditions”). Subject to the satisfaction of the Minimum Condition and the satisfaction (or waiver by Parent) of the other Offer Conditions, the Merger Agreement provides that Purchaser will, and Parent will cause Purchaser to, irrevocably accept for payment, and pay for, all Shares validly tendered (and not validly withdrawn) pursuant to the Offer as promptly as practicable (and in any event within three business days) after the Offer Acceptance Time (as defined below). Acceptance of all such validly tendered Shares for payment is pursuant to and subject to the conditions of the Offer, which will occur on May 23, 2022, following the Offer Expiration Date, unless one or more Offer Conditions is not satisfied as of such date, in which case we will extend the Offer pursuant to the terms of the Merger Agreement. The time at which Purchaser accepts for payment such number of Shares validly tendered and not properly withdrawn pursuant to the Offer as satisfies the Minimum Condition is referred to herein as the “Offer Acceptance Time,” and the date and time at which the Offer Acceptance Time occurs is referred to herein as the “Offer Closing.” The Offer may not be withdrawn prior to the Expiration Date (including any rescheduled Expiration Date) unless the Merger Agreement is terminated in accordance with its terms.

Purchaser expressly reserves the right to increase the Offer Price, waive any Offer Condition, or make any other changes to the terms and conditions of the Offer that are not inconsistent with the terms of the Merger Agreement. However, except as otherwise expressly provided in the Merger Agreement, without the prior written consent of the Company, Purchaser is not permitted to:

 

   

decrease the Offer Price;

 

   

change the form of consideration payable in the Offer;

 

   

decrease the maximum number of Shares sought to be purchased in the Offer;

 

20


   

impose conditions or requirements to the Offer in addition to the Offer Conditions;

 

   

amend or modify any of the Offer Conditions or any other terms or conditions of the Merger Agreement in a manner that adversely affects, or would reasonably be expected to adversely affect, any holder of Shares or that would, individually or in the aggregate, reasonably be expected to prevent or delay the consummation of the Offer or prevent, delay or impair the ability of Parent or Purchaser to consummate the Offer, the Merger or the other Transactions;

 

   

amend, modify or waive the Minimum Condition or the Termination Condition;

 

   

extend or otherwise change the Expiration Date in a manner other than as required or permitted by the Merger Agreement; or

 

   

provide any “subsequent offering period” within the meaning of Rule 14d-11 promulgated under the Exchange Act.

The Merger Agreement contains provisions to govern the circumstances in which Purchaser is required or permitted to extend the Expiration Date and in which Parent is required to cause Purchaser to extend the Expiration Date. Specifically, subject to our rights to terminate the Merger Agreement in accordance with its terms, the Merger Agreement provides that Purchaser must extend the Offer from time to time for:

 

   

any period required by applicable legal requirements, any interpretation or position of the SEC, the staff thereof or the NASDAQ applicable to the Offer; and

 

   

periods of up to ten business days per extension, until the Regulatory Condition (as defined below in Section 15 – “Conditions of the Offer”) has been satisfied.

Additionally, Purchaser may (and at the request of the Company, Purchaser shall) extend the Offer if, as of the then-scheduled Offer Expiration Date, the Minimum Condition or any other Offer Condition is not satisfied and has not been waived by Parent or Purchaser (to the extent permitted under the Merger Agreement) on one or more occasions in consecutive increments for up to ten business days each in order to permit the satisfaction of such Offer Condition. Purchaser will not be required to, and without the Company’s written consent Purchaser will not, extend the Offer beyond the earlier to occur of (i) the valid termination of the Merger Agreement in accordance therewith and (ii) the first business day immediately following the End Date. If we extend the Offer, such extension will extend the time that you will have to tender (or withdraw) your Shares.

Purchaser has agreed that it will (and Parent has agreed to cause Purchaser to) promptly terminate the Offer, and will not acquire any Shares pursuant thereto, upon any valid termination of the Merger Agreement prior to the Offer Acceptance Time.

Offer Conditions

The Offer Conditions are described in Section 15 – “Conditions of the Offer

Schedule 14D-9 and Board Recommendation

The Merger Agreement provides that as promptly as practicable on the date of commencement of the Offer, the Company will file with the SEC and disseminate to holders of Shares, to the extent required by applicable federal securities laws and regulations, including Rule 14D-9 under the Exchange Act, a Tender Offer Solicitation/Recommendation Statement on Schedule 14D-9 that reflect the Company Board Recommendation (as defined below) and a notice of appraisal rights as contemplated by Section 262 of the DGCL (subject to the terms and conditions of the Merger Agreement).

 

21


The Merger

Principal Terms of the Merger

The Merger Agreement provides that, following completion of the Offer and subject to the terms and conditions of the Merger Agreement, and in accordance with the DGCL, at the Effective Time, Purchaser will be merged with and into the Company, and the separate corporate existence of Purchaser will cease, and the Company will continue as the Surviving Corporation. The Merger will be governed by Section 251(h) of the DGCL and, assuming the conditions to the Merger have been satisfied or waived, will be effected at 8:00 a.m., Eastern Time, on the same date as the consummation of the Offer (unless otherwise agreed by the Company, Parent and Purchaser) without a vote on the adoption of the Merger Agreement by Company stockholders.

The certificate of incorporation of the Surviving Corporation will be amended and restated as of the Effective Time to conform to the form previously agreed to by the parties. The bylaws of the Surviving Corporation shall be amended and restated as of the Effective Time to conform to the bylaws of Purchaser as in effect immediately prior to the Effective Time.

Under the Merger Agreement, as of immediately after the Effective Time, the directors of Purchaser as of immediately prior to the Effective Time will be the directors of the Surviving Corporation and the officers of Purchaser as of immediately prior to the Effective Time will be the officers of the Surviving Corporation, in each case until their respective successors are duly elected or appointed and qualified, or until their earlier death, resignation or removal in accordance with the organizational documents of the Surviving Corporation.

The obligations of the Company, Parent and Purchaser to complete the Merger are subject to the satisfaction of the following conditions:

 

   

there must not have been issued by any court of competent jurisdiction in any jurisdiction in which Parent or the Company or any of their respective subsidiaries has any operations, assets or revenues and remain in effect any temporary restraining order, preliminary or permanent injunction or other order preventing the consummation of the Merger, nor shall any legal requirement or order promulgated, entered, enforced, enacted, issued or deemed applicable to the Merger, by any: (a) nation, state, commonwealth, province, territory, county, municipality, district or other jurisdiction or any nature; (b) federal, state, local, municipal, foreign or other government; or (c) governmental or quasi-governmental authority of any nature including any governmental division, department, agency, commission, instrumentality, official, ministry, fund, foundation, center, organization, unit, body or entity and any court, arbitrator or other tribunal (collectively, “Governmental Body”) in any jurisdiction in which Parent or the Company or any of their respective subsidiaries has any operations, assets or revenues, which directly or indirectly prohibits, or makes illegal, the consummation of the Merger; and

 

   

Purchaser (or Parent on Purchaser’s behalf) must have accepted for payment all Shares validly tendered pursuant to the Offer and not properly withdrawn.

The Offer Conditions are described in Section 15 – “Conditions of the Offer.”

Conversion of Capital Stock at the Effective Time

At the Effective Time, each Share issued and outstanding immediately prior to the Effective Time (being such date and at such time as the certificate of merger in respect of the Merger has been duly filed with the Secretary of State of the State of Delaware or at such later time and date as may be agreed upon by the parties to the Merger Agreement in writing and specified in the certificate of merger in accordance with the DGCL, the “Effective Time”) (other than Shares (a) held by the Company (or in the Company’s treasury), Parent, any other direct or indirect wholly owned subsidiary of Parent (other than Purchaser) or by stockholders of the Company who have properly exercised and perfected their statutory rights of appraisal under Delaware law, or

 

22


(b) irrevocably accepted by Purchaser for purchase in the Offer) will be converted into the right to receive an amount in cash equal to the Offer Price, without interest and subject to any withholding of taxes required by applicable legal requirements. As a result of the Merger, the Company will cease to be a publicly traded Company.

At the Effective Time, (i) any Shares held immediately prior to the Effective Time by the Company (or held in the Company’s treasury) will automatically be canceled and retired and shall cease to exist, and no consideration shall be delivered in exchange therefor; (ii) any Shares held immediately prior to the Effective Time by Parent, or any other direct or indirect wholly owned Subsidiary of Parent (other than Purchaser) will automatically be cancelled and shall cease to exist, and no consideration shall be delivered in exchange therefor; (iii) any Shares irrevocably accepted by Purchaser for purchase in the Offer will no longer be outstanding and shall automatically be canceled and will cease to exist, and no consideration will be delivered in exchange therefor and (iv) each share of common stock, $0.01 par value per share, of Purchaser then outstanding shall be converted into one share of common stock, $0.01 par value per share, of the Surviving Corporation.

At the close of business on the day of the Effective Time, the stock transfer books of the Company with respect to the Shares will be closed and thereafter there will be no further registration of transfers of Shares on the records of the Company. From and after the Effective Time, the holders of Shares outstanding immediately prior to the Effective Time will cease to have any rights with respect to such Shares other than the right to receive, upon surrender stock of certificates or book-entry shares in accordance with the procedures set forth in the Merger Agreement, the Merger Consideration, or, with respect to Shares of a holder who exercises appraisal rights in accordance with the DGCL, the rights set forth in Section 262 of the DGCL.

Treatment of Stock Options and Restricted Stock Units in the Merger

Under the terms of the Merger Agreement:

 

   

each Company Option that is outstanding immediately prior to the Effective Time will, to the extent unvested, accelerate and become fully vested and exercisable effective prior to the Effective Time. As of the Effective Time, by virtue of the Merger, each Company Option that is outstanding and unexercised as of immediately prior to the Effective Time will be cancelled and converted into the right to receive cash in an amount, net of any applicable withholding taxes, equal to the product of (i) the total number of Shares subject to such Company Option immediately prior to the Effective Time, multiplied by (ii) the excess (if any) of (A) the Merger Consideration over (B) the exercise price payable per Share underlying such Company Option. Any Company Option that has an exercise price that equals or exceeds the Merger Consideration will be canceled as of the Effective Time for no consideration;

 

   

as of the Effective Time, by virtue of the Merger, each Company RSU that is outstanding as of immediately prior to the Effective Time will be canceled and automatically converted into the right to receive a cash payment equal to the product of (i) the number of Shares subject to the Company RSU and (ii) the Merger Consideration; and

 

   

as of the Effective Time, by virtue of the Merger, each Company PSU that is outstanding as of immediately prior to the Effective Time will be canceled and automatically converted into the right to receive a cash payment equal to the product of (i) the number of Shares subject to the Company PSU (determined at the target level of performance) and (ii) the Merger Consideration.

Prior to the Effective Time, the Company and the Company Board and any Committee of the Company Board, as applicable, are required to adopt resolutions and take any actions that are necessary to effectuate the provisions of the Merger Agreement with respect to the treatment of the Company stock awards.

 

23


Adjustments to the Offer Price and Merger Consideration

The Merger Agreement provides that if, between the date of the Merger Agreement and the Offer Acceptance Time there is any change in the outstanding number or class of the Shares, including by reason of any stock split, division or subdivision of shares, stock dividend, reverse stock split, consolidation of shares, reclassification, recapitalization or other similar transaction, then the Offer Price will be appropriately adjusted to reflect such change.

Representations and Warranties

In the Merger Agreement, the Company has made customary representations and warranties to Parent and Purchaser with respect to:

 

   

due organization; subsidiaries, etc.;

 

   

certificate of incorporation and bylaws;

 

   

capitalization;

 

   

SEC filings; financial statements;

 

   

absence of changes;

 

   

title to assets;

 

   

real property;

 

   

intellectual property; data privacy

 

   

contracts;

 

   

liabilities;

 

   

compliance with legal requirements;

 

   

regulatory matters;

 

   

certain business practices;

 

   

governmental authorizations;

 

   

tax matters;

 

   

employee matters; benefit plans;

 

   

environmental matters;

 

   

insurance;

 

   

legal proceedings; orders;

 

   

authority; binding nature of agreement;

 

   

Section 203 of the DGCL;

 

   

merger approval;

 

   

non-contravention; consents;

 

   

opinion of financial advisor; and

 

   

brokers.

Some of the representations and warranties in the Merger Agreement made by the Company are qualified as to “materiality” or “Material Adverse Effect.” For purposes of the Merger Agreement, a “Material Adverse Effect

 

24


means an event, change, occurrence, circumstance or development that either (a) had or reasonably be expected to have a material adverse effect on the business, assets, financial condition or results of operations on the Company and its subsidiaries, taken as a whole, or (b) has prevented or materially delayed, or would reasonably be expected to prevent or materially delay the consummation by the Company of the Offer or the Merger; provided, that in the case of clause (a) of this definition, none of the following will be deemed in and of themselves, either alone or in combination, to constitute, and none of the following will be taken into account in determining whether there is, or would reasonably likely to be, a Material Adverse Effect on the Company:

 

   

any change in the market price or trading volume of the Company’s stock;

 

   

any event, change, occurrence, circumstance or development resulting from the execution, announcement, pendency or consummation of the Transactions other than for purposes of the non-contravention representation made by the Company;

 

   

any event, occurrence, circumstance, change or effect in the industries in which the Company or any of its subsidiaries operates or in the economy generally or other general business, financial or market conditions, except to the extent (and only to the extent) that the Company is adversely affected materially disproportionately relative to the other participants in such industries or the economy generally, as applicable;

 

   

any event, circumstance, change or effect arising directly or indirectly from or otherwise relating to fluctuations in the value of any currency;

 

   

any event, circumstance, change or effect arising directly or indirectly from or otherwise relating to any act of terrorism, war, national or international calamity, pandemic or epidemic (including COVID-19) or other outbreaks of diseases or quarantine restrictions, or any other similar event, except to the extent (and only to the extent) that such event, circumstance, change or effect materially disproportionately affects the Company relative to other participants in the industries or geographies in which the Company operates or the economy generally, as applicable;

 

   

the failure of the Company to meet internal or analysts’ expectations or projections or the results of operations of the Company;

 

   

any adverse effect arising directly from or otherwise directly relating to any action taken by the Company at the written direction of Parent or any action specifically required to be taken by the Company, or the failure of the Company to take any action that the Company is specifically prohibited by the terms of the Merger Agreement from taking to the extent Parent fails to give its consent thereto after a written request therefor pursuant to the Merger Agreement;

 

   

any event, occurrence, circumstance, change or effect resulting or arising from Parent’s or Purchaser’s breach of the Merger Agreement;

 

   

any event, occurrence, circumstance, change or effect arising directly or indirectly from or otherwise relating to any change in, or any compliance with or action taken for the purpose of complying with, any legal requirement or GAAP (or interpretations of any legal requirement or GAAP) or

 

   

any matters disclosed in the confidential disclosure schedule to the Merger Agreement;

However, the exceptions in the first and sixth bullet points set forth above will not prevent or otherwise affect a determination that the underlying cause of any such decline or failure referred to therein (if not otherwise falling within any of the other exceptions listed above) is or would be reasonably likely to be a Material Adverse Effect.

In the Merger Agreement, Parent and Purchaser have made representations and warranties to the Company with respect to:

 

   

due organization;

 

   

Purchaser;

 

25


   

authority; binding nature of the agreement;

 

   

non-contravention; consents;

 

   

disclosure;

 

   

absence of litigation;

 

   

funds;

 

   

ownership of Company Common Stock; and

 

   

acknowledgement by Parent and Purchaser.

Certain of Parent’s representations and warranties contained in the Merger Agreement are qualified as to “materiality” or “Parent Material Adverse Effect.” “Parent Material Adverse Effect,” as used in the Merger Agreement, means any event, change, occurrence or development that would prevent, materially delay or materially impair the ability of Purchaser or Parent to consummate the Transactions.

None of the representations and warranties of the parties to the Merger Agreement contained in the Merger Agreement (or in any certificate or other document delivered pursuant to the Merger Agreement) survive the Merger.

Covenants

Conduct of Business Pending the Merger

The Company has agreed that, during the period from the date of the Merger Agreement until the earlier of the Offer Acceptance Time and the termination of the Merger Agreement pursuant to its terms (the “Pre-Closing Period”), (i) except (w) as required under the Merger Agreement or as required by applicable legal requirements, (x) with the written consent of Parent, which consent shall not be unreasonably withheld, delayed or conditioned, (y) for any actions taken reasonably and in good faith in response to COVID-19 or COVID-19 measures and with prior written notice to Parent or (z) as set forth in the Company’s confidential disclosure schedule, the Company will, and will cause its subsidiaries to conduct their respective businesses and operations in all material respects in the ordinary course and in compliance in all material respects with all applicable legal requirements; and (ii) the Company will promptly notify Parent of (y) any knowledge of the receipt of any notice from any person alleging that the consent of such person is or may be required in connection with any of the Transactions and (z) any legal proceeding commenced, or, to its knowledge threatened in writing, relating to or involving the Company or any of its subsidiaries that seeks to enjoin the consummation of the Transactions. The Company shall, and shall cause each of its subsidiaries to, use their respective commercially reasonable efforts to (A) preserve intact, in all material respects, the material components of the Company’s and each such subsidiary’s current business organization, including keeping available the services of current officers and key employees, (B) maintain in all material respects the Company’s and each such subsidiary’s respective relations and goodwill with all material suppliers, material customers, Governmental Bodies and other material business relations and (C) take the actions set forth in the Company’s confidential disclosure schedule; provided, that no action by the Company or any of its subsidiaries with respect to matters specifically addressed by the restrictions set forth in the following paragraph will be deemed a breach of the restrictions set forth in this paragraph unless such action would constitute a breach of such other provision.

The Company has further agreed that, during the Pre-Closing Period, except (i) as required or otherwise contemplated under the Merger Agreement or as required by applicable legal requirements, (ii) with the written consent of Parent, which consent shall not be unreasonably withheld, delayed or conditioned, (iii) for any actions taken reasonably and in good faith in response to COVID-19 or COVID-19 measures, or (iv) as set forth in the Company’s confidential disclosure schedule, neither the Company nor any of its subsidiaries will, among other

 

26


things and subject to specified exceptions as set forth in the Merger Agreement and the Company’s confidential disclosure schedule:

 

   

establish a record date for, declare, accrue, set aside or pay any dividend or make any other distributions in respect of, any shares of its capital stock;

 

   

repurchase, redeem or otherwise reacquire any shares of its capital stock (including any Share), or any rights, warrants or options to acquire any shares of its capital stock, subject to customary exceptions;

 

   

split, combine, subdivide or reclassify any shares of its capital stock (including the Shares) or other equity interests;

 

   

sell, issue, grant, deliver, pledge, transfer, encumber or authorize the issuance, sale, delivery, pledge, transfer, encumbrance or grant by the Company of (a) any capital stock, Company stock awards or other equity interest or other security of the Company, (b) any option, call, warrant, restricted securities or right to acquire any capital stock, equity interest or other security of the Company or (c) any instrument convertible into or exchangeable for any capital stock, equity interest or other security of the Company, subject to customary exceptions;

 

   

(a) except as otherwise provided under the terms of the Merger Agreement or required under the existing terms of an existing employee plan, establish, adopt, terminate or amend, or waive any employee benefit plan, (b) make or grant to any employee of the Company who receives total annual base salary that equals or exceeds $150,000 any increase in compensation, bonuses or other benefits, (c) grant or amend any cash, equity or equity-based awards, (d) make or grant any severance, change in control, retention or termination payments to any current or former officer or other employee, or individual who is a current or former independent contractor, consultant or director of or to the Company and its subsidiaries, (e) accelerate the vesting or payment of any compensation for the benefit of any current or former officer or other employee, or individual who is a current or former independent contractor, consultant or director of or to the Company and its subsidiaries, (f) hire any person with an annual base salary in excess of $150,000 or (g) terminate (other than for cause) or layoff (or give notice of any such actions to) any individual service provider of the Company and its subsidiaries with an annual base salary in excess of $150,000;

 

   

amend or permit the adoption of any amendment to its or its subsidiaries’ organizational documents;

 

   

form any subsidiary, acquire any equity interest in any other entity or enter into any joint venture, partnership, limited liability corporation or similar arrangement;

 

   

make or authorize any capital expenditure other than pursuant to a specified budget and subject to other specified exceptions;

 

   

acquire, lease, license, sublicense, pledge, sell or otherwise dispose of, divest or spin-off, abandon, waive, relinquish or fail to renew, permit to lapse (other than any intellectual property right expiring at the end of its statutory term for which an extension or renewal cannot be obtained), transfer, assign, guarantee, exchange or swap, mortgage or otherwise encumber (including pursuant to a sale-leaseback transaction or securitization) or subject to any encumbrance (other than specified permitted encumbrances) any material right or other material asset or property, including material intellectual property rights, except (a) in the ordinary course of business (including entering into non-exclusive license agreements and materials transfer agreements in the ordinary course of business), (b) pursuant to dispositions of obsolete, surplus or worn out assets that are no longer useful for the conduct of the business of the Company, and (c) as provided for in the immediately preceding bullet point;

 

   

receive, collect, compile, use, store, process, share, safeguard, secure (technically, physically or administratively), dispose of, destroy, disclose, or transfer (including cross-border) any Personal Information (or fail to do any of the foregoing, as applicable) in violation of any (a) applicable privacy laws, (b) privacy policies or notices of the Company or any of its subsidiaries, or (c) any of the contractual obligations of the Company or any of its Subsidiaries with respect to any Personal Information;

 

27


   

(a) lend money or make capital contributions or advances to or material investments in, any person (other than between the Company and its wholly owned subsidiaries), or incur or guarantee any indebtedness, subject to certain customary exceptions;

 

   

amend or modify in any material respect, waive any rights under, terminate, replace or release, settle or compromise any material claim, liability or obligation under any material contract or enter into any contract which if entered into prior to the date hereof would have been a material contract, excluding any non-exclusive license agreements, or services agreements entered into in the ordinary course of business or any statement of work under existing material contracts not in excess of $750,000 individually;

 

   

commence any legal proceeding, except with respect to (i) routine matters in the ordinary course of business, (ii) in such cases where the Company reasonably determines in good faith that the failure to commence suit would result in a material impairment of a valuable aspect of its business (provided that the Company consults with Parent and considers in good faith the views and comments of Parent with respect to any such legal proceeding prior to commencement thereof), or (iii) in connection with a breach of the Merger Agreement or any other agreements contemplated thereby;

 

   

settle, release, waive or compromise any legal proceeding or other claim (or threatened legal proceeding or other claim), subject to certain customary exceptions;

 

   

except as required by applicable legal requirements, enter into any collective bargaining agreement or other agreement with any labor organization;

 

   

adopt or implement any stockholder rights plan or similar arrangement;

 

   

adopt a plan or agreement of complete or partial liquidation or dissolution, merger, consolidation, restructuring, recapitalization or other reorganization of the Company;

 

   

enter into any new material line of business (which does not include the commencement of certain preclinical or clinical studies) or any agreement, arrangement or commitment that materially limits or otherwise restricts the Company or any of its affiliates from engaging or competing in any line of business or in any geographic area or otherwise enter into any contracts imposing material restrictions on the Company’s assets, operations or business;

 

   

(A) commence any clinical study of which Parent has not been informed prior to the date of the Merger Agreement, (B) unless mandated by any regulatory authority or Governmental Body, discontinue, terminate or suspend any ongoing clinical study, or (C) except as required by applicable legal requirements, as determined in good faith by the Company, discontinue, terminate or suspend any ongoing IND-enabling preclinical study, in each case without first consulting with Parent in good faith;

 

   

(A) make, change or rescind any material tax election; (B) settle or compromise any material tax claim; (C) change (or request to change) any material method of accounting for tax purposes; (D) file any material amended tax return; (E) waive or extend any statute of limitations in respect of a period within which an assessment or reassessment of material taxes may be issued (other than any such extension that arises solely as a result of an extension of time to file a tax return obtained in the ordinary course of business); (F) surrender or compromise any claim for a material refund of taxes; or (G) enter into any “closing agreement” as described in Section 7121 of the Code (or any corresponding or similar provision of state, local, or non-U.S. tax legal requirements) with any Governmental Body; or

 

   

authorize any of, or agree or commit to take any of, the foregoing actions.

No Solicitation. The Company will, and will direct its representatives, to cease any direct or indirect solicitation, encouragement, discussions or negotiations with any person that may have been ongoing with respect to any Acquisition Proposal (as defined below). Except as otherwise described below, the Company will not, and will direct its representatives not to (i) continue any direct or indirect solicitation, knowing encouragement, knowing

 

28


facilitation (including by way of providing non-public information), discussions or negotiations with any persons that may be ongoing with respect to an Acquisition Proposal and (ii) directly or indirectly:

 

   

solicit, initiate or knowingly facilitate or knowingly encourage (including by way of furnishing non-public information) any inquiries regarding, or the making of any proposal or offer that constitutes, or could reasonably be expected to lead to, an Acquisition Proposal;

 

   

engage in, continue or otherwise participate in any discussions or negotiations regarding, or furnish to any other person any non-public information in connection with, or for the purpose of knowingly encouraging or facilitating, an Acquisition Proposal or any proposal or offer that could reasonably be expected to lead to an Acquisition Proposal; or

 

   

enter into any letter of intent, acquisition agreement, agreement in principle or similar agreement with respect to an Acquisition Proposal or any proposal or offer that could reasonably be expected to lead to an Acquisition Proposal.

In addition, as soon as reasonably practicable after the date of the Merger Agreement, the Company will deliver a written notice to each person that entered into a confidentiality agreement in anticipation of potentially making an Acquisition Proposal in the 180 days prior to the execution of the Merger Agreement, requesting the prompt return or destruction of all confidential information previously furnished to any person within the 180 days prior to the execution of the Merger Agreement for the purposes of evaluating a possible Acquisition Proposal.

For purposes of the Merger Agreement, the term “Acquisition Proposal” means any proposal or offer from any person or “group” (within the meaning of Section 13(d) of the Exchange Act), relating to, in a single transaction or series of related transactions, any of the following:

 

   

an acquisition or license of assets of the Company equal to 20% or more of the Company’s assets or to which 20% or more of the Company’s revenues or earnings are attributable;

 

   

an issuance or acquisition of 20% or more of the outstanding Shares;

 

   

a recapitalization, tender offer or exchange offer that if consummated would result in any person or group beneficially owning 20% or more of the outstanding Shares; or

 

   

a merger, consolidation, amalgamation, share exchange, business combination, recapitalization, liquidation, dissolution or similar transaction involving the Company that if consummated would result in any person or group beneficially owning 20% or more of the outstanding Shares.

Notwithstanding the foregoing, the Transactions are excluded from the definition of “Acquisition Proposal.”

For purposes of the Merger Agreement, the term “Superior Offer” means any bona fide written Acquisition Proposal that the Company Board determines, in its good faith judgment, after consultation with its outside legal counsel and its financial advisor(s), is reasonably likely to be consummated in accordance with its terms, taking into account all legal, regulatory and financing aspects (including certainty of closing) of the proposal and the person making the proposal and other aspects of the Acquisition Proposal that the Company Board deems relevant, and if consummated, would result in a transaction more favorable to the Company’s stockholders (solely in their capacity as such) from a financial point of view than the Transactions. However, for purposes of the definition of “Superior Offer,” the references to “20% or more” in the definition of Acquisition Proposal are deemed to be references to “more than 50%.”

Notwithstanding the restrictions described above, if at any time on or after the date of the Merger Agreement and prior to the Offer Acceptance Time the Company or any of its representatives receives a bona fide, unsolicited written Acquisition Proposal from any person or group of persons, which Acquisition Proposal did not result from a breach in any material respect of the restrictions described above, then:

 

   

the Company and its representatives may contact such person or group of persons solely to clarify the terms and conditions of such proposal and inform such person or group of persons of the terms of the Company’s non-solicit obligations; and

 

29


   

if the Company Board determines in good faith, after consultation with financial advisors and outside legal counsel, that such Acquisition Proposal constitutes or would reasonably be expected to lead to a Superior Offer, then the Company and its representatives may (x) furnish, pursuant to (but only pursuant to) an Acceptable Confidentiality Agreement (as defined below), information (including non-public information) with respect to the Company to the person or group of persons who has made such Acquisition Proposal (and the Company must as promptly as reasonably practicable (and in any event within 24 hours) provide to Parent any non-public information concerning the Company that is provided to any such person given such access which was not previously provided to Parent or its representatives) and (y) engage in or otherwise participate in discussions or negotiations with the person or group of persons making such Acquisition Proposal; provided, that the Company may only take the actions described in clauses (x) and (y) above if the Company Board determines, in good faith, after consultation with outside counsel, that the failure to take any such action would reasonably be expected to be inconsistent with its fiduciary duties under applicable legal requirements.

For purposes of the Merger Agreement, “Acceptable Confidentiality Agreement” means any customary confidentiality agreement that (i) contains provisions (other than standstill provisions) that are no less favorable in the aggregate to the Company than those contained in the confidentiality agreement between the Company and Parent as described in Section 11 – “Summary of the Merger Agreement and Certain Other Agreements – Summary of the Confidentiality Agreement” below, and (ii) does not prohibit the Company from providing any information to Parent in accordance with the Merger Agreement or otherwise prohibit the Company from complying with its obligations under the Merger Agreement.

In addition, the Company must:

 

   

promptly (and in any event within 24 hours) notify Parent if any inquiries, proposals or offers with respect to an Acquisition Proposal, or any inquiry, proposal or offer that could reasonably be expected to lead to, an Acquisition Proposal, are received by the Company or any of its representatives, including the identity of the person or group of persons making such Acquisition Proposal;

 

   

provide Parent a summary of the material terms and conditions of any Acquisition Proposal (and copies of all written correspondence and documentation related to such Acquisition Proposal);

 

   

keep Parent reasonably informed of any material developments, discussions or negotiations regarding any such Acquisition Proposal on a prompt basis; and

 

   

upon the request of Parent, reasonably inform Parent of the status of such Acquisition Proposal.

Change of the Company Board Recommendation. As described above, and subject to the provisions described below, the Company Board has unanimously resolved to recommend that the Company’s stockholders tender their Shares pursuant to the Offer. The foregoing recommendation is referred to herein as the “Company Board Recommendation.” Unless the Company Board has made a Company Adverse Change Recommendation (as defined below), the Company Board has also agreed to include the Company Board Recommendation in the Schedule 14D-9 and to permit Parent to refer to such recommendation in this Offer to Purchase and other documents related to the Offer.

Except as described below, during the Pre-Closing Period, neither the Company Board nor any committee of the Company Board may:

 

   

fail to make, withdraw (or modify or qualify in a manner adverse to Parent or Purchaser) or publicly propose to fail to make, withdraw (or modify or qualify in a manner adverse to Parent or Purchaser), the Company Board Recommendation;

 

   

approve, recommend or declare advisable, or publicly propose to approve, recommend, endorse or declare advisable, any Acquisition Proposal; or

 

30


   

fail to include the Company Board Recommendation in the Schedule 14D-9 when disseminated to the Company’s stockholders.

Any action described in the foregoing three bullet points is referred to as a “Company Adverse Change Recommendation.”

The Merger Agreement further provides that the Company Board will not (i) publicly make any recommendation in connection with a tender offer or exchange offer (other than the Offer) other than a recommendation against such offer or (ii) approve, recommend or declare advisable, or propose to approve, recommend or declare advisable, or allow the Company to execute or enter into any contract (other than an Acceptable Confidentiality Agreement as described above) with respect to any Acquisition Proposal, or requiring, or reasonably expected to cause, the Company to abandon, terminate, delay or fail to consummate, or that would otherwise materially impede, interfere with or be inconsistent with, the Transactions.

However, notwithstanding the foregoing, at any time prior to the Offer Acceptance Time, the Company Board may make a Company Adverse Change Recommendation in response to an Acquisition Proposal or, provided that such Acquisition Proposal did not arise out of a breach in any material respect of the obligations of the Company described above under “ – No Solicitation”, terminate the Merger Agreement in order to enter into an agreement with respect to such Superior Offer. However, such action may be taken if and only if:

 

   

the Company Board determines in good faith (after consultation with its outside legal counsel and financial advisors, as applicable) that the applicable Acquisition Proposal is a Superior Offer and the failure to take such action would be reasonably likely to be inconsistent with its fiduciary duties under applicable legal requirements;

 

   

the Company has given Parent prior written notice of its intention to consider making a Company Adverse Change Recommendation or terminate the Merger Agreement to accept such Superior Offer at least five business days prior to making any such Company Adverse Change Recommendation or termination (a “Determination Notice”);

 

   

the Company has provided to Parent a summary of the material terms and conditions of such Acquisition Proposal and the latest draft of any documentation being negotiated in connection with such Acquisition Proposal;

 

   

the Company has given Parent the five business days after Parent’s receipt of the Determination Notice to propose revisions to the terms of the Merger Agreement or make another proposal and has made the Company’s representatives reasonably available to negotiate in good faith with Parent (to the extent Parent desires to negotiate) with respect to such proposed revisions or other proposal, if any; and

 

   

after considering the results of any such negotiations and giving effect to any proposals made in writing by Parent after consultation with outside legal counsel and financial advisors, as applicable, the Company Board has determined, in good faith, that such Acquisition Proposal is a Superior Offer and that the failure to make the Company Adverse Change Recommendation or terminate the Merger Agreement to accept such Superior Offer would be reasonably likely to be inconsistent with its fiduciary duties under applicable legal requirements.

The above will also apply to any material amendment to any Acquisition Proposal, which shall require a new Determination Notice, except that the references to five business days therein will be deemed to be references to three business days.

Additionally, at any time prior to the Offer Acceptance Time, other than in connection with an Acquisition Proposal, the Company Board may make a Company Adverse Change Recommendation in response to a Change in Circumstance (as defined below). However, such action may be taken if and only if:

 

   

the Company Board determines in good faith (after consultation with its outside legal counsel and financial advisors, as applicable) that the failure to take such action would be reasonably likely to be inconsistent with its fiduciary duties under applicable legal requirements;

 

31


   

the Company has given Parent a Determination Notice at least five business days prior to making any such Company Adverse Change Recommendation;

 

   

the Company has specified the Change in Circumstance in reasonable detail;

 

   

the Company has given Parent five business days after the Determination Notice to propose revisions to the terms of the Merger Agreement or make another proposal, and has made the Company’s representatives reasonably available to negotiate in good faith with Parent (to the extent Parent desires to negotiate) with respect to such proposed revisions or other proposal, if any; and

 

   

after considering the results of any such negotiations and giving effect to any proposals made in writing by Parent after consultation with its outside legal counsel, the Company Board has determined, in good faith, that the failure to make the Company Adverse Change Recommendation in response to such Change in Circumstance would be inconsistent with the fiduciary duties of the Company Board to the Company’s stockholders under applicable legal requirements.

The above also will apply to any material change to the facts and circumstances relating to such Change in Circumstance, which shall require a new Determination Notice, except that the references to five business days therein will be deemed to be references to three business days.

For purposes of the Merger Agreement, a “Change in Circumstance” means any event or development or change in circumstances that materially affects the business, assets or operations of the Company (other than any event, occurrence, fact or change primarily resulting from a breach of the Merger Agreement by the Company) occurring or arising after the date of the Merger Agreement that was neither known to the Company Board nor reasonably foreseeable as of or prior to the date of the Merger Agreement, which event, occurrence, fact or change becomes known to the Company Board prior to the Offer Acceptance Time, other than (i) changes in the price of the Shares, in and of itself (however, the underlying reasons for such changes may constitute a Change in Circumstances), (ii) any Acquisition Proposal or (iii) the fact that, in and of itself, the Company exceeds any internal or published projections, estimates or expectations of the Company’s revenue, earnings or other financial performance or results of operations for any period, in and of itself (however, the underlying reasons for such events may constitute a Change in Circumstances).

None of the provisions described above under “ – No Solicitation” or elsewhere in the Merger Agreement will prohibit the Company from (i) taking and disclosing to its stockholders a position contemplated by Rule 14e-2(a), Rule 14d-9 or Item 1012(a) of Regulation M-A promulgated under the Exchange Act, (ii) making any disclosure to the Company’s stockholders that is required by applicable legal requirements or (iii) making any “stop, look and listen” communication pursuant to Rule 14d-9(f) promulgated under the Exchange Act, so long as any such action that would otherwise constitute a Company Adverse Change Recommendation is taken only in accordance with the provisions described in this Change of the Company Board Recommendation subsection.

Reasonable Best Efforts to Consummate the Merger; Regulatory Filings

Pursuant to the Merger Agreement, each of the parties has agreed to use its, and to cause its respective subsidiaries to use their, respective reasonable best efforts to take, or cause to be taken, all actions, to file, or cause to be filed, all documents and to do, or cause to be done, and to assist and cooperate with the other parties in doing, all things necessary, proper or advisable under applicable antitrust laws to consummate and make effective the Transactions as soon as reasonably practicable, including (i) the obtaining of all necessary actions or nonactions, waivers, consents, clearances, decisions, declarations, approvals and, expirations or terminations of waiting periods from Governmental Bodies and the making of all necessary registrations and filings and the taking of all steps as may be necessary to obtain any such consent, decision, declaration, approval, clearance or waiver, or expiration or termination of a waiting period by or from, or to avoid an action or proceeding by, any Governmental Body in connection with any antitrust law, (ii) the obtaining of all necessary consents, authorizations, approvals or waivers from third parties and (iii) the execution and delivery of any additional instruments necessary to consummate the Transactions.

 

32


In furtherance and not in limitation of the foregoing, if and to the extent necessary to consummate the Merger before the End Date, Parent will offer, negotiate, commit to and effect, by consent decree, hold separate order or otherwise, (i) the sale, divestiture, license or other disposition or holding separate (through the establishment of a trust or otherwise) of any assets or categories of assets of the Company or any of its Subsidiaries, or (ii) the imposition of any limitation or regulation on the ability of the Company or any of its Subsidiaries to freely conduct their business or own such assets; provided, that such efforts or action does not have or would not reasonably be expected to result in a Material Adverse Effect, provided, that neither the Parent nor Company will be required to agree to any such efforts or action unless conditioned on the consummation of the Merger. The parties have also agreed that neither Parent nor the Company shall have any obligation (A) sell, divest, license or otherwise dispose of or hold separate (through the establishment of a trust or otherwise) any assets or categories of assets of Parent or any of its subsidiaries or (B) to litigate or contest any administrative or judicial action or proceeding or any decree, judgment, injunction or other order, whether temporary, preliminary or permanent.

Subject to the terms and conditions of the Merger Agreement, each of the parties agreed, and agreed to cause their respective affiliates, to (i) as promptly as reasonably practicable and advisable, but in no event later than April 26, 2022 (unless Parent and the Company agree to a later date), make an appropriate filing of all Notification and Report forms as required by the HSR Act, with respect to the Transactions and (ii) cooperate with each other in determining whether, and promptly preparing and making, any other filings or notifications or other consents required to be made with, or obtained from, any other Governmental Bodies in connection with the Transactions.

Each of the parties also agreed to use its reasonable best efforts to (i) cooperate in all respects and consult with each other in connection with any filing or submission in connection with any investigation or other inquiry, including allowing the other party to have a reasonable opportunity to review in advance and comment on drafts of filings and submissions, (ii) give the other parties prompt notice of the making or commencement of any request, inquiry, investigation, action or legal proceeding brought by a Governmental Body or brought by a third party before any Governmental Body, in each case, with respect to the Transactions, (iii) keep the other Parties informed as to the status of any such request, inquiry, investigation, action or legal proceeding, (iv) promptly inform the other Parties of any material communication to or from the U.S. Federal Trade Commission (the “FTC”), the U.S. Department of Justice (the “DOJ”) or any other Governmental Body in connection with any such request, inquiry, investigation, action or legal proceeding, (v) on request, promptly furnish to the other party a copy of such communications, subject to a confidentiality agreement limiting disclosure to outside counsel and consultants retained by such counsel, and subject to redaction or withholding of documents as necessary (A) to comply with contractual arrangements, (B) to remove references to valuation of the Company, (C) to protect confidential and competitively sensitive information and (D) to address attorney-client privilege or other privilege concerns, (vi) to the extent reasonably practicable, consult in advance and cooperate with the other parties and consider in good faith the views of the other parties in connection with any substantive communication, analysis, appearance, presentation, memorandum, brief, argument, opinion or proposal to be made or submitted in connection with any such request, inquiry, investigation, action or legal proceeding, and (vii) except as may be prohibited by any Governmental Body, permit authorized representatives of the other parties to be present at each meeting and telephone or video conference relating to such request, inquiry, investigation, action or legal proceeding. Each party shall supply as promptly as practicable and advisable such information, documentation, other material or testimony that may be reasonably requested by any Governmental Body, including any “second request” under the HSR Act, received by any Party or any of their respective Subsidiaries from any Governmental Body in connection with such applications or filings for the Transactions. No party shall commit to or agree with any Governmental Body to stay, toll or extend any applicable waiting period or withdraw its filing under the HSR Act without the prior written consent of the other parties (such consent not be unreasonably withheld, delayed or conditioned). Purchaser shall pay all filing fees under the HSR Act.

Parent will have the principal responsibility for devising and implementing the strategy for obtaining any necessary antitrust or competition clearances and will take the lead in joint meetings with any Governmental

 

33


Body in connection with obtaining any necessary antitrust or competition clearances, provided, however, that, Parent and the Company will consult in advance with each other and in good faith take each other’s views into account prior to taking any material substantive position in any written submissions or, to the extent practicable, discussions with Governmental Bodies.

Each of the parties also agreed that the Company will consult with Parent prior to taking any material substantive position with respect to the filings under the HSR Act or required by any other Governmental Body.

Access to Information. During the Pre-Closing Period, the Company has agreed, solely for purposes of furthering the Transactions or integration planning relating thereto, on reasonable advance notice to the Company, the Company will, and will cause the respective representatives of the Company, to provide Parent and its representatives with reasonable access during normal business hours to the Company’s representatives, assets and all existing books, records, tax returns, work papers and other documents and information relating to the Company, and to provide copies of such existing books, records, tax returns, work papers and other documents and information relating to the Company, in each case, to the extent reasonably requested by Parent and its representatives for reasonable business purposes, subject to customary exceptions.

Employee Benefits

For a period of one year following the Effective Time, Parent will provide, or cause to be provided, to each employee of the Company who is employed by the Company as of immediately prior to the Effective Time and who continues to be employed by the Surviving Corporation (or any of its affiliates) during such one year period: (i) a base salary (or base wage, as the case may be) and a target annual cash incentive compensation opportunity (excluding any one time or long-term incentive awards), each of which is no less favorable than the base salary (or base wage, as the case may be) and target annual cash incentive compensation opportunity (excluding any one time or long-term incentive awards) provided to either (a) such continuing employee immediately prior to the Effective Time, or (b) similarly situated employees of Parent or an affiliate of Parent; (ii) broad-based employee benefits (excluding equity and equity-based awards, severance, retention, and change in control plans, programs, perquisites and arrangements) that are substantially comparable in the aggregate to the benefits (excluding equity and equity-based awards, severance, retention, and change in control plans, programs, perquisites and arrangements) provided to such continuing employees immediately prior to the Effective Time and (iii) with respect to any such continuing employee who suffers a termination of employment under circumstances that would have given such continuing employee a right to severance payments and benefits under the Company’s severance policy or plan in effect immediately prior to the Closing Date, as listed on the Company’s confidential disclosure schedules, severance payments and benefits no less favorable than those that would have been provided to such employee under such plan or policy.

Parent or an affiliate of Parent shall use commercially reasonable efforts to give each continuing employee of the Company who is employed by the Company as of immediately prior to the Effective Time service credit for purposes of (i) eligibility to participate and eligibility for vesting (excluding any Parent subsidies such as retiree medical benefits), and (ii) only under Parent’s and/or Surviving Corporation’s vacation, sick and/or PTO policies, levels of benefits, in each case under Parent’s and/or the Surviving Corporation’s employee benefit plans and arrangements to the extent such continuing employee is eligible to participate in such plans and arrangements and coverage under such plans and arrangements replaces coverage under a comparable employee plan in which such continuing employee participates immediately prior to the Closing Date, with respect to his or her length of service with the Company (and its predecessors) prior to the Closing Date, provided that the foregoing shall not result in the duplication of benefits under any such employee benefit plans and arrangements or under any defined benefit pension plan.

Parent will (i) use commercially reasonable efforts to waive all limitations as to pre-existing conditions, exclusions and waiting periods with respect to participation and coverage requirements applicable to continuing employees, to the extent that such conditions, exclusions and waiting periods would not apply under a similar

 

34


employee benefit plan in which such employees participated prior to the Effective Time and (ii) use commercially reasonable efforts to ensure that such health or welfare benefit plan will, for purposes of eligibility, vesting, deductibles, co-payments and out-of-pocket maximums and allowances, credit continuing employees for service and amounts paid prior to the Effective Time with the Company to the same extent that such service and amounts paid was recognized prior to the Effective Time under the corresponding health or welfare benefit plan of the Company.

Effective as of no later than the day immediately preceding the Closing Date, if requested by Parent in writing at least ten business days prior to the Closing Date, the Company will cause the Antares Pharma, Inc. 401(k) Plan to be terminated. If Parent provides such written notice to the Company, the Company shall provide Parent with evidence that the Antares Pharma, Inc. 401(k) Employee Savings Plan has been terminated (effective as of no later than the day immediately preceding the Closing Date), and the Company will have taken all steps necessary to terminate the Antares Pharma, Inc. 401(k) Plan as Parent may reasonably require. In the event of such termination, Parent shall designate a tax-qualified defined contribution retirement plan with a cash or deferred arrangement under Section 401(k) of the Code that is sponsored by Parent or one of its affiliates (the “Parent 401(k) Plan”) that will cover continuing employees effective as of, or as soon as practicable following, the Closing Date. In connection with the termination of the 401(k) Plan, if applicable, Parent shall cause the Parent 401(k) Plan to accept from the 401(k) Plan the “direct rollover” of the account balance (including the in-kind rollover of promissory notes evidencing all outstanding loans) of each continuing employee who participated in the 401(k) Plan as of the date such plan is terminated and who elects such direct rollover in accordance with the terms of the 401(k) Plan and the Code. The Company and Parent shall cooperate in good faith to take any and all commercially reasonable actions needed to permit each continuing employee with an outstanding loan balance under the 401(k) Plan as of the date such plan is terminated to continue to make scheduled loan payments to the 401(k) Plan after the Closing, pending the distribution and in-kind rollover of the promissory notes evidencing such loans from the 401(k) Plan to the Parent 401(k) Plan, as provided in the preceding sentence, such as to prevent, to the extent reasonably possible, a deemed distribution or loan offset with respect to such outstanding loans.

Parent also agreed to take the actions set forth on the Company’s confidential disclosure schedules.

Prior to making any written or oral communications to each current or former officer or other employee, or individual who is a current or former independent contractor, consultant or director, of or to the Company or its subsidiaries pertaining to compensation or benefits matters that are affected by the Transactions contemplated by the Merger Agreement, the Company shall provide Parent with a copy of the intended communication, Parent shall have a reasonable period of time to review and comment on the communication, and the Company shall consider any such comments in good faith.

The Merger Agreement does not confer upon any person (other than the Company, Parent and Purchaser) any rights with respect to the employee matters provisions of the Merger Agreement.

Directors’ and Officers’ Indemnification and Insurance. The Merger Agreement provides for indemnification and exculpation rights with respect to liabilities for acts and omissions occurring prior to the Effective Time, as well as related rights to advancement of expenses, in favor of the current and former directors and officers of the Company, who we refer to collectively as the “indemnitees.” Specifically, for a period of six years after the Effective Time, the provisions of the certificate of incorporation and bylaws of the Company as of the date of the Merger Agreement which relate to indemnification, exculpation and advancement of expenses, as well as certain indemnification agreements between an indemnitee and the Company made available to Parent, shall survive the Merger and must not be amended, repealed or otherwise modified in any manner that would adversely affect the rights thereunder of an indemnitee, and will be observed by the Surviving Corporation and its subsidiaries to the fullest extent available under Delaware (or other applicable) law during such six-year period.

The Merger Agreement also provides that, from the Effective Time until the sixth anniversary of the Effective Time, the Surviving Corporation must maintain (and Parent must cause the Surviving Corporation to maintain) in

 

35


effect the existing policy of directors’ and officers’ liability insurance maintained by the Company as of the date of the Merger Agreement for the benefit of the indemnitees who were covered by such policy as of the date of the Merger Agreement with respect to their acts and omissions occurring prior to the Effective Time in their capacities as directors and officers of the Company (as applicable), on terms with respect to coverage, deductibles and amounts no less favorable than the existing policy. Alternatively, at or prior to the Effective Time, Parent or the Company may, through a nationally recognized insurance broker approved by Parent (such approval not to be unreasonably withheld, delayed or conditioned) purchase a six-year “tail” policy for the Company policy in effect as of the date of the Merger Agreement, subject to specified limitations.

Security Holder Litigation. The Company has agreed to promptly notify Parent of any litigation against the Company and/or its directors relating to the Transactions. The Company shall control any legal proceeding brought by stockholders of the Company against the Company and/or its directors related to the Transactions. The Company will give Parent the right to review and comment on all material filings or responses to be made by the Company in connection with any such litigation, and the right to consult on the settlement with respect to such litigation, and the Company will in good faith take such comments into account. No such settlement will be agreed to without Parent’s prior written consent which shall not be unreasonably withheld, conditioned or delayed.

Takeover Laws. If any “moratorium,” “control share acquisition,” “fair price,” “supermajority,” “affiliate transactions,” “business combination statute or regulation” or other similar state anti-takeover laws and regulations (each, a “Takeover Law”) may become, or may purport to be, applicable to the Transactions, each of Parent and the Company and the members of their respective Boards of Directors will use their respective reasonable best efforts to grant such approvals and take such actions as are necessary so that the Transactions may be consummated as promptly as practicable on the terms and conditions contemplated by the Merger Agreement and otherwise act to lawfully eliminate the effect of any Takeover Law on any of the Transactions.

Section 16 Matters. The Company and the Company Board will, to the extent necessary, take appropriate action, prior to or as of the Offer Acceptance Time, to approve, for the purposes of Section 16(b) of the Exchange Act, the disposition and cancellation (or deemed disposition and cancellation) of Shares and the Company’s stock awards in the Merger by applicable individuals and to cause such dispositions and/or cancellations to be exempt under Rule 16b-3 promulgated under the Exchange Act.

Rule 14d-10 Matters. The Merger Agreement provides that prior to the Offer Acceptance Time and to the extent permitted by applicable legal requirements, the compensation committee of the Company Board will approve, as an “employment compensation, severance or other employee benefit arrangement” within the meaning of Rule 14d-10(d)(2) under the Exchange Act, each agreement, arrangement or understanding between the Company or any of its affiliates and any of the officers, directors or employees of the Company that are effective as of the date of the Merger Agreement pursuant to which compensation is paid to such officer, director or employee and will take all other action reasonably necessary to satisfy the requirements of the non-exclusive safe harbor set forth in Rule 14d-10(d)(2) under the Exchange Act.

Stock Exchange Delisting and Deregistration. Prior to the Closing Date, the Company has agreed to cooperate with Parent and to use its reasonable best efforts to take, or cause to be taken, all actions, and do or cause to be done all things, reasonably necessary, proper or advisable under applicable legal requirements and rules and policies of the NASDAQ to enable delisting by the Surviving Corporation of the Shares from the NASDAQ and the deregistration of the Shares under the Exchange Act as promptly as practicable after the Effective Time, and in any event no more than ten days after the date on which the closing of the Merger occurs.

Payoff. No later than three business days prior to the Closing Date, the Company will deliver or cause to be delivered to Parent customary payoff letters in respect of that certain Credit Agreement, dated as of November 1, 2021, by and among the Company, as the borrower, Wells Fargo, National Association, as administrative agent, and the lenders from time to time party thereto and customary lien release documentation providing for the

 

36


automatic and irrevocable release of all guarantees and security interests provided by the Company and/or its subsidiaries under such Indebtedness, in each case, in form and substance reasonably acceptable to Parent from the holders of such indebtedness (or the agents representing the foregoing).

Financing Cooperation.

Prior to the consummation of the Merger (the “Closing”) or termination of the Merger Agreement, the Company will, and will cause the Company’s subsidiaries and shall use its commercially reasonable efforts to cause its and their respective officers, directors (or equivalent managers), employees, accountants, consultants, legal counsel and agents and other representatives to, use commercially reasonable efforts to provide, at Parent’s sole cost and expense, such cooperation as Parent may reasonably request in connection with Parent obtaining the Debt Financing described in “Section 9 – Debt Financing” to finance the transactions contemplated by the Merger Agreement, including by using commercially reasonable efforts to:

 

   

reasonably assist Parent in the preparation of customary marketing and syndication documentation;

 

   

assist with the pledging of, and granting of security interests in, the collateral of the Company or the Company’s Subsidiaries in connection with the Debt Financing;

 

   

facilitate the taking of actions by the Company or its subsidiaries as may be reasonably necessary to permit the consummation of the Debt Financing on the Closing Date and to permit the proceeds thereof to be made available to Parent as of the Closing Date; and

 

   

at least four business days prior to the Closing Date (or such shorter timeframe as may be otherwise agreed), provide (A) all documentation and other information about the Company or its subsidiaries as has been reasonably requested by Parent in writing to the Company or its subsidiaries at least eight business days prior to the Closing Date under applicable “know your customer” and anti-money laundering rules and regulations and (B) a certification regarding beneficial ownership.

The Company and its subsidiaries shall not be required to: (i) pay any commitment, consent or other similar fee, incur or reimburse any costs or expenses, incur any personal liability, or provide or agree to provide any indemnity in connection with the Debt Financing prior to the Closing for which the Company is not reimbursed or otherwise indemnified by the Parent; (ii) take any action or do anything that would: (A) contravene any applicable legal requirement or its organizational documents or (B) contravene any of its material contracts; (iii) disclose any information that in the reasonable judgment of the Company would result in the disclosure of any trade secrets or similar non-financial proprietary information or violate any obligations of the Company, its subsidiaries or any other person with respect to confidentiality or could result in the loss of or jeopardize any attorney-client privilege, attorney work product protections or similar protections; (iv) waive or amend any terms of the Merger Agreement or cause any representation or warranty in the Merger Agreement to be breached or cause any condition to Closing to fail to be satisfied or otherwise cause any breach of the Merger Agreement; (v) deliver any certificate or opinion or take any other action described in this “ – Financing Cooperation” that would or would reasonably be expected to result in personal liability to the Company or its subsidiaries; (vi) provide cooperation that involves any binding commitment or agreement or instrument by the Company or its subsidiaries (or commitment or agreement which becomes effective prior to the Closing) which is not conditional on the Closing and does not terminate without liability to the Company or its subsidiaries upon the termination of the Merger Agreement; (vii) prepare any financial statements or information that are not reasonably available to it and prepared in the ordinary course of its financial reporting practice (including pro forma financial statements and projections); (viii) take any action in connection with this provision that would interfere unreasonably with the business or operations of the Company or its subsidiaries; (ix) cause any director, officer, employee or other representative of the Company or its subsidiaries to incur any actual or potential personal liability or breach any fiduciary duty; (x) change any fiscal period; (xi) require the Company or its subsidiaries to provide any solvency or other similar certificate of its chief financial officer or similar officer; or (xii) deliver or cause to be delivered any opinion of counsel, reliance letters or any certificate, comfort letter or similar deliverable in connection with the Debt Financing (other than customary authorization letters in

 

37


connection with any confidential information memorandum in connection with the Debt Financing). In addition, notwithstanding this provision, the board of directors of the Company or its subsidiaries shall not be required to approve or adopt any Debt Financing effective prior to the Closing.

Parent agreed that, prior to the Closing, the Company, its subsidiaries and their respective representatives will not have any responsibility for, or incur any liability to any person under, any financing that Parent may raise in connection with the transactions contemplated by the Merger Agreement (including the Debt Financing) or any cooperation provided pursuant to the first paragraph under this “ – Financing Cooperation”, and shall indemnify and hold harmless the Company, its subsidiaries and their respective representatives, from and against any and all losses suffered or incurred by any of them in connection with the Debt Financing or any alternative financing and any information utilized in connection with such financing.

The receipt or availability of any funds or financing (including, for the avoidance of doubt, the Debt Financing) by Parent, Purchaser or any of their respective affiliates or any other financing is not a condition to Parent’s or Purchaser’s obligations under the Merger Agreement.

Termination. The Merger Agreement may be terminated prior to the Effective Time under any of the following circumstances:

 

   

by mutual written consent of Parent and the Company at any time prior to the Offer Acceptance Time;

 

   

by either Parent or the Company if a court of competent jurisdiction or other Governmental Body of competent jurisdiction in any jurisdiction in which Parent or the Company has material assets has issued an order, decree or ruling, or has taken any other action, having the effect of permanently restraining, enjoining or otherwise prohibiting the acceptance for payment of Shares pursuant to the Offer or the Merger or making consummation of the Offer or the Merger illegal, which order, decree, ruling or other action is final and nonappealable (except that no party will be permitted to terminate the Merger Agreement pursuant to this provision if the issuance of such final and nonappealable order, decree, ruling or other action is primarily attributable to a failure on the part of such party to perform in any material respect any covenant or obligation in the Merger Agreement required to be performed by such party at or prior to the Effective Time);

 

   

by Parent, at any time prior to the Offer Acceptance Time, if, whether or not permitted to do so: (i) the Company Board has failed to include the Company Board Recommendation in the Schedule 14D-9 when mailed, or has effected a Company Adverse Change Recommendation; (ii) the Company Board has failed to publicly reaffirm its recommendation of the Merger Agreement within ten business days after Parent so requests in writing, except that Parent may only make such request once every 30 days; or (iii) in the case of a tender offer (other than the Offer as contemplated herein) or exchange offer subject to Regulation 14D under the Exchange Act, the Company Board fails to recommend, in a Solicitation/Recommendation Statement on Schedule 14D-9, rejection of such tender offer or exchange offer within ten business days of the commencement of such tender offer or exchange offer. We refer herein to any termination of the Merger Agreement pursuant to this provision as a “Change in Recommendation Termination”;

 

   

by either Parent or the Company if the Offer Acceptance Time has not occurred on or prior to 5 p.m. Eastern Time on the End Date (except that no party will be permitted to terminate the Merger Agreement pursuant to this provision if the failure of the Offer Acceptance Time to occur prior to the End Date is primarily attributable to the failure on the part of such party to perform in any material respect any covenant or obligation in the Merger Agreement required to be performed by such party). We refer to any termination of the Merger Agreement pursuant to this provision as an “End Date Termination”;

 

   

by the Company, at any time prior to the Offer Acceptance Time, in order to accept a Superior Offer and substantially concurrently enter into a binding written definitive acquisition agreement providing

 

38


 

for the consummation of a transaction constituting a Superior Offer, so long as the Company has complied in all material respects with the requirements described above under “ – No Solicitation” and “ – Change of the Company Board Recommendation” with respect to such Superior Offer, and concurrently with such termination pays the Termination Fee (as defined below). We refer to any termination of the Merger Agreement pursuant to this provision as a “Superior Offer Termination”;

 

   

by Parent, at any time prior to the Offer Acceptance Time, if a breach of any representation or warranty contained in the Merger Agreement or failure to perform any covenant or obligation in the Merger Agreement on the part of the Company has occurred such that the Representations Condition or the Obligations Condition (each as defined below) would not be satisfied and cannot be cured by the Company by the End Date, or if capable of being cured by the End Date, has not been cured within 30 days of the date Parent gives the Company notice of such breach or failure to perform (except that Parent will not be permitted to terminate the Merger Agreement pursuant to this provision if either Parent or Purchaser is then in material breach of any representation, warranty, covenant or obligation under the Merger Agreement). We refer to any termination of the Merger Agreement pursuant to this provision as a “Company Breach Termination”;

 

   

by the Company, at any time prior to the Offer Acceptance Time, if a breach of any representation or warranty contained in the Merger Agreement or failure to perform any covenant or obligation in the Merger Agreement on the part of Parent or Purchaser has occurred, in each case if such breach or failure has prevented or would reasonably be expected to prevent Parent or Purchaser from consummating the Transactions and such breach or failure cannot be cured by Parent or Purchaser, as applicable, by the End Date, or if capable of being cured by the End Date, has not been cured within 30 days of the date the Company gives Parent notice of such breach or failure to perform (except that the Company will not be permitted to terminate the Merger Agreement pursuant to this provision if the Company is then in material breach of any representation, warranty, covenant or obligation under the Merger Agreement). We refer to any termination of the Merger Agreement pursuant to this provision as a “Parent Breach Termination”; or

 

   

by the Company if Purchaser has failed to (i) commence (within the meaning of Rule 14d-2 under the Exchange Act) the Offer by August 26, 2022 (other than due to a breach by the Company of its obligations to provide required information to Purchaser) or (ii) accept and pay for all Shares validly tendered (and not validly withdrawn) as of the expiration of the Offer (as it may be extended).

Effect of Termination. If the Merger Agreement is terminated, it will be of no further force or effect and there will be no liability on the part of Parent, Purchaser or the Company or their respective directors, officers and affiliates following any such termination, except that (i) certain specified provisions of the Merger Agreement, as well as the confidentiality agreement between Parent and the Company (as described below), will survive such termination, including the provisions described in “ – Company Termination Fee” below, and (ii) no such termination will relieve any party from any liability for fraud or willful breach of the Merger Agreement prior to such termination.

Company Termination Fee. The Company has agreed to pay Parent a termination fee of $33,000,000 in cash (the “Termination Fee”) in the event that;

 

   

the Merger Agreement is terminated by the Company pursuant to a Superior Offer Termination;

 

   

the Merger Agreement is terminated by Parent pursuant to a Change in Recommendation Termination; or

 

   

(i) the Merger Agreement is terminated pursuant to an End Date Termination (but, in the case of a termination by the Company, only if at such time Parent would not be prohibited from terminating the Merger Agreement pursuant to the exception described in the End Date Termination) or a Company Breach Termination, (ii) any person shall have publicly disclosed a bona fide Acquisition Proposal after the date of the Merger Agreement and shall not have publicly withdrawn such Acquisition

 

39


 

Proposal prior to (1) in the case of the Merger Agreement being subsequently terminated due to an End Date Termination, the date that is two (2) business days prior to the Expiration Date or (2) in the case of the Merger Agreement being subsequently terminated pursuant to a Company Breach Termination, the time of the breach or failure to perform giving rise to such termination and (iii) within twelve months of such termination the Company consummates an Acquisition Proposal or enters into a definitive agreement with respect to an Acquisition Proposal (except that for purposes of determining if the Termination Fee is payable under this prong (iii), the references to “20%” in the definition of “Acquisition Proposal” described above under “ – No Solicitation” will be deemed to be references to “50%”).

In no event will the Company be required to pay the Termination Fee on more than one occasion. In the event Parent or its designee receives the Termination Fee, such receipt will be deemed to be liquidated damages for any and all losses or damages suffered or incurred by Parent, Purchaser, any of their respective affiliates or any other person in connection with the Merger Agreement (and the termination thereof), the Transactions (and the abandonment thereof) or any matter forming the basis for such termination, and none of Parent, Purchaser or any of their respective affiliates or any other person will be entitled to bring or maintain any claim, action or proceeding against the Company, Parent, Purchaser or any of their respective affiliates arising out of or in connection with the Merger Agreement, any of the Transactions or any matters forming the basis for such termination (except that such receipt will not limit the rights of Parent or Purchaser with respect to fraud or willful breach).

Specific Performance. Parent, Purchaser and the Company have agreed that irreparable damage, for which monetary damages (even if available) would not be an adequate remedy, would occur in the event that the parties to the Merger Agreement do not perform their obligations under the provisions of the Merger Agreement in accordance with its specified terms or if they otherwise breach such provisions. Accordingly, each party will be entitled to an injunction or injunctions, specific performance, or other equitable relief to prevent breaches of the Merger Agreement and to enforce specifically the terms and provisions of the Merger Agreement, without proof of damages or otherwise, in addition to any other remedy to which they are entitled under the terms of the Merger Agreement.

Expenses. Except in limited circumstances expressly specified in the Merger Agreement, all fees and expenses incurred in connection with the Merger Agreement and the Transactions will be paid by the party incurring such fees or expenses, whether or not the Offer and the Merger are consummated.

Transfer Taxes. Except as expressly provided limited circumstances expressly specified in the Merger Agreement, all transfer, documentary, sales, use, stamp, registration, value-added and other similar Taxes and fees incurred in connection with the Merger Agreement and the transactions contemplated thereby shall be paid by Parent and Purchaser when due.

Governing Law. The Merger Agreement is governed by and will be construed in accordance with the laws of the State of Delaware, without giving effect to any laws, rules or provisions that would cause the application of the laws of any jurisdiction other than the State of Delaware. The documents entered into in accordance with the Debt Financing and any dispute concerning and against the Debt Financing sources arising under, out of, in connection with or related in any manner to the Merger Agreement will be governed by and construed in accordance with the laws of the State of New York except as otherwise provided in the applicable documents relating to the Debt Financing.

Other Agreements

Confidentiality Agreement

Parent and the Company entered into a non-disclosure agreement, dated February 18, 2022 (the “Confidentiality Agreement”). Under the terms of the Confidentiality Agreement, Parent and the Company agreed that, subject to

 

40


certain exceptions including the ability to make disclosures required by applicable law, any confidential information each may make available to the other and their respective representatives will not be disclosed or used for any purpose other than for each party’s consideration of a possible negotiated merger or acquisition of the Company by Parent. The Confidentiality Agreement includes a standstill provision for the benefit of both parties, and permits Parent to privately and confidentially made a proposal to acquire the Company directly to the board of directors of the Company or to the CEO of the Company during the standstill period, as well as a fall-away provision that is triggered upon (among other events) (i) a party’s announcement of entry into a definitive agreement with a person other than the other party for the acquisition of all or a majority of such party’s equity securities or all or substantially all of the such party’s assets, (ii) recommendation by a party’s board in favor of a bona fide tender or exchange offer or (iii) the other party publicly discloses that it has authorized a process for the solicitation of competing offers or indications of interest in respect of an alternative transaction. This summary of the Confidentiality Agreement is only a summary and is qualified in its entirety by reference to the Confidentiality Agreement, which is filed as Exhibit (d)(2) of the Schedule TO and is incorporated herein by reference.

Exclusivity Agreement

On March 17, 2022, Parent and the Company entered into an exclusivity agreement (the “Exclusivity Agreement”), pursuant to which the Company agreed that from March 17, 2022 until the earlier of (i) 11:59 p.m. Eastern Time on April 11, 2022 and (ii) if at any time Parent or any of its representatives initiates any discussion with the Company or its representatives of reduction in the $5.60 per share price set forth in Parent’s March 13, 2022 proposal, the Company would not, and would cause its subsidiaries not to, and direct its and its subsidiaries’ respective representatives not to (other than with respect to Parent or any of its representatives), directly or indirectly, (i) solicit, initiate, continue or enter into discussions with, or knowingly encourage, or provide any non-public information to, any corporation, partnership or other entity or group or person that constitutes, or would be expected to lead to, an acquisition proposal, (ii) engage in, continue or otherwise participate in any discussions or negotiations relating to, enter into any agreement, arrangement or understanding relating to, an acquisition proposal or any inquiry, proposal or offer that would be expected to lead to an acquisition proposal, or (iii) grant any waiver, amendment or release under any standstill or confidentiality agreement relating, directly or indirectly, to an acquisition proposal.

The Company also agreed to and cause its subsidiaries to, and direct its and its subsidiaries’ respective representatives to immediately cease and cause to be terminated any and all contracts, discussions and negotiations with any third party with respect to an acquisition proposal or that could reasonably be expected to lead to an acquisition proposal. This summary of the Exclusivity Agreement is only a summary and is qualified in its entirety by reference to the Exclusivity Agreement, which is filed as Exhibit (d)(3) of the Schedule TO and is incorporated herein by reference.

Debt Commitment Letter

The description of the Debt Commitment Letter included in Section 9 – “Source and Amount of Funds – Debt Financing” is incorporated into this Section 11 by reference.

 

12.

Purpose of the Offer; Plans for the Company

Purpose of the Offer

The purpose of the Offer is for Parent, through Purchaser, to acquire control of, and would be the first step in Parent’s acquisition of the entire equity interest in, the Company. The Offer is intended to facilitate the acquisition of all outstanding Shares. The purpose of the Merger is to acquire all outstanding Shares not tendered and purchased pursuant to the Offer. If the Offer is consummated, Purchaser intends to complete the Merger as promptly as practicable thereafter subject to the satisfaction and waiver of the other conditions to Merger set forth in the Merger Agreement.

 

41


The Company Board has unanimously: (i) determined that the Merger Agreement, the Offer and the Merger are fair to, and in the best interest of, the Company and its stockholders; (ii) declared that it is advisable for the Company to enter into the Merger Agreement; (iii) approved the execution, delivery and performance by the Company of the Merger Agreement and the consummation of the transactions contemplated by the Merger Agreement, including the Offer and the Merger; (iv) agreed that the Merger shall be effected under Section 251(h) of the DGCL; and (v) resolved to recommend that the Company’s stockholders accept the Offer and tender their Shares pursuant to the Offer. Section 251(h) of the DGCL provides that following consummation of a successful tender offer for a public corporation, and subject to certain statutory provisions, if the acquirer holds at least the amount of shares of each class of stock of the constituent corporation that would otherwise be required to approve a merger for the constituent corporation, and the other stockholders receive the same consideration for their stock in the merger as was payable in the tender offer, the acquirer can effect a merger without the action of the other stockholders of the constituent corporation. Accordingly, if we consummate the Offer, we are required pursuant to the Merger Agreement to complete the Merger without a vote of the Company’s stockholders in accordance with Section 251(h) of the DGCL.

Plans for the Company

In connection with Parent’s consideration of the Offer, Parent is developing a plan, on the basis of available information, for the combination of the business of the Company with that of Parent. Parent plans to keep the Company as a separate operating business. Parent will continue to evaluate and refine the plan and may make changes to it as additional information is obtained.

After completion of the Offer and the Merger, the Company will be a wholly owned subsidiary of Parent. From and after the consummation of the Merger, until successors are duly elected or appointed and qualified in accordance with applicable law, or until their earlier death, resignation or removal, the directors and officers of Purchaser as of immediately prior to the Effective Time will be the directors and officers of the Company as of immediately after the Effective Time.

Except as set forth in this Offer to Purchase and the Merger Agreement, Parent and Purchaser have no present plans or proposals that would relate to or result in (i) any extraordinary corporate transaction involving the Company (such as a merger, reorganization, liquidation, relocation of any operations or sale or other transfer of a material amount of assets), (ii) any sale or transfer of a material amount of assets of the Company, (iii) any material change in the Company’s capitalization, indebtedness or dividend policy or (iv) any other material change in the Company’s corporate structure or business.

 

13.

Certain Effects of the Offer

Because the Merger will be governed by Section 251(h) of the DGCL, no vote of the Company’s stockholders will be required to consummate the Merger. Promptly after the consummation of the Offer, and subject to the satisfaction of the remaining conditions set forth in the Merger Agreement, we and the Company will consummate the Merger at 8:00 a.m., Eastern Time, on the same date as the consummation of the Offer (unless otherwise agreed by the Company, Parent and Purchaser) pursuant to Section 251(h) of the DGCL. Immediately following the Merger, all of the outstanding shares of the Company’s common stock will be held by Parent.

Market for the Shares. The purchase of Shares pursuant to the Offer will reduce the number of holders of Shares and the number of Shares that might otherwise trade publicly, which could adversely affect the liquidity and market value of the remaining Shares. We cannot predict whether the reduction in the number of Shares that might otherwise trade publicly would have an adverse or beneficial effect on the market price for, or marketability of, the Shares or whether such reduction would cause future market prices to be greater or less than the Offer Price. If the Offer is successful, there will be no market for the Shares because Purchaser intends to consummate the Merger as soon as practicable following the Offer Closing.

 

42


Stock Quotation. The Shares are currently listed on NASDAQ. Immediately following the consummation of the Merger (which is required to occur at 8:00 a.m., Eastern Time, on the same date as the consummation of the Offer, unless otherwise agreed by the Company, Parent and Purchaser), the Shares will no longer meet the requirements for continued listing on NASDAQ, and Parent will seek to cause the listing of Shares on NASDAQ to be discontinued as soon as the requirements for termination of the listing are satisfied.

Margin Regulations. The Shares are currently “margin securities” under the Regulations of the Board of Governors of the Federal Reserve System (the “Federal Reserve Board”), which has the effect, among other things, of allowing brokers to extend credit based on the use of Shares as collateral. Depending upon factors similar to those described above regarding the market for the Shares and stock quotations, it is possible that, following the Offer, the Shares would no longer constitute “margin securities” for the purposes of the margin regulations of the Federal Reserve Board and, therefore, could no longer be used as collateral for loans made by brokers.

Exchange Act Registration. The Shares are currently registered under the Exchange Act. Such registration may be terminated upon application of the Company to the SEC if the Shares are neither listed on a national securities exchange nor held by 300 or more holders of record. Termination of registration of the Shares under the Exchange Act would substantially reduce the information required to be furnished by the Company to its stockholders and to the SEC and would make certain provisions of the Exchange Act no longer applicable to the Company, such as the short-swing profit recovery provisions of Section 16(b) of the Exchange Act, the requirement of furnishing a proxy statement pursuant to Section 14(a) of the Exchange Act in connection with stockholders’ meetings and the related requirement of furnishing an annual report to stockholders and the requirements of Rule 13e-3 under the Exchange Act with respect to “going private” transactions. Furthermore, the ability of “affiliates” of the Company and persons holding “restricted securities” of the Company to dispose of such securities pursuant to Rule 144 under the Securities Act of 1933, as amended, may be impaired or eliminated. If registration of the Shares under the Exchange Act were terminated, the Shares would no longer be “margin securities” or be eligible for listing on NASDAQ. Parent intends to, and will cause the Surviving Corporation to, terminate the registration of the Shares under the Exchange Act as soon after consummation of the Merger as the requirements for termination of registration are met.

 

14.

Dividends and Distributions

The Merger Agreement provides that from the date of the Merger Agreement to the Effective Time, without the prior written consent of Parent, the Company will not establish a record date for, declare, accrue, set aside or pay any dividend or make any other distribution in respect of the Company’s capital stock.

 

15.

Conditions of the Offer

For purposes of this Section 15, capitalized terms used but not defined in this Section 15 and defined in the Merger Agreement have the meanings set forth in the Merger Agreement, a copy of which is filed as Exhibit (d)(1) to the Schedule TO and is incorporated herein by reference. The obligation of Purchaser to accept for payment and pay for Shares validly tendered (and not validly withdrawn) pursuant to the Offer is subject to the satisfaction of the Minimum Condition and the other conditions below.

The Offer is not subject to any financing condition. Purchaser will not be required to accept for payment or, subject to any applicable rules and regulations of the SEC, including Rule 14e-l(c) under the Exchange Act (relating to Purchaser’s obligation to pay for or return tendered Shares promptly after the termination or withdrawal of the Offer), to pay for, any Shares tendered pursuant to the Offer and may delay the acceptance for payment of or, subject to any applicable rules and regulations of the SEC, the payment for, any tendered Shares, and (subject to the provisions of the Merger Agreement) may amend the Offer as otherwise permitted by the Merger Agreement if, at one minute following 11:59 p.m. Eastern Time on any scheduled Expiration Date (as it may be extended or subject to any requirements to extend), (i) the Minimum Condition or the Termination

 

43


Condition has not been satisfied, or (ii) any of the following other conditions shall not be satisfied or (to the extent permitted by applicable law) waived:

 

   

any waiting period (and any timing agreements, any extensions of any waiting period, any understandings or commitments obtained by request or other action of the FTC and/or the DOJ, as applicable) imposed under the HSR Act applicable to the Transactions shall have expired or been terminated (the “HSR Condition”);

 

   

(i) there shall not have been issued by (A) any court of competent jurisdiction in any legal proceeding involving a Governmental Body or (B) any court of competent jurisdiction in any legal proceeding involving a non-Governmental Body in a jurisdiction in which Parent or the Company or their respective subsidiaries has assets, operations or revenues or remain in effect any judgment, temporary restraining order, preliminary or permanent injunction or other order preventing the acquisition of or payment for Shares pursuant to the Offer or the consummation of the Offer or the Merger and (ii) no action shall have been taken, or any legal requirement or order promulgated, entered, enforced, enacted, issued or deemed applicable to the Offer or the Merger by any Governmental Body which directly or indirectly prohibits, or makes illegal, the acquisition of or payment for Shares pursuant to the Offer, or the consummation of the Merger; provided, that Parent and Purchaser shall not be permitted to invoke this clause unless they shall have taken all actions required under the Merger Agreement to avoid any such order or have any such order lifted (each of the conditions in this bullet point and the preceding bullet point (in the case of this bullet point, as such condition relates to the HSR Act), the “Regulatory Condition”);

 

   

after the date of the Merger Agreement, there not having occurred a Company Material Adverse Effect that is continuing (the “MAE Condition”);

 

   

the Company having complied with or performed in all material respects each of the covenants and agreements it is required to comply with or perform at or prior to the Offer Acceptance Time (the “Obligations Condition”);

 

   

the Merger Agreement not having been terminated in accordance with its terms (the “Termination Condition”);

 

   

(1) the representations and warranties of the Company as set forth in Section 3.1 of the Merger Agreement (Due Organization; Subsidiaries, Etc.) Section 3.20 (Authority; Binding Nature of Agreement) and Section 3.22 (Merger Approval) being accurate in all material respects as of the date of the Merger Agreement and shall be accurate in all material respects at and as of the Offer Acceptance Time as if made at and as of such time (it being understood that the accuracy of those representations or warranties that address matters only as of a specific date shall be measured (subject to the applicable materiality standard as set forth in this clause (1)) only as of such date), (2) each of the representations and warranties of the Company as set forth in Section 3.5(a) (Absence of Changes) shall have been accurate as of the date of the Merger Agreement and shall be accurate at and as of the Offer Acceptance Time as if made on and as of such time (it being understood that the accuracy of those representations or warranties that address matters only as of a specific date shall be measured (subject to the applicable materiality standards set forth in this clause (2)) only as of such date), (3) the representations and warranties of the Company as set forth in subsections (a), (c) (first sentence only) and (e) of Section 3.3 (Capitalization, Etc.) shall have been accurate in all respects as of the date of the Merger Agreement and shall be accurate in all respects at and as of the Offer Acceptance Time as if made on and as of such time, other than de minimis inaccuracies (it being understood that the accuracy of those representations or warranties that address matters only as of a specific date shall be measured (subject to the applicable de minimis standard as set forth in this clause (3)) only as of such date); and (4) the representations and warranties of the Company as set forth in the Merger Agreement (other than those referred to in clauses (1), (2) and (3) above) shall have been accurate in all respects as of the date of the Merger Agreement, and shall be accurate in all respects at and as of the Offer Acceptance Time as if made at and as of such time, except that any inaccuracies in such representations and warranties

 

44


 

shall be disregarded if the circumstances giving rise to all such inaccuracies (considered collectively) do not constitute, and would not reasonably be expected to have, a Material Adverse Effect (it being understood that, for purposes of determining the accuracy of such representations and warranties, (A) all “Material Adverse Effect” qualifications and other materiality qualifications contained in such representations and warranties shall be disregarded (except where the term material is part of a defined term under the Merger Agreement and the use of such defined term therein) and (B) the accuracy of those representations or warranties that address matters only as of a specific date shall be measured (subject to the applicable materiality standard as set forth in this clause (4) only as of such date) (the “Representations Condition”); and

 

   

Parent having received from the Company a certificate signed on behalf of the Company by an executive officer of the Company confirming that the Representations Condition and the Obligations Condition have been duly satisfied.

The foregoing conditions are in addition to, and not a limitation of, the rights of Parent and Purchaser to extend, terminate or modify the Offer pursuant to the terms of the Merger Agreement.

The foregoing conditions are for the sole benefit of Parent and Purchaser and, except for the Minimum Condition and the Termination Condition (which may only be waived with the prior written consent of the Company), may be waived by Parent or Purchaser in whole or in part at any time and from time to time, in each case prior to the Offer Expiration Time, and in the sole discretion of Parent or Purchaser, subject in each case to the terms of the Merger Agreement and applicable law. Any reference in this Section 15 or elsewhere in the Merger Agreement to a condition or requirement being satisfied will be deemed to be satisfied if such condition or requirement is so waived.

Purchaser expressly reserves the right to (i) increase the Offer Price, (ii) waive any Offer Condition and (iii) make any other changes in the terms and conditions of the Offer not inconsistent with the Merger Agreement; provided, that unless otherwise provided by the Merger Agreement, without the prior written consent of the Company, Purchaser is not permitted to (A) decrease the Offer Price; (B) change the form of consideration payable in the Offer; (C) decrease the maximum number of Shares sought to be purchased in the Offer; (D) impose conditions or requirements to the Offer in addition to the Offer Conditions; (E) amend or modify any of the Offer Conditions or any other terms or conditions of the Merger Agreement in a manner that adversely affects, or would reasonably be expected to adversely affect, any holder of Shares or that would, individually or in the aggregate, reasonably be expected to prevent or delay the consummation of the Offer or prevent, delay or impair the ability of Parent or Purchaser to consummate the Offer, the Merger or the other Transactions; (F) amend, modify or waive the Minimum Condition or the Termination Condition; (G) extend or otherwise change the Expiration Date in a manner other than as required or permitted by the Merger Agreement; or (H) provide any “subsequent offering period” within the meaning of Rule 14d-11 under the Exchange Act. Parent may not withdraw the Offer prior to any Expiration Date of the Offer, unless the Merger Agreement is terminated in accordance with its terms.

 

16.

Certain Legal Matters; Regulatory Approvals

General. Based on our examination of publicly available information filed by the Company with the SEC and other publicly available information concerning the Company, we are not aware of any governmental license or regulatory permit that appears to be material to the Company’s business that would be adversely affected by our acquisition of Shares pursuant to the Offer or, except as set forth below in this Section 16, of any approval or other action by any government or governmental administrative or regulatory authority or agency, domestic or foreign, that would be required for our purchase of Shares pursuant to the Offer. Should any such approval or other action be required or desirable, we currently contemplate that, except for takeover laws in jurisdictions other than Delaware as described below under “State Takeover Laws,” such approval or other action will be sought. However, except for observance of the waiting periods and the obtaining of the required approvals

 

45


summarized under “Antitrust Compliance” below in this Section 16, we do not anticipate delaying the purchase of Shares tendered pursuant to the Offer pending the outcome of any such matter. There can be no assurance that any such approval or action, if needed, will be obtained or, if obtained, that it will be obtained without substantial conditions; and there can be no assurance that, in the event that such approvals were not obtained or such other actions were not taken, adverse consequences might not result to the Company’s business or that certain parts of the Company’s business might not have to be disposed of or held separate, any of which may give us the right to terminate the Offer at any Expiration Date without accepting for payment any Shares validly tendered (and not validly withdrawn) pursuant to the Offer. Our obligation under the Offer to accept for payment and pay for Shares is subject to the Offer Conditions, including, among other conditions, the Regulatory Condition. See Section 15 – “Conditions of the Offer.”

Antitrust Compliance

U.S. Antitrust Compliance

Under the HSR Act, certain acquisition transactions, including Purchaser’s purchase of Shares pursuant to the Offer, may not be consummated until certain information and documentary material has been furnished for review by the FTC and the Antitrust Division of the DOJ (the “Antitrust Division”) and certain waiting period requirements have expired or been terminated.

Under the HSR Act, the purchase of Shares may not be completed until the expiration of a 15-calendar day waiting period following the filing of certain required information and documentary material concerning the Offer with the FTC and the Antitrust Division. If the 15 calendar day waiting period expires on a federal holiday (as defined in 5 U.S.C. 6103(a)), a Saturday, or Sunday, the waiting period is automatically extended until 11:59 p.m., Eastern Time, the next business day. Each of Parent and the Company filed their Premerger Notification and Report Form under the HSR Act with the FTC and the Antitrust Division in connection with the purchase of Shares in the Offer and the Merger on April 26, 2022 and therefore the waiting period will expire on May 11, 2022, unless earlier terminated by the FTC and the Antitrust Division, Parent receives a request for additional information or documentary material prior to that time, or Parent voluntarily withdraws and refiles its notification so as to provide the FTC and the Antitrust Division an additional 15 days to review the transaction. Expiration or termination of the waiting period under the HSR Act is a condition to the consummation of the Offer.

The FTC and the Antitrust Division frequently scrutinize the legality under the U.S. antitrust laws of transactions like the Offer and the Merger. At any time, the FTC or the Antitrust Division could take any action under the antitrust laws that it considers necessary or desirable in the public interest, including seeking (i) to enjoin the purchase of Shares pursuant to the Offer, (ii) to enjoin the Merger, (iii) to require Purchaser (or, after completion of the Merger, Parent) to divest the Shares, or (iv) to require us or the Company to divest substantial assets or seek other conduct relief as a condition of consummating the acquisition. Private parties, as well as state attorneys general, also may bring legal actions under the antitrust laws of the United States or state antitrust laws. At any time before or after the consummation of the Merger, notwithstanding the expiration or early termination of the applicable waiting period under the HSR Act, any state or private party could file suit seeking to enjoin the consummation of the Merger or seeking other structural or conduct relief or damages. See Section 15 – “Conditions of the Offer.”

Based upon an examination of publicly available information and other information relating to the businesses in which the Company is engaged, Parent and the Company believe that neither the purchase of Shares by Purchaser pursuant to the Offer nor the consummation of the Merger should violate applicable antitrust laws. Nevertheless, neither Parent nor the Company can be certain that a challenge to the Offer or the Merger on antitrust grounds will not be made, or, if such challenge is made, what the result will be. See Section 15 – “Conditions of the Offer.”

 

46


State Takeover Laws

The Company is incorporated under the laws of the State of Delaware. In general, Section 203 of the DGCL (“Section 203”) prevents a Delaware corporation from engaging in a “business combination” (defined to include mergers and certain other actions) with an “interested stockholder” (including a person who owns or has the right to acquire 15% or more of a corporation’s outstanding voting stock) for a period of three years following the date such person became an “interested stockholder” unless, among other things, the “business combination” is approved by the board of directors of such corporation before such person became an “interested stockholder.” The Company Board approved the Merger Agreement and the Transactions, and the restrictions on “business combinations” described in Section 203 are inapplicable to the Merger Agreement and the Transactions.

The Company may be deemed to be conducting business in a number of states throughout the United States, some of which have enacted takeover laws. We do not know whether any of these laws will, by their terms, apply to the Offer or the Merger and have not attempted to comply with any such laws. Should any person seek to apply any state takeover law, we will take such action as then appears desirable, which may include challenging the validity or applicability of any such statute in appropriate court proceedings. In the event any person asserts that the takeover laws of any state are applicable to the Offer or the Merger, and an appropriate court does not determine that it is inapplicable or invalid as applied to the Offer or the Merger, we may be required to file certain information with, or receive approvals from, the relevant state authorities. In addition, if enjoined, we may be unable to accept for payment any Shares tendered pursuant to the Offer, or be delayed in continuing or consummating the Offer and the Merger. In such case, we may not be obligated to accept for payment any Shares tendered in the Offer. See Section 15 – “Conditions of the Offer.”

 

17.

Appraisal Rights

No appraisal rights are available to the holders of Shares in connection with the Offer. If the Merger is completed, appraisal rights will be available in connection with the Merger as further described below, but, although the availability of appraisal rights depends on the Merger being completed, stockholders who wish to exercise such appraisal rights must do so no later than the time of the consummation of the Offer and 20 days after the mailing of the Schedule 14D-9, even though the Merger will not have been completed as of such time. If the Merger is completed, the holders of Shares who (i) did not tender their Shares in the Offer; (ii) followed the procedures set forth in Section 262 of the DGCL to exercise and perfect their appraised demand; and (iii) do not thereafter lose their appraisal rights (by withdrawal, failure to perfect or otherwise), in each case in accordance with the DGCL, will be entitled to have their Shares appraised by the Delaware Court of Chancery and receive payment of the “fair value” of such Shares, exclusive of any element of value arising from the accomplishment or expectation of the Merger, together with a fair rate of interest, as determined by such court. Unless the Delaware Court of Chancery in its discretion determines otherwise for good cause shown, interest from the effective date of the Merger through the date of payment of the judgment will be compounded quarterly and will accrue at 5% over the Federal Reserve discount rate (including any surcharge) as established from time to time during the period between the effective date of the Merger and the date of payment of the judgment.

The “fair value” of any Shares could be based upon considerations other than, or in addition to, the price paid in the Offer and the market value of such Shares. Moreover, the “fair value” so determined could be higher or lower than, or the same as, the Offer Price. Moreover, we may argue in an appraisal proceeding that, for purposes of such proceeding, the fair value of such Shares is less than the Offer Price.

Section 262 of the DGCL provides that, if a merger was approved pursuant to Section 251(h) of the DGCL, either a constituent corporation before the effective date of the merger or the surviving corporation within ten days thereafter shall notify each of the holders of any class or series of stock of such constituent corporation who are entitled to appraisal rights of the approval of the merger and that appraisal rights are available for any or all shares of such class or series of stock of such constituent corporation, and shall include in such notice a copy of

 

47


Section 262 of the DGCL. The Schedule 14D-9 constitutes the formal notice by the Company to its stockholders of appraisal rights in connection with the Merger under Section 262 of the DGCL.

As described more fully in the Schedule 14D-9, if a stockholder wishes to elect to exercise appraisal rights under Section 262 of the DGCL in connection with the Merger, such stockholder must do all of the following:

 

   

within the later of the consummation of the Offer and twenty days after the date of mailing of the formal notice of appraisal rights, deliver to the Company a written demand for appraisal of Shares held, which demand must reasonably inform the Company of the identity of the stockholder and that the stockholder is demanding appraisal;

 

   

not tender such stockholder’s Shares in the Offer;

 

   

continuously hold of record the Shares from the date on which the written demand for appraisal is made through the Effective Time; and

 

   

comply with the procedures of Section 262 of the DGCL for perfecting appraisal rights thereafter.

Under Section 262 of the DGCL, a demand for appraisal rights must be made by the record holder of Shares. If you do not hold your Shares of record and desire to exercise appraisal rights in connection with the Merger, you will need to arrange for the record holder to make the demand for appraisal rights on your behalf in compliance with Section 262 of the DGCL.

The foregoing summary of the appraisal rights of stockholders under the DGCL does not purport to be a complete statement of the procedures to be followed by the stockholders desiring to exercise any appraisal rights available thereunder and is qualified in its entirety by reference to Section 262 of the DGCL. The proper exercise of appraisal rights requires strict and timely adherence to the applicable provisions of the DGCL. A copy of Section 262 of the DGCL is included as Annex II to the Schedule 14D-9.

The information provided above is for informational purposes only with respect to your alternatives if the Merger is completed. If you tender your Shares into the Offer, you will not be entitled to exercise appraisal rights with respect to your Shares, but, instead, upon the terms and subject to the conditions to the Offer, you will receive the Offer Price for your Shares.

 

18.

Fees and Expenses

Purchaser has retained D.F. King & Co., Inc. to be the Information Agent, and Equiniti Trust Company to be the Depositary in connection with the Offer. The Information Agent may contact holders of Shares by mail, telephone, telecopy and personal interview and may request banks, brokers, dealers and other nominees to forward materials relating to the Offer to beneficial owners of Shares.

The Information Agent and the Depositary each will receive reasonable and customary compensation for their respective services in connection with the Offer, will be reimbursed for reasonable out-of-pocket expenses and will be indemnified against certain liabilities and expenses in connection therewith, including certain liabilities under federal securities laws.

None of Parent or Purchaser will pay any fees or commissions to any broker or dealer or to any other person (other than to the Depositary and the Information Agent) in connection with the solicitation of tenders of Shares pursuant to the Offer. Brokers, dealers, commercial banks and trust companies will, upon request, be reimbursed by Purchaser for customary mailing and handling expenses incurred by them in forwarding offering materials to their customers. In those jurisdictions where applicable laws or regulations require the Offer to be made by a licensed broker or dealer, the Offer shall be deemed to be made on behalf of Purchaser by one or more registered brokers or dealers licensed under the laws of such jurisdiction to be designated by Purchaser.

 

48


19.

Miscellaneous

The Offer is being made to all holders of Shares. We are not aware of any jurisdiction in which the making of the Offer or the acceptance thereof would be prohibited by securities, “blue sky” or other valid laws of such jurisdiction. If we become aware of any U.S. state in which the making of the Offer or the acceptance of Shares pursuant thereto would not be in compliance with an administrative or judicial action taken pursuant to a U.S. state statute, we will make a good faith effort to comply with any such law. If, after such good faith effort, we cannot comply with any such law, the Offer will not be made to (nor will tenders be accepted from or on behalf of) the holders of Shares in such state. In any jurisdictions where applicable laws require the Offer to be made by a licensed broker or dealer, the Offer shall be deemed to be made on behalf of Purchaser by one or more registered brokers or dealers licensed under the laws of such jurisdiction to be designated by Purchaser.

No person has been authorized to give any information or to make any representation on behalf of Parent or Purchaser not contained herein or in the Letter of Transmittal, and, if given or made, such information or representation must not be relied upon as having been authorized. No broker, dealer, bank, trust company, fiduciary or other person shall be deemed to be the agent of Parent, Purchaser the Depositary or the Information Agent for the purposes of the Offer.

Parent and Purchaser have filed with the SEC a Tender Offer Statement on Schedule TO pursuant to Rule 14d-3 under the Exchange Act, together with exhibits furnishing certain additional information with respect to the Offer, and may file amendments thereto. In addition, the Company has filed or will file, pursuant to Rule 14d-9 under the Exchange Act, the Schedule 14D-9 with the SEC, together with exhibits, setting forth the recommendation of the Company Board with respect to the Offer and the reasons for such recommendation and furnishing certain additional related information. A copy of such documents, and any amendments thereto, may be examined at, and copies may be obtained from, the SEC in the manner set forth in Section 7 – “Certain Information Concerning the Company” above.

Atlas Merger Sub, Inc.

April 26, 2022

 

49


SCHEDULE I

DIRECTORS AND EXECUTIVE OFFICERS OF PURCHASER AND PARENT

 

1.

PURCHASER

The name, business address, present principal occupation or employment and material occupations, positions, offices or employment for the past five years of the directors and executive officers of Purchaser are set forth below. The business address of each such director and executive officer is c/o Atlas Merger Sub, Inc., 11388 Sorrento Valley Road, San Diego, California, 92121. The telephone number at such office is (858) 704-6440. Except as otherwise indicated, all directors and executive officers listed below are citizens of the United States.

 

Name and Position

  

Present Principal Occupation or Employment; Material

Positions Held During the Last Five Years;
Citizenship (if not United States)

Helen Torley

Director; President

  

Helen Torley is a board member of Quest Diagnostics Incorporated, a diagnostic information services company.

 

Dr. Torley previously served as Chief Commercial Officer at Onyx pharmaceuticals from 2011-2013 until the acquisition of Onyx by Amgen in 2013. From 2002-2011 Dr. Torley held several senior commercial positions at Amgen including Vice President and General Manager US Bone Health and Vice President and General Manager US Nephrology. From 1997-2002 she held various senior management positions at Bristol-Myers Squibb, including Regional Vice President of Cardiovascular and Metabolic Sales and Head of Cardiovascular Global Marketing. She began her industry career at Sandoz, which merged with Ciba-Geigy to become Novartis in 1996, where she held a range of positions of increasing responsibility in Clinical Development, culminating in the position of Vice President of Medical Affairs, responsible for overseeing the design and conduct of a broad portfolio of clinical studies across nephrology, rheumatology, oncology and CNS indications.

 

Dr. Torley has served as CEO of Parent since 2014 and as Director and President of Purchaser since 2022.

 

Dr. Torley is a citizen of England.

 

Nicole LaBrosse

Director; Treasurer

  

Nicole LaBrosse was appointed Chief Financial Officer of Parent in 2022. Previously Ms. LaBrosse served as Parent’s Vice President, Finance and Accounting from January 2020 to February 2022 and as the Company’s Executive Director, Controller from July 2017 to December 2019. From June 2015 to June 2017, she was Parent’s Senior Director, Financial Reporting. Before joining Parent, Ms. LaBrosse was with PricewaterhouseCoopers, LLP from 2004 to 2015.

 

Ms. LaBrosse has served Director and Treasurer of Purchaser since 2022.

 

2.

PARENT

The name, business address, present principal occupation or employment and material occupations, positions, offices or employment for the past five years of each of the directors and executive officers of Parent are set forth below. The business address of each such director and executive officer is c/o Atlas Merger Sub, Inc., 11388

 

50


Sorrento Valley Road, San Diego, California, 92121. The telephone number at such office is (858) 704-6440. Except as otherwise indicated, each director and executive officer is a citizen of the United States.

 

Name and Position

  

Present Principal Occupation or Employment; Material

Positions Held During the Last Five Years;
Citizenship (if not United States)

Connie Matsui

Chair of the Board

  

Connie Matsui is a board member of Artelo Biosciences, Inc., a biopharmaceutical company and Sutro Biopharma, Inc., a biopharmaceutical company.

 

Ms. Matsui retired from Biogen Idec Inc., a biotechnology company, in January 2009 as the Executive Vice President, Knowledge and Innovation Networks. She served as an Executive Committee member at both Biogen Idec and IDEC Pharmaceuticals, a predecessor of Biogen Idec. Among the many major roles she played after joining IDEC Pharmaceuticals in November 1992 was Senior Vice President, overseeing investor relations, corporate communications, human resources, project management and strategic planning. Prior to entering the biotechnology industry, Ms. Matsui worked for Wells Fargo Bank in general management, marketing and human resources.

 

Helen Torley

Director; President, Chief Executive Officer

  

Helen Torley is a board member of Quest Diagnostics Incorporated, a diagnostic information services company.

 

Dr. Torley previously served as Chief Commercial Officer at Onyx pharmaceuticals from 2011-2013 until the acquisition of Onyx by Amgen in 2013. From 2002-2011 Dr. Torley held several senior commercial positions at Amgen including Vice President and General Manager US Bone Health and Vice President and General Manager US Nephrology. From 1997-2002 she held various senior management positions at Bristol-Myers Squibb, including Regional Vice President of Cardiovascular and Metabolic Sales and Head of Cardiovascular Global Marketing. She began her industry career at Sandoz, which merged with Ciba-Geigy to become Novartis in 1996, where she held a range of positions of increasing responsibility in Clinical Development, culminating in the position of Vice President of Medical Affairs, responsible for overseeing the design and conduct of a broad portfolio of clinical studies across nephrology, rheumatology, oncology and CNS indications.

 

Dr. Torley has served as CEO of Parent since 2014.

 

Dr. Torley is a citizen of England.

 

Jeffrey Henderson

Director

  

Jeffrey Henderson is a board member of Becton Dickinson and Company, a medical technology company, Fibrogen, Inc., a biotechnology company and Qualcomm, Inc., a wireless communications and semiconductor company.

 

Mr. Henderson has served as President of JWH Consulting LLC, an investment and business advisory firm, since January 2018. From 2015 to 2019, he served as a Healthcare Advisory Director to Berkshire Partners LLC. Mr. Henderson previously served as the Chief Financial

 

51


Name and Position

  

Present Principal Occupation or Employment; Material

Positions Held During the Last Five Years;
Citizenship (if not United States)

  

Officer of Cardinal Health, Inc., a multinational health care services company, from May 2005 to November 2014, and in an executive capacity until his retirement from Cardinal in August 2015. From 1998 to 2005, Mr. Henderson held various senior management positions at Eli Lilly and Company, a multinational pharmaceutical company, including President and General Manager, Eli Lilly Canada, Inc. and Controller and Treasurer of Eli Lilly, Inc.

 

Bernadette Connaughton

Director

  

Bernadette Connaughton is a board member of Editas Medicine, Inc., a clinical stage biotechnology company, Syneos Health Inc., a biopharmaceutical services company and Zealand Pharma A/S, a biotechnology company.

 

Ms. Connaughton retired from Bristol-Myers Squibb Pharmaceutical Company, a multinational pharmaceutical company, where she served in senior management positions from 2004 to October 2017. She most recently served as Bristol-Myers Squibb’s President, Intercontinental Region. Ms. Connaughton was recently a member of the board of directors of Visterra, Inc., a private clinical stage biotechnology company, acquired by Otsuka. She also previously served on the European Federation of Pharmaceutical Industry Association, Patient Access and European Markets Committees.

 

Matthew Posard

Director

  

Matthew Posard is the chairman of the board of DermTech, Inc., a precision dermatology company, the chairman of the board Nautilus Biotechnology, Inc., a development stage life sciences company and a board member of Talis Biomedical, a developer of diagnostic tests for infectious diseases.

 

Mr. Posard is Founding Principal of Explore DNA, a life sciences executive consulting firm, a position he has held since March 2016. Since 2017, he has provided advisory services to CEOs for several emerging life sciences companies. From February 2017 to April 2018, Mr. Posard served as President and Chief Commercial Officer of GenePeeks, Inc., a genetic research company. From March 2015 to April 2016, he served as Chief Commercial Officer of Trovagene, Inc., a molecular diagnostic biotechnology company. From February 2006 to February 2015, he held various commercial and general management positions at Illumina, Inc., a genomics company focusing on DNA sequencing, including senior executive positions overseeing Global Sales, Marketing, and General Manager of Clinical and Consumer Genomics as well as New and Emerging Markets.

 

Moni Miyashita

Director

   Moni Miyashita has served as the Chief Strategy Officer of Valo Health, LLC, a technology company built to transform the drug discovery and development process using human-centric data and artificial intelligence computation since May 2019. Prior to Valo Health, from August 2015 to May 2019, she was a Partner at Innosight Consulting, where she provided growth strategy consulting services for businesses in the biotech, healthcare and technology industries. From 2011 to 2015, she

 

52


Name and Position

  

Present Principal Occupation or Employment; Material

Positions Held During the Last Five Years;
Citizenship (if not United States)

  

was a Senior Advisor at McKinsey where she advised senior executive leadership teams on executing strategic M&A. Prior to McKinsey, she served as Vice President, Corporate Development at IBM Corporation, an information technology company, from 1998 to 2011.

 

Jean-Pierre Bizzari

Director

  

Jean-Pierre Bizzari is a board member of Compugen Ltd., a biotechnology company, Nordic Nanovector ASA, a biotechnology company and Transgene S.A., a biopharmaceutical company.

 

Dr. Bizzari retired from Celgene Corporation, a global pharmaceutical company, having served as Executive Vice President and Global Head of Oncology from October 2012 to December 2015 and as Senior Vice President for Clinical Development Oncology from 2008 to October 2012. Dr. Bizzari was also an assistant in the medical oncology department at La Pitié-Salpêtrière hospital in Paris.

 

Dr. Bizzari is a citizen of France and the United States.

 

James Daly

Director

  

James Daly is a board member of Acadia Pharmaceutical, Inc., a biopharmaceutical company, argenx S.E., a biopharmaceutical company, Bellicum Pharmaceuticals, Inc., a biopharmaceutical company and Madrigal Pharmaceuticals, Inc., a biopharmaceutical company.

 

Mr. Daly retired from Incyte Corporation, a biopharmaceutical company, where he served as Executive Vice President and Chief Commercial Officer from October 2012 to June 2015. Prior to Incyte, Mr. Daly served in various senior management and commercial positions at Amgen, Inc., a global pharmaceutical company, from January 2002 to December 2011. Prior to Amgen, he worked at GlaxoSmisthKline from 1985 to 2001 in various positions of increasing responsibilities.

 

Mark Snyder

Senior Vice President, General Counsel, Chief Compliance Officer and Corporate Secretary

  

Mark Snyder joined Parent in January 2022 as Senior Vice President, General Counsel, Chief Compliance Officer and Secretary. Mr. Snyder has nearly 30 years of experience in legal and business management roles. Prior to joining Parent, from January 2008 to December 2021, Mr. Snyder served in various senior positions in the legal department at Qualcomm Incorporated, a wireless communications company, including his most recent positions as Senior Vice President & Deputy General Counsel, Litigation, from April 2016 to December 2021 and Vice President, Patent Counsel, from October 2010 to April 2016. Before Qualcomm, Mr. Snyder served as Lead Intellectual Property Counsel at Kyocera Wireless Corp., a wireless communications company, and has held legal and business management roles in two smaller companies. Mr. Snyder began his legal career as a patent attorney at the law firm of Sheridan Ross & McIntosh.

 

Nicole LaBrosse

Senior Vice President, Chief Financial Officer

   Nicole LaBrosse has served as the Senior Vice President, Chief Financial Officer since February 2022 and has over 18 years of public accounting and corporate finance experience. She previously served as Parent’s Vice President, Finance and Accounting from January 2020 to February 2022

 

53


Name and Position

  

Present Principal Occupation or Employment; Material

Positions Held During the Last Five Years;
Citizenship (if not United States)

  

and as Parent’s Executive Director, Controller from July 2017 to December 2019. From June 2015 to June 2017, she was the Parent’s Senior Director, Financial Reporting. Prior to joining Parent, Ms. LaBrosse was an auditor with PricewaterhouseCoopers, LLP from 2004 to 2015.

 

Michael LaBarre

Senior Vice President,

Chief Technical Officer

   Michael LaBarre joined Parent in June 2008 as Vice President, Product Development and has served in various officer positions most recently as Senior Vice President, Chief Technical Officer since January 2020. Prior to joining Parent, Dr. LaBarre served as Vice President, Product Development at Paramount BioSciences, a pharmaceutical company, from April 2006 to June 2008. Prior to that he served as Director, Analytical and Protein Biochemistry, Discovery Research at Biogen Idec, a pharmaceutical company, from December 2003 to April 2006. He also served in various research and development roles at IDEC Pharmaceuticals Corporation, a pharmaceutical company, from November 1995 to December 2003 most recently as Director, Analytical and Formulation Sciences, R&D. Prior to joining IDEC, Dr. LaBarre held research and development positions at various pharmaceutical companies from July 1992 to November 1995.

Manually signed facsimiles of the Letter of Transmittal, properly completed, will be accepted. The Letter of Transmittal and certificates evidencing Shares and any other required documents should be sent by each holder or such holder’s broker, dealer, commercial bank, trust company or other nominee to the Depositary at one of its addresses set forth below:

The Depositary for the Offer is:

Equiniti Trust Company

 

If delivering by mail:

Equiniti Trust Company

Shareowner Services

Voluntary Corporate Actions

P.O. Box 64858

St. Paul, Minnesota 55164-0858

  

If delivering by hand, express mail, courier

or any other expedited service:

Equiniti Trust Company

Shareowner Services

Voluntary Corporate Actions

1110 Centre Pointe Curve, Suite 101
Mendota Heights, Minnesota 55120

Questions or requests for assistance may be directed to the Information Agent at the address and telephone numbers listed below. Additional copies of this Offer to Purchase, the Letter of Transmittal and any related materials may also be obtained from the Information Agent. Stockholders may also contact brokers, dealers, commercial banks or trust companies for assistance concerning the Offer.

The Information Agent for the Offer is:

D.F. King & Co., Inc.

48 Wall Street, 22nd Floor

New York, New York 10005

Banks and Brokers may call: (212) 269-5550

Stockholders may call toll free: (888) 628-1041

ATRS@dfking.com

 

 

54

EX-99.(A)(1)(B) 3 d347764dex99a1b.htm EXHIBIT (A)(1)(B) Exhibit (a)(1)(B)

Exhibit (a)(1)(B)

LETTER OF TRANSMITTAL

To Tender Shares of Common Stock

of

ANTARES PHARMA, INC.

at

$5.60 Per Share, Net in Cash

Pursuant to the Offer to Purchase dated April 26, 2022

by

ATLAS MERGER SUB, INC.

a wholly owned subsidiary

of

HALOZYME THERAPEUTICS, INC.

 

THE OFFER AND WITHDRAWAL RIGHTS WILL EXPIRE AT ONE MINUTE FOLLOWING

11:59 P.M., EASTERN TIME, ON MAY 23, 2022,

UNLESS THE OFFER IS EXTENDED OR EARLIER TERMINATED.

The Depositary for the Offer is:

Equiniti Trust Company

Method of delivery of the certificate(s) is at the option and risk of the owner thereof. See Instruction 2.

Mail or deliver this Letter of Transmittal, or a facsimile, together with the certificate(s) representing your shares, to:

 

If delivering by mail:

Equiniti Trust Company

Shareowner Services

Voluntary Corporate Actions

P.O. Box 64858

St. Paul, Minnesota 51164-0858

  

If delivering by hand, express mail, courier

or any other expedited service:

Equiniti Trust Company

Shareowner Services

Voluntary Corporate Actions

1110 Centre Pointe Curve, Suite 101

Mendota Heights, Minnesota 55120

 

DESCRIPTION OF SHARES TENDERED

Name(s) and Address(es) of Registered Owner(s)
(If blank, please fill in exactly  as name(s)

appear(s) on share certificate(s))

 

Shares Tendered

(attach additional list if necessary)

     Certificated Shares**   Book entry Shares
    

Certificate

Number(s)*

 

Total Number

of Shares

Represented by

Certificate(s)*

 

Number of Shares

Represented by
Certificate(s)

Tendered**

 

Book Entry

Shares

Tendered

                 
                 
                 
                 
    Total Shares            

 

*

Need not be completed by stockholders tendering solely by book-entry transfer.

**

Unless otherwise indicated, it will be assumed that all shares of common stock represented by certificates described above are being tendered hereby. See Instruction 4.

 

Lost Certificates. I have lost my certificate(s) for __________ shares and require assistance in replacing them. A $75.00 replacement fee must be sent in with the completed letter of transmittal. The check must be made payable to Equiniti Trust Company Shareowner Services. If additional forms and fees are needed, you will be contacted by the Company’s transfer agent, Equiniti Trust Company regarding the requirements for replacement.


THE INSTRUCTIONS ACCOMPANYING THIS LETTER OF TRANSMITTAL SHOULD BE READ CAREFULLY BEFORE THIS LETTER OF TRANSMITTAL IS COMPLETED.

DELIVERY OF THIS LETTER OF TRANSMITTAL TO AN ADDRESS OTHER THAN AS SET FORTH ABOVE FOR THE DEPOSITARY WILL NOT CONSTITUTE VALID DELIVERY. YOU MUST SIGN THIS LETTER OF TRANSMITTAL IN THE APPROPRIATE SPACE PROVIDED BELOW, WITH SIGNATURE GUARANTEE, IF REQUIRED, AND COMPLETE THE IRS FORM W-9 SET FORTH BELOW (OR AN APPROPRIATE IRS FORM W-8 IF YOU ARE A NON-U.S. STOCKHOLDER), IF REQUIRED.

ALL QUESTIONS REGARDING THE OFFER SHOULD BE DIRECTED TO THE INFORMATION AGENT, D.F. KING & CO., INC. (THE “INFORMATION AGENT”), AT (888) 628-1041 (toll free in the United States) OR THE ADDRESS SET FORTH ON THE BACK PAGE OF THE OFFER TO PURCHASE.

IF YOU WOULD LIKE ADDITIONAL COPIES OF THIS LETTER OF TRANSMITTAL OR ANY OF THE OTHER OFFERING DOCUMENTS, YOU SHOULD CONTACT THE INFORMATION AGENT AT (888) 628-1041 (toll free in the United States).

This Letter of Transmittal is being delivered to you in connection with the offer by Atlas Merger Sub, Inc., a Delaware corporation (“Purchaser”) and a wholly owned subsidiary of Halozyme Therapeutics, Inc., a Delaware corporation, to purchase all of the outstanding shares of common stock, par value $0.01 per share (the “Shares”), of Antares Pharma, Inc., a Delaware corporation (the “Company”), at a purchase price of $5.60 per Share in cash, without interest and subject to any withholding of taxes required by applicable legal requirements, upon the terms and subject to the conditions set forth in this Letter of Transmittal and the related Offer to Purchase by Purchaser, dated April 26, 2022 (the “Offer to Purchase,” which, together with this Letter of Transmittal, as they may be amended or supplemented from time to time, collectively constitute the “Offer”). The Offer expires at one minute following 11:59 P.M., Eastern Time, on the Expiration Date. “Expiration Date” means May 23, 2022, unless we, in accordance with the Offer, terminate the Offer or extend the period during which the Offer is open, in which event the term “Expiration Date” means the date on which the Offer, as so extended, expires.

The Offer is being made to all holders of Shares. Purchaser is not aware of any jurisdiction in which the making of the Offer or the acceptance thereof would be prohibited by securities, “blue sky” or other valid laws of such jurisdiction. If Purchaser becomes aware of any U.S. state in which the making of the Offer or the acceptance of Shares pursuant thereto would not be in compliance with an administrative or judicial action taken pursuant to a U.S. state statute, Purchaser will make a good faith effort to comply with any such law. If, after such good faith effort, Purchaser cannot comply with any such law, the Offer will not be made to (nor will tenders be accepted from or on behalf of) the holders of Shares in such state. In any jurisdictions where applicable laws require the Offer to be made by a licensed broker or dealer, the Offer shall be deemed to be made on behalf of Purchaser by one or more registered brokers or dealers licensed under the laws of such jurisdiction to be designated by Purchaser.

You should use this Letter of Transmittal to deliver to Equiniti Trust Company (the “Depositary”), Shares represented by stock certificates, or held in book-entry form on the books of the Company, for tender. If you are delivering your Shares by book-entry transfer to an account maintained by the Depositary at The Depository Trust Company (“DTC”), you must use an Agent’s Message (as defined in Instruction 2 below). In this Letter of Transmittal, stockholders who deliver certificates representing their Shares are referred to as “Certificate Stockholders.”

If any certificate representing any Shares you are tendering with this Letter of Transmittal has been lost, stolen, destroyed or mutilated, you should check the lost certificate box above. A $75 lost certificate replacement fee must be mailed in with your completed Letter of Transmittal. If there are additional forms or fees needed, you will be contacted by the Company’s stock transfer agent, Equinity Trust Company (the “Transfer Agent”) regarding the requirements for replacement. You may be required to post a bond to secure against the risk that such certificates may be subsequently recirculated. See Instruction 9.

 

2


   CHECK HERE IF TENDERED SHARES ARE BEING DELIVERED BY BOOK-ENTRY TRANSFER TO THE ACCOUNT MAINTAINED BY THE DEPOSITARY WITH DTC AND COMPLETE THE FOLLOWING (ONLY FINANCIAL INSTITUTIONS THAT ARE PARTICIPANTS IN DTC MAY DELIVER SHARES BY BOOK-ENTRY TRANSFER):
   Name of Tendering Institution:  

 

   DTC Participant Number:  

 

   Transaction Code Number:  

 

 

3


NOTE: SIGNATURES MUST BE PROVIDED BELOW.

PLEASE READ THE ACCOMPANYING INSTRUCTIONS CAREFULLY.

Ladies and Gentlemen:

The undersigned hereby tenders to Atlas Merger Sub, Inc., a Delaware corporation (“Purchaser”) and a wholly owned subsidiary of Halozyme Therapeutics, Inc., a Delaware corporation (“Parent”), the above-described shares of common stock, par value $0.01 per share (the “Shares”), of Antares Pharms, Inc., a Delaware corporation (the “Company”), pursuant to Purchaser’s offer to purchase each outstanding Share that is validly tendered and not validly withdrawn, at a purchase price of $5.60 per Share in cash (the “Offer Price”), without interest and subject to any withholding of taxes required by applicable legal requirements, upon the terms and subject to the conditions (including the Minimum Condition, as defined in the Introduction to the Offer to Purchase) set forth in the Offer to Purchase by Purchaser, dated April 26, 2022, which the undersigned hereby acknowledges the undersigned has received (the “Offer to Purchase,” which, together with this Letter of Transmittal, as they may be amended or supplemented from time to time, collectively constitute the “Offer”). The Offer expires at one minute following 11:59 P.M., Eastern Time, on the Expiration Date (the “Offer Expiration Time”). “Expiration Date” means May 23, 2022, unless we, in accordance with the Offer, terminate the offer or extend the period during which the Offer is open, in which event the term “Expiration Date” means the date on which the Offer, as so extended, expires.

Upon the terms and subject to the conditions of the Offer (including, if the Offer is extended or amended, the terms and conditions of such extension or amendment), subject to, and effective upon, acceptance for payment for the Shares validly tendered herewith and not validly withdrawn on or prior to the Expiration Date in accordance with the terms of the Offer, the undersigned hereby sells, assigns and transfers to, or upon the order of, Purchaser, all right, title and interest in and to all of the Shares being tendered hereby and any and all cash dividends, distributions, rights, other Shares or other securities issued or issuable in respect of such Shares on or after the date hereof (collectively, “Distributions”). In addition, the undersigned hereby irrevocably appoints Equiniti Trust Company, (the “Depositary”) as the true and lawful agent and attorney-in-fact and proxy of the undersigned with respect to such Shares and any Distributions with full power of substitution (such proxies and power of attorney being deemed to be an irrevocable power coupled with an interest in the tendered Shares and any Distributions) to the full extent of such stockholder’s rights with respect to such Shares and any Distributions (a) to deliver certificates representing such Shares (the “Share Certificates”) and any Distributions, or transfer of ownership of such Shares and any Distributions on the account books maintained by The Depository Trust Company (“DTC”) or otherwise held in book-entry form, together, in either such case, with all accompanying evidence of transfer and authenticity, to or upon the order of Purchaser, (b) to present such Shares and any Distributions for transfer on the books of the Company, and (c) to receive all benefits and otherwise exercise all rights of beneficial ownership of such Shares and any Distributions, all upon the terms and subject to the conditions of the Offer.

The undersigned hereby irrevocably appoints each of the designees of Purchaser the attorneys-in-fact and proxies of the undersigned, each with full power of substitution, to the full extent of such stockholder’s rights with respect to the Shares tendered hereby which have been accepted for payment and with respect to any Distributions. The designees of Purchaser will, with respect to such Shares and associated Distributions, be empowered to exercise all voting and any other rights of such stockholder, as they, in their sole discretion, may deem proper at any annual, special or adjourned meeting of the Company’s stockholders, by written consent in lieu of any such meeting or otherwise as such designee, in its, his or her sole discretion, deems proper with respect to all Shares and any associated Distributions. This proxy and power of attorney shall be irrevocable and coupled with an interest in the tendered Shares and any Distributions. Such appointment is effective when, and only to the extent that, Purchaser accepts the Shares tendered with this Letter of Transmittal for payment pursuant to the Offer. Upon the effectiveness of such appointment, without further action, all prior powers of attorney, proxies and consents given by the undersigned with respect to such Shares and any associated Distributions (other than prior powers of attorney, proxies or consent given by the undersigned to Purchaser or

 

4


the Company) will be revoked, and no subsequent powers of attorney, proxies, consents or revocations (other than powers of attorney, proxies, consents or revocations given to Purchaser or the Company) may be given (and, if given, will not be deemed effective).

Purchaser reserves the right to require that, in order for Shares to be deemed validly tendered, immediately upon Purchaser’s acceptance for payment of such Shares, Purchaser must be able to exercise full voting, consent and other rights, to the extent permitted under applicable law, with respect to such Shares and any associated Distributions, including voting at any meeting of stockholders or executing a written consent concerning any matter.

The undersigned hereby represents and warrants that the undersigned has full power and authority to tender, sell, assign and transfer the Shares and any Distributions tendered hereby and, when the same are accepted for payment by Purchaser, Purchaser will acquire good, marketable and unencumbered title thereto, free and clear of all liens, restrictions, charges and encumbrances, and that the same will not be subject to any adverse claim. The undersigned hereby represents and warrants that the undersigned is the registered owner of the Shares, or the Share Certificate(s) have been endorsed to the undersigned in blank, or the undersigned is a participant in DTC whose name appears on a security position listing as the owner of the Shares. The undersigned will, upon request, execute and deliver any additional documents deemed by the Depositary or Purchaser to be necessary or desirable to complete the sale, assignment and transfer of the Shares tendered hereby and any associated Distributions. In addition, the undersigned shall promptly remit and transfer to the Depositary for the account of Purchaser any and all Distributions in respect of the Shares tendered hereby, accompanied by appropriate documentation of transfer and, pending such remittance or appropriate assurance thereof, Purchaser shall be entitled to all rights and privileges as owner of any such Distributions and may withhold the entire Offer Price or deduct from the Offer Price the amount or value thereof, as determined by Purchaser in its sole discretion.

It is understood that the undersigned will not receive payment for the Shares unless and until the Shares are accepted for payment and until the Share Certificate(s) owned by the undersigned are received by the Depositary at the address set forth above, together with such additional documents as the Depositary may require, or, in the case of Shares held in book-entry form, ownership of Shares is validly transferred on the account books maintained by DTC, and until the same are processed for payment by the Depositary.

THE METHOD OF DELIVERY OF THE SHARES (OR SHARE CERTIFICATES), THIS LETTER OF TRANSMITTAL AND ALL OTHER REQUIRED DOCUMENTS IS AT THE ELECTION AND RISK OF THE SURRENDERING STOCKHOLDER. DELIVERY OF THE SHARES (OR SHARE CERTIFICATES), THIS LETTER OF TRANSMITTAL AND ALL OTHER REQUIRED DOCUMENTS WILL BE DEEMED MADE, AND RISK OF LOSS OF THE SHARE CERTIFICATES SHALL PASS, ONLY WHEN THEY (OR EFFECTIVE AFFIDAVITS OF LOSS IN LIEU THEREOF) ARE ACTUALLY RECEIVED BY THE DEPOSITARY (INCLUDING, IN THE CASE OF A BOOK-ENTRY TRANSFER OF SHARES, BY BOOK-ENTRY CONFIRMATION WITH RESPECT TO SUCH SHARES). IF SUCH DELIVERY IS BY MAIL, IT IS RECOMMENDED THAT THE SHARES (OR SHARE CERTIFICATES OR EFFECTIVE AFFIDAVITS OF LOSS IN LIEU THEREOF), THIS LETTER OF TRANSMITTAL AND ALL OTHER REQUIRED DOCUMENTS BE SENT BY PROPERLY INSURED REGISTERED MAIL WITH RETURN RECEIPT REQUESTED. IN ALL CASES, SUFFICIENT TIME SHOULD BE ALLOWED TO ENSURE TIMELY DELIVERY.

All authority conferred or agreed to be conferred pursuant to this Letter of Transmittal shall not be affected by, and shall survive, the death or incapacity of the undersigned and any obligation of the undersigned hereunder shall be binding upon the heirs, executors, administrators, trustees in bankruptcy, personal representatives, successors and assigns of the undersigned. Except upon the terms and subject to the conditions of the Offer, this tender is irrevocable.

The undersigned understands that the acceptance for payment by Purchaser of Shares tendered pursuant to one of the procedures described in Section 3 of the Offer to Purchase and in the instructions hereto will constitute a

 

5


binding agreement between the undersigned and Purchaser upon the terms and subject to the conditions of the Offer. The undersigned recognizes that under certain circumstances, upon the terms and subject to the conditions of the Offer, Purchaser may not be required to accept for payment any of the Shares tendered hereby.

Unless otherwise indicated herein under “Special Payment Instructions,” please issue the check for the Offer Price in the name(s) of, and/or return any Share Certificates representing Shares not tendered or accepted for payment to, the registered owner(s) appearing under “Description of Shares Tendered.” Similarly, unless otherwise indicated under “Special Delivery Instructions,” please mail the check for the Offer Price and/or return any Share Certificates representing Shares not tendered or accepted for payment (and accompanying documents, as appropriate) to the address(es) of the registered owner(s) appearing under “Description of Shares Tendered.”

In the event that both the Special Delivery Instructions and the Special Payment Instructions are completed, please issue the check for the Offer Price and/or issue any Share Certificates representing Shares not tendered or accepted for payment (and any accompanying documents, as appropriate) in the name of, and deliver such check and/or return such Share Certificates (and any accompanying documents, as appropriate) to, the person or persons so indicated. Unless otherwise indicated herein in the box titled “Special Payment Instructions,” please credit any Shares tendered hereby or by an Agent’s Message and delivered by book-entry transfer, but which are not purchased, by crediting the account at DTC designated above. The undersigned recognizes that Purchaser has no obligation pursuant to the Special Payment Instructions to transfer any Shares from the name of the registered owner thereof if Purchaser does not accept for payment any of the Shares so tendered.

SPECIAL PAYMENT INSTRUCTIONS

(See Instructions 1, 4, 5 and 7)

To be completed ONLY if Share Certificate(s) not tendered or not accepted for payment and/or the check for the Offer Price in consideration of Shares accepted for payment are to be issued in the name of someone other than the undersigned or if Shares tendered by book-entry transfer which are not accepted for payment are to be returned by credit to an account maintained at DTC other than that designated above.

 

Issue: ☐ Check and/or ☐ Share Certificates to:
Name:   

 

Please Print)
Address:   

 

 

 

(Include Zip Code)

 

(U.S. Taxpayer Identification Number (e.g., Social Security Number or Employer Identification Number))

   Credit Shares tendered by book-entry transfer that are not accepted for payment to the DTC account set forth below.

 

(DTC Account Number)

 

6


SPECIAL DELIVERY INSTRUCTIONS

(See Instructions 1, 4, 5 and 7)

To be completed ONLY if Share Certificate(s) not tendered or not accepted for payment and/or the check for the Offer Price of Shares accepted for payment are to be sent to someone other than the undersigned or to the undersigned at an address other than that shown in the box titled “Description of Shares Tendered” above.

 

Issue: ☐ Check and/or ☐ Share Certificates to:
Name:   

 

(Please Print)
Address:   

 

 

 

(Include Zip Code)

IMPORTANT—SIGN HERE

(U.S. Holders Please Also Complete the Enclosed IRS Form W-9)

(Non-U.S. Holders Please Obtain and Complete IRS Form W-8BEN, W-8BEN-E or Other

Applicable IRS Form W-8)

 

 

(Signature(s) of Stockholder(s))

Dated:                , 20    

(Must be signed by registered owner(s) exactly as name(s) appear(s) on Share Certificate(s) or on a security position listing or by person(s) authorized to become registered owner(s) by certificates and documents transmitted herewith. If signature is by trustees, executors, administrators, guardians, attorneys-in-fact, agents, officers of corporations or others acting in a fiduciary or representative capacity, please set forth full title and see Instruction 5. For information concerning signature guarantees, see Instruction 1.)

 

Name:   

 

   (Please Print)

 

Capacity (full title):   

 

 

Address:   

 

 

 

(Include Zip Code)

 

Area Code and Telephone Number:   

 

Taxpayer Identification No.   
(e.g., Social Security No):   

 

 

7


GUARANTEE OF SIGNATURE(S)

(For use by Eligible Institutions only;

see Instructions 1 and 5)

 

Name of Firm:  

 

 

 

(Include Zip Code)
Authorized Signature  

 

 

Name:  

 

 

 

(Please Type or Print)

 

Area Code and Telephone Number:  

 

 

Dated:                    , 20      

 

 

Place medallion guarantee in space below

INSTRUCTIONS

Forming Part of the Terms and Conditions of the Offer

1. Guarantee of Signatures for Shares. No signature guarantee is required on this Letter of Transmittal (a) if this Letter of Transmittal is signed by the registered holder(s) (which term, for purposes of this Section 1, includes any participant in DTC’s systems whose name appears on a security position listing as the owner of the Shares) of the Shares tendered therewith, unless such holder or holders have completed either the box entitled “Special Delivery Instructions” or the box entitled “Special Payment Instructions” on the cover of this Letter of Transmittal or (b) if the Shares are tendered for the account of a financial institution (including most commercial banks, savings and loan associations and brokerage houses) that is a member in good standing of the Security Transfer Agents Medallion Program or any other “eligible guarantor institution,” as such term is defined in Rule 17Ad-15 of the Exchange Act (each an “Eligible Institution” and collectively “Eligible Institutions”) (for example, the Security Transfer Agents Medallion Program, the New York Stock Exchange Medallion Signature Program and the Stock Exchanges Medallion Program). In all other cases, all signatures on this Letter of Transmittal must be guaranteed by an Eligible Institution. See Instruction 5.

2. Delivery of Letter of Transmittal and Certificates or Book-Entry Confirmations. This Letter of Transmittal is to be completed by stockholders if Share Certificates are to be forwarded herewith. A manually executed facsimile of this Letter of Transmittal may be used in lieu of the original. If Shares represented by Share Certificates are being tendered, such Share Certificates, as well as this Letter of Transmittal properly completed and duly executed with any required signature guarantees, and any other documents required by this Letter of Transmittal, must be received by the Depositary at its address set forth herein on or prior to the Offer Expiration Time. If Shares are to be tendered by book-entry transfer, the procedures for tender by book-entry transfer set forth in Section 3 of the Offer to Purchase must be followed, and an Agent’s Message and confirmation of a book-entry transfer into the Depositary’s account at DTC of Shares tendered by book-entry transfer (such a confirmation, a “Book-Entry Confirmation”) must be received by the Depositary on or prior to the Offer Expiration Time.

The term “Agent’s Message” means a message, transmitted through electronic means by DTC in accordance with the normal procedures of DTC to, and received by, the Depositary and forming part of a Book-Entry Confirmation, that states that DTC has received an express acknowledgment from the participant in DTC

 

8


tendering the Shares that are the subject of such Book-Entry Confirmation that such participant has received and agrees to be bound by the terms of, this Letter of Transmittal, and that Purchaser may enforce such agreement against such participant. The term “Agent’s Message” also includes any hard copy printout evidencing such message generated by a computer terminal maintained at the Depositary’s office.

THE METHOD OF DELIVERY OF THE SHARES (OR SHARE CERTIFICATES), THIS LETTER OF TRANSMITTAL AND ALL OTHER REQUIRED DOCUMENTS, INCLUDING DELIVERY THROUGH DTC, IS AT THE ELECTION AND RISK OF THE TENDERING STOCKHOLDER. DELIVERY OF THE SHARES (OR SHARE CERTIFICATES), THIS LETTER OF TRANSMITTAL AND ALL OTHER REQUIRED DOCUMENTS WILL BE DEEMED MADE, AND RISK OF LOSS OF THE SHARE CERTIFICATES SHALL PASS, ONLY WHEN THEY ARE ACTUALLY RECEIVED BY THE DEPOSITARY (INCLUDING, IN THE CASE OF A BOOK-ENTRY TRANSFER OF SHARES, BY BOOK-ENTRY CONFIRMATION WITH RESPECT TO SUCH SHARES). IF SUCH DELIVERY IS BY MAIL, IT IS RECOMMENDED THAT THE SHARES (OR SHARE CERTIFICATES), THIS LETTER OF TRANSMITTAL AND ALL OTHER REQUIRED DOCUMENTS BE SENT BY PROPERLY INSURED REGISTERED MAIL WITH RETURN RECEIPT REQUESTED. IN ALL CASES, SUFFICIENT TIME SHOULD BE ALLOWED TO ENSURE TIMELY DELIVERY.

No alternative, conditional or contingent tenders will be accepted and no fractional Shares will be purchased. All tendering stockholders, by execution of this Letter of Transmittal (or facsimile thereof), waive any right to receive any notice of the acceptance of their Shares for payment.

All questions as to the validity, form and eligibility (including time of receipt) will be determined by Purchaser, in its sole discretion, which determination shall be final and binding on all parties, to the fullest extent permitted by law, subject to the rights of holders of Shares to challenge such determination with respect to their shares in a court of competent jurisdiction. Purchaser reserves the absolute right to reject any and all tenders determined by it not to be in proper form or the acceptance for payment of which may, in its opinion, be unlawful. Purchaser also reserves the absolute right to waive any defect or irregularity in the tender of any Shares of any particular stockholder, whether or not similar defects or irregularities are waived in the case of other stockholders. No tender of Shares will be deemed to have been validly made until all defects and irregularities have been cured or waived to Purchaser’s satisfaction. None of Purchaser, Parent or any of their respective affiliates or assigns, the Depositary, the Information Agent or any other person will be under any duty to give notification of any defects or irregularities in tenders or incur any liability for failure to give any such notification. Our interpretation of the terms and conditions of the Offer (including this Letter of Transmittal and the instructions hereto) will be final and binding, subject to applicable law as applied by a court of competent jurisdiction, the terms of the Merger Agreement and the rights of holders of Shares to challenge such interpretation with respect to their Shares in a court of competent jurisdiction. No alternative, conditional or contingent tenders will be accepted and no fractional Shares will be purchased.

3. Inadequate Space. If the space provided herein is inadequate, the Share Certificate numbers and/or the number of Shares should be listed on a separate schedule attached hereto and separately signed on each page thereof in the same manner as this Letter of Transmittal is signed.

4. Partial Tenders (Applicable to Certificate Stockholders Only). If fewer than all the Shares evidenced by any Share Certificate delivered to the Depositary are to be tendered, stockholders should contact the Company’s stock transfer agent, Equiniti Trust Company (the “Transfer Agent”), at (800) 468-9716 (toll free in the United States) to arrange to have such Share Certificate divided into separate Share Certificates representing the number of shares to be tendered and the number of shares to not be tendered. The stockholder should then tender the Share Certificate representing the number of Shares to be tendered as set forth in this Letter of Transmittal. All Shares represented by Share Certificates delivered to the Depositary will be deemed to have been tendered.

 

9


5. Signatures on Letter of Transmittal; Stock Powers and Endorsements. If this Letter of Transmittal is signed by the registered owner(s) of the Shares tendered hereby, the signature(s) must correspond with the name(s) as written on the face of the Share Certificate(s) without alteration or any other change whatsoever.

If any Shares tendered hereby are owned of record by two or more joint owners, all such owners must sign this Letter of Transmittal.

If any tendered Shares are registered in the names of different holder(s), it will be necessary to complete, sign and submit as many separate Letters of Transmittal (or facsimiles thereof) as there are different registrations of such Shares.

If this Letter of Transmittal or any certificates or stock powers are signed by trustees, executors, administrators, guardians, attorneys-in-fact, officers of corporations or others acting in a fiduciary or representative capacity, such persons should so indicate when signing, and proper evidence satisfactory to Purchaser of their authority so to act must be submitted.

If this Letter of Transmittal is signed by the registered owner(s) of the Shares listed and transmitted hereby, no endorsements of Share Certificates or separate stock powers are required unless payment is to be made to, or Share Certificates representing Shares not tendered or accepted for payment are to be issued in the name of, a person other than the registered owner(s), in which case the Share Certificates representing the Shares tendered by this Letter of Transmittal must be endorsed or accompanied by appropriate stock powers, in either case, signed exactly as the name(s) of the registered owner(s) or holder(s) appear(s) on the Share Certificates. Signatures on such Share Certificates or stock powers must be guaranteed by an Eligible Institution.

If this Letter of Transmittal is signed by a person other than the registered owner(s) or holder(s) of the Share(s) listed, the Share Certificate(s) must be endorsed or accompanied by the appropriate stock powers, in either case, signed exactly as the name or names of the registered owner(s) or holder(s) appear(s) on the Share Certificate(s). Signatures on such Share Certificates or stock powers must be guaranteed by an Eligible Institution.

6. Transfer Taxes. Except as otherwise provided in this Instruction 6, all transfer taxes with respect to the exchange of Shares contemplated hereby shall be paid by Parent and Purchaser when due. For the avoidance of doubt, transfer taxes do not include U.S. federal income taxes or withholding taxes. If payment of the Offer Price is to be made to, or (in the circumstances permitted hereby) if Share Certificates not tendered or accepted for payment are to be registered in the name of, any person other than the registered owner(s) or holder(s), or if tendered Share Certificates are registered in the name of any person other than the person signing this Letter of Transmittal, payment of the Offer Price will be conditioned on the Depository’s receipt of satisfactory evidence that any transfer taxes required by reason of payment of the Offer Price to a person other than the registered owner(s) or holder(s) have been paid or are not applicable.

7. Special Payment and Delivery Instructions. If a check for the Offer Price is to be issued, and/or Share Certificates representing Shares not tendered or accepted for payment are to be issued or returned to, a person other than the signer(s) of this Letter of Transmittal or to an address other than that shown in the box titled “Description of Shares Tendered” above, the appropriate boxes on this Letter of Transmittal must be completed. Stockholders delivering Shares tendered hereby or by Agent’s Message by book-entry transfer may request that Shares not purchased be credited to an account maintained at DTC as such stockholder may designate in the box titled “Special Payment Instructions” herein. If no such instructions are given, all such Shares not purchased will be returned by crediting the same account at DTC as the account from which such Shares were delivered.

8. Requests for Assistance or Additional Copies. Questions or requests for assistance may be directed to D.F. King & Co., Inc. (the “Information Agent”) at its address and telephone number set forth below or to your broker, dealer, commercial bank or trust company. Additional copies of the Offer to Purchase, this Letter of Transmittal and other tender offer materials may be obtained from the Information Agent as set forth below, and will be furnished at Purchaser’s expense.

 

10


9. Lost, Destroyed, Mutilated or Stolen Share Certificates. If any Share Certificate has been lost, destroyed, mutilated or stolen, the stockholder should check the lost certificate box above. A $75 lost certificate replacement fee must be mailed in with your completed Letter of Transmittal. If there are additional forms or fees needed, you will be contacted by the Transfer Agent. The stockholder will then be instructed as to the steps that must be taken in order to replace the Share Certificate. This Letter of Transmittal and related documents cannot be processed until the procedures for replacing lost, mutilated, destroyed or stolen Share Certificates have been followed.

10. Waiver of Conditions. Purchaser expressly reserves the right, in its sole discretion, to, upon the terms and subject to the conditions of the Offer, increase the Offer Price, waive any Offer Condition (as defined in the Offer to Purchase) or make any other changes to the terms and conditions of the Offer.

IMPORTANT: THIS LETTER OF TRANSMITTAL (OR A MANUALLY EXECUTED FACSIMILE COPY THEREOF) OR AN AGENT’S MESSAGE, TOGETHER WITH SHARE CERTIFICATE(S) OR BOOK-ENTRY CONFIRMATION OR A PROPERLY COMPLETED AND ALL OTHER REQUIRED DOCUMENTS, MUST BE RECEIVED BY THE DEPOSITARY ON OR PRIOR TO THE OFFER EXPIRATION TIME.

IMPORTANT U.S. FEDERAL TAX INFORMATION

Under U.S. federal income tax law, a stockholder that is or is treated as a non-exempt United States person (for U.S. federal income tax purposes) whose tendered Shares are accepted for payment, is required by law to provide the Depositary (as payer) with such stockholder’s correct Taxpayer Identification Number (“TIN”) and to certify that such stockholder is not subject to backup withholding on the IRS Form W-9 below. If such stockholder is an individual, the TIN is generally such stockholder’s social security number. If the Depositary is not provided with the correct certifications or an adequate basis for an exemption, the stockholder may be subject to penalties imposed by the IRS and payments that are made to such stockholder with respect to Shares purchased pursuant to the Offer may be subject to backup withholding.

If backup withholding of U.S. federal income tax on payments for Shares made in the Offer applies, the Depositary is required to withhold 24% (or the then applicable rate) of any payments of the Offer Price made to the stockholder. Backup withholding is not an additional tax. Rather, taxpayers may claim amounts withheld as a credit against their U.S. federal income tax liability. If withholding results in an overpayment of taxes, a refund may be obtained from the IRS provided a timely claim for refund is filed.

IRS Form W-9

To prevent backup withholding, each U.S. stockholder that is a “United States person” (within the meaning of Section 7701(a)(30) of the Internal Revenue Code of 1986, as amended) must provide the Depositary of such stockholder’s correct TIN by completing a properly completed and executed IRS Form W-9 below, certifying, under penalties of perjury, (i) that the TIN provided on the IRS Form W-9 is correct (or that such stockholder is awaiting a TIN), (ii) that such stockholder is not subject to backup withholding because (a) such stockholder has not been notified by the IRS that such stockholder is subject to backup withholding as a result of a failure to report all interest or dividends, (b) the IRS has notified such stockholder that such stockholder is no longer subject to backup withholding or (c) such stockholder is exempt from backup withholding, and (iii) that such stockholder is a United States person.

If a tendering U.S. stockholder has been notified by the IRS that such stockholder is subject to backup withholding, such stockholder must cross out item 2 in Part II of the IRS Form W-9, unless such stockholder has since been notified by the IRS that such stockholder is no longer subject to backup withholding.

 

11


What Number to Give the Depositary

Each U.S. stockholder is generally required to give the Depositary its TIN (generally a social security number or employer identification number). If the tendering stockholder has not been issued a TIN and has applied for a number or intends to apply for a number in the near future, the stockholder should write “Applied For” in Part I, sign and date the IRS Form W-9 below. Notwithstanding that “Applied For” is written in Part I, and the Depositary will withhold 24% (or the then applicable rate) of all payments of the Offer Price to such stockholder until a TIN is provided to the Depositary. Such amounts will be refunded to such surrendering stockholder if a TIN is provided to the Depositary within 60 days. If the Share Certificate(s) are held in more than one name or are not held in the name of the actual owner, consult the instructions following the IRS Form W–9 for additional guidance on which number to report.

Exempt Stockholders

Certain stockholders (including, among others, corporations, non-resident foreign individuals and foreign entities) are not subject to these backup withholding and reporting requirements. To prevent possible erroneous backup withholding, an exempt stockholder that is a United States person should complete IRS Form W-9, including the “Exemptions” field in box 4 on the Form W-9. See the W-9 Specific Instructions for additional instructions. In order to demonstrate an exemption, a tendering stockholder who is a foreign individual or a foreign entity should properly complete, sign under penalties of perjury, and submit to the Depositary the appropriate IRS Form W-8, and any other required documentation, prior to the time payment is made, attesting to such exempt status. The appropriate IRS Form W-8 may be downloaded from the IRS’s website at the following address: http://www.irs.gov.

If the stockholder is a domestic entity that is disregarded as an entity separate from its owner for U.S. federal income tax purposes and has a foreign owner that is treated as a separate entity for U.S. federal income tax purposes, the owner must use the appropriate IRS Form W-8, and not the IRS Form W-9. See the instructions to the enclosed IRS Form W-9 for more information.

The information contained herein is for informational purposes only. Please consult your accountant or tax advisor for further guidance regarding the completion of the IRS Form W-9, IRS Form W-8BEN or W-8BEN-E, or another version of IRS Form W-8 to claim exemption from backup withholding, or contact the Depositary. Failure to complete the IRS Form W-9 or the appropriate IRS Form W-8 will not, by itself, cause Shares to be deemed invalidly tendered, but may require the Depositary to withhold a portion of the amount of any payments of the Offer Price pursuant to the Offer.

 

12


LOGO

Request for Taxpayer Form W-9 Give Form to the (Rev. October 2018) Identification Number and Certification requester. Do not Department of the send to the IRS. Treasury Internal Revenue Service Go to www.irs.gov/FormW9 for instructions and the latest information. 1 Name (as shown on your income tax return). Name is required on this line; do not leave this line blank. 3 . 2 Business name/disregarded entity name, if different from above 3 Check appropriate box for federal tax classification of the person whose name is entered on line 1. Check only one of the 4. Exemptions (codes apply only to page following seven boxes certain entities, not individuals; see on Individual/sole proprietor or instructions on page 3): single-member LLC C Corporation S Corporation Partnership Trust/estate Exempt payee code (if any) type Limited liability company. Enter the tax classification (C=C corporation, S=S corporation, P=Partnership) or Note: Check the appropriate box in the line above for the tax classification of the single-member owner. Do not check LLC Exemption from FATCA reporting if the LLC is classified as a single-member LLC that is disregarded from the owner unless the owner of the LLC is another code (if any) Instructions LLC that is not disregarded from the owner for U.S. federal tax purposes. Otherwise, a single-member LLC that is Print disregarded from the owner should check the appropriate box for the tax classification of its owner. Other(see instructions) (Applies to accounts maintained outside the U.S.) Specific 5 Address (number, street, and apt. or suite no.) See instructions. Requester’s name and address (optional) See 6 City, state, and ZIP code 7 List account number(s) here (optional) Part I Taxpayer Identification Number (TIN) Enter your TIN in the appropriate box. The TIN provided must match the name given on line 1 to Social security number avoid backup withholding. For individuals, this is generally your social security number (SSN). However, for a resident alien, sole proprietor, or disregarded entity, see the instructions for Part I, later. For other entities, it is your employer identification number (EIN). If you do not have a number, or see How to get a TIN, later. Employer identification number Note: If the account is in more than one name, see the instructions for line 1. Also see What Name and Number To Give the Requester for guidelines on whose number to enter. Part II Certification Under penalties of perjury, I certify that: 1. The number shown on this form is my correct taxpayer identification number (or I am waiting for a number to be issued to me); and 2. I am not subject to backup withholding because: (a) I am exempt from backup withholding, or (b) I have not been notified by the Internal Revenue Service (IRS) that I am subject to backup withholding as a result of a failure to report all interest or dividends, or (c) the IRS has notified me that I am no longer subject to backup withholding; and 3. I am a U.S. citizen or other U.S. person (defined below); and 4. The FATCA code(s) entered on this form (if any) indicating that I am exempt from FATCA reporting is correct. Certification instructions. You must cross out item 2 above if you have been notified by the IRS that you are currently subject to backup withholding because you have failed to report all interest and dividends on your tax return. For real estate transactions, item 2 does not apply. For mortgage interest paid, acquisition or abandonment of secured property, cancellation of debt, contributions to an individual retirement arrangement (IRA), and generally, payments other than interest and dividends, you are not required to sign the certification, but you must provide your correct TIN. See the instructions for Part II, later. Sign Signature of Here U.S. person Date General Instructions Form 1099-DIV (dividends, including those from stocks or mutual funds) Section references are to the Internal Revenue Code unless otherwise Form 1099-MISC (various types of income, prizes, awards, or gross proceeds) noted. Future developments. For the latest information about developments related to Form 1099-B (stock or mutual fund sales and certain other transactions by brokers) Form W-9 and its instructions, such as legislation enacted after they were Form 1099-S (proceeds from real estate transactions) published, go to www.irs.gov/FormW9. Form 1099-K (merchant card and third party network transactions) Purpose of Form An individual or entity (Form W-9 requester) who is required to file an Form 1098 (home mortgage interest), 1098-E (student loan interest), 1098-T information return with the IRS must obtain your correct taxpayer identification (tuition) number (TIN) which may be your social security number (SSN), individual Form 1099-C (canceled debt) taxpayer identification number (ITIN), adoption taxpayer identification number (ATIN), or employer identification number (EIN), to report on an information Form 1099-A (acquisition or abandonment of secured property) return the amount paid to you, or other amount reportable on an information Use Form W-9 only if you are a U.S. person (including a resident alien), to provide return. Examples of information returns include, but are not limited to, the your correct TIN. following. Form 1099-INT (interest earned or paid) If you do not return Form W-9 to the requester with a TIN, you might be subject to backup withholding. See What is backup withholding, later. Cat. No. 10231X Form W-9 (Rev. 10-2018 The Depositary for the Offer to Purchase is: Equiniti Trust Company

 

13


The Depositary for the Offer to Purchase is:

Equiniti Trust Company

 

If delivering by mail:

Equiniti Trust Company

Shareowner Services

Voluntary Corporate Actions

P.O. Box 64858

St. Paul, Minnesota 51164-0858

  

If delivering by hand or courier:

Equiniti Trust Company

Shareowner Services

Voluntary Corporate Actions

1110 Centre Pointe Curve, Suite 101

Mendota Heights, Minnesota 55120

DELIVERY OF THIS LETTER OF TRANSMITTAL TO AN ADDRESS OTHER THAN AS SET FORTH ABOVE WILL NOT CONSTITUTE A VALID DELIVERY TO THE DEPOSITARY.

Any questions or requests for assistance may be directed to the Information Agent at its telephone number and location listed below. Requests for additional copies of this Letter of Transmittal and the Offer to Purchase may be directed to the Information Agent at its telephone number and location listed below. You may also contact your broker, dealer, commercial bank or trust company or other nominee for assistance concerning the Offer.

The Information Agent for the Exchange Offer is:

D.F. King & Co., Inc.

48 Wall Street, 22nd Floor

New York, New York 10005

Banks and Brokers may call: (212) 269-5550

Stockholders may call toll free: (888) 628-1041

ATRS@dfking.com

 

14

EX-99.(A)(1)(C) 4 d347764dex99a1c.htm EXHIBIT (A)(1)(C) Exhibit (a)(1)(C)

Exhibit (a)(1)(C)

Offer to Purchase

All Outstanding Shares of Common Stock

of

ANTARES PHARMA, INC.

at

$5.60 PER SHARE, NET IN CASH

Pursuant to the Offer to Purchase dated April 26, 2022

by

ATLAS MERGER SUB, INC.

a wholly owned subsidiary

of

HALOZYME THERAPEUTICS, INC.

 

THE OFFER AND WITHDRAWAL RIGHTS WILL EXPIRE AT ONE MINUTE FOLLOWING 11:59 P.M., EASTERN TIME, ON MAY 23, 2022, UNLESS THE OFFER IS EXTENDED OR EARLIER TERMINATED.

April 26, 2022

To Brokers, Dealers, Commercial Banks, Trust Companies and Other Nominees:

We have been engaged by Atlas Merger Sub, Inc., a Delaware corporation (“Purchaser”) and a wholly owned subsidiary of Halozyme Therapeutics, Inc., a Delaware corporation (“Parent”), to act as information agent (the “Information Agent”) in connection with Purchaser’s offer to purchase all of the outstanding shares of common stock, par value $0.01 per share (the “Shares”), of Antares Pharma, Inc., a Delaware corporation (the “Company”), at a purchase price of $5.60 per Share in cash, without interest and subject to any withholding of taxes required by applicable legal requirements, upon the terms and subject to the conditions set forth in the Offer to Purchase, dated April 26, 2022 (the “Offer to Purchase”) and in the related letter of transmittal (the “Letter of Transmittal”, which, together with the Offer to Purchase, as they may be amended or supplemented from time to time, collectively constitute the “Offer”) enclosed herewith. Please furnish copies of the enclosed materials to those of your clients for whom you hold Shares registered in your name or in the name of your nominee.

THE BOARD OF DIRECTORS OF THE COMPANY HAS UNANIMOUSLY RECOMMENDED THAT STOCKHOLDERS TENDER ALL OF THEIR SHARES TO PURCHASER PURSUANT TO THE OFFER.

The Offer is not subject to any financing condition. The conditions to the Offer are described in Section 15 of the Offer to Purchase.

For your information and for forwarding to your clients for whom you hold Shares registered in your name or in the name of your nominee, we are enclosing the following documents:

1.    The Offer to Purchase;

2.    The Letter of Transmittal (together with the included Internal Revenue Service Form W-9) for your use in accepting the Offer and tendering Shares and for the information of your clients;

3.    A form of letter which may be sent to your clients for whose accounts you hold Shares registered in your name or in the name of your nominee, with space provided for obtaining such clients’ instructions with regard to the Offer; and

4.    The Company’s Solicitation/Recommendation Statement on Schedule 14D-9, dated April 26, 2022.


We urge you to contact your clients as promptly as possible. Please note that the Offer will expire at one minute following 11:59 P.M., Eastern Time, on May 23, 2022, unless the Offer is extended by the Purchaser or earlier terminated. Previously tendered Shares may be withdrawn at any time until the Offer has expired, and if not previously accepted for payment at any time, after June 27, 2022, pursuant to SEC (as defined in the Offer to Purchase) regulations or earlier terminated in accordance with its terms or the terms of the Merger Agreement (as defined below).

The Offer is being made pursuant to an Agreement and Plan of Merger, dated as of April 12, 2022 (as it may be amended, modified or supplemented from time to time, the “Merger Agreement”), among the Company, Parent and Purchaser, pursuant to which, unless otherwise agreed by the Company, Parent and Purchaser, at 8:00 a.m., Eastern Time, on the same date as the consummation of the Offer and subject to the satisfaction or waiver of certain conditions and in accordance with the relevant provisions of the Delaware General Corporation Law (the “DGCL”) and other applicable legal requirements, Purchaser will merge with and into the Company (the “Merger”), and the separate existence of Purchaser will cease and the Company will continue as the surviving corporation and as a wholly owned subsidiary of Parent, upon the terms and subject to the conditions set forth in the Merger Agreement. The Merger will be governed by Section 251(h) of the DCGL, and effected without a vote of the Company stockholders.

The Board of Directors of the Company has unanimously: (i) determined that the Merger Agreement, the Offer and the Merger are fair to, and in the best interest of, the Company and its stockholders; (ii) declared that it is advisable for the Company to enter into the Merger Agreement; (iii) approved the execution, delivery and performance by the Company of the Merger Agreement and the consummation of the transactions contemplated by the Merger Agreement, including the Offer and the Merger; (iv) agreed that the Merger shall be effected under Section 251(h) of the DGCL; and (v) resolved to recommend that the Company’s stockholders accept the Offer and tender their Shares pursuant to the Offer. For Shares to be properly tendered to the Purchaser pursuant to the Offer, the share certificates or confirmation of receipt of such Shares under the procedure for book-entry transfer, together with a properly completed and duly executed Letter of Transmittal, including any required signature guarantees, or an “Agent’s Message” (as defined in the Offer to Purchase) in the case of book-entry transfer, and any other documents required in the Letter of Transmittal, must be timely received by Equiniti Trust Company (the “Depositary and Paying Agent”).

Except as set forth in the Offer to Purchase, Purchaser will not pay any fees or commissions to any broker or dealer or to any other person (other than to the Depositary and Paying Agent and the Information Agent as described in the Offer to Purchase) in connection with the solicitation of tenders of Shares pursuant to the Offer. Purchaser will, however, upon request, reimburse brokers, dealers, commercial banks and trust companies for customary mailing and handling expenses incurred by them in forwarding materials to their customers. Purchaser will pay all stock transfer taxes applicable to its purchase of Shares pursuant to the Offer, subject to Instruction 6 of the Letter of Transmittal.

Any inquiries you may have with respect to the Offer should be addressed to, and additional copies of the enclosed materials may be obtained from, the Information Agent or the undersigned at the addresses and telephone numbers set forth below.

Very truly yours,

D.F. King & Co., Inc.

 

2


Nothing contained herein or in the enclosed documents shall render you the agent of Purchaser, the Information Agent or the Depositary and Paying Agent or any affiliate of any of them or authorize you or any other person to use any document or make any statement on behalf of any of them in connection with the Offer including the Merger or the other transactions contemplated by the Merger Agreement other than the enclosed documents and the statements contained therein.

The Information Agent for the Offer is:

D.F. King & Co., Inc.

48 Wall Street, 22nd Floor

New York, New York 10005

Banks and Brokers may call: (212) 269-5550

Stockholders may call toll free: (888) 628-1041

ATRS@dfking.com

 

3

EX-99.(A)(1)(D) 5 d347764dex99a1d.htm EXHIBIT (A)(1)(D) Exhibit (a)(1)(D)

Exhibit (a)(1)(D)

Offer to Purchase

All Outstanding Shares of Common Stock

of

ANTARES PHARMA, INC.

at

$5.60 PER SHARE, NET IN CASH

Pursuant to the Offer to Purchase dated April 26, 2022

by

ATLAS MERGER SUB, INC.

a wholly owned subsidiary

of

HALOZYME THERAPEUTICS, INC.

 

THE OFFER AND WITHDRAWAL RIGHTS WILL EXPIRE AT ONE MINUTE FOLLOWING 11:59 P.M., EASTERN TIME, ON MAY 23, 2022, UNLESS THE OFFER IS EXTENDED OR EARLIER TERMINATED.

April 26, 2022

To Our Clients:

Enclosed for your consideration are the Offer to Purchase, dated April 26, 2022 (the “Offer to Purchase”), and the related letter of transmittal (the “Letter of Transmittal”) in connection with the offer by Atlas Merger Sub, Inc., a Delaware corporation (“Purchaser”) and a wholly owned subsidiary of Halozyme Therapeutics, Inc., a Delaware corporation (“Parent”), to purchase all of the outstanding shares of common stock, par value $0.01 per share (the “Shares”) of Antares Pharma, Inc., a Delaware corporation (the “Company”), at a purchase price of $5.60 per Share in cash, without interest and subject to any withholding of taxes required by applicable legal requirements, upon the terms and subject to the conditions set forth in the Offer to Purchase and in the related Letter of Transmittal (which, together with the Offer to Purchase, as they may be amended or supplemented from time to time, collectively constitute the “Offer”).

Also enclosed is the Company’s Solicitation/Recommendation Statement on Schedule 14D-9.

THE BOARD OF DIRECTORS OF THE COMPANY UNANIMOUSLY RECOMMENDS THAT STOCKHOLDERS TENDER ALL OF THEIR SHARES TO PURCHASER PURSUANT TO THE OFFER.

We or our nominees are the holder of record of Shares held for your account. A tender of such Shares can be made only by us as the holder of record and pursuant to your instructions. The Letter of Transmittal is furnished to you for your information only and cannot be used by you to tender Shares held by us for your account.

We request instructions as to whether you wish us to tender any or all of the Shares held by us for your account, upon the terms and subject to the conditions set forth in the enclosed Offer to Purchase and the Letter of Transmittal.

Please note carefully the following:

1.    The offer price for the Offer is $5.60 per Share in cash, which will be paid, without interest and subject to any withholding of taxes required by applicable legal requirements.

2.    The Offer is being made for all outstanding Shares.


3.    The Offer is being made pursuant to an Agreement and Plan of Merger, dated as of April 12, 2022 (as it may be amended from time to time, the “Merger Agreement”), among the Company, Parent and Purchaser. The Merger Agreement provides, among other things, that unless otherwise agreed by the Company, Parent and Purchaser, at 8:00 a.m., Eastern Time, on the same date as the consummation of the Offer and subject to the satisfaction or waiver of certain conditions in accordance with the relevant provisions of the General Corporation Law of the State of Delaware, as amended (the “DGCL”), Purchaser will merge with and into the Company (the “Merger”) and the separate existence of Purchaser will cease and the Company will continue as the surviving corporation and a wholly owned subsidiary of Parent, upon the terms and subject to the conditions set forth in the Merger Agreement. The Merger will be governed by 251(h) of the DGCL, and effected without a vote of the Company stockholders.

4.    The Board of Directors of the Company has unanimously: (i) determined that the Merger Agreement, the Offer and the Merger are fair to, and in the best interest of, the Company and its stockholders; (ii) declared that it is advisable for the Company to enter into the Merger Agreement; (iii) approved the execution, delivery and performance by the Company of the Merger Agreement and the consummation of the transactions contemplated by the Merger Agreement, including the Offer and the Merger; (iv) agreed that the Merger shall be effected under Section 251(h) of the DGCL; and (v) resolved to recommend that the Company’s stockholders accept the Offer and tender their Shares pursuant to the Offer.

5.    The Offer will expire at one minute following 11:59 P.M., Eastern Time, on May 23, 2022, unless the Offer is extended by the Purchaser or earlier terminated. Previously tendered Shares may be withdrawn at any time until the Offer has expired, and if not previously accepted for payment at any time, after June 27, 2022, pursuant to SEC (as defined in the Offer to Purchase) regulations or earlier terminated in accordance with its terms or the terms of the Merger Agreement.

6.    The Offer is not subject to a financing condition. The obligation of Purchaser to accept for payment and pay for Shares validly tendered (and not validly withdrawn) pursuant to the Offer is subject to the conditions set forth in Section 15 of the Offer to Purchase (collectively, the “Offer Conditions”). Among the Offer Conditions are: (i) the Minimum Condition (as defined in the Offer to Purchase); (ii) Regulatory Condition (as defined in the Offer to Purchase) and the HSR Condition (as defined in the Offer to Purchase); (iii) the accuracy of the Company’s representations and warranties set forth in the Merger Agreement as of specified times, and the performance of the Company’s covenants set forth in the Merger Agreement, in each case, to specified standards of materiality; and (iv) since the date of the Merger Agreement, there not having occurred a Material Adverse Effect (as defined in the Offer to Purchase) that is continuing.

If you wish to have us tender any or all of your Shares, then please so instruct us by completing, executing, detaching and returning to us the Instruction Form on the detachable part hereof. An envelope to return your instructions to us is enclosed. If you authorize tender of your Shares, all such Shares will be tendered unless otherwise specified on the Instruction Form.

Your prompt action is requested. Your Instruction Form should be forwarded to us in ample time to permit us to submit the tender on your behalf before the expiration of the Offer.

The Offer is being made to all holders of Shares. Purchaser is not aware of any jurisdiction in which the making of the Offer or the acceptance thereof would be prohibited by securities, “blue sky” or other valid laws of such jurisdiction. If Purchaser becomes aware of any U.S. state in which the making of the Offer or the acceptance of Shares pursuant thereto would not be in compliance with an administrative or judicial action taken pursuant to a U.S. state statute, Purchaser will make a good faith effort to comply with any such law. If, after such good faith effort, Purchaser cannot comply with any such law, the Offer will not be made to (nor will tenders be accepted from or on behalf of) the holders of Shares in such state. In any jurisdictions where applicable laws require the Offer to be made by a licensed broker or dealer, the Offer shall be deemed to be made on behalf of Purchaser by one or more registered brokers or dealers licensed under the laws of such jurisdiction to be designated by Purchaser.

 

2


INSTRUCTION FORM

With Respect to the Offer to Purchase

All Outstanding Shares of Common Stock

of

ANTARES PHARMA, INC.

at

$5.60 PER SHARE, NET IN CASH

Pursuant to the Offer to Purchase dated April 26, 2022

by

ATLAS MERGER SUB, INC.

a wholly owned subsidiary

of

HALOZYME THERAPEUTICS, INC.

The undersigned acknowledge(s) receipt of your letter and the enclosed Offer to Purchase, dated April 26, 2022, and the related letter of transmittal (the “Letter of Transmittal”), in connection with the offer by Atlas Merger Sub, Inc., a Delaware corporation (“Purchaser”) and a wholly owned subsidiary of Halozyme Therapeutics, Inc., a Delaware corporation (“Parent”), to purchase all of the outstanding shares of common stock, par value $0.01 per share (the “Shares”), of Antares Pharma, Inc., a Delaware corporation (the “Company”), at a purchase price of $5.60 per Share in cash, without interest and subject to any withholding of taxes required by applicable legal requirements, upon the terms and subject to the conditions set forth in the Offer to Purchase, dated April 26, 2022 (the “Offer to Purchase”) and in the related Letter of Transmittal (which, together with the Offer to Purchase, as they may be amended or supplemented from time to time, collectively constitute the “Offer”).

The undersigned hereby instruct(s) you to tender to Purchaser the number of Shares indicated below (or, if no number is indicated, all Shares) which are held by you for the account of the undersigned, upon the terms and subject to the conditions set forth in the Offer.

The method of delivery of this document is at the election and risk of the tendering stockholder. If delivery is by mail, then using registered mail with return receipt requested, properly insured, is recommended. In all cases, sufficient time should be allowed to ensure delivery by the expiration of the Offer.

 

  Number of Shares to be Tendered:

   SIGN HERE
   

  Shares*

    

  

Signature(s)

   

  Account No.                                                             

  

 

   

  Dated                 , 20    

  

 

   

  __________________________

  Area Code and Phone Number

  

 

Tax Identification Number or Social Security Number    Please Print name(s) and address(es) here

Unless otherwise indicated, it will be assumed that all Shares held by us for your account are to be tendered.

 

3

EX-99.(A)(1)(E) 6 d347764dex99a1e.htm EXHIBIT (A)(1)(E) Exhibit (a)(1)(E)

Exhibit (a)(1)(E)

This announcement is neither an offer to purchase nor a solicitation of an offer to sell Shares (as defined below). The Offer (as defined below) is made solely pursuant to the Offer to Purchase, dated April 26, 2022, and the related Letter of Transmittal and any amendments or supplements to such Offer to Purchase or Letter of Transmittal, and is being made to all holders of Shares. The Offer is not being made to (nor will tenders be accepted from or on behalf of) holders of Shares in any jurisdiction in which the making of the Offer or the acceptance thereof would not be in compliance with the securities, “blue sky” or other laws of such jurisdiction. In those jurisdictions where applicable laws or regulations require the Offer to be made by a licensed broker or dealer, the Offer shall be deemed to be made on behalf of Purchaser (as defined below) by one or more registered brokers or dealers licensed under the laws of such jurisdiction to be designated by Purchaser.

Notice of Offer to Purchase

All Outstanding Shares of Common Stock

of

ANTARES PHARMA, INC.

at

$5.60 PER SHARE, NET IN CASH

Pursuant to the Offer to Purchase dated April 26, 2022

by

ATLAS MERGER SUB, INC.

a wholly owned subsidiary

of

HALOZYME THERAPEUTICS, INC.

Atlas Merger Sub, Inc., a Delaware corporation (“Purchaser”) and a wholly owned subsidiary of Halozyme Therapeutics, Inc., a Delaware corporation (“Parent”), is offering to purchase all of the outstanding shares of common stock, par value $0.01 per share (the “Shares”), of Antares Pharma, Inc., a Delaware corporation (the “Company”), at a purchase price of $5.60 per Share in cash (the “Offer Price”), without interest and subject to any withholding of taxes required by applicable legal requirements, upon the terms and subject to the conditions set forth in the Offer to Purchase, dated April 26, 2022, and in the related letter of transmittal (the “Letter of Transmittal” which, together with the Offer to Purchase, as they may be amended or supplemented from time to time, collectively constitute the “Offer”).

Stockholders of record who tender directly to Equiniti Trust Company (the “Depositary”) will not be obligated to pay brokerage fees or commissions or, except as may be set forth in the Letter of Transmittal, stock transfer taxes with respect to the purchase of Shares by Purchaser pursuant to the Offer. Stockholders who hold their Shares through a broker, banker or other nominee should consult such institution as to whether it charges any service fees or commissions.

THE OFFER AND WITHDRAWAL RIGHTS WILL EXPIRE AT ONE MINUTE FOLLOWING 11:59 P.M., EASTERN TIME, ON MAY 23, 2022 (SUCH DATE, OR ANY SUBSEQUENT DATE TO WHICH THE EXPIRATION OF THE OFFER IS EXTENDED, THE “EXPIRATION DATE”), UNLESS THE OFFER IS EXTENDED OR EARLIER TERMINATED.

 

 

The Offer is being made pursuant to an Agreement and Plan of Merger, dated as of April 12, 2022 (as it may be amended from time to time, the “Merger Agreement”), among the Company, Parent and Purchaser. The Merger Agreement provides, among other things, that, unless otherwise agreed by the Company, Parent and Purchaser, at 8:00 a.m., Eastern Time, on the same date as the consummation of the Offer and subject


to the satisfaction or waiver of certain conditions, Purchaser will merge with and into the Company pursuant to Section 251(h) of the General Corporation Law of the State of Delaware, as amended (the “DGCL”), upon the terms and subject to the conditions set forth in the Merger Agreement, with the Company continuing as the surviving corporation and a wholly owned subsidiary of Parent (the “Merger”). In the Merger, each Share issued and outstanding immediately prior to the effective time of the Merger (the “Effective Time”) (other than Shares (a) held by the Company (or in the Company’s treasury), Parent, any other direct or indirect wholly owned subsidiary of Parent (other than Purchaser) or by stockholders of the Company who have properly exercised and perfected their statutory rights of appraisal under Delaware law or (b) irrevocably accepted for purchase in the Offer) will be converted into the right to receive an amount in cash equal to the Offer Price, without interest and subject to any withholding of taxes required by applicable legal requirements. As a result of the Merger, the Company will cease to be publicly traded.

The Offer is not subject to a financing condition. The obligation of Purchaser to accept for payment and pay for Shares validly tendered (and not validly withdrawn) pursuant to the Offer is subject to the conditions set forth in Section 15 of the Offer to Purchase (collectively, the “Offer Conditions”). Among the Offer Conditions are: (i) the Minimum Condition (as defined below); (ii) the Regulatory Condition (as defined in the Offer to Purchase) and the HSR Condition (as defined below); (iii) the accuracy of the Company’s representations and warranties set forth in the Merger Agreement as of specified times, and the performance of the Company’s covenants set forth in the Merger Agreement, in each case, to specified standards of materiality; and (iv) since the date of the Merger Agreement, there not having occurred a Material Adverse Effect (as defined in the Offer to Purchase) that is continuing. The “Minimum Condition” means that the number of Shares validly tendered and not validly withdrawn together with any Shares owned by Parent or any of its wholly owned subsidiaries (including Purchaser) (but excluding Shares tendered pursuant to guaranteed delivery procedures that have not yet been “received” (as such term is defined in Section 251(h)(6)(f) of the DGCL)), represents one more than 50% of the total number of Shares outstanding at the time of the expiration of the Offer. The “HSR Condition” means that any waiting period (and any timing agreements, any extensions of any waiting period, any understandings or commitments obtained by request or other action of the U.S. Federal Trade Commission and/or the U.S. Department of Justice, as applicable) under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended, and the rules and regulations promulgated thereunder will have been terminated or expired, as the case may be.

The Board of Directors of the Company has unanimously: (i) determined that the Merger Agreement, the Offer and the Merger are fair to, and in the best interest of, the Company and its stockholders; (ii) declared that it is advisable for the Company to enter into the Merger Agreement; (iii) approved the execution, delivery and performance by the Company of the Merger Agreement and the consummation of the transactions contemplated by the Merger Agreement, including the Offer and the Merger; (iv) agreed that the Merger shall be effected under Section 251(h) of the DGCL; and (v) resolved to recommend that the Company’s stockholders accept the Offer and tender their Shares pursuant to the Offer.

The Merger Agreement provides that, subject to the parties’ respective termination rights in the Merger Agreement, (a) if, as of the then-scheduled Expiration Date, any Offer Condition is not satisfied and has not been waived, Purchaser may, in its discretion (and without the consent of the Company or any other person), extend the Offer on one or more occasions, for an additional period of up to ten business days per extension, to permit such Offer Condition to be satisfied, (b) Purchaser will extend the Offer: (i) for any period required by any legal requirement, any interpretation or position of the Securities and Exchange Commission (the “SEC”), the staff thereof or NASDAQ Global Select Stock Market (“NASDAQ”) applicable to the Offer; and (ii) for periods of up to ten business days per extension until the Regulatory Condition has been satisfied; and (c) if, as of the scheduled Expiration Date, any Offer Condition is not satisfied and has not been waived, Purchaser will, at the request of the Company, extend the Offer on one or more occasions for an additional period of up to ten business days per extension, to permit such Offer Condition to be satisfied. Purchaser will not be required to, and without the Company’s prior written

 

2


consent is not permitted to, extend the Offer beyond the earlier to occur of (x) the valid termination of the Merger Agreement in accordance therewith and (y) the first business day immediately following the End Date. The “End Date” means October 12, 2022.

If the Offer is consummated, Purchaser will not seek the approval of the Company’s remaining stockholders before effecting the Merger. Parent, Purchaser and the Company have elected to have the Merger Agreement and the transactions contemplated thereby governed by Section 251(h) of the DGCL and agreed that, subject to the satisfaction or waiver of certain conditions, the Merger will be effected at 8:00 a.m., Eastern Time, on the same date as the consummation of the Offer (unless otherwise agreed by the Company, Parent and Purchaser). Under Section 251(h) of the DGCL, the consummation of the Merger does not require a vote or action by written consent of the Company’s stockholders.

The Merger Agreement provides, among other things, that, without the prior written consent of the Company, Purchaser will not (A) decrease the Offer Price; (B) change the form of consideration payable in the Offer; (C) decrease the maximum number of Shares sought to be purchased in the Offer; (D) impose conditions or requirements to the Offer in addition to the Offer Conditions; (E) amend or modify any of the Offer Conditions or any other terms or conditions of the Merger Agreement in a manner that would or would reasonably be expected to adversely affect any holder of Shares or that would, individually or in the aggregate, reasonably be expected to prevent or delay the consummation of the Offer or prevent, delay or impair the ability of Parent or Purchaser to consummate the Offer, the Merger or the other transactions contemplated by the Merger Agreement; (F) amend, modify or waive the Minimum Condition of the Termination Condition (as defined in the Merger Agreement); (G) extend or otherwise change the Expiration Date in a manner other than as required or permitted by the Merger Agreement; or (H) provide any “subsequent offering period” within the meaning of Rule 14d-11under the Exchange Act (as defined in the Merger Agreement).

Except as set forth above, subject to the terms of the Merger Agreement and the applicable rules and regulations of the SEC and other applicable laws and regulations, Purchaser expressly reserves the right to waive any Offer Condition, to increase the Offer Price and to make any other changes in the terms and conditions of the Offer not inconsistent with the terms of the Merger Agreement. Any extension, delay, termination or amendment of the Offer will be followed as promptly as practicable by a public announcement thereof, and such announcement in the case of an extension will be made no later than 9:00 a.m., Eastern Time, on the next business day after the previously scheduled Expiration Date.

For purposes of the Offer, Purchaser will be deemed to have accepted for payment, and thereby purchased, Shares validly tendered to Purchaser and not validly withdrawn as, if and when it gives oral or written notice to the Depositary of its acceptance for payment of such Shares pursuant to the Offer. Upon the terms and subject to the conditions of the Offer, payment for Shares accepted for payment pursuant to the Offer will be made by deposit of the Offer Price for such Shares with the Depositary, which will act as agent for tendering stockholders for the purpose of receiving payments from Parent and Purchaser and transmitting such payments to tendering stockholders whose Shares have been accepted for payment. Under no circumstances will Parent or Purchaser pay interest on the Offer Price for Shares, regardless of any extension of the Offer or any delay in making such payment.

In all cases, Purchaser will pay for Shares tendered and accepted for payment pursuant to the Offer only after timely receipt by the Depositary of (i) the certificates evidencing such Shares (the “Share Certificates”) or timely confirmation of a book-entry transfer of such Shares into the Depositary’s account at The Depository Trust Company (“DTC”) pursuant to the procedures set forth in Section 3 of the Offer to Purchase and (ii) the Letter of Transmittal (or a manually signed facsimile thereof), properly completed and duly executed, with any required signature guarantees and (iii) any other documents required by the Letter of Transmittal or, in the case of a book-entry transfer, an Agent’s Message (as defined in the Offer to

 

3


Purchase) in lieu of the Letter of Transmittal and such other documents. Accordingly, tendering stockholders may be paid at different times depending upon when Share certificates or book-entry transfers with respect to Shares are actually received by the Depositary.

Shares tendered pursuant to the Offer may be withdrawn at any time prior to the Expiration Date. Thereafter, tenders are irrevocable, except that Shares tendered may also be withdrawn after June 27, 2022 if Purchaser has not accepted them for payment by the end of June 27, 2022. For a withdrawal of Shares to be effective, the Depositary must timely receive a written or facsimile transmission notice of withdrawal at one of its addresses set forth on the back cover of the Offer to Purchase. Any notice of withdrawal must specify the name of the person who tendered the Shares to be withdrawn, the number of Shares to be withdrawn and the names in which the Share Certificates are registered, if different from that of the person who tendered such Shares. If the Shares to be withdrawn have been delivered to the Depositary, a signed notice of withdrawal must be submitted before the release of such Shares. In addition, such notice must specify, in the case of Shares tendered by delivery, or other identification to the Depositary, of Share Certificates, the serial numbers shown on the Share Certificates evidencing the Shares to be withdrawn or, in the case of Shares tendered by book-entry transfer, the name and number of the account at DTC to be credited with the withdrawn Shares. Withdrawals of tenders of Shares may not be rescinded and any Shares properly withdrawn will be deemed not validly tendered for purposes of the Offer. Withdrawn Shares may, however, be retendered by following one of the procedures for tendering Shares described in Section 3 of the Offer to Purchase at any time prior to the Expiration Date.

The information required to be disclosed by paragraph (d)(1) of Rule 14d-6 under the Exchange Act, is contained in the Offer to Purchase and is incorporated herein by reference.

The Company provided Purchaser with the Company’s stockholder list and security position listings for the purpose of disseminating the Offer to Purchase, the related Letter of Transmittal and related documents to holders of Shares. The Offer to Purchase and related Letter of Transmittal will be mailed to record holders of Shares whose names appear on the Company’s stockholder list and will be furnished for subsequent transmittal to beneficial owners of Shares to brokers, dealers, commercial banks, trust companies and similar persons whose names, or the names of whose nominees, appear on the stockholder list or, if applicable, who are listed as participants in a clearing agency’s security position listing.

The receipt of cash by a holder of Shares pursuant to the Offer or the Merger will be a taxable transaction to U.S. stockholders for U.S. federal income tax purposes. See Section 5 of the Offer to Purchase for a more detailed discussion of the tax treatment of the Offer. Stockholders should consult with their own tax advisor to determine the particular U.S. federal income tax consequences of the Offer and the Merger to them in light of their particular circumstances, as well as the tax consequences that may arise under other U.S. federal tax laws and the laws of any state, local or non-U.S. taxing jurisdiction and the possible effects of changes in such tax laws. For a summary description of U.S. federal income tax consequences and the Merger, see the Offer to Purchase. The Offer to Purchase, the related Letter of Transmittal and the Company’s Solicitation/Recommendation Statement on Schedule 14D-9 (which contains the recommendation of the Company’s Board of Directors and the reasons therefor) contain important information. Stockholders should carefully read all documents in their entirety before any decision is made with respect to the Offer.

Questions or requests for assistance may be directed to D.F. King & Co., Inc. (the “Information Agent”) at the address and telephone numbers set forth below. Requests for copies of the Offer to Purchase, the related Letter of Transmittal and other tender offer materials may be directed to the Information Agent or to brokers, dealers, commercial banks or trust companies. Such copies will be furnished promptly at Purchaser’s expense. Purchaser will not pay any fees or commissions to any broker or dealer or any other

 

4


person (other than the Information Agent or the Depositary) for soliciting tenders of Shares pursuant to the Offer.

The Information Agent for the Offer is:

D.F. King & Co., Inc.

48 Wall Street, 22nd Floor

New York, NY 10005

Banks and Brokers may call: (212) 269-5550

Shareholders may call toll free: (888) 628-1041

ATRS@dfking.com

April 26, 2022

 

5

EX-99.(A)(5)(J) 7 d347764dex99a5j.htm EXHIBIT (A)(5)(J) Exhibit (a)(5)(J)

Exhibit (a)(5)(J)

 

LOGO

HALOZYME COMMENCES TENDER OFFER FOR ALL OUTSTANDING SHARES OF COMMON STOCK OF ANTARES PHARMA

SAN DIEGO, April 26, 2022 — Halozyme Therapeutics, Inc. (NASDAQ: HALO) (“Halozyme”) today announced that it is commencing, through a wholly owned subsidiary, Atlas Merger Sub, Inc. (“Purchaser”), a cash tender offer to purchase all outstanding shares of common stock of Antares Pharma, Inc. (NASDAQ: ATRS) (“Antares”) for $5.60 per share in cash. The offer is being made pursuant to the previously announced Agreement and Plan of Merger, dated as of April 12, 2022, by and among Halozyme, Purchaser and Antares (the “Merger Agreement”).

The tender offer is scheduled to expire at one minute past 11:59 p.m. Eastern Time, on May 23, 2022, unless extended in accordance with the terms of the Merger Agreement. The closing of the tender offer is subject to certain conditions, including the tender of shares representing at least a majority of the total number of Antares’ outstanding shares of common stock, the expiration or termination of the HSR waiting period, and other customary conditions. The transaction is expected to close in the first half of 2022, as previously announced.

Halozyme filed today with the U.S. Securities and Exchange Commission (the “SEC”) a tender offer statement on Schedule TO, which includes the terms of the tender offer. Additionally, Antares filed a Schedule 14D-9 with the SEC containing the recommendation of its Board of Directors that Antares stockholders accept the tender offer and tender their shares. The Schedule TO, Schedule 14D-9, related letter of transmittal (together with any amendments or supplements thereto) and other tender offer documents can be obtained free of charge at the website maintained by the SEC at www.sec.gov or by contacting the information agent for the tender offer, D.F. King & Co., Inc., as described in the tender offer documents.

About Halozyme

Halozyme is a biopharmaceutical company bringing disruptive solutions to significantly improve patient experiences and outcomes for emerging and established therapies. Halozyme advises and supports its biopharmaceutical partners in key aspects of new drug development with the goal of improving patients’ lives while helping its partners achieve global commercial success. As the innovators of the ENHANZE® technology, which can reduce hours-long treatments to a matter of minutes, Halozyme’s commercially-validated solution has touched more than 600,000 patient lives in post-marketing use via five commercialized products across more than 100 global markets. Halozyme and its world-class partners are currently advancing multiple therapeutic programs intended to deliver innovative therapies, with the potential to improve the lives of patients around the globe. Halozyme’s proprietary enzyme rHuPH20 forms the basis of the ENHANZE® technology and is used to facilitate the delivery of injected drugs and fluids, potentially reducing the treatment burden of other drugs to patients. Halozyme has licensed its ENHANZE® technology to leading pharmaceutical and biotechnology companies including Roche, Baxalta, Pfizer, AbbVie, Eli Lilly, Bristol-Myers Squibb, Alexion, argenx, Horizon Therapeutics, ViiV Healthcare and Chugai Pharmaceutical. Halozyme derives revenues from these collaborations in the form of milestones and royalties as Halozyme’s partners make progress developing and commercializing their products being developed using ENHANZE®. Halozyme is headquartered in San Diego. For more information visit www.halozyme.com and connect with us on LinkedIn and Twitter.


LOGO

 

About Antares

Antares Pharma, Inc. is a specialty pharmaceutical company focused primarily on the development and commercialization of pharmaceutical products and technologies that address patient needs in targeted therapeutic areas. Antares develops, manufactures and commercializes, for itself or with partners, novel therapeutic products using its advanced drug delivery systems that are designed to provide commercial or functional advantages such as improved safety and efficacy, convenience, improved tolerability, and enhanced patient comfort and adherence. Antares has a portfolio of proprietary and partnered commercial products and ongoing product development programs in various stages of development. Antares has formed partnership arrangements with several different industry leading pharmaceutical companies.

Forward-Looking Statements

This press release contains “forward-looking statements”. All statements, other than statements of historical fact, included herein, including without limitation those regarding our future product development and regulatory events and goals, product collaborations, our business intentions and financial estimates and anticipated results, are, or may be deemed to be, forward-looking statements. Words such as “expect,” “anticipate,” “intend,” “plan,” “believe,” “seek,” “estimate,” “think,” “may,” “could,” “will,” “would,” “should,” “continue,” “potential,” “likely,” “opportunity,” “project” and similar expressions or variations of such words are intended to identify forward-looking statements, but are not the exclusive means of identifying forward-looking statements in this press release. Although Halozyme’s and Antares’ management each believes that the expectations reflected in such forward-looking statements are reasonable, investors are cautioned that forward-looking information and statements are subject to various risks and uncertainties, many of which are difficult to predict and generally beyond the control of Halozyme and Antares, that could cause actual results and developments to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements. These risks and uncertainties include among other things, risks related to Halozyme’s and Antares’ ability to complete the proposed acquisition on the proposed terms or on the proposed timeline, including the receipt of required regulatory approvals, the possibility that competing offers will be made, other risks associated with executing proposed acquisition, such as the risk that the businesses will not be integrated successfully, that such integration may be more difficult, time-consuming or costly than expected or that the expected benefits of the proposed acquisition will not be realized, risks related to future opportunities and plans for the combined company, including uncertainty of the expected financial performance and results of the combined company following completion of the proposed acquisition, disruption from the proposed acquisition making it more difficult to conduct business as usual or to maintain relationships with customers, employees, manufacturers or suppliers, and the possibility that, if the combined company does not achieve the perceived benefits of the proposed acquisition as rapidly or to the extent anticipated by financial analysts or investors, the market price of Halozyme’s shares could decline, as well as other risks related Halozyme’s and Antares’ respective businesses, including the ability to grow sales and revenues from existing products and to develop, commercialize or market new products, competition, including potential generic competition, the uncertainties inherent in research and development, including future clinical data and analysis, regulatory obligations and oversight by regulatory authorities, such as the U.S. Food and Drug Administration, including decisions of such authorities regarding whether and when to approve any drug, device or biological application that may be filed for any product candidates as well as decisions regarding labelling and other matters that could affect the availability or commercial potential


LOGO

 

of any product candidates, the absence of a guarantee that any product candidates, if approved, will be commercially successful, Halozyme’s ability to execute its share repurchase program according to plan, Halozyme’s ability to benefit from external growth opportunities, to complete related transactions and/or obtain regulatory clearances, risks associated with Halozyme’s and Antares’ intellectual property and any related pending or future litigation and the ultimate outcome of such litigation, trends in exchange rates and prevailing interest rates, volatile economic and market conditions, cost containment initiatives and subsequent changes thereto, and the impact that COVID-19 will have on Halozyme and on Antares and their respective customers, suppliers, vendors, and other business partners, and the financial condition of any one of them, as well as on Halozyme’s and Antares’ employees and on the global economy as a whole. Any material effect of COVID-19 on any of the foregoing could also adversely impact Halozyme and Antares. This situation is changing rapidly and additional impacts may arise of which Halozyme and Antares are not currently aware and may exacerbate other previously identified risks. While the list of factors presented here is representative, no list should be considered a statement of all potential risks, uncertainties or assumptions that could have a material adverse effect on Halozyme’s consolidated financial condition or results of operations. The foregoing factors should be read in conjunction with the risks and cautionary statements discussed or identified in the public filings with the U.S. Securities and Exchange Commission made by Halozyme, including those listed under “Risk Factors” and “Cautionary Statement Regarding Forward-Looking Statements” in Halozyme’s annual report on Form 10-K for the year ended December 31, 2021 and Antares’ annual report on Form 10-K for the year ended December 31, 2021. The forward-looking statements speak only as of the date hereof and, other than as required by applicable law, Halozyme and Antares do not undertake any obligation to update or revise any forward-looking information or statements. Investors are urged not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release.

About the Offer

This press release is for informational purposes only and is neither an offer to purchase nor a solicitation of an offer to sell shares of Antares common stock. Halozyme and its acquisition subsidiary have filed with the SEC a tender offer statement on Schedule TO, and Antares has filed a Solicitation/Recommendation Statement on Schedule 14D-9, all with respect to the Offer (as defined in those documents).

HOLDERS OF SHARES OF ANTARES ARE URGED TO CAREFULLY READ THE RELEVANT TENDER OFFER MATERIALS (INCLUDING THE OFFER TO PURCHASE, THE RELATED LETTER OF TRANSMITTAL AND THE OTHER TENDER OFFER DOCUMENTS) AND THE SOLICITATION/RECOMMENDATION STATEMENT ON SCHEDULE 14D-9 BECAUSE THEY CONTAIN IMPORTANT INFORMATION THAT ANTARES’ STOCKHOLDERS SHOULD CONSIDER BEFORE MAKING ANY DECISION REGARDING TENDERING THEIR SHARES.

The Offer to Purchase, the related Letter of Transmittal and certain other tender offer documents, as well as the Solicitation/Recommendation Statement, are available to all holders of shares of Antares’ stock at no expense to them. The tender offer materials and the Solicitation/Recommendation Statement are available for free at the SEC’s website at www.sec.gov. Additional copies may be obtained for free by contacting Halozyme or Antares. Copies of the documents filed with the SEC by Antares will be available free of charge on Antares’ internet website at https://www.antarespharma.com/investors/sec-filings or by contacting Antares’ Investor Relations Department at +1 609-359-3016. Copies of the documents filed with the SEC by Halozyme will be


LOGO

 

available free of charge on Halozyme’s internet website at https://ir.halozyme.com or by contacting Halozyme’s Investor Relations Department at ir@halozyme.com.

Additional Information

In addition to the Offer to Purchase, the related Letter of Transmittal and certain other tender offer documents, as well as the Solicitation/Recommendation Statement, Halozyme files annual, quarterly and special reports and other information with the SEC and Antares files annual, quarterly and special reports and other information with the SEC. You may read and copy any reports or other information filed by Halozyme and Antares at the SEC public reference room at 100 F. Street, N.E., Washington D.C. 20549. Please call the SEC at 1-800-SEC-0330 for further information on the public reference room. Halozyme’s and Antares’ filings with the SEC are also available to the public from commercial document-retrieval services and at the website maintained by the SEC at www.sec.gov.

Contacts

For investor inquiries please contact:

Dawn Schottlandt / Claudia Styslinger

Argot Partners

212-600-1902

Halozyme@argotpartners.com

For media inquiries please contact:

Eric Brielmann / Kelly Sullivan / Amy Feng / Caroline Lipe

Joele Frank, Wilkinson Brimmer Katcher

212-355-4449

EX-99.(B)(1) 8 d347764dex99b1.htm EXHIBIT (B)(1) Exhibit (b)(1)

Exhibit (b)(1)

BANK OF AMERICA, N.A.

BOFA SECURITIES, INC.

One Bryant Park

New York, New York 10036

CONFIDENTIAL

April 12, 2022

PROJECT ATLAS

$75.0 million Revolving Credit Facility

$375.0 million Term Loan Facility

Commitment Letter

Halozyme Therapeutics, Inc.

11388 Sorrento Valley Road

San Diego, CA 92121

Email: legal@halozyme.com

Phone: (858) 794-8889

Ladies and Gentlemen:

Halozyme Therapeutics, Inc., a Delaware corporation (the “Company” or “you”), has advised BofA Securities, Inc. (together with its designated affiliates, “BofA Securities” and the “Lead Arranger”) and Bank of America, N.A. (“Bank of America” and the “Initial Lender”, together with BofA Securities, “BofA”; the Initial Lender and the Lead Arranger are collectively referred to herein as the “Commitment Parties”, “we” or “us”) that it (directly or through one or more of its wholly owned subsidiaries) intends to acquire (the “Acquisition”) Antares Pharma, Inc., a Delaware corporation (“Atlas”), pursuant to the Agreement and Plan of Merger among the Company, Atlas Merger Sub, Inc. and Atlas, dated as of April 12, 2022 (the “Transaction Agreement”) and to consummate the other Transactions (as defined below). Each capitalized term used but not defined herein shall have the meaning assigned to it in the Summary of Terms and Conditions attached hereto as Exhibit B (the “Term Sheet”) or in the Existing Credit Agreement (as defined below), as applicable.

In connection with the consummation of the Acquisition and the incurrence of the Term Loan Facility (as defined below), you have advised us that you intend to either (i) amend that certain Credit Agreement dated as of December 23, 2021, by and among the Company, Halozyme, Inc., a California corporation, each lender from time to time party thereto, and Bank of America, N.A., as administrative agent, a swing line lender and an L/C issuer (the “Existing Credit Agreement” and the revolving credit facility thereunder, the “Existing Revolving Credit Facility”) to make the changes described on Exhibit A hereto (the “Amendment”) or (ii) terminate the commitments under the Existing Revolving Credit Facility and repay all outstanding obligations thereunder and obtain a new $75.0 million revolving credit facility with terms consistent with the Existing Credit Agreement as modified as described in Exhibit A hereto (the “Revolving Credit Facility”). Each Initial Lender that is a lender under the Existing Credit Agreement hereby agrees to consent to the Amendment. Upon the request of the Company, the Lead Arranger agrees to use its commercially reasonable efforts to assist the Company with

 

1


obtaining the consents of the lenders under the Existing Credit Agreement to the Amendment. The Company’s receipt of written consents to the Amendment from each of the Lenders under the Existing Credit Agreement shall be referred to herein as the “Amendment Event”.

You have further advised us that you intend to finance the Acquisition and the costs and expenses related to the Transactions (as hereinafter defined) with (1) a new senior secured term loan credit facility in the aggregate amount of $375.0 million (the “Term Loan Facility” and together with the either the Existing Revolving Credit Facility, as amended by the Amendment, or the Revolving Credit Facility, as applicable, the “Facilities”) and (2) cash on hand.

The solicitation of consents to the Amendment; the Acquisition; the entering into and initial funding of the Facilities (as applicable); the repayment, prepayment, repurchase, redemption, defeasance or discharge (and release of any liens related thereto) or arrangements reasonably satisfactory to the Lead Arranger (other than in respect of letters of credit that are either rolled into or back-stopped by letter(s) of credit issued under the Facilities or cash collateralized by the Borrower or its subsidiaries or contingent obligations not then due and payable) and termination of all commitments thereunder (and termination and release of all related security interests) on or prior to the Closing Date of all indebtedness under (i) the Credit Agreement, dated November 1, 2021, by and among Atlas, as borrower, the lenders party thereto and Wells Fargo Bank, National Association, as administrative agent and (ii) if the Amendment Event does not occur on or prior to the Closing Date, the Existing Revolving Credit Facility (collectively, the “Refinancing”); the payment of fees and expenses in connection therewith; and all related transactions are hereinafter collectively referred to as the “Transactions”.

In connection with the foregoing, Bank of America is pleased to advise you of its commitment to provide (a) 100.0% of the aggregate principal amount of the Term Loan Facility and (b) in the event the Amendment Event does not occur on or prior to the Closing Date, 100.0% of the aggregate principal amount of commitments under the Revolving Credit Facility, in each case, upon the terms and subject to the conditions set forth or referred to in this Commitment Letter and the Term Sheet.

It is agreed that (i) the Lead Arranger will act as the sole lead arranger and sole bookrunner for the Facilities and (ii) Bank of America will act as administrative agent and collateral agent for the Facilities, and each of them will, in such capacities, perform the duties and exercise the authority customarily performed and exercised by it in such roles. You and the Commitment Parties further agree that no other titles will be awarded, and no other compensation will be paid (other than as expressly contemplated by this Commitment Letter and the Fee Letter referred to below) in connection with the Facilities unless you and the Lead Arranger shall so agree.

Notwithstanding the foregoing, you shall have the right (in consultation with the Lead Arranger), at any time on or prior to the 15th business day following the date of this Commitment Letter, to appoint one additional joint lead arranger and joint bookrunner or confer other titles with respect to the Facilities in a manner and with economics determined by you and reasonably acceptable to the Lead Arranger (the “Additional Agent”); provided that the aggregate economics payable to such Additional Agent in respect of the Facilities shall not exceed twenty percent (20%) of the total economics which would otherwise be payable to the Initial Lender pursuant to the Fee Letter (exclusive of any fees payable to the administrative agent in its capacity as such) (it being understood that (i) the commitment of the Initial Lender hereunder will be reduced dollar-for-dollar by the amount of the commitments of such Additional Agent (or its relevant affiliate) (each, an “Additional Initial Lender”) under each Facility, upon the execution of customary joinder documentation reasonably satisfactory to the Lead Arranger and (ii) the commitments assumed by such Additional Initial Lender for each Facility will be in proportion to the economics allocated to such Additional Agent and ratable across all Facilities. Each party hereto agrees to

 

2


execute such joinder agreements, amendments, amendments and restatements and other documents with respect to this Commitment Letter and the Fee Letter as are required to give effect to this paragraph.

The Initial Lender reserves the right, prior to or after the execution of definitive documentation for any Facility, to syndicate all or a portion of its commitments in respect of such Facility hereunder to one or more financial institutions identified by the Lead Arranger in consultation with you and reasonably acceptable to the Lead Arranger and you (such consent not to be unreasonably withheld or delayed), that will become parties to such definitive documentation pursuant to a syndication to be managed by the Lead Arranger (the Initial Lender and other the financial institutions becoming parties to such definitive documentation being collectively referred to as the “Lenders”). You agree until the date that is the earlier of (i) 60 days after the Closing Date and (ii) the date on which a Successful Syndication (as defined in the Fee Letter) is achieved (such earlier date referred to in clauses (i) and (ii), the “Syndication Date”) actively to assist, and to use commercially reasonable efforts (consistent with the terms of the Transaction Agreement) to cause Atlas to assist, the Lead Arranger in completing an orderly Successful Syndication of each Facility. In that regard, you agree promptly to prepare and provide to the Lead Arranger such information with respect to the Company and its subsidiaries, and to use commercially reasonable efforts (consistent with the terms of the Transaction Agreement) to cause Atlas promptly to prepare and provide to the Lead Arranger such information with respect to Atlas and its subsidiaries, in each case including financial information, as the Lead Arranger may reasonably request in connection with the arrangement and syndication of each Facility; provided that the only financial statements that you or Atlas shall be required to deliver are those financial statements described in paragraph 3 of Exhibit C attached hereto. Your assistance shall also include (a) your using commercially reasonable efforts to ensure that the syndication efforts benefit from your existing lending and investment banking relationships, (b) direct contact between appropriate senior management of the Company and the proposed Lenders, (c) your assistance, and your using commercially reasonable efforts (consistent with the terms of the Transaction Agreement) to cause Atlas to assist, in the preparation of a confidential information memorandum and other marketing materials to be used in connection with the syndication of each Facility (collectively, “Information Materials”) and (d) the hosting, with the Lead Arranger, of a single lender meeting and a reasonable number of conference calls with prospective Lenders at times to be mutually agreed. In addition, to facilitate an orderly Successful Syndication of each Facility, you agree that, until the later of the Closing Date and the completion of a Successful Syndication of each Facility you and your subsidiaries will not (and you will use commercially reasonable efforts (consistent with the terms of the Transaction Agreement) to cause Atlas and its subsidiaries not to) issue, sell, offer, place or arrange any debt securities or commercial bank or other credit facilities of the Company, Atlas or their respective subsidiaries that could reasonably be expected to materially and adversely impair the primary syndication of such Facility, other than (i) the Facilities, (ii) any debt facilities of the Company arranged by the Lead Arranger and (iii) any debt permitted to be incurred by the Transaction Agreement, in each case without the written consent of the Lead Arranger (not to be unreasonably withheld or delayed). Without limiting your obligations to assist with the syndication efforts as set forth herein and notwithstanding anything to the contrary contained in this Commitment Letter, the Term Sheet, the Fee Letter or the definitive documentation for the Facilities and the Amendment, the Initial Lender agrees that neither the commencement of any syndication nor the completion of a Successful Syndication nor the obtaining of ratings nor your compliance with this paragraph in any other manner shall constitute a condition to the funding under any Facility and the effectiveness of the Amendment on the Closing Date.

You agree, at the request of the Lead Arranger, to assist, and to use commercially reasonable efforts (consistent with the terms of the Transaction Agreement) to cause Atlas to assist, in the preparation of an additional version of the Information Materials to be used by prospective Lenders’ public-side employees and representatives who do not wish to receive material non-public information (within the meaning of United States Federal securities laws) with respect to the Company, Atlas, their

 

3


respective subsidiaries and any securities of any of the foregoing (“MNPI”) and who may be engaged in investment and other market related activities with respect to the Company, Atlas, their respective subsidiaries or any securities of any of the foregoing. It is understood that, in connection with your assistance described above, you will provide customary authorization letters (and you will use commercially reasonable efforts consistent with the terms of the Transaction Agreement, to have Atlas provide such letters) to the Lead Arranger authorizing the distribution of the Information Materials to prospective Lenders and, in the case of any distribution of any Information Materials to “public-siders”, containing a representation that such Information Materials do not contain MNPI and a customary “10b-5” representation. You agree that the following documents may be distributed to both “private-siders” and “public-siders” unless you advise the Lead Arranger in writing (including by email) within a reasonable time prior to their intended distribution that such materials should only be distributed to “private-siders” and provided that you shall have been given a reasonable opportunity to review such documents: (a) the Term Sheet, (b) administrative materials prepared by any Lead Arranger for prospective Lenders (such as lender meeting invitations, lender allocations and funding and closing memoranda), (c) notifications of changes in the terms of the Facilities and the Amendment, and (d) drafts of the definitive documentation for the Facilities and Amendment. If you advise us that any of the foregoing should be distributed only to “private-siders”, then “public-siders” will not receive such materials without further discussions with you.

You hereby represent and covenant that (a) all written information, other than the Projections (as defined below) and information of a general economic or industry nature, that has been or will be made available to either the Initial Lender or Lead Arranger by or on behalf of you in connection with the Transactions (the “Information”) is or, when furnished, will be, in each case when taken as a whole and in light of the circumstances when furnished, correct in all material respects at the time furnished and does not or will not at the time furnished contain any untrue statement of a material fact or omit to state a material fact necessary in order to make the statements contained therein, taken as a whole, not materially misleading in light of the circumstances under which such statements are made and (b) the projections, financial estimates, forecasts and other forward-looking information that have been or will be made available to either the Initial Lender or Lead Arranger by or on behalf of you in connection with the Transactions (the “Projections”) have been or will be prepared in good faith based upon assumptions believed by you to be reasonable at the time made and at the time the Projections are so made available (it being understood that the Projections, by their nature, are inherently uncertain and no assurances are being given that the results reflected in the Projections will be achieved); provided that, with respect to any Information or Projections prepared by or relating to Atlas or its subsidiaries, the foregoing representations are made only to the best of your knowledge. You agree that if at any time until the later of the Syndication Date and the Closing Date you become aware that the representations in the immediately preceding sentence would not be true in any material respect if the Information and Projections were being furnished, and such representations were being made, at such time, then you will (and with respect to Atlas, use your commercially reasonable efforts to cause Atlas to) promptly supplement the Information and the Projections so that such representations or warranties would be true in all material respects under those circumstances. You understand that in connection with the syndication of the Facilities and the Amendment we will use and rely on the Information without independent verification thereof. Notwithstanding the foregoing, it is understood that the Initial Lender’s commitments hereunder are not subject to or conditioned upon the accuracy of the representations set forth in this paragraph, and notwithstanding anything to the contrary contained in this Commitment Letter, the Term Sheet, the Fee Letter or the definitive documentation for the Facilities, the accuracy of such representations shall not constitute a condition to the funding under any Facility or the effectiveness of the Amendment on the Closing Date.

 

4


The Lead Arranger will, in consultation with you, manage all aspects of the syndication of the Facilities, including decisions as to the selection of institutions to be approached and when they will be approached, when their commitments will be accepted, which institutions will participate, the allocations of the commitments among the Lenders, the allocation of any title or role to any Lender and the amount and distribution of fees among the Lenders; it being understood and agreed that we will not syndicate to those persons identified in writing to the Lead Arranger on or prior to our execution of this Commitment Letter and, with respect to persons who are competitors of you or your subsidiaries or Atlas or its subsidiaries, identified in writing from time to time after the date of this Commitment Letter and, in each case, their affiliates (other than bona fide debt fund affiliates of competitors) to the extent such affiliates are identified in writing or are otherwise clearly identifiable on the basis of name (but, in each case, without retroactive effect) (collectively, the “Disqualified Lenders”). Notwithstanding the Lead Arranger’s right to syndicate the Facilities (but subject to the seventh paragraph of this Commitment Letter), the Initial Lender shall not be relieved or released from its commitment hereunder prior to the funding thereof on the Closing Date in connection with any syndication, assignment or participation of any Facility (and unless you otherwise agree in writing, the Initial Lender and Lead Arranger shall at all times retain exclusive control over all its rights and obligations with respect to such Facility and its commitments in respect thereof, including all rights with respect to consents, modifications, supplements, waivers and amendments of this Commitment Letter and the definitive documentation with respect to such Facility).

As consideration for the Initial Lender’s commitment hereunder and our agreements to perform the services described herein, you agree to pay to us the fees as set forth in the fee letter dated the date hereof and delivered herewith (the “Fee Letter”).

The commitments of the Initial Lender and the agreements of the Initial Lender and the Lead Arranger hereunder in respect of each Facility and the Amendment are subject only to satisfaction or waiver of the following conditions (collectively, the “Funding Conditions”): (a) the execution and delivery by the Borrower and the Guarantors of definitive documentation for such Facility and the Amendment consistent with this Commitment Letter, the Term Sheet and the Fee Letter and subject to the Documentation Provision and (b) the satisfaction or waiver of the other conditions expressly set forth in Exhibit C attached hereto. It is understood that there are no conditions (implied or otherwise) to the commitments hereunder (including compliance with the terms of this Commitment Letter, the Term Sheet, the Fee Letter, the definitive documentation for the Facilities or otherwise) other than the Funding Conditions (and upon satisfaction or waiver of the Funding Conditions, the initial funding duly requested by any Borrower under any Facility to be made on or after the date on which the Effective Time occurs shall occur (the date of such funding, the “Closing Date”)).

Notwithstanding anything in this Commitment Letter, the Term Sheet, the Fee Letter, the definitive documentation for the Facilities or any other letter agreement or undertaking concerning the financing of the Transactions to the contrary, (a) the only representations the accuracy of which shall be a condition to availability of the Facilities and the effectiveness of the Amendment on the Closing Date shall be (i) such representations made by Atlas in the Transaction Agreement as are material to the interests of the Lenders, but only to the extent that you (or your affiliates) have the right under the Transaction Agreement to terminate your obligations under the Transaction Agreement or not to consummate the Acquisition as a result of such representations in the Transaction Agreement being inaccurate (the “Transaction Agreement Representations”) and (ii) the Specified Representations (as defined below) and (b) the terms of the definitive documentation for each Facility shall be in a form such that such Facility is available on the Closing Date if the Funding Conditions are satisfied or waived (it being understood that (I) with respect to any Collateral of the Company and its subsidiaries (other than Atlas and its subsidiaries), to the extent any such Collateral (other than to the extent that a lien on such Collateral may be perfected by (i) the filing of a financing statement under the Uniform Commercial Code

 

5


or (ii) the delivery of stock certificates of any material U.S. subsidiary of the Company or any Guarantor (other than Atlas or any subsidiary of Atlas) which are required to be pledged under the Term Sheet) is not or cannot be provided or perfected on the Closing Date after your use of commercially reasonable efforts to do so (consistent with the Transaction Agreement) and (II) with respect to any Collateral of Atlas or any of its subsidiaries, in the case of each of (I) and (II), the provision or perfection of a security interest in such Collateral shall not constitute a condition precedent to the availability of the Facilities and the making of the initial loans and other extensions of credit thereunder on the Closing Date, but shall be required to be provided and perfected within 90 days after the Closing Date (subject to extensions granted by the applicable Administrative Agent, in its reasonable discretion)). For purposes hereof, (x) “Specified Representations” means the representations and warranties of the Borrower and each of the Guarantors set forth in the applicable Term Sheet with respect to (A) their legal existence and power, authorization, due execution and delivery, in each case as they relate to the entering into and performance of the definitive documentation for such Facility by the Borrower and the Guarantors; (B) the enforceability with respect to the Borrower and Guarantors of the definitive documentation for such Facility (subject to customary enforceability exceptions); (C) noncontravention by the definitive documentation for such Facility with respect to the organizational documents of the Borrower and the Guarantors; (D) Federal Reserve margin regulations; (E) Investment Company Act status of the Borrower and the Guarantors; (F) OFAC, FCPA and other applicable sanctions, anti-corruption, anti-money laundering laws; (G) the creation, validity and perfection of the security interests in the Collateral (subject in all respects to customary permitted liens and the limitations set forth above in this paragraph), (H) the PATRIOT Act, and (I) solvency as of the Satisfaction Date of the Company and its subsidiaries (including Atlas and its subsidiaries) on a consolidated basis (with solvency to be defined in a manner consistent with the form of solvency certificate attached as Exhibit D) (the “Solvency Specified Representation”). The provisions of this paragraph are referred to as the “Documentation Provision”.

You agree (a) to indemnify and hold harmless the Initial Lender and Lead Arranger and each of their affiliates, and each of the respective officers, directors, employees, members, partners, trustees, advisors, agents and controlling persons of the foregoing and their respective successors and assigns (each, an “indemnified person”), from and against any and all losses, claims, damages and liabilities, and expenses reasonably related thereto, to which any such indemnified person may become subject arising out of or in connection with this Commitment Letter, the Term Sheet, the Fee Letter, the Facilities and the actual or proposed use of the proceeds thereof or any claim, litigation, investigation or proceeding relating to any of the foregoing, regardless of whether any indemnified person is a party thereto (and regardless of whether such matter is initiated by you or by any other person) (any of the foregoing, a “Proceeding”), and to reimburse each indemnified person upon demand for any reasonable and documented out-of-pocket legal or other out-of-pocket expenses incurred in connection with investigating or defending any Proceeding (it being agreed that, notwithstanding the foregoing, you shall not be responsible for the reimbursement of fees, charges and disbursements of more than one firm of counsel for all the indemnified persons and, if deemed reasonably necessary by us, one firm of regulatory counsel and/or one firm of local counsel in each appropriate jurisdiction, in each case for all indemnified persons, except where any indemnified person reasonably believes that an actual or perceived conflict of interest exists affecting such indemnified person and informs you of such conflict, in which case you shall also be responsible for the reimbursement of fees, charges and disbursements of one firm of counsel (and, if deemed reasonably necessary by such indemnified person, one firm of regulatory and/or one firm of local counsel in each appropriate jurisdiction) for such indemnified person); provided that the foregoing indemnity will not, as to any indemnified person, apply to losses, claims, damages, liabilities or related expenses (i) to the extent they are determined by a final, non-appealable judgment of a court of competent jurisdiction to have resulted from the willful misconduct or gross negligence of such indemnified person or any Related Person thereof (as defined below) or a material breach of the agreements set forth herein of such indemnified person or any of its Related Persons or (ii) to the extent resulting from any Proceeding

 

6


that does not involve an act or omission of you or any of your affiliates and that is brought by an indemnified person against any other indemnified person, other than claims against the Initial Lender or Lead Arranger in its capacity in fulfilling its role as an agent or arranger or any other similar role under the Facilities; and (b) to reimburse the Initial Lender, the Lead Arranger and each of their affiliates upon demand for all reasonable and documented out-of-pocket expenses (including reasonable fees, charges and disbursements of one firm of outside counsel (and, if deemed reasonably necessary by us, one firm of regulatory counsel and/or one firm of local counsel in each appropriate jurisdiction)) incurred in connection with the Facilities and any related documentation (including this Commitment Letter, the Term Sheet, the Fee Letter and the definitive documentation for the Facilities) or the amendment, modification or waiver of any thereof. No indemnified person shall be liable for any damages arising from the use of Information or other materials obtained through electronic, telecommunications or other information transmission systems, except to the extent any such damages are found by a final, non-appealable judgment of a court of competent jurisdiction to arise from the gross negligence or willful misconduct of such indemnified person or any of its Related Persons. For purposes hereof, a “Related Person” of an indemnified person means (a) any controlling person, controlled affiliate or subsidiary of such indemnified person, (b) the respective directors, officers or employees of such indemnified person or any of its subsidiaries, controlled affiliates or controlling persons, and (c) the respective agents and advisors of such indemnified person or any of its subsidiaries, controlled affiliates or controlling persons (with respect to this clause (c), in each case acting at the direction of such indemnified person or such subsidiaries, controlled affiliates or controlling persons). You acknowledge that the Commitment Parties may receive a benefit, including, without limitation, a discount, credit or other accommodation, from any such counsel based on the fees such counsel may receive on account of their relationship with us, including without limitation, fees paid pursuant hereto. If any amount previously paid to an indemnified person pursuant to this paragraph is subsequently determined to be ineligible for indemnification as a result of a final, non-appealable judgment of a court of competent jurisdiction, such indemnified person shall promptly reimburse such amount to you.

You agree that (i) in no event shall the Lead Arranger, its affiliates and their respective officers, directors, employees, advisors, and agents (each, and including, without limitation, the Lead Arranger, an “Arranger-Related Person”) or you (or any of your subsidiaries or affiliates) have any Liabilities, on any theory of liability, for any special, indirect, consequential or punitive damages arising out of, in connection with, or as a result of, this Commitment Letter, the Fee Letter or any other agreement or instrument contemplated hereby and (ii) no Arranger-Related Person shall have any Liabilities arising from, or be responsible for, the use by others of Information or other materials (including, without limitation, any personal data) obtained through electronic, telecommunications or other information transmission systems, including an electronic platform or otherwise via the internet (except to the extent such damages have resulted from the willful misconduct or gross negligence of any Arranger-Related Person or any of its Related Persons or a material breach by such Arranger-Related Person or any of its Related Persons of the terms of this Commitment Letter, the Fee Letter or any other agreement or instrument contemplated hereby); provided that, nothing in this paragraph shall relieve you of any obligation you may have to indemnify an indemnified person, as and to the extent provided in the immediately preceding paragraph, against any special, indirect, consequential or punitive damages asserted against such indemnified person by a third party. You agree, to the extent permitted by applicable law, to not assert any claims against any Arranger-Related Person with respect to any of the foregoing. As used herein, the term “Liabilities” shall mean any losses, claims (including intraparty claims), demands, damages or liabilities of any kind.

You will not, without the prior written consent of the applicable indemnified person (which shall not be unreasonably withheld or delayed), settle, compromise, consent to the entry of any judgment in or otherwise seek to terminate any Proceeding in respect of which indemnification may be

 

7


sought hereunder (whether or not any indemnified person is a party thereto) unless such settlement, compromise, consent or termination (i) includes an unconditional release of such indemnified person from all liability or claims that are the subject matter of such Proceeding and (ii) does not include a statement as to, or an admission of, fault, culpability, or a failure to act by or on behalf of such indemnified person. You will not be liable for any settlement, compromise, consent or termination of any pending or threatened Proceeding effected without your prior written consent (which shall not be unreasonably withheld); provided that the foregoing indemnity will apply to any such settlement, compromise, consent or termination in the event that you were offered the ability to assume the defense of the action that was the subject matter of such settlement, compromise, consent or termination and elected not to assume such defense; and provided, further, that if a Proceeding is settled, compromised, consented to or terminated with your prior written consent or if there is a final judgment in any such Proceeding, you agree to indemnify and hold harmless each indemnified person to the extent and in the manner set forth above.

This Commitment Letter shall not be assignable by you without the prior written consent of the Initial Lender and the Lead Arranger (and any purported assignment without such consent shall be null and void), is intended to be solely for the benefit of the parties hereto and the indemnified persons and is not intended to confer any benefits upon, create any rights in favor of or be enforceable by or at the request of any person other than the parties hereto and the indemnified persons. Except as provided in the seventh paragraph of this Commitment Letter, the Initial Lender may not assign all or any portion of their respective commitments in respect of any Facility hereunder (and any purported assignment without such consent shall be null and void). Any and all obligations of, and services to be provided by, the Initial Lender or Lead Arranger hereunder may be performed, and any and all rights of the Initial Lender or Lead Arranger hereunder may be exercised, by or through its affiliates; provided that the Initial Lender or Lead Arranger shall not be relieved of any of its obligations hereunder in the event any such affiliate shall fail to perform such obligation in accordance with the terms hereof.

This Commitment Letter may not be amended or waived except by an instrument in writing signed by you and us. This Commitment Letter may be executed in any number of counterparts, each of which shall be an original and all of which, when taken together, shall constitute one agreement. Delivery of an executed counterpart of a signature page of this Commitment Letter by facsimile or other electronic transmission shall be effective as delivery of a manually executed counterpart hereof. Section headings used herein are for convenience of reference only, are not part of this Commitment Letter and are not to affect the construction of, or to be taken into consideration in interpreting, this Commitment Letter. The words “execution,” “signed,” “signature” and words of like import in this Commitment Letter relating to the execution and delivery of this Commitment Letter shall be deemed to include electronic signatures, which shall be of the same legal effect, validity or enforceability as a manually executed signature to the extent and as provided in any applicable law, including the Federal Electronic Signatures in Global and National Commerce Act, the New York State Electronic Signatures and Records Act, or any other similar state laws based on the Uniform Electronic Transactions Act.

This Commitment Letter and the Fee Letter are the only agreements that have been entered into among the parties hereto with respect to the Facilities and set forth the entire understanding of the parties hereto with respect thereto.

THIS COMMITMENT LETTER SHALL BE GOVERNED BY, AND CONSTRUED IN ACCORDANCE WITH, THE LAWS OF THE STATE OF NEW YORK; provided that (a) the accuracy of any Transaction Agreement Representations and whether as a result of a breach thereof you (or any of your affiliates) have the right under the Transaction Agreement to terminate your obligations under the Transaction Agreement or not to consummate the Acquisition as a result of such representations in the Transaction Agreement being inaccurate and (b) whether the Acquisition has been consummated in accordance with the Transaction Agreement, shall be governed by, and construed in accordance with the

 

8


laws of the State of Delaware, without regard to the conflicts of law rules or principles that would result in the application of the law of any other state or jurisdiction. Each party hereto irrevocably and unconditionally submits to the exclusive jurisdiction of any state or Federal court sitting in the county of New York over any suit, action or proceeding directly or indirectly arising out of, relating to, based upon or as a result of this Commitment Letter, the Term Sheet, the Fee Letter or the transactions contemplated hereby. Each party hereto agrees that service of any process, summons, notice or document by registered mail addressed to it at the address set forth above shall be effective service of process for any suit, action or proceeding brought in any such court. Each party hereto irrevocably and unconditionally waives any objection to the laying of venue of any such suit, action or proceeding brought in any such court and any claim that any such suit, action or proceeding has been brought in any inconvenient forum. Each party hereto agrees that a final judgment in any such suit, action or proceeding brought in any such court shall be conclusive and binding upon it and may be enforced in any other courts to whose jurisdiction it is or may be subject, by suit upon judgment. EACH PARTY HERETO HEREBY WAIVES, TO THE FULLEST EXTENT PERMITTED BY APPLICABLE LAW, ANY RIGHT IT MAY HAVE TO A TRIAL BY JURY IN ANY LEGAL PROCEEDING DIRECTLY OR INDIRECTLY ARISING OUT OF, RELATING TO OR BASED UPON OR AS A RESULT OF THIS COMMITMENT LETTER, THE TERM SHEET, THE FEE LETTER OR THE TRANSACTIONS CONTEMPLATED HEREBY.

This Commitment Letter is delivered to you on the understanding that none of this Commitment Letter, the Term Sheet, the Fee Letter or any of their terms or substance shall be disclosed, directly or indirectly, by you to any other person, except that (a) this Commitment Letter, the Term Sheet, the Fee Letter and their terms and substance may be disclosed to you and your subsidiaries, and the respective directors, officers, employees, agents, auditors, attorneys and other advisors and representatives of each of you and your subsidiaries who are directly involved in the consideration of this matter and informed of the confidential nature thereof, in each case, on a confidential and need-to-know basis; (b) this Commitment Letter, the Term Sheet and their terms and substance (and a version of the Fee Letter redacted in the manner reasonably acceptable to the Lead Arranger) may be disclosed to Atlas and its directors, officers, employees, agents, auditors, attorneys and other advisors and representations who are directly involved in the consideration of the Acquisition and informed of the confidential nature thereof, in each case, on a confidential and need-to-know basis; (c) this Commitment Letter, the Term Sheet and their terms and substance (but not the Fee Letter or, except as specified below, their terms or substance) may be disclosed in one or more filings with the Securities and Exchange Commission; provided that, notwithstanding the foregoing, you may disclose the aggregate amount payable as fees under the Fee Letter in any of the foregoing as part of the generic aggregate transaction expenses included in any sources and uses disclosure; (d) this Commitment Letter, the Term Sheet, the Fee Letter and their terms and substance otherwise may be disclosed as may be compelled in a judicial or administrative proceeding or as otherwise required by law or requested by governmental authority (in which case you agree to the extent permitted by applicable law to inform us promptly thereof); (e) this Commitment Letter, the Term Sheet, the Fee Letter and their terms and substance may be disclosed in connection with the exercise of any remedies hereunder or any suit, action or proceeding relating to this Commitment Letter, the Fee Letter, or the transactions contemplated hereby or thereby or enforcement hereof or thereof and (f) after you countersign this Commitment Letter and the Fee Letter, this Commitment Letter, the Term Sheet, the Fee Letter and their terms and substance may be disclosed to any potential Additional Agent or potential Additional Initial Lender on a confidential basis; provided that the foregoing restrictions shall cease to apply (except in respect of the Fee Letter and its terms and substance) after this Commitment Letter has been accepted by you and it has become publicly available or, if not made publicly available, on the date that is two years following the termination of this Commitment Letter in accordance with its terms.

 

9


The Lead Arranger and Initial Lender shall use all non-public information provided to it by or on behalf of you hereunder solely for the purpose of providing the services that are the subject of this letter agreement and shall treat confidentially all such information, except in each case for information that was or becomes publicly available other than by reason of disclosure by the Lead Arranger or Initial Lender in violation of this letter agreement, provided that nothing herein shall prevent the Lead Arranger or Initial Lender from disclosing any such information (i) to lenders or prospective lenders, participants or assignees under the Facilities or prospective hedge providers, in each case, on a confidential basis, (ii) as may be compelled in a judicial or administrative proceeding or as otherwise required by law or requested by governmental authority (in which case we agree to the extent permitted by applicable law to inform you promptly thereof (except with respect to any audit or examination conducted by bank accountants or any self-regulatory authority or governmental or regulatory authority exercising examination or regulatory authority)), (iii) to the Lead Arranger’s or Initial Lender’s employees, legal counsel, directors, officers, service providers, independent auditors and other experts or agents who need to know such information and are informed of the confidential nature of such information, (iv) to any of its affiliates (with the Lead Arranger or Initial Lender being responsible for its affiliate’s compliance with this paragraph) and its affiliates’ employees, legal counsel, directors, officers, service providers, independent auditors and other experts or agents who need to know such information and are informed of the confidential nature of such information, (v) upon the request or demand of any regulatory authority having jurisdiction over it or any of its affiliates, (vi) to the extent any such information becomes publicly available other than by reason of disclosure by us, our respective affiliates or any of our respective representatives in breach of this Commitment Letter, (vii) to the extent that such information is independently developed by us or is received by us from a third party that is not, to our knowledge, subject to confidentiality obligations owing to you, Atlas, or any of your or its respective affiliates or related parties, (viii) to establish a due diligence defense or (ix) to enforce their respective rights hereunder or under the Fee Letter. In addition, the Lead Arranger and Initial Lender may disclose the existence of the Facilities and customary information about the Facilities to market data collectors, similar services providers to the lending industry and service providers to the Lead Arranger or Initial Lender in connection with the administration and management of the Facilities. This undertaking by the Lead Arranger and Initial Lender shall automatically terminate on the date that is two years from the date hereof. Nothing in this letter agreement precludes either Lead Arranger or Initial Lender or their affiliates from using or disclosing any confidential information in connection with any suit, action or proceeding for the purpose of defending itself, reducing its liability or protecting or exercising any of its rights, remedies or interests.

You agree that each of us will act under this Commitment Letter as an independent contractor and that nothing in this Commitment Letter or the Fee Letter, or the communications pursuant hereto or otherwise, will be deemed to create an advisory, fiduciary or agency relationship or fiduciary duty between any of us, on the one hand, and you, Atlas or your or its subsidiaries, affiliates or equityholders, on the other, irrespective of whether any of us has advised or is advising you on other matters. You acknowledge and agree that (a) the financing transactions contemplated by this Commitment Letter and the Fee Letter, the solicitation of consents to the Amendment and any related arranging or other services described in this Commitment Letter are arm’s-length commercial transactions among us and you, (b) in connection therewith and with the process leading to such transactions, each of us is acting solely as a principal and not as an agent or fiduciary of you, Atlas, your or its subsidiaries and affiliates or any other person, and none of us has assumed (and will not be deemed on the basis of our communications or activities hereunder to have assumed) an advisory or fiduciary responsibility or any other obligation in favor of you, Atlas, your or its subsidiaries or affiliates or any other person (irrespective of whether any of us or any of our affiliates are concurrently providing other services to you), and (c) you are responsible for making your own independent judgment with respect to such transactions and the process leading thereto and have consulted your own legal and financial advisors to

 

10


the extent you have deemed appropriate. You hereby waive, to the fullest extent permitted by law, any claims you may have against any of us for breach of fiduciary duty or alleged breach of fiduciary duty in connection with the financing transactions contemplated by this Commitment Letter and agree that none of us shall have any liability (whether direct or indirect) in connection with the financing transactions contemplated by this Commitment Letter to you in respect of such a fiduciary duty claim or to any person asserting a fiduciary duty claim on behalf of or in right of you, including your stockholders, employees and creditors.

You acknowledge that each of us and our affiliates may be providing debt financing, equity capital or other services (including financial advisory services) to other companies in respect of which you or Atlas may have conflicting interests. Each of us agrees that it will not use confidential information obtained from you in connection with the transactions contemplated hereby in connection with the performance by it of services for other companies nor will it furnish any such information to other companies. You also acknowledge that none of us has any obligation to use in connection with the transactions contemplated hereby, or to furnish to you, confidential information obtained from other companies.

You further acknowledge that each of us, together with our affiliates, is a full service securities firm engaged in securities trading and brokerage activities as well as providing investment banking and other financial services. In the ordinary course of business, each of us and our affiliates may provide investment banking and other financial services to, and/or acquire, hold or sell, for our own accounts and the accounts of customers, equity, debt and other securities and financial instruments (including bank loans and other obligations) of, you and your subsidiaries and other companies with which you or your subsidiaries may have commercial or other relationships. With respect to any securities and/or financial instruments so held by any of us, any of our affiliates or any of our or their customers, all rights in respect of such securities and financial instruments, including any voting rights, will be exercised by the holder of the rights, in its sole discretion; other than as expressly set forth herein with respect to our consent to the Amendment.

BofA Securities and/or its affiliates have been retained as the buy-side financial advisor (in such capacity, the “Financial Advisor”) to the Company in connection with the Transaction. You agree to any such retention, and further agree not to assert any claim you might allege based on any actual or potential conflicts of interest that might be asserted to arise or result from, on the one hand, the engagement of the Financial Advisor or from BofA Securities’ and/or its affiliates’ arranging or providing or contemplating arranging or providing financing for a competing bidder and, on the other hand, our relationship with you as described and referred to herein.

The provisions contained herein relating to compensation, expense reimbursement, indemnification, governing law, submission to jurisdiction, waiver of breach of fiduciary duty or alleged breach of fiduciary duty, waiver of jury trial and confidentiality and in the Fee Letter shall remain in full force and effect notwithstanding the termination of this Commitment Letter or the commitment hereunder, and whether or not definitive documentation for any Facility shall be executed (except to the extent a similar provision relating to expense reimbursement and indemnification (covering the parties and matters covered by the analogous provisions of this Commitment Letter) is also in the definitive documentation for such Facility, in which case such provision in the definitive documentation for such Facility shall govern upon execution thereof). The provisions contained herein relating to syndication and information shall remain in full force and effect until the Syndication Date whether or not definitive documentation for any Facility shall be executed.

The Initial Lender and Lead Arranger hereby notify you that pursuant to the requirements of the USA Patriot Act (Title III of Pub. L. 107-56 (signed into law October 26, 2001)) (the “Patriot Act”)

 

11


and the requirements of 31 C.F.R. §1010.230 (the “Beneficial Ownership Regulation”), it and the Lenders are required to obtain, verify and record information that identifies the Borrower and the Guarantors, which information includes the name and address and other information of the Borrower and the Guarantors that will allow the Initial Lender, Lead Arranger and Lenders to identify the Borrower and the Guarantors in accordance with the Patriot Act or the Beneficial Ownership Regulation.

Each of the parties hereto agrees that this Commitment Letter is a binding and enforceable agreement (subject to the effects of bankruptcy, insolvency, fraudulent transfer, fraudulent conveyance, reorganization and other similar laws relating to or affecting creditors’ rights generally and general principles of equity) with respect to the subject matter contained herein, including an agreement to fund or otherwise extend credit under the commitments hereunder subject only to satisfaction of the Funding Conditions and the good faith negotiation of the definitive documentation of the Facilities.

If the foregoing correctly sets forth our agreement, please indicate your acceptance of the terms hereof and of the Term Sheet and the Fee Letter by returning to us an executed counterpart hereof and of the Fee Letter, to the Lead Arranger, in each case not later than 11:59 p.m. New York City time, on April 17, 2022, failing which the Initial Lender’s commitments and the agreements of the Initial Lender and Lead Arranger hereunder will expire at such time. In the event the Closing Date does not occur on or before 11:59 p.m. (New York time), on the End Date (as defined in the Transaction Agreement as in effect on the date hereof), the Initial Lender’s commitments and the agreements of the Commitment Parties hereunder will automatically expire and terminate at such time, without any further action or notice and without any further obligation. Notwithstanding the foregoing, this Commitment Letter shall also terminate upon the earlier of (i) the valid termination of the Transaction Agreement in accordance with its terms or (ii) the consummation of the Acquisition with the use of the Facilities (after the funding thereof) or without the use of the Facilities (unless the Commitment Parties have failed to fund in breach of their obligations hereunder); provided that the termination of any commitment pursuant to this sentence does not prejudice our or your rights and remedies in respect of any breach of this Commitment Letter.

[Signature pages follow.]

 

12


We are pleased to have been given the opportunity to assist you in connection with this important financing.

 

Very truly yours,

BofA SECURITIES, INC.

By:

 

/s/ Matthew Curtin

 

Name:     Matthew Curtin

 

Title:       Managing Director

BANK OF AMERICA, N.A.

By:

 

/s/ Matthew Curtin

 

Name:     Matthew Curtin

 

Title:       Managing Director

 

 

[Signature Page to Project Atlas Commitment Letter]


Accepted and agreed to as of

the date set forth above by:

 

HALOZYME THERAPEUTICS, INC.,

by

 

/s/ Nicole LaBrosse

 

Name: Nicole LaBrosse

 

Title: SVP, CFO

 

 

[Signature Page to Project Atlas Commitment Letter]


EXHIBIT A

PROJECT ATLAS

Amendments to the Existing Revolving Credit Facility1

The contemplated Amendment to the Existing Credit Agreement shall include the following changes:

 

  1.

expressly permit the Acquisition under the Existing Credit Agreement;

 

  2.

expressly permit the incurrence of the Term Loan Facility under Section 7.02 of the Existing Credit Agreement;

 

  3.

expressly permit the liens securing the Term Loan Facility under Section 7.01 of the Existing Credit Agreement;

 

  4.

modify the definition of “Consolidated Funded Net Indebtedness” in the Existing Credit Agreement to provide that all cash and cash equivalents may be netted for purposes of such definition up to a maximum amount of $250.0 million;

 

  5.

modify Section 7.11(b) of the Existing Credit Agreement to increase the maximum Consolidated Net Leverage Ratio thereunder to 4.75:1.00, subject to (i) a 25 basis point reduction on each of the first, second and third anniversaries of the Closing Date and (ii) in the event of a Material Acquisition (to be defined in the Amendment Event documentation), a 50 basis point increase for twelve (12) months commencing on the date of such Material Acquisition; provided that the maximum Consolidated Net Leverage Ratio after giving effect to such increase shall at no time exceed 4.75:1.00;

 

  6.

modify Section 6.12 to provide for post-closing Collateral requirements consistent with the Documentation Provision;

 

  7.

modify Section 7.06 in a manner consistent with the “Negative Covenants” section of Exhibit B; and

 

  8.

such other changes as the Borrower and the Initial Lenders reasonably agree are necessary to permit the consummation of the Transactions.

 

1 

Capitalized terms used but not otherwise defined in this Exhibit A have the meanings assigned thereto in the Commitment Letter to which this Exhibit A is attached, including the other exhibits thereto.

 

A-1


EXHIBIT B

PROJECT ATLAS

$375.0 million Term Loan A Facility

Summary of Terms and Conditions2

 

Borrower:

  

Halozyme Therapeutics, Inc., a Delaware corporation.

Facilities:

  

A $375.0 million term loan facility (the “Term Loan Facility”).

Lead Arranger

and Lead Bookrunner:

  

BofA Securities (in such capacity, the “Lead Arranger”).

Administrative

and Collateral Agent:

  

Bank of America (in such capacities, the “Administrative Agent” and the “Collateral Agent”).

Lenders:

  

A syndicate of lenders, including Bank of America and excluding Disqualified Lenders (collectively, the “Lenders”).

Availability:

  

The Term Loan Facility will be available in a single drawing on the Closing Date. Amounts borrowed under the Term Loan Facility that are repaid or prepaid may not be reborrowed.

Guarantors:

  

Same as under the Existing Credit Agreement (as defined below), as well as Atlas and each of its subsidiaries (other than a CFC (as defined in the Existing Credit Agreement) or any Subsidiary that is held directly or indirectly by a CFC).

Security:

  

Same as under the Existing Credit Agreement and shall also include the assets of Atlas and each of its subsidiaries that become Loan Parties on substantially the same basis as the collateral of the existing Loan Parties.

Unrestricted Subsidiaries:

  

Same as under the Existing Credit Agreement (as defined below).

Use of Proceeds:

  

The proceeds of the Term Loan Facility will be used on the Closing Date, together with cash on hand, to finance the Transactions.

Maturity Date and

Amortization:

  

The Term Loan Facility will mature on November 30, 2026 (the “Maturity Date”) and will amortize on a quarterly basis in arrears (beginning with the first full fiscal quarter following the Closing Date) at a rate of 2.50% per annum during the first year following the Closing Date, 5.00% per annum during the second year following the Closing Date, 5.00% per annum during the third year following the Closing Date, 7.50% per annum during the fourth year following the Closing Date and 10.00% per annum during the fifth year following the Closing Date, with the balance of the principal amount of the Term Loan Facility to be paid on the Maturity Date.

 

2 

Capitalized terms used but not otherwise defined in this Exhibit B have the meanings assigned thereto in the Commitment Letter to which this Exhibit B is attached, including the other exhibits thereto.

 

B-1


Incremental Facilities:

  

The definitive documentation with respect to the Facilities will permit the Borrower to add one or more incremental term loan facilities to the Facilities (each, an “Incremental Facility” and the loans made under such facility or facilities, the “Incremental Term Loans”) in an aggregate principal amount for all such increases and incremental facilities not to exceed an amount such that the Total Net Leverage Ratio on a pro forma basis after giving effect to the incurrence of any such Incremental Facility and the use of the proceeds thereof (and after giving effect to any acquisition consummated concurrently therewith and all other appropriate pro forma adjustment events and calculated excluding any cash constituting proceeds of any Incremental Facility), does not exceed the Total Net Leverage Ratio that is 0.25 to 1.00 less than the Total Net Leverage Ratio required by the Financial Covenant, provided that:

 

i.   no existing Lender will be required to participate in any such Incremental Facility without its consent;

 

ii.  no event of default under the Facilities would exist after giving effect thereto (provided that, in the case of Incremental Facilities used to finance a permitted acquisition, this clause (ii) shall be tested at the time of the execution of the acquisition agreement related to such permitted acquisition);

 

iii.   all of the representations and warranties contained in the definitive documentation for the Facilities shall be true and correct in all material respects (or, in all respects, if qualified by materiality); provided that in the case of Incremental Facilities used to finance a permitted acquisition, this clause (iii) shall be subject only to customary “specified representations” and “acquisition agreement representations” (i.e., those representations of the seller or the target (as applicable) in the applicable acquisition agreement that are material to the interests of the Lenders and only to the extent that the Borrower or its applicable subsidiary has the right to terminate its obligations under the applicable acquisition agreement as a result of the failure of such representations to be accurate);

 

iv.   the maturity date of any such Incremental Facility shall be no earlier than the maturity date of the Term Loan Facility and the weighted average life of such Incremental Facility shall not be shorter than the then longest remaining weighted average life of the Term Loan Facility;

 

v.  the Incremental Facilities will not be guaranteed by the Borrower or any of its subsidiaries that do not guarantee the Facilities and, if secured, will be secured on an equal and ratable basis or junior basis with, and by the same Collateral (as defined above) securing, the Facilities;

 

vi.   any Incremental Term Facility shall share not greater than ratably in any mandatory prepayments of the Term Loan

 

B-2


  

Facility and such Incremental Term Facility;

 

vii.  any Incremental Term Facility shall otherwise be on terms (including pricing and fees) and pursuant to documentation to be determined by the Borrower and the Additional Incremental Lenders (as defined below) providing the Incremental Term Facility; provided that to the extent such terms (other than pricing and fees) and documentation are not consistent with the applicable Facility (except to the extent permitted above in clauses (i)-(vi)), they shall be reasonably satisfactory to the Administrative Agent (it being understood that, to the extent that any term is added for the benefit of any Incremental Term Facility, no consent shall be required from Lenders under the Term Loan Facility to the extent that such term is (a) also added for the benefit of the Term Loan Facility or (b) is only applicable after the maturity of the Term Loan Facility);

 

viii.  the Borrower shall be in compliance with the financial covenants on a pro forma basis to the extent then applicable (provided that, in the case of Incremental Facilities used to finance a Limited Condition Acquisition (to be defined in a manner to be agreed), this clause (viii) and compliance with any representations, warranties, defaults or events of default may be tested at the Borrower’s election at the time of the execution of the acquisition agreement related to such Limited Condition Acquisition); and

 

i.   any Incremental Term Facility that is secured shall be subject to intercreditor terms reasonably agreed between the Borrower and the Administrative Agent.

 

The Borrower may seek commitments in respect of the Incremental Facilities from existing Lenders (each of which shall be entitled to agree or decline to participate in its sole discretion) and additional banks, financial institutions and other lenders (other than Disqualified Lenders) who will become Lenders in connection therewith (“Additional Incremental Lenders”).

Hedging Agreements:

  

Same as under the Existing Credit Agreement.

Interest Rates and Fees:

  

As set forth on Annex I hereto.

Optional Commitment

Reduction and

Prepayment:

  

The Borrower will be permitted, upon written notice, to terminate in whole, or from time to time reduce in part, the commitments of the Lenders under the Facilities without penalty, in minimum amounts equal to the lesser of $5,000,000 and the commitment of such Lender outstanding and in integral multiples of $1,000,000 over $5,000,000.

  

The Borrower will be permitted, upon same day notice for Base Rate loans and at least three business days’ notice for Term SOFR loans, to prepay loans under the Facilities in whole or in part without penalty or premium, in minimum amounts equal to, in the case of Term SOFR loans, the lesser of $5,000,000 and the amount outstanding and in

 

B-3


  

integral multiples of $1,000,000 over $5,000,000 and, in the case of Base Rate loans, the lesser of $500,000 and the amount outstanding and in integral multiples of $100,000 over $500,000.

Mandatory Prepayment:

  

After the Closing Date, the following amounts will be applied to prepay loans under the Term Loan Facility, in each case consistent with the Credit Agreement Documentation Principles:

 

(a)   100% of the net cash proceeds of any incurrence of Indebtedness after the Closing Date (other than indebtedness permitted under the definitive documents for the Facilities (other than refinancing debt)) by the Borrower or any of its restricted subsidiaries; and

 

(b)   100% of the net cash proceeds received by the Borrower or any of its subsidiaries of any non-ordinary course asset sales of assets by the Borrower or any of its restricted subsidiaries, subject to (i) a de minimis threshold in an amount to be agreed and (ii) rights to reinvest within 12 months of receipt (or, if the Borrower or the applicable Subsidiary has entered into a binding commitment with respect to such reinvestment within such 12 month period, within 18 months of receipt).

 

Any Lender may elect not to accept its pro rata portion of any mandatory prepayment.

Documentation:

  

The Facilities will be documented under a credit agreement and related agreements and documentation to be based on that certain Credit Agreement dated as of December 23, 2021, by and among the Company, Halozyme, Inc., a California corporation, each lender from time to time party thereto, and Bank of America, N.A., as administrative agent, a swing line lender and an L/C issuer (the “Existing Credit Agreement”), as modified to reflect the proposed Transactions and the terms and conditions set forth herein, in the annexes hereto and in the Commitment Letter (as modified by the “flex” provisions of the Fee Letter, if applicable); provided that (a) such changes shall be made thereto as are necessary or reasonably appropriate to reflect the terms set forth in this Exhibit B and in the Commitment Letter to which this Exhibit B is attached, (b) updates due to accounting changes and changes in law and other modifications as may be mutually agreed shall be included and (c) modifications to reflect reasonable operational and administrative agency requirements of the Administrative Agent (the “Credit Agreement Documentation Principles”).

Representations

and Warranties:

  

Same as under the Existing Credit Agreement.

Conditions Precedent

to Funding:

  

The borrowings and other extensions of credit under the Facilities on the Closing Date will be subject solely to the Funding Conditions.

Affirmative Covenants:

  

Same as under the Existing Credit Agreement, and an additional covenant to move the principal deposit accounts of the Loan Parties to Bank of America (or an affiliate thereof) within six (6) months of the

 

B-4


  

Closing Date.

Negative Covenants:

  

Same as under the Negative Covenants set forth in the Existing Credit Agreement, except:

 

•  modifications consistent with those set forth in Exhibit A;

 

•  modify certain covenants to permit the Transaction; and

 

•  modify the restricted payments covenant to:

 

   replace the basket in Section 7.06(e) with (i) a general basket for restricted payments in an amount not exceed in the aggregate the greater of $85.0 million and 25% of Consolidated EBITDA, subject to no default or event of default and (ii) a general basket for share repurchases in an amount not exceed in the aggregate the greater of $85.0 million and 25% of Consolidated EBITDA, subject to no default or event of default;

 

   add a basket for unlimited restricted payments subject to (i) a Consolidated Total Net Leverage Ratio of not greater than 2.75:1.00, calculated on a pro forma basis giving effect to such restricted payment and (ii) no default or event of default; and

 

   add an “available amount” basket for restricted payments and investments based on 50.0% of cumulative Consolidated Net Income and other customary builders, subject to (i) pro forma compliance with the financial covenants referred to below and (ii) no default or event of default.

Financial Covenants:

  

Maximum Consolidated Net Leverage Ratio: 4.75:1.00, subject to (i) a 25 basis point reduction on each of the first, second and third anniversaries of the Closing Date and (ii) in the event of a Material Acquisition (to be defined in the definitive documentation), a 50 basis point increase for twelve (12) months commencing on the date of such Material Acquisition; provided the maximum Consolidated Net Leverage Ratio after giving effect to such increase shall at no time exceed 4.75:1.00. “Consolidated Net Leverage Ratio” shall be defined as set forth in the Existing Credit Agreement except that all cash and cash equivalents may be netted for purposes of such definition up to a maximum amount of $250.0 million.

 

Minimum Consolidated Interest Coverage Ratio (as defined in the Existing Credit Agreement): 3.00:1.00.

Events of Default:

  

Same as under the Existing Credit Agreement.

Voting Rights:

  

Same as under the Existing Credit Agreement.

Assignments and

  

Same as under the Existing Credit Agreement (as modified to reflect the

 

B-5


Participations:

  

term loan nature of the facility).

Expenses and

Indemnification:

  

Same as under the Existing Credit Agreement (as defined below).

Governing Law and

Jurisdiction:

  

Same as under the Existing Credit Agreement (as defined below); provided that (a) the accuracy of any Transaction Agreement Representations and whether as a result of a breach thereof the Borrower (or any of the Borrower’s subsidiaries) has the right under the Transaction Agreement not to consummate the Acquisition as a result of such representations in the Transaction Agreement being inaccurate and (b) whether the Acquisition has been consummated in accordance with the Transaction Agreement, shall be governed by, and construed in accordance with the laws of the State of Delaware, without giving effect to any choice or conflict of laws provision or rule (whether of the State of Delaware or any other jurisdiction) that would cause the application of the Laws of any jurisdiction other than the State of Delaware.

Counsel to Lead Arranger

and Administrative

Agent:

  

Cahill Gordon & Reindel LLP

 

B-6


ANNEX I: Pricing

 

Interest Rates:

  

Interest will be payable on loans under the Term Loan Facility at the following rates per annum:

 

(a)   in the case of Term SOFR loans, Term SOFR plus the Applicable Margin per annum, and

 

(b)   in the case of Base Rate loans, the Base Rate plus the Applicable Margin per annum.

 

As used herein:

 

Base Rate means for any day a fluctuating rate per annum equal to the highest of (a) the Federal Funds Rate plus 1/2 of 1%, (b) the rate of interest in effect for such day as publicly announced from time to time by Bank of America as its “prime rate”, (c) the Secured Overnight Financing Rate published on such day by the SOFR Administrator on the Federal Reserve Bank of New York’s website (or any successor source) plus 1.00% and (d) 1.00%. The “prime rate” is a rate set by Bank of America based upon various factors including Bank of America’s costs and desired return, general economic conditions and other factors, and is used as a reference point for pricing some loans, which may be priced at, above, or below such announced rate. Any change in such prime rate announced by Bank of America shall take effect at the opening of business on the day specified in the public announcement of such change. If the Base Rate is being used as an alternate rate of interest hereof, then the Base Rate shall be the greater of clauses (a) and (b) above and shall be determined without reference to clause (c) above.

 

Term SOFR” means a forward-looking term rate for SOFR, if any, identified by the SOFR Administrator as reflecting term-based quotations of SOFR that has been selected or recommended by the Relevant Governmental Body, in each case as published on an information service as selected by the Administrative Agent from time to time in its reasonable discretion, plus the SOFR Adjustment. If the rate as so determined would be less than 0.00%, such rate shall be deemed to be 0.00% for purposes of this Agreement.

 

Applicable Margin” shall mean a percentage per annum based on the applicable “Pricing Level” set forth in the below pricing grid (the “Pricing Grid”) and determined quarterly based on meeting a Consolidated Net Leverage Ratio.

 

B-I-1


           Applicable Margin
   Pricing Level    Consolidated
Net Leverage Ratio
   SOFR Margin    Base Rate Margin
   1    < 1.50:1.00    1.25%    0.25%
   2    ≥ 1.50:1.00 but < 2.50:1.00    1.50%    0.50%
   3    ≥ 2.50:1.00 but < 3.50:1.00    1.75%    0.75%
   4    ≥ 3.50:1.00 but < 4.00:1.00    2.00%    1.00%
   5    ≥ 4.00:1.00    2.25%    1.25%

 

Federal Funds Rate” means, for any day, the rate per annum calculated by the Federal Reserve Bank of New York based on such day’s federal funds transactions by depository institutions (as determined in such manner as the Federal Reserve Bank of New York shall set forth on its public website from time to time) and published on the next succeeding business day by the Federal Reserve Bank of New York as the federal funds effective rate; provided that if the Federal Funds Rate as so determined would be less than 0.00%, such rate shall be deemed to be 0.00% for purposes of this Agreement.

 

Relevant Governmental Body” means the Federal Reserve Board and/or the Federal Reserve Bank of New York, or a committee officially endorsed or convened by the Federal Reserve Board and/or the Federal Reserve Bank of New York.

 

SOFR Adjustment” shall mean 0.10% (10 basis points).

Term SOFR borrowings may be made for interest periods of 1, 3 or 6 months, as selected by the Borrower.

Interest on Term SOFR loans and all fees will be payable in arrears on the basis of a 360-day year, calculated on the basis of the actual number of days elapsed. Interest on Base Rate loans will be payable in arrears on the basis of a 365-day year (or a 366-day year in a leap year) calculated on the basis of the actual number of days elapsed. Interest will be payable on Term SOFR loans on the last day of the

 

B-I-2


  

applicable interest period (or at the end of each three months, in the case of interest periods longer than three months) and upon prepayment, and on Base Rate loans quarterly and upon prepayment.

 

The Borrower may select interest periods of one, three or six months for Term SOFR loans, subject to availability. Interest on Term SOFR loans shall be payable at the end of the selected interest period, but no less frequently than every three months, and on the Maturity Date.

Default Rate:

  

With respect to overdue principal, the applicable interest rate plus 2.00% per annum and, with respect to any other overdue amount, the interest rate applicable to Base Rate loans under the Facilities plus 2.00% per annum.

 

B-I-3


EXHIBIT C

PROJECT ATLAS

$75.0 million Revolving Credit Facility

$375.0 million Term Loan Facility

Additional Conditions Precedent3

The initial borrowings under each Facility shall be subject to the following conditions precedent:

 

1.

The Acquisition shall have been consummated, or substantially concurrently with the funding under such Facility, on substantially the terms set forth in the Transaction Agreement without giving effect to any amendments, waivers or consents under the Transaction Agreement by the Company or its applicable subsidiary that (x) are materially adverse to the Lenders in their capacities as such (each, a “Materially Adverse Modification”) and (y) have not been approved by the Lead Arranger (such approval not to be unreasonably withheld, conditioned or delayed) (it being understood and agreed that any change to the definition of “Material Adverse Effect” in the Transaction Agreement shall be deemed to be materially adverse to the Lenders in their capacities as such).

 

2.

The Solvency Specified Representation, the Transaction Agreement Representations and each other Specified Representation shall be true and correct in all material respects as of the Closing Date; provided that, in each case, any representation and warranty that is qualified as to “materiality,” “Material Adverse Effect” or similar language shall be true and correct (after giving effect to any qualification therein) in all respects at such time on such date. In the event that the Amendment Event has not occurred on or prior to the Closing Date, the Existing Credit Agreement, all commitments thereunder and all guarantees and Liens thereon shall have been terminated and all loans thereunder shall have been repaid.

 

3.

The Lead Arranger shall have received a pro forma consolidated balance sheet and related pro forma consolidated statement of income of the Company and its subsidiaries, in a form customary for inclusion in a confidential information memorandum used to syndicate a bank credit facility, as of and for the 12-month period ending on the last day of the most recently completed four-fiscal quarter period ended at least 45 days (or 90 days, in case such four fiscal-quarter period is the end of the Company’s fiscal year) prior to the Closing Date, prepared after giving effect to the Transactions as if the Transactions had occurred as of such date (in the case of such balance sheet) or at the beginning of such period (in the case of such statement of income), it being understood that such pro forma financial statements shall not be required to include any purchase accounting adjustments.

 

4.

The Administrative Agent shall have received a customary borrowing notice, customary secretary’s certificates for the Borrower and each Guarantor, a customary closing officer’s certificate (which, for the avoidance of doubt, shall not include any representation or statement as to the absence (or existence) of any default or event of default or a bring-down of any representations and warranties that are not a specified Funding Condition), customary legal opinions as to the loan documents and the Borrower and Guarantors, a certificate from the chief financial officer of Borrower in the form set forth in Exhibit D, certifying that the Borrower and

 

3 

Capitalized terms used but not otherwise defined herein have the meanings assigned thereto in the Commitment Letter to which this Exhibit C is attached, including the other exhibits thereto.

 

C-1


 

its subsidiaries on a consolidated basis immediately after giving effect to the Transactions are solvent, in each case subject to the Documentation Provision.

 

5.

The Lead Arranger shall have received (a) at least 3 business days prior to the Closing Date, all documentation and other information required by regulatory authorities with respect to the Borrower and the Guarantors under applicable “know your customer” and anti-money laundering rules and regulations, including, without limitation, the Patriot Act, as reasonably requested by the Lead Arranger in writing at least 10 business days prior to the Closing Date and (b) at least three business days prior to the Closing Date, if the Borrower qualifies as a “legal entity” customer under the Beneficial Ownership Regulation and the Administrative Agent or a Lender has requested such certification at least ten business days prior to the Closing Date, a beneficial ownership certification in relation to such Borrower.

 

6.

The Lead Arranger and the Administrative Agent shall have received (or substantially simultaneously with the initial funding of the Facilities on the Closing Date, shall receive) all fees and expenses required to be paid to any of them by the Company on or prior to the Closing Date pursuant to the Fee Letter or hereunder and, with respect to expenses, invoiced to the Company at least three business days prior to the Closing Date.

 

7.

Subject to the Documentation Provision, with respect to the Facilities, all documents and instruments required to be entered into or delivered by the Borrower and the Guarantors to create and perfect the security interests of the collateral agent and the other secured parties thereunder in the Collateral shall have been executed and delivered and, if applicable, be in proper form for filing as and to the extent required hereby, subject in each case to the Documentation Provision.

 

8.

The Closing Date shall not occur prior to the date that is 30 days from the date hereof.

 

9.

After the date hereof, there shall not have occurred a Material Adverse Effect (as defined in the Transaction Agreement) that is continuing.

 

10.

The Refinancing shall have been consummated or shall be consummated substantially concurrently with the closing under the Facilities.

 

C-2


EXHIBIT D: FORM OF SOLVENCY CERTIFICATE

Pursuant to the Credit Agreement4, the undersigned hereby certifies, solely in such undersigned’s capacity as [chief financial officer] of Halozyme Therapeutics, Inc. (the “Company”), and not individually, and without any personal liability, as follows:

After giving effect to the consummation of the Transaction, including the making of the Loans under the Credit Agreement on the Closing Date, and after giving effect to the application of the proceeds of such Loans, [she][he] is of the opinion that:

a. The fair value of the assets of the Company and its Subsidiaries, on a consolidated basis, exceeds, on a consolidated basis, their debts and liabilities, subordinated, contingent or otherwise;

b. The present fair saleable value of the property of the Company and its Subsidiaries, on a consolidated basis, is greater than the amount that will be required to pay the probable liability, on a consolidated basis, of their debts and other liabilities, subordinated, contingent or otherwise, as such debts and other liabilities become absolute and matured;

c. The Company and its Subsidiaries, on a consolidated basis, are able to pay their debts and liabilities, subordinated, contingent or otherwise, as such liabilities become absolute and matured; and

d. The Company and its Subsidiaries, on a consolidated basis, are not engaged in, and are not about to engage in, business for which they have unreasonably small capital.

For purposes of this Certificate, the amount of any contingent liability at any time shall be computed as the amount that would reasonably be expected to become an actual and matured liability. Capitalized terms used but not otherwise defined herein shall have the meanings assigned to them in the Credit Agreement.

The undersigned is familiar with the business and financial position of the Company and its Subsidiaries. In reaching the conclusions set forth in this Certificate, the undersigned has made such other investigations and inquiries as the undersigned has deemed appropriate, having taken into account the nature of the particular business anticipated to be conducted by the Company and its Subsidiaries after consummation of the transactions contemplated by the Commitment Letter.

 

 

4 

Credit Agreement to be defined.

 

D-1

EX-99.(D)(2) 9 d347764dex99d2.htm EXHIBIT (D)(2) Exhibit (d)(2)

Exhibit (d)(2)

CONFIDENTIALITY AGREEMENT

This agreement (this “Agreement”), dated February 18, 2022 (the “Effective Date”), shall serve to set forth the terms and conditions between Antares Pharma, Inc. (“Antares”), a Delaware corporation having its principal place of business at 100 Princeton South Corporate Center, Suite 300 Ewing, New Jersey 08628 USA, and Halozyme Therapeutics, Inc. (“Company”), a Delaware corporation having its principal place of business at 11388 Sorrento Valley Road, San Diego California 92121 (each, a “Party,” and collectively, the “Parties”), under which each Party may disclose and/or deliver to the other Party, either directly or indirectly through a Representative (as defined below), proprietary and confidential, oral and written information relating to its business and operations (such Party when disclosing such information being the “Disclosing Party” and such Party when receiving such information being the “Receiving Party”) solely for each Party’s consideration of a possible negotiated merger or acquisition of Antares by Company (a “Transaction”).

As a condition to, and as consideration for, the Disclosing Party furnishing its Confidential Information (as defined below) to the Receiving Party, the Receiving Party agrees, as set forth below, to treat confidentially such Confidential Information of the Disclosing Party, which includes any and all information or material relating to the Disclosing Party and any other information that the Disclosing Party or its directors, managers, officers, employees, agents, affiliates (as defined in Rule 12b-2 promulgated under the Securities Exchange Act of 1934, as amended to date (the “Exchange Act”)) or other representatives (including, without limitation, attorneys, accountants, consultants or financial advisors) (with respect to either Party, such Persons (as defined below) collectively referred to herein as, “Representatives”) furnish or make available to the Receiving Party, regardless of whether or not such information is marked or identified as “confidential” or “proprietary”, and regardless of the format or manner in which it is furnished, before, on or after the Effective Date, together with any and all analyses, compilations, abstracts, studies, summaries or other documents, reports or records prepared that contain or otherwise reflect or, in whole or in part, are generated from, such information or material (collectively, the “Confidential Information”). For purposes of this Agreement, with respect to the Company, the term “Representatives” shall include Wells Fargo and Bank of America, as financial advisors and potential financing sources.

1. The Receiving Party acknowledges and agrees that the Confidential Information of the Disclosing Party is a valuable asset of the Disclosing Party, has competitive value and is of a confidential nature.

2. Without the Disclosing Party’s prior written consent, the Receiving Party will not, and will direct its Representatives to not, disclose to any Person (including, without limitation, any of its equity or debt partners, financing sources (other than, with respect to the Company, Wells Fargo and Bank of America, solely in their capacities as financial advisors and potential financing sources) and any of the Disclosing Party’s employees whom it has not been otherwise directed to contact) the fact that these discussions (or any other discussions between or involving the Parties) are taking or have taken place or other facts with respect to such discussions concerning a possible Transaction, or any of the terms thereof, including, without limitation, the status thereof, or the fact that any Confidential Information has been made available to it, nor otherwise make any public disclosure (whether written or oral) with respect to this Agreement or the matters contemplated hereby, except as permitted by Section 3 and Section 5. For purposes of this Agreement, the existence of this Agreement and all information described in the foregoing sentence that shall not be publicly disclosed except as permitted by Section 3 and Section 5, shall be deemed to be Confidential Information of each party. The term “Person” as used herein will be interpreted broadly to include, among others, any corporation, company, limited liability company, partnership, trust, association, joint venture, governmental or self-regulatory agency or body, other entity, group or individual.

3. The Receiving Party agrees that it will treat all of the Disclosing Party’s Confidential Information confidentially using the same degree of care employed to protect its own confidential information, but in no event less than a reasonable standard of care to protect and maintain the confidentiality of the Disclosing Party’s Confidential Information. Additionally, the Receiving Party agrees that it will not disclose or otherwise


disseminate to any Person all or any portion of the Disclosing Party’s Confidential Information and will use such Confidential Information solely for the purposes of evaluating, negotiating and consummating the Transaction and for no other purpose; provided, however, that the Receiving Party may disclose such Confidential Information or portions thereof only to its Representatives who need to know such information solely for the purposes described above (it being understood that each such Representative shall be informed by the Receiving Party of the confidential nature of the Disclosing Party’s Confidential Information and agree to be bound by the terms hereof and, in any event, the Receiving Party shall disclose to such Representatives only that portion of such Confidential Information necessary for such Representative’s participation in the Receiving Party’s evaluation, negotiation and consummation of the Transaction and the Receiving Party shall be liable and responsible for any breach of this Agreement by any of its Representatives).

4. The term “Confidential Information” shall not include information which (i) is, or becomes, generally available to the public other than as a result of a disclosure by the Receiving Party or its Representatives in violation of this Agreement, (ii) is, or becomes, available to the Receiving Party from a source other than the Disclosing Party or its Representatives, provided that such source is not, and was not, reasonably known to the Receiving Party to be bound by a confidentiality agreement with, or any other contractual, fiduciary or other legal obligation of confidentiality to the Disclosing Party, or any of its affiliates or Representatives, (iii) was within the Receiving Party’s possession on a non-confidential basis prior to disclosure to the Receiving Party by the Disclosing Party or its Representatives, provided that such source of such information is not, and was not, reasonably known to the Receiving Party to be bound by a confidentiality agreement with, or any other contractual, fiduciary or other legal obligation of confidentiality to the Disclosing Party, or any of its affiliates or Representatives or (iv) is developed by the Receiving Party or any of its Representatives without reliance on any Confidential Information of the Disclosing Party.

5. If the Receiving Party or any of its Representatives are requested or required (by deposition, interrogatory, request for documents, subpoena, civil investigative demand or similar process) to disclose any of the Confidential Information of the Disclosing Party, the Receiving Party will notify the Disclosing Party promptly (if legally permissible) so that the Disclosing Party may seek any appropriate protective order and/or take any other action. The Receiving Party agrees to reasonably cooperate with the Disclosing Party (at the Disclosing Party’s sole expense) in its reasonable efforts to do so. In the event that such protective order is not obtained, or that the Disclosing Party waives compliance with the provisions hereof, the Receiving Party or such Representative, as the case may be, may disclose to any tribunal or other Person only that portion of the Disclosing Party’s Confidential Information which the Receiving Party is advised by legal counsel is legally required to be disclosed and shall use its commercially reasonable efforts to obtain assurance that confidential treatment will be accorded such.

6. Each Party hereby acknowledges that it is aware (and that its respective Representatives who are involved in the Transaction have been or will be advised) that the other Party is a public company whose shares are listed on the NASDAQ Capital Markets and that the United States securities laws restrict persons with material non-public information about a company obtained directly or indirectly from that company from purchasing or selling securities of such company and from communicating such information to any other person under circumstances in which it is reasonably foreseeable that such person is likely to purchase or sell such securities. Each Party agrees to comply with such laws and recognize that the other Party will be damaged by its non-compliance. In addition, each Party hereby acknowledges that unauthorized disclosure of the other Party’s Confidential Information may be in violation of the securities laws, including Regulation FD as promulgated by the U.S. Securities and Exchange Commission.

7. Each Party hereby represents that, as of the Effective Date, neither it nor any of its affiliates beneficially owns, directly or indirectly, any voting securities of the other Party. In consideration of each Party being provided with the other Party’s Confidential Information, and in view of the fact that each Party’s Confidential Information consists and will consist of confidential, material non-public and proprietary information, each Party agrees that, for a period of twelve (12) months from the Effective Date (the “Standstill Period”), neither it nor any of its controlled affiliates will, directly or indirectly, without the consent of the other

 

Page 2 of 7


Party: (i) acquire or agree, offer, seek or propose to acquire, or cause to be acquired, by purchase or otherwise, ownership (including, without limitation, beneficial ownership as defined in Rule 13d-3 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”)) of any voting securities or direct or indirect rights or options to acquire any voting securities of the other Party or any subsidiary thereof or any assets (except in the ordinary course of business) of the other Party or any subsidiary thereof; (ii) seek or propose to influence or control the management, Board of Directors or policies of the other Party or to obtain representation on the other Party’s Board of Directors, or make, or in any way participate in, any “solicitation” of any “proxies” (as such terms are used in the Exchange Act) or consents with respect to any securities of the other Party; (iii) make any public announcement with respect to, or submit on a public or non-public basis a proposal for, indication of interest in, inquiry regarding or offer of (with or without conditions), any merger, consolidation, business combination, acquisition, tender or exchange offer, restructuring or other extraordinary transaction involving the other Party or any of its subsidiaries or their securities or assets; (iv) enter into any discussions, negotiations, arrangements or understandings (whether written or oral) with any third party with respect to any of the foregoing, or otherwise form, join or in any way participate in a “group” (as defined in Section 13(d)(3) of the Exchange Act) in connection with any of the foregoing; or (v) seek or request permission, or participate in any effort, to do any of the foregoing or make or seek permission to make any public announcement with respect to any of the foregoing. Each Party and its respective Representatives (on its behalf) also agree during such period not to make, in each case to the other Party or a third party, any proposal, statement or inquiry, or disclose any intention, plan or arrangement, whether written or oral, inconsistent with the foregoing. Each Party will promptly advise the other Party of any inquiry or proposal made to it with respect to any of the foregoing; provided, however, that nothing contained in this Section 7 shall preclude Company from making a proposal to acquire Antares directly to the Board of Directors or CEO of Antares, without making any public disclosure thereof. Notwithstanding the foregoing, each Party and its respective affiliates and Representatives shall not be restricted from taking the actions contemplated by this Paragraph 7 (and for the avoidance of doubt, the Standstill Period shall terminate solely with respect to the other Party) from and after the date, if any, (1) that the other Party announces its entry into an agreement with any one or more third parties (not affiliated with such other Party) providing for (A) a merger, amalgamation, consolidation, tender or exchange offer or other business combination involving such other Party as a constituent party that would result in the acquisition of more than 50% of such other Party’s outstanding equity securities, (B) a sale of 50% or more of the consolidated assets of such other Party and its subsidiaries (including equity securities of subsidiaries) or equity securities of such other Party in a single transaction or series of related transactions, (C) a recapitalization or other transaction involving such other Party that results in one person or “group” (within the meaning of Section 13(d)(3) of the Exchange Act) acquiring beneficial ownership (within the meaning of Rule 13d-3 under the Exchange Act) of 50% or more of the equity securities of such other Party or (D) any other single transaction or series of related transactions that results in a change of control of such other Party (any of the transactions referred to in the foregoing clauses (A) through (D), an “Alternative Transaction”), (2) that is the second business day following the recommendation by the other Party’s Board of Directors in favor of a bona fide tender offer or exchange offer for more than 50% of such other Party’s outstanding equity securities or (3) the other Party shall publicly disclose that it has authorized a process for the solicitation of competing offers or indications of interest in respect of an Alternative Transaction, and such Party is not invited to participate in the process on substantially the same terms as applied to other participants in such process (any event described in clauses (1) through (3) above, a “Standstill Termination Event”).

8. Each Party agrees that for a period of twelve (12) months from the Effective Date, neither it nor any of its controlled affiliates will directly or indirectly solicit for employment or hire, employ or otherwise contract for the services of (i) any officer of the other Party or (ii) any key employee of the other Party who becomes known or comes in contact with such Party solely as a result of such Party’s evaluation of the Transaction; provided that this Section 8 shall not preclude such Party from hiring any employee of the other Party who (i) responds to a general solicitation through a public medium or general or mass mailing by such Party or on its behalf and not directly or indirectly targeted at employees of the other Party; (ii) contacts such Party directly on their own sole initiative, without any direct or indirect solicitation or inducement by such Party, or (iii) has been terminated by the other Party prior to commencement of employment discussions between such Party and such employee. The provisions of this Section 8 shall be deemed to be in furtherance of, and not a limitation upon, the other provisions of this Agreement.

 

Page 3 of 7


9. At any time during or after the term of this Agreement, at the Disclosing Party’s written request, the Receiving Party shall and shall direct its Representatives to promptly return all the Confidential Information provided by the Disclosing Party, or destroy all such copies and certify in writing to the Disclosing Party that such Confidential Information has been destroyed; provided that the Receiving Party may retain a single archival copy of the Disclosing Party’s Confidential Information for the sole purpose of determining its obligations under this Agreement. Such archival copy shall remain the property of the Disclosing Party and shall continue to be governed by the confidentiality, non-disclosure and nonuse obligations set forth in this Agreement until such time such copy is no longer Confidential Information as defined in this Agreement. Notwithstanding anything contained herein to the contrary, the Receiving Party and its Representatives shall not be required to destroy any computer files and electronic mail that are stored securely by the Receiving Party and/or its Representatives and that are created during automatic system back-up or as part of normal security or disaster recovery retention procedures, provided that (i) any Confidential Information of the Disclosing Party contained in such computer files and electronic mail shall remain subject to the confidentiality, non-disclosure and nonuse obligations hereunder, and (ii) the Receiving Party and its Representatives shall not be entitled to make use of such computer files and electronic mail for any purpose other than as provided in this Agreement.

10. The Receiving Party understands and agrees that, except pursuant to a definitive agreement entered into between the Parties in connection with a Transaction, if and when entered into, neither the Disclosing Party nor any of its Representatives (i) have made or make any representation or warranty, expressed or implied, as to the accuracy or completeness of the Disclosing Party’s Confidential Information or (ii) shall have any liability whatsoever to the Receiving Party or any of its Representatives relating to or resulting from the use of the Disclosing Party’s Confidential Information or any errors therein or omissions therefrom; it being understood that the Receiving Party and its representatives shall assume full responsibility for all conclusions derived from any Confidential Information of the Disclosing Party. Without limiting the generality of the immediately preceding sentence, the Confidential Information may include certain statements, estimates and projections with respect to the anticipated future performance of the Disclosing Party. Such statements, estimates and projections reflect various assumptions made by the Disclosing Party concerning its respective anticipated results, which assumptions may or may not prove to be correct. No representations are made as to the accuracy of such assumptions, statements, estimates or projections. The only Confidential Information that will have any legal effect will be specifically represented in a definitive agreement, subject to such limitations and restrictions as may be specified therein.

11. Each Party acknowledges that the other Party and its respective Representatives may establish procedures and guidelines (the “Procedures”) for the submission of proposals with respect to any Transaction with or involving such other Party. Each Party and its respective Representatives agree to act in accordance with the Procedures and to be bound by the terms and conditions that may be established pursuant to the Procedures, including adhering to any timing conditions that may be established relating to when proposals for such a Transaction may be submitted. Each Party agrees that all (i) communications regarding the Transaction, (ii) requests for additional information, facility tours or management meetings, and (iii) discussions or questions regarding the Procedures with respect to the Transaction, will be submitted or directed only to a Representative of the other Party, as designated by such other Party from time to time. For greater certainty, neither Party nor its respective Representative shall directly contact any officer, director or employee of the other Party regarding the Transaction without the prior consent of the other Party. Each Party acknowledges and agrees that (a) the other Party and its Representatives are free to conduct the process relating to a possible Transaction as such other Party and its Representatives, in their sole discretion, determine (including, without limitation, conduct of the due diligence process, negotiating with one or more prospective interested parties and entering into a preliminary or definitive agreement to effect a Transaction) without prior notice to the Party or any other Person, and (b) the other Party reserves the right, in its sole discretion, to change the Procedures at any time without prior notice to the Party or any other Person.

12. It is understood and agreed that money damages would not be a sufficient remedy for any breach of this Agreement by a Party (the “Breaching Party”) or its respective Representatives and that the other Party

 

Page 4 of 7


(the “Non-Breaching Party”) shall be entitled to specific performance and injunctive relief as a remedies for any such breach, and the Breaching Party further agrees to waive, and to use its commercially reasonable efforts to cause each of its Representatives to waive any requirement for the securing or posting of any bond in connection with such remedy. Such remedies shall not be deemed to be the exclusive remedies for the breach of this Agreement by the Breaching Party or its Representatives, but shall be in addition to all other remedies available at law or in equity to the Non-Breaching Party. In the event of litigation relating to this Agreement, if a court of competent jurisdiction determines that the Breaching Party or any of its Representatives have breached this Agreement, the Breaching Party shall be liable and pay to the Non-Breaching Party the reasonable legal fees incurred by the Non-Breaching Party or any of its affiliates in connection with such litigation, including any appeal therefrom. Without qualifying the Breaching Party’s other obligations hereunder, the Breaching Party shall promptly notify the Non-Breaching Party in writing as soon as practicable after becoming aware of any breach by the Breaching Party or its Representatives of any obligation the Breaching Party or its Representatives may have under the terms of this Agreement.

13. It is further understood that no failure or delay by either Party in exercising any right, power or privilege hereunder shall operate as a waiver thereof, nor shall any single or partial exercise thereof preclude any other or further exercise thereof or the exercise of any right, power or privilege hereunder.

14. It is agreed that unless and until a definitive written agreement has been executed and delivered, neither Party nor any of its affiliates and Representatives shall be under any legal or other obligation to enter into a Transaction with the other Party nor will either Party nor any of its affiliates and Representatives have any liability to the other Party with respect to the Transaction or any obligation of any kind whatsoever with respect to the Transaction, whether by virtue of this Agreement, any other written or oral expression with respect to the Transaction or otherwise, except regarding matters specifically agreed to in this Agreement. Either Party may, in its sole and absolute discretion, reject any proposals with regards to a Transaction. It is further agreed that either Party may cease or terminate discussions or negotiations with respect to a Transaction at any time for any reason or no reason; provided that the cessation of such discussions or negotiations shall not affect either Party’s obligations under this Agreement.

15. This Agreement, and all disputes between the Parties under or related to this Agreement or the facts and circumstances leading to its execution, whether in contract, tort or otherwise, shall be governed by and construed in accordance with the internal laws of the State of Delaware, without giving effect to any choice or conflict of law provision or rule (whether of the State of Delaware or any other jurisdiction) that would cause the application of laws of any jurisdiction other than those of the State of Delaware. Any judicial proceeding regarding any dispute arising out of this Agreement or any matter related hereto shall be brought in the state or Federal courts located in Wilmington, Delaware, and, by execution and delivery of this Agreement, each Party accepts the exclusive jurisdiction of such courts. Each Party hereby agrees that service of any process, summons, notice or document by U.S. registered mail (postage prepaid and return receipt requested) addressed to such Party shall be effective service of process for any action, suit or proceeding brought against such Party in any such court. Each Party hereby irrevocably and unconditionally waives any objection to the laying of venue of any such suit, action or proceeding brought in any such court and any claim that any such suit, action or proceeding brought in any such court has been brought in an inconvenient forum. Each Party agrees that a final judgment in any such suit, action or proceeding brought in any such court shall be conclusive and binding upon such Party and may be enforced in any other courts to whose jurisdiction such Party is or may be subject, by suit upon such judgment. Each Party hereby expressly waives to the fullest extent permitted by applicable law any right it may have to a trial by jury with respect to any litigation directly or indirectly arising out of, under or in connection with this Agreement or the transactions contemplated hereby.

16. In the event that any provision or portion of this Agreement is determined to be invalid, illegal or unenforceable for any reason, in whole or in part, the remaining provisions of this Agreement shall be unaffected thereby and shall remain in full force and effect to the fullest extent permitted by applicable law.

17. This Agreement constitutes the entire agreement between the Parties relating to confidential

 

Page 5 of 7


treatment and use of the Confidential Information, and supersedes and replaces all prior writings, discussions and rights relating thereto; and no obligation of any kind relating thereto is assumed by or implied against either Party except for those obligations expressly stated herein. This Agreement may only be amended by a written instrument signed by the Parties.

18. Notices hereunder will be effective only if in writing and upon receipt if delivered personally or by overnight courier or fax, or three (3) days after deposit in the U.S. mail, first class postage prepaid, return receipt requested. All notices addressed to a Party shall include a copy to such Party’s General Counsel at such Party’s address set forth above.

19. The individual executing this Agreement on behalf of a corporation or other legal entity personally represents that he or she is duly authorized to execute this Agreement on behalf of such entity and that this Agreement is binding upon such entity.

20. Nothing herein shall be construed to obligate the Disclosing Party to disclose any Confidential Information to the Receiving Party, or as granting a license to any of the Disclosing Party’s Confidential Information. The Disclosing Party shall retain all right, title and interest in and to its Confidential Information. It is acknowledged by the Parties that this Agreement does not obligate the Parties to enter into any further agreement or to proceed with or participate in any Transaction.

21. Except with respect to the obligations in Sections 7 and 8 (which shall expire in the time period specified in that Section), all obligations, including, without limitation, its obligations of confidentiality, non-use and other obligations, under this Agreement shall expire on the fourth (4th) anniversary of Effective Date, irrespective any earlier termination by the Parties.

22. This Agreement may be electronically signed and/or executed in counterparts, each of which is deemed an original, but all of which constitute one and the same agreement. The Parties agree that: (i) the electronic signatures appearing on this Agreement are the same as handwritten signatures for the purposes of validity, enforceability and admissibility, and (ii) delivery of an executed counterpart of this Agreement electronically (including by .pdf) shall be effective as delivery of an original executed counterpart of this Agreement.

[Signature Page Follows.]

 

Page 6 of 7


IN WITNESS WHEREOF, the Parties have caused this Agreement to be duly executed as of the day and year written above.

 

ANTARES PHARMA, INC.

     

HALOZYME THERAPEUTICS, INC.

By

  

/s/ Peter Graham

     

By

  

/s/ Mark Snyder

Print Name

  

Peter Graham

     

Print Name

  

Mark Snyder

Title

  

Executive Vice President, General Counsel

     

Title

  

Senior Vice President, General Counsel

 

Page 7 of 7

EX-99.(D)(3) 10 d347764dex99d3.htm EXHIBIT (D)(3) Exhibit (d)(3)

Exhibit (d)(3)

 

LOGO

STRICTLY PRIVATE AND CONFIDENTIAL

March 17, 2022

Robert F. Apple

President and Chief Executive Officer

Antares Pharma, Inc.

100 Princeton South, Suite 300

Ewing, New Jersey 08628

Re:      Exclusivity Agreement

Dear Bob:

Reference is made to our discussions regarding a possible negotiated acquisition (the “Proposed Transaction”) of all of the issued and outstanding shares of common stock of Antares Pharma, Inc. (the “Company”) by Halozyme Therapeutics, Inc. (“Halozyme”). In order to facilitate and expedite continued discussions between the Company and Halozyme with respect to the Proposed Transaction, and to induce Halozyme to continue to devote substantial time and effort to the evaluation and documentation of the Proposed Transaction, the parties hereto hereby agree as set forth below (the “Exclusivity Agreement”).

 

1)

Exclusivity. During the Exclusivity Period (as defined below), the Company shall not, and shall cause its subsidiaries not to, and shall direct its and its subsidiaries’ respective Representatives (as defined below) not to (other than with respect to Halozyme or any of its Representatives), directly or indirectly, (i) solicit, initiate, continue or enter into discussions with, or knowingly encourage, or provide any non-public information to, any corporation, partnership or other entity or group or person that constitutes, or would be expected to lead to, an Acquisition Proposal, (ii) engage in, continue or otherwise participate in any discussions or negotiations relating to, enter into any agreement, arrangement or understanding relating to, an Acquisition Proposal or any inquiry, proposal or offer that would be expected to lead to an Acquisition Proposal, or (iii) grant any waiver, amendment or release under any standstill or confidentiality agreement relating, directly or indirectly, to an Acquisition Proposal. During the Exclusivity Period, the Company shall, and shall cause its subsidiaries to, and direct its and its subsidiaries’ respective Representatives to, immediately cease and cause to be terminated any and all contacts, discussions and negotiations with third parties (other than Halozyme and its Representatives) with respect to an Acquisition Proposal or that could reasonably be expected to lead to an Acquisition Proposal. If, during the Exclusivity Period, the Company or any of its subsidiaries or their respective Representatives receives any inquiry, offer, proposal or expression of interest regarding an Acquisition Proposal (or any proposed


Mr. Robert F. Apple

Antares Pharma, Inc.

March 17, 2022

Page 2

 

 

amendment or modification thereto (including of any inquiry, offer, proposal or expression of interest regarding an Acquisition Proposal received prior to the date of this Exclusivity Agreement)), the Company shall (x) promptly (and in any event within 24 hours) notify Halozyme of such receipt and (y) other than confirming receipt or otherwise in accordance with this paragraph 1, during the Exclusivity Period, not contact or respond to such person, and not accept, recommend or endorse (or publicly propose or announce any intention or desire to accept, recommend or endorse) any such inquiry, offer, proposal or expression of interest regarding an Acquisition Proposal. The parties hereby agree that the Company shall be responsible for any breach of the terms of this Exclusivity Agreement by its subsidiaries and its Representatives.

 

2)

Certain Definitions. For purposes of this Exclusivity Agreement, the following terms shall have the following meanings:

 

  a)

Acquisition Proposal” means any inquiry, offer, proposal or indication of interest (in writing or otherwise) from any third party relating to any transaction or series of related transactions involving (i) any merger, consolidation, change of control, investment, financing or other similar combination, recapitalization, reorganization or transaction involving the Company, (ii) any purchase or acquisition of equity or any security convertible into equity of the Company (other than in the ordinary course of business pursuant to the exercise of employee incentives and/or stock options outstanding pursuant to the Company’s security-based compensation arrangements as of the date of this Exclusivity Agreement), (iii) any sale or other transfer or disposition (whether by sale, license or other means) of all or a portion of the assets of the Company (other than in the ordinary course of business) or (iv) any other similar transaction involving the Company.

 

  b)

Exclusivity Period” means the period commencing upon the Company’s execution and delivery of this Exclusivity Agreement and ending upon the earlier of (i) 11:59 p.m. Eastern Time on April 11, 2022, and (ii) if at any time Halozyme or any of its Representatives initiates any discussion with the Company or its Representatives of a reduction in the $5.60 per share price set forth in Halozyme’s March 13, 2022 proposal.

 

  c)

Representatives” of a person means, such person’s respective affiliates and each of such person’s and such affiliates’ respective officers, directors and employees, agents, advisors (including legal counsel and financial advisors), consultants, and any other persons acting under their direction, and the representatives of any of the foregoing.

 

3)

No Obligation. The parties hereto agree that unless and until a written definitive agreement with respect to the Proposed Transaction has been executed and delivered (and in that case, subject to the terms, conditions and limitations set forth therein), neither Halozyme nor the Company will be under any legal obligation of any kind whatsoever with respect to the Proposed Transaction by virtue of this Exclusivity Agreement or any written or oral expression with respect to the Proposed Transaction by any of the respective Representatives of either Halozyme or the Company, in each case except for the following (which shall constitute


Mr. Robert F. Apple

Antares Pharma, Inc.

March 17, 2022

Page 3

 

 

binding and legally enforceable obligations of the applicable parties): (a) the express undertakings of the parties pursuant to this Exclusivity Agreement and (b) the obligations of the parties set forth in the Confidential Disclosure Agreement, dated as of February 18, 2022 by and between the Company and Halozyme (the “Confidentiality Agreement”).

 

4)

Confidentiality. This Exclusivity Agreement, including the terms, status, nature and substance of the discussions of the parties related to the Proposed Transaction is strictly confidential, and will be treated as “Confidential Information” in accordance with the terms of the Confidentiality Agreement.

 

5)

Remedies. Each party hereto agrees that irreparable harm would occur as a result of, and that monetary damages would not be a sufficient remedy for, any breach of this Exclusivity Agreement and that the non-breaching party shall be entitled to equitable relief, including an injunction or injunctions and specific performance, as a remedy for any such breach (in any case without any requirement to prove damages or securing or posting any bond in connection with such remedy), and that such remedy shall not be deemed to be the exclusive remedy for a breach by any party of this Exclusivity Agreement but shall be in addition to all other remedies available at law or in equity. No failure or delay by either party hereto in exercising any right, power or privilege hereunder shall operate as a waiver thereof, nor shall any single or partial exercise thereof preclude any other or further exercise thereof or the exercise of any right, power or privilege hereunder.

 

6)

Governing Law and Venue; Waiver of Jury Trial. This Exclusivity Agreement, and all claims, proceedings or causes of action (whether in contract, tort, statute or otherwise) that may be based upon, arise out of or relate to this Exclusivity Agreement, or the negotiation, execution or performance of this Exclusivity Agreement, shall be governed by and construed in accordance with the internal laws of the State of Delaware, without giving effect to conflicts of law principles or rules (whether of the State of Delaware or any other jurisdiction) that would cause the application of laws of any jurisdiction other than those of the State of Delaware, without regard to any borrowing statute that would result in the application of the statute of limitations of any other jurisdiction. Each party hereby irrevocably and unconditionally (a) consents and submits to the exclusive jurisdiction of the Court of Chancery of the State of Delaware sitting in the City of Wilmington, Delaware (or, solely in the event the Court of Chancery of the State of Delaware declines to exercise such jurisdiction, the exclusive jurisdiction of any federal or state court sitting in the City of Wilmington, Delaware) (collectively, the “Courts”), for any lawsuits, actions, claims or other proceedings that may be based upon, arise out of or relate to this Exclusivity Agreement, or the negotiation, execution or performance of this Exclusivity Agreement and (b) waive any objection you may now or may hereafter have to laying of venue in the Courts, including, without limitation, based on improper venue or forum non conveniens. Each party agrees not to commence any such lawsuit, action, claim or other proceeding except in the Courts. ANY RIGHT TO TRIAL BY JURY WITH RESPECT TO ANY LAWSUIT, ACTION, CLAIM OR OTHER PROCEEDING BASED UPON, ARISING OUT OF OR RELATING TO THIS EXCLUSIVITY AGREEMENT IS EXPRESSLY AND IRREVOCABLY WAIVED.


Mr. Robert F. Apple

Antares Pharma, Inc.

March 17, 2022

Page 4

 

7)

Entire Agreement. The parties hereto acknowledge and agree that the mutual covenants contained in this Exclusivity Agreement, and other good and valuable consideration provided by Halozyme contemplated herein, constitute good and sufficient consideration for the grant by the Company of the rights and obligations set forth in this Exclusivity Agreement. This Exclusivity Agreement, together with the Confidentiality Agreement, constitutes the entire agreement of the parties relating to the subject matter hereof and supersede all other prior and contemporaneous agreements and understandings, both written and oral, between the parties with respect to the subject matter hereof. This Exclusivity Agreement may be waived, amended or modified only by an instrument in writing signed by the party against which such waiver, amendment or modification is sought to be enforced, and such written instrument shall set forth specifically the provisions of this Exclusivity Agreement that are to be so waived, amended or modified. Neither party hereto shall assign this Exclusivity Agreement or its rights or obligations hereunder without the prior written consent of the other party.

This Exclusivity Agreement may be executed in any number of counterparts, including by .pdf transmission, each of which shall be deemed an original and all of which together shall constitute one agreement. This Exclusivity Agreement may be amended, modified or extended only by a written agreement signed by each of the parties hereto.

[Remainder of this page intentionally left blank.]


Very truly yours,

HALOZYME THERAPEUTICS, INC.

By:

 

/s/ Helen Torley

 

Name: Helen Torley

 

Title: Chief Executive Officer

Accepted and agreed as of the date first set forth above:

ANTARES PHARMA, INC.

By:

 

/s/ Robert F. Apple

 

Name: Robert F. Apple

 

Title: President and Chief Executive Officer

[Signature Page to Exclusivity Agreement]

EX-FILING FEES 11 d347764dexfilingfees.htm EX-FILING FEES EX-FILING FEES

Exhibit 107

Calculation of Filing Fee Tables

Schedule TO-T

(Rule 14d-100)

ANTARES PHARMA, INC.

(Name of Subject Company (Issuer))

ATLAS MERGER SUB, INC.

a wholly owned subsidiary of

HALOZYME THERAPEUTICS, INC.

(Names of Filing Persons (Offerors))

Table 1-Transaction Valuation

 

     Transaction
Valuation*
     Fee rate      Amount of
Filing Fee**
 

Fees to Be Paid

   $ 1,052,850,809        0.0000927      $ 97,599  

Fees Previously Paid

   $ 0         $ 0  
  

 

 

    

 

 

    

 

 

 

Total Transaction Valuation

   $ 1,052,850,809        

Total Fees Due for Filing

         $ 97,599  

Total Fees Previously Paid

         $ 0  

Total Fee Offsets

         $ 0  

Net Fee Due

         $ 97,599  

 

*

Estimated solely for purposes of calculating the filing fee. This calculation is based on the offer to purchase all of the issued and outstanding shares of common stock, par value $0.01 per share, of Antares Pharma, Inc. (the “Company”) at a purchase price of $5.60 per share, net to the seller in cash, without interest and subject to any withholding of taxes required by applicable legal requirements. Such shares consist of, as of 5:00 p.m., Eastern Time, on April 22, 2022 (the most recent practicable date): (i) 170,782,427 shares of common stock of the Company (“Company Common Stock”) that are issued and outstanding; (ii) 14,804,581 options, representing the right to purchase (subject to the terms thereof) an aggregate of 14,804,581 shares of Company Common Stock, (iii) 1,606,322 restricted stock units with respect to an aggregate of up to 1,606,322 shares of Company Common Stock and (iv) 815,743 performance stock units with respect to an aggregate of up to 815,743 shares of Company Common Stock.

**

The filing fee was calculated in accordance with Rule 0-11 under the Securities Exchange Act of 1934, as amended, and Fee Rate Advisory No. 1 for Fiscal Year 2022 beginning on October 1, 2021, issued August 22, 2021, by multiplying the transaction value by 0.0000927.

GRAPHIC 12 g347764g01s42.jpg GRAPHIC begin 644 g347764g01s42.jpg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end GRAPHIC 13 g347764g0423094854933.jpg GRAPHIC begin 644 g347764g0423094854933.jpg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end GRAPHIC 14 g347764page014.jpg GRAPHIC begin 644 g347764page014.jpg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�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ͯ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end